<SEC-DOCUMENT>0001213900-21-017776.txt : 20210325
<SEC-HEADER>0001213900-21-017776.hdr.sgml : 20210325
<ACCEPTANCE-DATETIME>20210325170403
ACCESSION NUMBER:		0001213900-21-017776
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		63
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210325
DATE AS OF CHANGE:		20210325

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aditx Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001726711
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				823204328
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39336
		FILM NUMBER:		21773175

	BUSINESS ADDRESS:	
		STREET 1:		2569 WYANDOTTE, ST.
		STREET 2:		SUITE 101
		CITY:			MOUNTAIN
		STATE:			CA
		ZIP:			94043
		BUSINESS PHONE:		909-488-0844

	MAIL ADDRESS:	
		STREET 1:		2569 WYANDOTTE, ST.
		STREET 2:		SUITE 101
		CITY:			MOUNTAIN
		STATE:			CA
		ZIP:			94043

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADiTx Therapeutics, Inc.
		DATE OF NAME CHANGE:	20171229
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>f10k2020_aditxtherap.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WASHINGTON,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>FORM
10-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&#9746;</B></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
fiscal year ended: <B>December 31, 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OR</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&#9744;</B></FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the transition period from _______________ to _______________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number: 001-39336</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>Aditx
Therapeutics, Inc.</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 14pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Exact name of registrant as specified in its charter)</FONT></P>


<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>82-3204328</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction
    of<BR>
incorporation or
    organization)</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer<BR>
Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2569
    Wyandotte, St., Suite 101</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mountain
    View, CA</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>94043</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal
    executive offices)</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&rsquo;s
telephone number, including area code:&nbsp;<B>(650) 870-1200</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section&nbsp;12(b)&nbsp;of the Act:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 33%; font-weight: bold; text-align: center">Title of Each Class</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 33%; font-weight: bold; text-align: center">Trading Symbol(s)</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%; font-weight: bold; text-align: center">Name of Each Exchange on Which<BR>
 Registered</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: center"><FONT STYLE="font-style: normal; font-weight: normal">Common
    Stock, par value $0.001 per share</FONT></TD><TD STYLE="vertical-align: top; font-weight: bold; text-align: center"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: center"><FONT STYLE="font-style: normal; font-weight: normal">ADTX</FONT></TD><TD STYLE="vertical-align: top; font-weight: bold; text-align: center"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font-weight: bold; text-align: center"><FONT STYLE="font-style: normal; font-weight: normal">The
    Nasdaq Stock Market LLC</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section&nbsp;12(g)&nbsp;of the Act:&nbsp;<B>None</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes
&#9744;&nbsp;&nbsp;No &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. Yes
&#9744;&nbsp;&nbsp;No &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act
during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past 90 days. Yes &#9746;&nbsp;&nbsp;No &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted posted
pursuant to Rule 405 of Regulation S-T (&sect; 232.405 of this chapter) during the preceding 12 months (or for such shorter period
that the registrant was required to submit and post such files). Yes &#9746;&nbsp;&nbsp;No &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions
of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company,&rdquo; and &ldquo;emerging
growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</FONT></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 25%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</FONT></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 25%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer </FONT></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company </FONT></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&#9746;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</FONT></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
&#9744;&nbsp;&nbsp;No &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant on June 30, 2020, based
on a closing price of $5.06 was approximately $20,079,659.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 7pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 24, 2020, the registrant had 14,225,301 and 14,124,498
shares of common stock, $0.001 par value per share, issued and outstanding, respectively.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DOCUMENTS
INCORPORATED BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Portions
of the Registrant&rsquo;s definitive proxy statement relating to its 2021 annual meeting of stockholders (the &ldquo;2021 Proxy
Statement&rdquo;) are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. The 2021 Proxy
Statement will be filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) within 120 days after the end of the
fiscal year to which this report relates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ADITX
THERAPEUTICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANNUAL
REPORT ON FORM 10-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR
THE YEAR ENDED DECEMBER 31, 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 81%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A HREF="#a_001">PART I</A></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 9%">1</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_002">Item 1</A></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_002">Business</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">1</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_003">Item 1A</A></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_003">Risk Factors</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">14</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_004">Item 1B</A></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_004">Unresolved Staff Comments</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">32</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_005">Item 2</A></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_005">Properties</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">32</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_006">Item 3</A></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_006">Legal Proceedings</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">32</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_007">Item 4</A></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_007">Mine Safety Disclosures</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">32</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A HREF="#a_008">PART II</A></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">33</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_009">Item 5</A></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_009">Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">33</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_010">Item 6</A></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_010">Selected Financial Data</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">33</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_011">Item 7</A></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_011">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">34</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_012">Item 7A</A></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_012">Quantitative and Qualitative Disclosures About Market Risk</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">40</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_013">Item 8</A></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_013">Financial Statements and Supplementary Data</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">40</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_014">Item 9</A></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_014">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">41</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_015">Item 9A</A></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_015">Controls and Procedures</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">41</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_016">Item 9B</A></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_016">Other Information</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">41</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A HREF="#a_017">PART III</A></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">42</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_018">Item 10</A></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_018">Directors, Executive Officers and Corporate Governance</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">42</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_019">Item 11</A></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_019">Executive Compensation</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">42</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_020">Item 12</A></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_020">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">42</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_021">Item 13</A></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_021">Certain Relationships and Related Transactions, and Director Independence</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">42</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_022">Item 14</A></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_022">Principal Accountant Fees and Services</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">42</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A HREF="#a_023">PART IV</A></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">43</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_024">Item 15</A></FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_024">Exhibits and Financial Statement Schedules</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">43</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_025">SIGNATURES</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">44</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995 under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals,
expectations, anticipations, assumptions, estimates, intentions and future performance, and involve known and unknown risks, uncertainties
and other factors, which may be beyond our control, and which may cause our actual results, performance or achievements to be
materially different from future results, performance or achievements expressed or implied by such forward-looking statements.
All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify
these forward-looking statements through our use of words such as &ldquo;may,&rdquo; &ldquo;can,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;assume,&rdquo; &ldquo;should,&rdquo; &ldquo;indicate,&rdquo; &ldquo;would,&rdquo; &ldquo;believe,&rdquo; &ldquo;contemplate,&rdquo;
&ldquo;expect,&rdquo; &ldquo;seek,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;plan,&rdquo; &ldquo;point to,&rdquo;
&ldquo;project,&rdquo; &ldquo;predict,&rdquo; &ldquo;could,&rdquo; &ldquo;intend,&rdquo; &ldquo;target,&rdquo; &ldquo;potential&rdquo;
and other similar words and expressions of the future. The matters discussed in these forward-looking statements are subject to
risks, uncertainties and other factors that could cause our actual results to differ materially from those projected, anticipated
or implied in the forward-looking statements. As a result, you should not place undue reliance on any forward-looking statements.
Except to the limited extent required by applicable law, we undertake no obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RISK
FACTOR SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to numerous risks and uncertainties, including those highlighted in Section 1A titled &ldquo;Risk Factors,&rdquo;
that represent challenges that we face in connection with the successful implementation of our strategy. The occurrence of one
or more of the events or circumstances described in the section titled &ldquo;Risk Factors,&rdquo; alone or in combination with
other events or circumstances, may have an adverse effect on our business, cash flows, financial condition and results of operations.
Such risks include, but are not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we have
    generated no revenue from commercial sales to date and our future profitability is uncertain;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if we fail to obtain
    the capital necessary to fund our operations, we will be unable to continue or complete our product development and you will
    likely lose your entire investment;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our financial situation
    creates doubt whether we will continue as a going concern;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may need to raise
    additional funding, which may not be available on acceptable terms, or at all;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">even if we can raise
    additional funding, we may be required to do so on terms that are dilutive to you.;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the regulatory approval
    process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of
    our future product candidates, if any;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may encounter
    substantial delays in completing our clinical studies which in turn will require additional costs, or we may fail to demonstrate
    adequate safety and efficacy to the satisfaction of applicable regulatory authorities;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if our future pre-clinical
    development and future clinical Phase I/II studies are unsuccessful, we may be unable to obtain regulatory approval of, or
    commercialize, our product candidates on a timely basis or at all;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">even if we receive
    regulatory approval for any of our product candidates, we may not be able to successfully commercialize the product and the
    revenue that we generate from their sales, if any, may be limited;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse events involving
    our products may lead the FDA or applicable foreign regulatory agency to delay or deny clearance for our products or result
    in product recalls that could harm our reputation, business and financial results;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our technology is
    subject to licenses from LLU and Stanford, each of which are revocable in certain circumstances, including in the event we
    do not achieve certain payments and milestone deadlines. Without these licenses, we may not be able to continue to develop
    our product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if we were to lose our CLIA
certification or state laboratory licenses, whether as a result of a revocation, suspension or limitation, we would no longer be able
to offer our assays (including our AditxtScore&trade; platform), which would limit our revenues and harm our business. If we were to lose,
or fail to obtain, a license in any other state where we are required to hold a license, we would not be able to test specimens from those
states;</FONT><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE>



<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our results of operations
    will be affected by the level of royalty and milestone payments that we are required to pay to third parties;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we face substantial
    competition, which may result in others discovering, developing or commercializing products before or more successfully than
    we do;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our technologies
    and products under development, and our business, may fail if we are not able to successfully commercialize them and ultimately
    generate significant revenues as a result;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">customers may not
    adopt our products quickly, or at all;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COVID-19 may impact
    our business and operations;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the failure to obtain
    or maintain patents, licensing agreements and other intellectual property could materially impact our ability to compete effectively;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">some of our intellectual
    property may be subject to &ldquo;march-in&rdquo; rights by the U.S. federal government;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we do not expect
    to pay dividends in the foreseeable future;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if our stock price
    fluctuates after the offering, you could lose a significant part of your investment;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the delisting of
    our securities by Nasdaq; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exclusive forum
    provisions in our amended and restated certificate of incorporation and amended and restated bylaws.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_001"></A>PART
I</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><A NAME="a_002"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
1.</B>&nbsp;<B>Business.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a biotech innovation company with a mission of prolonging life and enhancing its quality by improving the health of the immune
system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing biotechnologies specifically focused on improving the health of the immune system through immune reprogramming
and monitoring. Our immune reprogramming technologies are currently at the pre-clinical stage and are designed to retrain the
immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies.
Our immune monitoring technologies are designed to provide a personalized comprehensive profile of the immune system and we plan
to utilize them in our upcoming reprogramming clinical trials to monitor subjects&rsquo; immune response before, during and after
drug administration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immune
Reprogramming</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
discovery of immunosuppressive (anti-rejection and monoclonal) drugs over 40 years ago has made possible life-saving organ transplantation
procedures and blocking of unwanted immune responses in autoimmune diseases. However, immune suppression leads to significant
undesirable side effects, such as increased susceptibility to life-threatening infections and cancers, because it indiscriminately
and broadly suppresses immune function throughout the body. While the use of these drugs has been justifiable because they prevent
or delay organ rejection, their use for treatment of autoimmune diseases and allergies may not be acceptable because of the above-mentioned
side effects. Furthermore, transplanted organs often ultimately fail despite the use of immune suppression, and about 40% of transplanted
organs survive no more than 5 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New,
focused therapeutic approaches are needed that modulate only the small portion of immune cells that are involved in rejection
of the transplanted organ, as this approach can be safer for patients than indiscriminate immune suppression.&nbsp;Such approaches
are referred to as immune tolerance, and when therapeutically induced, may be safer for patients and also potentially allow long-term
survival of transplanted tissues and organs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the late 1990s, academic research on these approaches was conducted at the Transplant Center at Loma Linda University in connection
with a project that secured initial grant funding from the U.S. Department of Defense.&nbsp;The focus of that project was for
skin grafting for burn victims.&nbsp;Twenty years of research at LLU and an affiliated incubator led to a series of discoveries
that have been translated into a large patent portfolio of therapeutic approaches that may be applied to the modulation of the
immune system in order to induce tolerance to self and transplanted organs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have an exclusive worldwide license from LLU for commercializing this nucleic acid-based technology (which is currently at the
pre-clinical stage), called Apoptotic DNA Immunotherapy&trade; (ADi&trade;), which utilizes a novel approach that mimics the way
our bodies naturally induce tolerance to our own tissues (&ldquo;therapeutically induced immune tolerance&rdquo;). While immune
suppression requires continuous administration to prevent rejection of a transplanted organ, induction of tolerance has the potential
to retrain the immune system to accept the organ for longer periods of time. Thus, ADi&trade; may allow patients to live with
transplanted organs with significantly reduced immune suppression. ADi&trade; is a technology platform, which we believe can be
engineered to address a wide variety of indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing ADi&trade; products for organ transplantation including skin grafting, autoimmune diseases, and allergies, with the initial
focus on skin allografts and psoriasis, as we believe these indications will be most efficient in providing safety and efficacy data
in clinical trials. To submit a Biologics License Application (&ldquo;BLA&rdquo;) for a biopharmaceutical product, clinical safety and
efficacy must be demonstrated in a series of clinical studies conducted with human subjects. For products in our class of drugs, the
first-in-human trials will be a combination of Phase I (safety/tolerability) and Phase II (efficacy) in affected subjects. To obtain
approval to initiate the Phase I/IIa studies, an Investigational New Drug Application will be submitted to compile non-clinical efficacy
data as well as manufacturing and pre-clinical safety/toxicology data. To date, we have conducted non-clinical studies in a stringent
model of skin transplantation using genetically mismatched donor and recipient animals demonstrating a 3-fold increase in the survival
of the skin graft in animals that were tolerized with ADi&trade; compared to animals that receive immune suppression alone. Prolongation
of graft life was observed despite discontinuation of immune suppression after the first 5 weeks. Additionally, in an induced non-clinical
model for psoriasis, ADi&trade; treatment resulted in a 69% reduction in skin thickness and a 38% decrease in skin flaking (two clinical
parameters for assessment of psoriasis skin lesions). The Phase I/IIa studies in psoriasis will evaluate the safety/tolerability of ADi&trade;
in patients diagnosed with psoriasis. Since the drug will be administered in subjects diagnosed with psoriasis, effectiveness of the
drug to improve psoriatic lesions will also be evaluated. In another Phase I/IIa study, patients requiring skin allografts will receive
weekly intra-dermal injections of ADi&trade; in combination with standard immune suppression to assess safety/tolerability and possibility
of reducing levels of immunosuppressive drugs as well as prolongation of graft life. Later phase trials are planned after successful
completion of these studies in preparation for submission for a BLA to regulatory agencies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>ADi&trade;
Advantages</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADi&trade;
is a nucleic acid-based technology (<I>e.g.</I>, plasmid DNA-based) which we believe selectively suppresses only those immune
cells involved in the rejection of tissue and organ transplants. It does so by tapping into the body&rsquo;s natural process of
cell death (apoptosis) to reprogram the immune system to stop unwanted attacks on self or transplanted tissues. Apoptosis is a
natural process of &ldquo;immune tolerance&rdquo; used by the body to clear dying cells and to allow recognition and tolerance
to self-tissue. ADi&trade; triggers this process enabling the natural immune system cells to recognize the targeted tissues as
&ldquo;self&rdquo;. Conceptually, it is designed to retrain the immune system to become accepting of the organ similar to how
natural apoptosis reminds our immune system to be tolerant to our own &ldquo;self&rdquo; tissues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
efforts have been made by various groups to promote tolerance through cell therapies and&nbsp;<I>ex vivo</I>&nbsp;manipulation
of patient cells (takes place outside the body typically requiring hospitalization), to our knowledge, we will be unique in our
approach of using in-body induction of apoptosis to promote tolerance to specific tissues.&nbsp;In addition, ADi&trade; treatment
itself will not require hospitalization, only an injection in minute amounts into the skin.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Reduce
Chronic Rejection</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
immunosuppressants control acute rejection during the early time-period after receiving an organ, chronic rejection of the organ
that occurs one or more years after the transplant procedure continues to pose a major challenge for organ recipients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chronic
rejection has been likened to autoimmunity (a misdirected immune response that occurs when the immune system goes awry), where
specific tissues in the transplanted organ are attacked by the immune system.&nbsp;In other words, chronic rejection may not be
caused just by differences between the donor and the recipient, but rather by an immune response by the recipient to specific
tissues in the organ.&nbsp;Our pre-clinical studies suggest that ADi&trade; has the ability to tolerize to specific tissues in
a transplanted organ, and conceivably, reducing incidences of chronic rejection.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
preclinical studies have demonstrated that ADi&trade; treatment significantly and substantially prolongs graft survival, in addition
to successfully &ldquo;reversing&rdquo; other established immune-mediated inflammatory processes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Reduce
immune suppression</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Studies
in animal models have shown that conditioning/desensitizing the animals to receive the transplant, prolongs the survival of the
transplanted tissue or organ.&nbsp;These studies have used repeated exposure to low doses of protein components in specific organs
to reduce immunologic recognition and attack on the transplanted organ.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on some of our data, we believe that with ADi&trade; treatment, recipients can be conditioned/desensitized ahead of transplantation,
thereby retraining the immune system to more readily accept the organ and also reduce the levels of immunosuppressive drugs needed
post-transplantation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Preformed
Antibodies</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Studies
have shown that presence of preformed antibodies prior to transplantation procedures increases the rate of organ rejection. Preformed
antibodies can develop in previously transplanted patients, patients who have given birth, and patients who have previously received
blood transfusions. With more than 113,000 patients on transplant waiting lists in the U.S. alone, patients with pre-existing
antibodies have much lower chances at qualifying to receive organs due to their increased risk of rejection &ndash; even with
immune suppression.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sadly,
transplanted patients have a probability of needing re-transplantation at some point due to eventual chronic rejection of their
transplanted organ, with the possible exception of some newborn recipients. With increased incidence of preformed antibodies,
these patients may never have the opportunity to receive another organ. Based on experimental data, we believe that ADi&trade;
may have the potential to address this issue providing these individuals better opportunities at receiving an organ transplantation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>ADi&trade;
Key Differentiators</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Ease
of Delivery</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therapeutic
products are typically administered systemically (i.e., by mouth in pill form or injected intramuscularly/intravenously). This
requires repeated large doses of the drug to allow sufficient concentrations to reach the affected sites. ADi&trade; is a DNA-based
product that can be injected directly into the skin where the target cells of the immune system reside, thereby significantly
simplifying the delivery of the product and reducing the amount of product needed.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Repeat
Dosing</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DNA-based
products are less likely to result in formation of neutralizing antibodies, which lend themselves to repeat dosing as may be required
by ADi&trade; products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Cost
of Goods Advantage</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADi&trade;
products are DNA-based and cost-effective to manufacture. Furthermore, DNA-based products are very stable and do not require adherence
to cold chain (temperature-controlled) protocols for shipping. This also makes the product ideal for global distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Simplified
Therapy Delivery System</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that tolerance induction using ADi&trade; may potentially obviate the need for hospitalization because it can simply be
injected into the skin. This approach reduces treatment costs and complexities in treatment delivery.&nbsp;The anticipated administration
of ADi&trade; will include an initial priming regimen that will require injections administered once a week for several weeks.&nbsp;Thereafter,
booster or maintenance doses will be provided on an individual basis as determined by immune and inflammation testing.&nbsp;ADi&trade;
treatments will be significantly more convenient and comfortable for patients because they do not require removal of patient cells
for&nbsp;<I>ex vivo</I>&nbsp;manipulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>ADi&trade;
Technology Platform</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADi&trade;
utilizes a novel approach that mimics the way our bodies naturally induce tolerance to our own tissues.&nbsp;It is a technology
platform which we believe can be engineered to address a wide variety of indications. ADi&trade; includes two DNA molecules which
are designed to deliver signals to induce tolerance.&nbsp;The first DNA molecule encodes a pro-apoptotic protein, which induces
&lsquo;programmed&rsquo; cell death.&nbsp;This is a core component of the technology because it is intended to greatly increase
the recruitment of dendritic cells, which are implicated in regulating the immune system.&nbsp;The second DNA molecule encodes
the protein of interest (guiding antigen), which is modified to promote a path of tolerance.&nbsp;The guiding antigen is intended
to result in tolerance induction specific to the tissue where the protein is found.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="img_001.jpg" ALT="" STYLE="height: 269px; width: 375px"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADi&trade;
has been successfully tested in several preclinical models (skin grafting, psoriaris, type 1 diabetes, alopecia areata) and its
efficacy can be attributed to multiple factors:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADi&trade;
    does not rely on a single mechanistic approach.&nbsp;It has multiple components (interchangeable target antigen, apoptosis,
    methylated plasmid DNA) that affect different arms of the immune system, which can be manipulated.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADi&trade;
    activates key immune cells known to maintain tolerance in test animals and humans.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADi&trade;
    has been successfully applied to a stringent transplantation model.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADi&trade;
    lends itself to repeat dosing, which may be required to achieve its full potential therapeutic effect.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Proof
of Concept: Skin Grafting</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Results
shown are 5 weeks post-transplantation</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proof of concept experiment performed in transplantation was a skin allograft transplantation procedure in which the donor skin
was obtained from white BALB/c mice and transplanted to black C57BL/6 mice. The experiment was designed to address a more challenging
scenario where the donor tissue was obtained from a donor which is genetically mismatched with the recipient. This is unlike clinical
scenarios where the donor and recipient are genetically matched as much as possible. While these experiments were repeated in
several separate experiments, the results shown here were obtained from a study conducted with 14 mice in the ADi&trade; treatment
group and 7 mice in the control group. Prior to submission of an Investigational New Drug Application, additional non-clinical
studies will be conducted in a pig model to establish the precise protocol (e.g. timing of vaccine administration, dosing, and
appropriate immunosuppressive agents that will be used in combination with ADi&trade;) that will be used in the clinical trials.
In addition, IND-enabling safety/toxicology studies will be conducted by a GLP lab to ensure product safety for clinical testing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B><IMG SRC="img_002.jpg" ALT="" STYLE="height: 327px; width: 550px"></B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="img_003.jpg" ALT="" STYLE="height: 401px; width: 550px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Proof
of Concept: Psoriasis</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="img_004.jpg" ALT="" STYLE="width: 650px; height: 227px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Psoriasis
    causes increased skin thickness and scaling in an established 10-day psoriasis model</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADi&trade;
    treatment resulted in a 69% reduction in skin thickening and 38% reduction in scaling over the 10-day study period</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Proof
of Concept: Type 1 Diabetes</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="img_005.jpg" ALT="" STYLE="height: 264px; width: 350px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">90%
of female NOD mice developed spontaneous autoimmune diabetes. Disease progression may be different for individual animals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="img_006.jpg" ALT="" STYLE="height: 273px; width: 350px"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADi&trade;
was administered once a week for 8 weeks after each animal developed hyperglycemia. All animals responded with 80% showing durable
response for the entire 40-week study period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type
    1 or autoimmune diabetes is a condition where the body&rsquo;s immune system mistakenly attacks cells in the pancreas resulting
    in diminished production of insulin</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADi&trade;
    incorporates an antigen (GAD) expressed in the pancreas</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Administration
    of ADi&trade; using GAD as the antigen over an 8-week period in animals with T1D restores insulin production and reverses hyperglycemia</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Proof
of Concept: Alopecia Areata</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADi&trade;
protects hair follicles from autoimmune attack</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="img_007.jpg" ALT="" STYLE="height: 250px; width: 650px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immune
Monitoring</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that understanding the status of an individual&rsquo;s immune system is key to developing and administering immunotherapies
such as ADi&trade;. We have secured an exclusive worldwide license for commercializing a technology platform which provides a
personalized comprehensive profile of the immune system. It is intended to be informative for individual immune responses to viruses,
bacterial antigens, peptides, drugs, bone marrow and solid organ transplants, and cancer. It has broad applicability to many other
agents of clinical interest impacting the immune system, including those not yet identified such as future infectious agents.
We plan to brand this technology, and other future licensed and/or in-house developed monitoring technologies collectively as
AditxtScore&trade;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AditxtScore&trade;
is being designed to allow individuals to understand, manage and monitor their immune profiles in order to be informed about attacks
on or by their immune system. We believe AditxtScore&trade; can also assist the medical community in anticipating possible immune
responses and reactions to viruses, bacteria, allergens and transplanted organs. It can be useful in anticipating attacks on the
body by having the ability to determine its potential response and for developing a plan to deal with an undesirable reaction
by the immune system. Its advantages include the ability to provide a simple, rapid, accurate, high throughput, single platform
assay that can be multiplexed to determine the immune status with respect to several factors simultaneously, in 3-16 hours, as
well as detect antigen and antibody in a single test (i.e. infectious, recovered, immune). In addition, it can determine and differentiate
between various types of cellular and humoral immune responses (T and B cells). It also provides for simultaneous monitoring of
cell activation and levels of cytokine release (i.e., cytokine storms).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to utilize AditxtScore&trade; in our upcoming clinical trials to monitor subjects&rsquo; immune response before, during and
after ADi&trade; drug administration. We are working with regulatory consultants with the objective to obtain FDA approval for
AditxtScore&trade; as a clinical assay. We are currently securing marketing and distribution partnerships for application of AditxtScore&trade;
in the infectious diseases market. To obtain FDA approval to use AditxtScore&trade; as a clinical assay, we are performing validation
studies to demonstrate AditxtScore&trade;&rsquo;s utility to evaluate various components of the immune system reproducibly. We
believe that these data will show AditxtScore&trade;&rsquo;s ability to measure various components of the immune system (e.g.
humoral and cell-mediated immune responses) to provide a broader view of the immune system and its status in health and disease.
Our plan is to submit a 510(K) application to the FDA after compilation of these data. Beyond infectious diseases, we plan to
develop AditxtScore&trade; for applications in additional markets such as organ rejection, allergies, drug/vaccine response, and
disease susceptibility. The following are further descriptions of the applications of AditxtScore<SUP>TM</SUP>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(1)&nbsp;<U>Organ
Rejection</U></I></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Typically,
by the time a transplanted or a native organ shows signs of failure, the damage is already done, and reversal of the tissue injury
becomes challenging. Access to early warning signs of damage would be invaluable to reverse or even prevent the damage. There
are currently no practical, efficient assays available to measure cellular immune responses and available tools do not provide
timely information for patients. AditxtScore&trade; can be used to provide a sensitive and rapid tool to determine T cell response
and to differentiate between various types of cellular immune responses. It can be multiplexed providing information about the
number of cells responding as well as quantifying the amounts of various cytokines released by the cells in a single assay. Determination
of cellular response has valuable applications for prediction, monitoring, early detection, and treatment of disease, including
organ failure/rejection, as well as treatment efficacy. It can also reveal dysfunction of the immune system potentially contributing
to more severe disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(2)
<U>Allergies</U></I></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
immune system protects us by acting as a barrier against foreign substances and by eliminating them when they penetrate our bodies.
Once the initial exposure has occurred, memory cells develop to prepare the body against a future exposure. This process
is called immunity. In certain situations, however, instead of immunity, the immune system develops memory cells that result
in a more severe reaction during a future exposure to the same substance. This type of response is called a hypersensitivity
response, commonly known as an allergic response. AditxtScore&trade; can be used to develop multiplex assays each designed to
test and monitor immune response to allergens. Based on the ability of this technology to run multiple tests in a single assay,
100 or more substances can potentially be tested for simultaneously.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(3)
<U>Drug/Vaccine Response</U></I></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are currently no effective assays to predict and easily assess responses to vaccination. To determine whether an individual has
responded to a particular vaccine, antibody titers are measured. This process may take several days. Furthermore, for vaccines
that require a series of injections, titers are not measured between injections and may not be known for months. AditxtScore&trade;
can be used to determine whether a patient is a responder or non-responder. It can provide an effective and rapid tool for potentially
determining beneficial responses to a vaccine and can be used to monitor titer development post vaccination. It can allow evaluation
of multiple vaccines in a single test (for memory B cell detection). This application can be useful for vaccines, cancer therapeutics
anti-rejection drugs, anti-viral drugs, among others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(4)
<U>Disease Susceptibility</U></I></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disease
susceptibility can vary from one individual to another and it can be a function of various factors, including genetic variability
and differences in human leukocyte antigens (HLA) encoded by major histocompatibility complex (MHC) and responsible for regulation
of the immune system in humans. People with certain HLA types may have higher or lower susceptibility to diseases. AditxtScore&trade;
can be used to develop assays to evaluate differences in HLA types in individuals to help elucidate the relationship between certain
HLA types and susceptibility to various diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(5)
<U>Infectious Diseases</U></I></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Infectious
diseases can cause a major predicament for scientific and medical professionals, epidemiologists, and infectious disease specialists,
among others, who need to determine how to treat patients in real time while efficacious therapies are still being developed.
Proper decision making requires understanding why some affected individuals show minor or no symptoms, some recover, and others
die. This is fundamental to creating effective targeted therapeutics which may differ depending on the underlying profile of the
individual at risk for, or with, disease. The immune system plays a major role in how any given individual responds to the infectious
agent. This response can be inadequate or too robust or appropriately effective. Regardless, the kinetics of the response by the
cellular and humoral (antibody) immune systems to the infectious agent are often unknown. A basic critical question, then, is
what do the dynamics of the immune response look like from exposure to and through the disease period and during convalescence
for those who survive and those who don&rsquo;t; and how might vaccines and therapies alter these profiles such that predictions
of vaccine/drug efficacy could be inferred prior to vaccination/treatment and/or disease severity or progression be prognosticated.
AditxtScore&trade; can be used to help address these questions with multiplex assays each designed to test and monitor the immune
response to infectious agents. Based on the ability to run multiple tests in a single assay, 100 or more agents can potentially
be tested for simultaneously.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License
Agreement with Loma Linda University</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 8, 2018, we entered into an Assignment Agreement (the &ldquo;Assignment Agreement&rdquo;) with Sekris Biomedical, Inc. (&ldquo;Sekris&rdquo;).
Sekris was a party to a License Agreement with Loma Linda University (&ldquo;LLU&rdquo;), entered into and made effective on May
25, 2011, and amended on June 24, 2011, July 16, 2012 and December 27, 2012 (the &ldquo;Original Agreement,&rdquo; and together
with the Assignment Agreement, the &ldquo;Sekris Agreements&rdquo;). Pursuant to the Assignment Agreement, Sekris transferred
and assigned all of its rights and obligations in and to and liabilities under the Original Agreement, of whatever kind or nature,
to us. In exchange, on March 8, 2018, we issued a warrant to Sekris to purchase up to 500,000 shares of our common stock (the
&ldquo;Sekris Warrant&rdquo;). The warrant was immediately exercisable and has an exercise price of $4.00 per share. The expiration
date of the warrant is March 8, 2023. On March 15, 2018, as amended on July 1, 2020, we entered into a LLU License Agreement directly
with Loma Linda University, which amends and restates the Sekris Agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the LLU License Agreement, we obtained the exclusive royalty-bearing worldwide license in and to all intellectual property,
including patents, technical information, trade secrets, proprietary rights, technology, know-how, data, formulas, drawings, and
specifications, owned or controlled by LLU and/or any of its affiliates (the &ldquo;LLU Patent and Technology Rights&rdquo;) and
related to therapy for immune-mediated inflammatory diseases (the ADi&trade; technology). In consideration for the LLU License
Agreement, we issued 25,000 shares of common stock to LLU.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the LLU License Agreement, we are required to pay an annual license fee to LLU. Also, we paid LLU $455,000 in July
2020 for outstanding milestone payments and license fees. We are also required to pay to LLU milestone payments in connection
with certain development milestones. Specifically, we are required to make the following milestone payments: $175,000 on March
31, 2022; $100,000 on March 31, 2024; $500,000 on March 31, 2026; and $500,000 on March 31, 2027. Additionally, as consideration
for prior expenses incurred by LLU to prosecute, maintain and defend the LLU Patent and Technology Rights, we made&nbsp;the following
payments to LLU:, $70,000 due at the end of December 2018, and a final payment of $60,000 due at the end of March 2019. We are
required to defend the LLU Patent and Technology Rights during the term of the LLU License Agreement. Additionally, we will owe
royalty payments of (i) 1.5% of Net Product Sales and Net Service Sales on any Licensed Products (defined as any finished pharmaceutical
products which utilizes the LLU Patent and Technology Rights in its development, manufacture or supply), and (ii) 0.75% of Net
Product Sales and Net Service Sales for Licensed Products and Licensed Services not covered by a valid patent claim for technology
rights and know-how for a three (3) year period beyond the expiration of all valid patent claims. We also are required to produce
a written progress report to LLU, discussing our development and commercialization efforts, within 45 days following the end of
each year. All intellectual property rights in and to LLU Patent and Technology Rights shall remain with LLU (other than improvements
developed by or on our behalf).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
LLU License Agreement shall terminate on the last day that a patent granted  to us by LLU is valid and enforceable or the day
that the last patent application licensed to us is abandoned. The LLU License Agreement may be terminated by mutual agreement
or by us upon 90 days written notice to LLU. LLU may terminate the LLU License Agreement in the event of (i) non-payments or late
payments of royalty, milestone and license maintenance fees not cured within 90 days after delivery of written notice by LLU,
(ii) a breach of any non-payment provision (including the provision that requires us to meet certain deadlines for milestone events
(each, a &ldquo;Milestone Deadline&rdquo;)) not cured within 90 days after delivery of written notice by LLU and (iii) LLU delivers
notice to us of three or more actual breaches of the LLU License Agreement by us in any 12-month period. Additional Milestone
Deadlines include: (i) the requirement to have regulatory approval of an IND application to initiate a first-in-human clinical
trials on or before March 31, 2022, (ii) the completion of first-in-human (phase I/II) clinical trials by March 31, 2024, (iii)
the completion of Phase III clinical trials by March 31, 2026 and (iv) biologic licensing approval by the FDA by March 31, 2027.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License
Agreement with Leland Stanford Junior University (&ldquo;Stanford&rdquo;)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 3, 2020, we entered into an exclusive license agreement (the &ldquo;February 2020 License Agreement&rdquo;) with Stanford
with regard to a patent concerning a method for detection and measurement of specific cellular responses. Pursuant to the February
2020 License Agreement, we received an exclusive worldwide license to Stanford&rsquo;s patent with regard to use, import, offer,
and sale of Licensed Products (as defined in the agreement). The license to the patented technology is exclusive, including the
right to sublicense, beginning on the effective date of the agreement and ending when the patent expires. Under the exclusivity
agreement, we acknowledged that Stanford had already granted a non-exclusive license in the Nonexclusive Field of Use, under the
Licensed Patents in the Licensed Field of Use in the Licensed Territory (as those terms are defined in the February 2020 License
Agreement&rdquo;). However, Stanford agreed to not grant further licenses under the Licensed Patents in the Licensed Field of
Use in the Licensed Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">We
were obligated to pay and paid a fee of $25,000 to Stanford within 60 days of February 3, 2020. We also issued 18,750 shares of the Company&rsquo;s
common stock to Stanford. An annual licensing maintenance fee is payable by us on the first anniversary of the February 2020 License
Agreement in the amount of $40,000 for 2021 through 2024 and $60,000 starting in 2025 until the license expires upon the expiration of
the patent. The Company is required to pay and has paid $25,000 for the issuances of certain patents. The Company will pay milestone
fees of $50,000 on the first commercial sales of a licensed product and $25,000 at the beginning of any clinical study for regulatory
clearance of an in vitro diagnostic product developed and a potential licensed product. We are also required to: (i) provide a listing
of the management team or a schedule for the recruitment of key management positions by March 31, 2020 (which has been completed), (ii)
provide a business plan covering projected product development, markets and sales forecasts, manufacturing and operations, and financial
forecasts until at least $10,000,000 in revenue by June 30, 2020 (which has been completed), (iii) conduct validation studies by September
30, 2020 (which has been completed), (iv) hold a pre-submission meeting with the FDA by September 30, 2020 (which has been completed),
(v) submit a 510(k) application to the FDA, Emergency Use Authorization (&ldquo;EUA&rdquo;), or a Laboratory Developed Test (&ldquo;LDT&rdquo;)
by March 31, 2021, (vi) obtain FDA approval by December 31, 2021, (vii) complete a prototype assay kit by December 31, 2021 and (viii)
have a written agreement with Stanford on further development and commercialization milestones for specific fields of use by December
31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the annual license maintenance fees outlined above, we will pay Stanford royalties on Net Sales (as such term is defined
in the February 2020 License Agreement) during the of the term of the agreement as follows: 4% when Net Sales are below or equal
to $5 million annually or 6% when Net Sales are above $5 million annually. The February 2020 License Agreement may be terminated
upon our election on at least 30 days advance notice to Stanford, or by Stanford if we: (i) are delinquent on any report or payment;
(ii) are not diligently developing and commercializing Licensed Product; (iii) miss certain performance milestones; (iv) are in
breach of any provision of the February 2020 License Agreement; or (v) provide any false report to Stanford. Should any events
in the preceding sentence occur, we have a thirty (30) day cure period to remedy such violation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Plan
of Operations &ndash; Immune Reprogramming</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">High-level
objectives for skin allograft clinical program:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dose
    optimization to determine optimum dose/ratio of product candidate in human subjects requiring skin and other organ and/or
    tissue allografts</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical Phase I/IIa
    First-In-Human (FIH) Study to demonstrate safety and clinical proof-of-concept in human subjects requiring skin allografts</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
FIH clinical studies will combine Phase I (designed to test clinical safety) and Phase IIa (designed to obtain proof of effectiveness
in human subjects), in subjects requiring skin and other organ and/or tissue allografts. We have selected this indication for
several reasons, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    existing preclinical data has shown promising results of ADi&trade; in prolonging skin allografts;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    relative ease of visualization of the graft without the need for biopsies; and</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    need for therapies that allow reduction of levels of immune suppression that are currently used for skin allografts to prevent
    rejection of skin, which is highly antigenic.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have already identified a clinical trial center with adequate patients, which we believe will simplify and reduce the time required
for patient recruitment. Upon approval by the FDA and/or the applicable regulatory agency, and once the exact protocol has been
determined in the preclinical studies, clinical trials will be initiated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">High-level
objectives for psoriasis clinical program:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dose
    optimization to determine optimum dose of product candidate in psoriasis subjects</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical Phase I/IIa
    FIH Study to demonstrate safety and clinical proof-of-concept in psoriasis</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
FIH clinical studies will combine Phase I (designed to test clinical safety) and Phase IIa (designed to obtain proof of effectiveness
in human subjects), in psoriasis patients. We have selected this indication for several reasons, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    existing preclinical data has shown promising results of ADi&trade; in reducing scaling and skin thickness in the mouse model;
    and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The relative ease
    of visualization of the lesions to determine clinical effectiveness of the test article.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will be identifying clinical trial centers with adequate patients. Upon approval by the FDA and/or the applicable regulatory agency
clinical trials will be initiated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing our immune monitoring platforms with the objective of utilizing them as clinical assays in pre-clinical and clinical
studies. The multiplex technologies could potentially allow evaluation of more analytes with less tissue samples.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Drug
Approval Process</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, FDA approval is required before any new drugs can be introduced to the market.&nbsp;We currently have a product
candidate for our first-in-human studies, but as of the date of report, we have not submitted an application to the regulatory
agencies for approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are working with a contract manufacturer who has the know-how, product ingredients including plasmid DNA molecules, and our patent-pending
bacterial strain.&nbsp;Several batch runs have been successfully completed to demonstrate our ability to produce the DNA plasmids
in a GMP facility. Based on validation studies, we are reasonably confident in our ability to produce clinical grade product candidates
at larger scales. The contract manufacturer has provided a proposal for manufacturing of our clinical grade material, which will
be signed and accepted once we are ready to initiate GMP manufacturing. We are not currently party to an agreement with this contract
manufacturer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
product candidate selected for clinical trials must be subjected to pre-clinical safety/toxicology studies by an independent GLP
(Good Laboratory Practice) laboratory to demonstrate its suitability for clinical testing in human patients.&nbsp;Upon completion
of manufacturing and safety/toxicology testing, an Investigational New Drug (IND) application will be prepared for submission to
the regulatory agencies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
receipt of clearance to initiate clinical testing, the ADi&trade; product can be tested in human patients.&nbsp;Our product will
be tested in clinical trials, one in patients with psoriasis and one in patients who require skin allografting. Therefore, our
first-in-human studies will be combined Phase I/Phase IIa studies in which safety and efficacy data will be obtained.&nbsp;We
plan to start with in skin indications (psoriasis and skin allografting) because we believe these indications will be most efficient
in providing safety and efficacy data in clinical trials.&nbsp;In parallel, we will continue to develop additional product formulations
for other indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing our immune monitoring platforms with the objective of utilizing them as clinical assays in pre-clinical and clinical
studies. The multiplex technologies could potentially allow evaluation of more analytes with less tissue samples.&nbsp;In the
U.S., FDA approval is required before any In Vitro Diagnostic (&ldquo;IVD&rdquo;) device can be introduced to the market for clinical
use (excluding research purposes).&nbsp;This process does not require clinical trials, but it does require validation data demonstrating
accuracy of the device.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Target
Market</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S. alone, there are over 36,000 patients who receive organ transplantations each year, with more than 113,000 on transplant
waiting lists.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
field of organ transplantation has been made possible and continues to rely on broad-acting immunosuppressive drugs, high levels
of which can result in a compromised immune system that renders organ recipients susceptible to cancer and potentially life-threatening
infections including re-activation of latent viruses.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, immunosuppressants control acute rejection during the early time-period after receiving an organ but chronic rejection
of the organ remains an unmet challenge for surgeons and transplant recipients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
efforts have been made by various groups to promote tolerance through cell therapies and&nbsp;<I>ex vivo</I>&nbsp;manipulation
of patient cells, these procedures take place outside the body and typically require hospitalization.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
transplanted patients will need re-transplantation at some point, with the possible exception of some newborn recipients. With
increased incidence of preformed antibodies, these patients may never have the opportunity to receive another organ. Preformed
antibodies can develop in previously transplanted patients, patients who have given birth, and patients who have previously received
blood transfusions.&nbsp;These patients have much lower chances at qualifying to receive organs due to their increased risk of
rejection &ndash; even with immune suppression.&nbsp;The potential to reduce formation of preformed antibodies in these patients
will provide better opportunities for them to receive another transplanted organ.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are gaps between current approaches and what the market needs.&nbsp;We believe that ADi&trade; addresses these gaps.&nbsp;ADi&trade;
is easy to administer (does not require&nbsp;<I>ex-vivo&nbsp;</I>treatment of patient cells), it does not appear to suppress the
immune system, it may allow patients to live with transplanted organs with significantly reduced immune suppression, it may provide
for long-term survival of transplanted tissues and organs, may be more effective because it does not rely on a single immune pathway/mechanism,
and potentially provides patients with pre-existing antibodies a chance to qualify to receive organs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">While
these advantages present opportunities for unmet medical needs in the field of organ transplantation, the industry in which we
operate is highly competitive. A small company such as us will meet significant challenges including regulatory requirements for
approval of a new class of therapeutic agents, challenges in large scale manufacturing and marketing, cost of developing a novel
therapeutic agent, which may require co-development partners who may or may not be willing to work with us, and the willingness
of transplant surgeons to adopt our therapeutic vaccines in their existing immune suppression protocols. These challenges pose
risks that we may not be able to overcome.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Operational
Advantages</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Location</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
lease laboratory space in Mountain View, CA, located near resources including Stanford University (&ldquo;Stanford&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Strategic
Partners</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
plan is to work with strategic partners to leverage common resources to accomplish milestones over the next 3 years and potentially
get access to expertise, materials, and infrastructure (such as laboratory space) which we believe can be advantageous to our
development. We hope that this strategy will reduce costs by obviating the need to duplicate resources.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Intellectual
Property (IP)</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
strive to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to our
business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties.
Our policy is to seek to protect our proprietary position by, among other methods, filing patent applications in the United States
and in jurisdictions outside of the United States, to protect our proprietary technology, inventions, improvements and product
candidates that are important to the development and implementation of our business. We also rely on trade secrets and know-how
relating to our proprietary technology and product candidates, continuing innovation, and in-licensing opportunities to develop,
strengthen and maintain our proprietary position in the field of immuno-therapy. We also plan to rely on data exclusivity, market
exclusivity, and patent term extensions when available. Our commercial success will depend in part on our ability to obtain and
maintain patent and other proprietary protection for our technology, inventions, and improvements; to preserve the confidentiality
of our trade secrets; to obtain and maintain licenses to use intellectual property owned by third parties; to defend and enforce
our proprietary rights, including any patents that we may own in the future; and to operate without infringing on the valid and
enforceable patents and other proprietary rights of third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ADi&trade; technology and its various components are protected by multiple families of patents and patent applications, including
several U.S. and non-U.S. issued patents. As of the date of this report, our patent portfolio licensed from LLU includes 8 U.S.
patents, 3 U.S. pending patent applications, 87 foreign patents, and 14 foreign pending patent applications directed to ADi&trade;
and related technologies. The ADi&trade; patents are broadly categorized into three groups, one for autoimmune diseases and type
1 diabetes; one for organ transplantation and a method of producing plasmid DNA that is mammalian-like to prevent immune activation;
and one providing patent protection for a composition of matter for a tolerance delivery system for antigens of interest that
would be relevant for various given indications. The third group is the basis for a platform allowing development of a new class
of immunotherapeutics for various indications. The projected expiration dates for these ADi&trade; patents ranges from 2021 to
2034. The AditxtScore&trade; technology licensed from Stanford is protected by a U.S. patent which encompasses methods, systems
and kits for detection and measurement of specific immune responses. The patent has been issued by the USPTO and expires on December
28, 2037. We also possess and/or in-license substantial know-how and trade secrets relating to the development and commercialization
of our product candidates, including related manufacturing processes and technology. We plan to continue expanding and strengthening
our IP portfolio with additional patent applications in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
March 2021, Aditxt has signed an agreement with a regulatory consultant based in&nbsp;Munich, Germany, which will play a central
role in navigating the first AditxtReprogramming<SUP>TM</SUP> therapeutic program through the clinical trial and regulatory
process. The firm will work with the Aditxt's AditxtReprogramming<SUP>TM</SUP> team to submit an Investigational New Drug
application (IND) to the regulatory agency in Germany. Psoriasis is the first indication being targeted for clinical trial in
the AditxtReprogramming<SUP>TM</SUP> therapeutics pipeline. Other candidates that are advancing toward clinical trials include
ADi&trade; for type 1 diabetes and skin allografting.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Plan of Operations &ndash; Immune Monitoring</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">As previously announced
on August 6, 2020, the initial application of the platform will be AditxtScore&trade; for COVID-19 which has been designed to provide
a more complete assessment of an individual&rsquo;s infection and immunity status with respect to the SARS-CoV-2 virus. Infection
status will be determined by evaluating the presence or absence of the virus, and immunity status by measuring levels of antibodies
against viral antigens and their ability to neutralize the virus. We will soon be expanding the panel to measure other components
of the immune response such as cellular immunity. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, we filed for an Emergency Use Authorization (EUA) with the FDA with the ultimate objective of filing a 510(K) application.
We are in the process of filing an amended application to incorporate additional data and information about the use of the assay. In
the meantime, we are providing AditxtScore&trade; as a service as a Laboratory Developed Test (LDT) to assess immunity status to COVID-19.</FONT><FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif; font-size: 8pt">&nbsp;&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In early 2021, we established
our AditxtScore&trade; Immune Monitoring Center in Richmond, Virginia (the &ldquo;Center&rdquo;). The Center operates as a Clinical Laboratory
Improvement Amendments (CLIA) certified facility for the processing of our AditxtScore&trade; for COVID-19 Lab Developed Test (LDT) for
our prospective channel partners, including labs and hospitals.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have forty-three (43)
full time employees. We consider the relations with our employees to be good.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_003"></A>Item
1A. Risk Factors.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>You
should carefully consider the risks described below, as well as general economic and business risks and the other information
in this Annual Report on Form&nbsp;10-K. The occurrence of any of the events or circumstances described below or other adverse
events could have a material adverse effect on our business, results of operations and financial condition and could cause the
trading price of our common stock to decline. Additional risks or uncertainties not presently known to us or that we currently
deem immaterial may also harm our business.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Financial Position and Need for Capital</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have generated no revenue from commercial sales to date and our future profitability is uncertain.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated in September 2017 and have a limited operating history and our business is subject to all of the risks inherent
in the establishment of a new business enterprise. Our likelihood of success must be considered in light of the problems, expenses,
difficulties, complications and delays frequently encountered in connection with development and expansion of a new business enterprise.
Since inception, we have incurred losses and expect to continue to operate at a net loss for at least the next several years as
we commence our research and development efforts, conduct clinical trials and develop manufacturing, sales, marketing and distribution
capabilities. Our net loss for the years ended December 31, 2020 and 2019 was $9,149,227 and $5,827,728, respectively, and our
accumulated deficit as of December 31, 2020 was $20,879,178. There can be no assurance that the products under development by
us will be approved for sale in the U.S. or elsewhere. Furthermore, there can be no assurance that if such products are approved,
they will be successfully commercialized, and the extent of our future losses and the timing of our profitability are highly uncertain.
If we are unable to achieve profitability, we may be unable to continue our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to obtain the capital necessary to fund our operations, we will be unable to continue or complete our product development
and you will likely lose your entire investment.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will need to continue to seek capital from time to time to continue development of our lead drug candidate beyond our initial
combined Phase I/IIa clinical trial and to acquire and develop other product candidates. Once approved for commercialization,
we cannot provide any assurances that any revenues it may generate in the future will be sufficient to fund our ongoing operations.
Our current cash position, we expect to be sufficient to satisfy our capital requirements sufficient to fund our operations
for the foreseeable future. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business or operations may change in a manner that would consume available funds more rapidly than anticipated and substantial
additional funding may be required to maintain operations, fund expansion, develop new or enhance products, acquire complementary
products, business or technologies or otherwise respond to competitive pressures and opportunities, such as a change in the regulatory
environment or a change in preferred treatment modalities. In addition, we may need to accelerate the growth of our sales capabilities
and distribution beyond what is currently envisioned, and this would require additional capital. However, we may not be able to
secure funding when we need it or on favorable terms We may not be able to raise sufficient funds to commercialize the product
candidates we intend to develop.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we cannot raise adequate funds to satisfy our capital requirements, we will have to delay, scale back or eliminate our research
and development activities, clinical studies or future operations. We may also be required to obtain funds through arrangements
with collaborators, which arrangements may require us to relinquish rights to certain technologies or products that we otherwise
would not consider relinquishing, including rights to future product candidates or certain major geographic markets. This could
result in sharing revenues which we might otherwise retain for ourselves. Any of these actions may harm our business, financial
condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount of capital we may need depends on many factors, including the progress, timing and scope of our product development programs;
the progress, timing and scope of our preclinical studies and clinical trials; the time and cost necessary to obtain regulatory
approvals; the time and cost necessary to further develop manufacturing processes and arrange for contract manufacturing; our
ability to enter into and maintain collaborative, licensing and other commercial relationships; and our partners&rsquo; commitment
of time and resources to the development and commercialization of our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
financial situation creates doubt whether we will continue as a going concern.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was incorporated on September 28, 2017 and through the date of this report has generated no revenues. For the years ended
December 31, 2020 and 2019, the Company had a net loss of $9,149,227 and $5,827,728, respectively. There can be no assurances
that we will be able to achieve a level of revenues adequate to generate sufficient cash flow from operations or additional financing
through private placements, public offerings and/or bank financing necessary to support our working capital requirements. To the
extent that funds generated from any private placements, public offerings and/or bank financing are insufficient, we will have
to raise additional working capital. No assurance can be given that additional financing will be available, or if available, will
be on acceptable terms. These conditions raise substantial doubt about our ability to continue as a going concern. If adequate
working capital is not available, we may be forced to discontinue operations, which would cause investors to lose their entire
investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary
capital when needed may force us to delay, limit or terminate our product development efforts or other operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our current cash position will be sufficient to fund our current operations for at least the next 18 months.
However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional
funds sooner than planned, through public or private equity or debt financings, government or other third-party funding, marketing
and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or a combination of these
approaches. In any event, we will require additional capital to obtain regulatory approval for, and to commercialize, our product
candidates. Raising funds in the current economic environment may present additional challenges. Even if we believe we have sufficient
funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have
specific strategic considerations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability
to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available
in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings
or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility
of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible securities
may dilute our existing stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and we
may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations
on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely
impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners
or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our
technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect
on our business, operating results and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more
of our research or development programs or the commercialization of any product candidate or be unable to expand our operations
or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition
and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we can raise additional funding, we may be required to do so on terms that are dilutive to you.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
capital markets have been unpredictable in the past for unprofitable companies such as ours. In addition, it is generally difficult
for development stage companies to raise capital under current market conditions. The amount of capital that a company such as
ours is able to raise often depends on variables that are beyond our control. As a result, we may not be able to secure financing
on terms attractive to us, or at all. If we are able to consummate a financing arrangement, the amount raised may not be sufficient
to meet our future needs. If adequate funds are not available on acceptable terms, or at all, our business, including our results
of operations, financial condition and our continued viability will be materially adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Product Development, Regulatory Approval, Manufacturing and Commercialization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
regulatory approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization
of our future product candidates, if any.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will not be permitted to market our product candidates in the United States until we receive approval from the FDA, or in any
foreign countries until we receive the requisite approval from corresponding agencies in such countries. The testing, manufacturing,
labeling, approval, selling, marketing and distribution of health- and life science-related products are subject to extensive
regulation, which regulations differ from country to country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successfully
completing our clinical program and obtaining approval of a Biologics License Application (&ldquo;BLA&rdquo;) is a complex, lengthy,
expensive and uncertain process, and the FDA or other applicable foreign regulator may delay, limit or deny approval of our product
candidates for many reasons, including, among others, because:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may not be able to demonstrate that our product candidates are safe and effective in treating patients to the satisfaction
    of the FDA or foreign regulator;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of our clinical trials may not meet the level of statistical or clinical significance required by the FDA or foreign
    regulator for marketing approval;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or foreign regulator may disagree with the number, design, size, conduct or implementation of our clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or foreign regulator may require that we conduct additional clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or foreign regulator may not approve the formulation, labeling or specifications of our product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    contract research organizations (CROs) and other contractors that we may retain to conduct our clinical trials may take actions
    outside of our control that materially adversely impact our clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or foreign regulator may find the data from preclinical studies and clinical trials insufficient to demonstrate that our
    product candidate(s) are safe and effective for their proposed indications;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or foreign regulator may disagree with our interpretation of data from our preclinical studies and clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or foreign regulator may not accept data generated at our clinical trial sites or may disagree with us over whether to
    accept efficacy results from clinical trial sites outside the United States or outside the EU, as applicable, where the standard
    of care is potentially different from that in the United States or in the EU, as applicable;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    and when our BLAs or foreign equivalents are submitted to the applicable regulatory authorities, such agencies may have difficulties
    scheduling the necessary review meetings in a timely manner, may recommend against approval of our application or may recommend
    or require, as a condition of approval, additional preclinical studies or clinical trials, limitations on approved labeling
    or distribution and use restrictions;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or foreign regulator may require development of a Risk Evaluation and Mitigation Strategy (REMS), which would use risk
    minimization strategies to ensure that the benefits of certain prescription drugs outweigh their risks, as a condition of
    approval or post-approval;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or other applicable foreign regulatory agencies may not approve the manufacturing processes or facilities of third-party
    manufacturers with which we contract; or</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or the other applicable foreign regulatory agencies may change their approval policies or adopt new regulations.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may encounter substantial delays in completing our clinical studies which in turn will require additional costs, or we may fail
to demonstrate adequate safety and efficacy to the satisfaction of applicable regulatory authorities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is difficult to predict if or when any of our product candidates, will prove safe or effective in humans or&nbsp;will&nbsp;receive
regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we
must conduct extensive clinical studies to demonstrate the safety and efficacy of the product candidates in humans. Clinical testing
is expensive, time-consuming and uncertain as to outcome. We cannot guarantee that any clinical studies will be conducted as planned
or completed on schedule, if at all. A failure of one or more clinical studies can occur at any stage of testing. Events that
may prevent successful or timely completion of clinical development include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in reaching, or failing to reach, a consensus with regulatory agencies on study design;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in reaching, or failing to reach, agreement on acceptable terms with a sufficient number of prospective contract research
    organizations (&ldquo;CROs&rdquo;) and clinical study sites, the terms of which can be subject to extensive negotiation and
    may vary significantly among different CROs and trial sites;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in obtaining required Institutional Review Board (&ldquo;IRB&rdquo;) or Ethics Committee (&ldquo;EC&rdquo;) approval at each
    clinical study site;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in recruiting a sufficient number of suitable patients to participate in our clinical studies;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition
    of a clinical hold by regulatory agencies, after an inspection of our clinical study operations or study sites;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    by our&nbsp;CROs, other third parties or us to adhere to the clinical study, regulatory or legal requirements;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to perform in accordance with the FDA&rsquo;s good clinical practices (&ldquo;GCP&rdquo;) or applicable regulatory guidelines
    in other countries;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in the testing, validation, manufacturing and delivery of sufficient quantities of our product candidates to the clinical
    sites;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in having patients&rsquo; complete participation in a study or return for post-treatment follow-up;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    study sites or patients dropping out of a study;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
    or failure to address any patient safety concerns that arise during the course of a trial;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
    costs or increases in costs of clinical trials of our product candidates;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">occurrence
    of serious adverse events associated with the product candidates that are viewed to outweigh their potential benefits; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in regulatory requirements and guidance that require amending or submitting new clinical protocols.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs or ECs of the institutions in which
such trials are being conducted, by an independent Safety Review Board (&ldquo;SRB&rdquo;) for such trial or by the FDA, European
Medicines Agency (&ldquo;EMA&rdquo;), or other regulatory authorities. Such authorities&nbsp;may&nbsp;suspend or terminate a clinical
trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or
our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA, or other regulatory authorities
resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit
from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical
trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability
to generate revenues from product sales, regulatory and commercialization milestones and royalties. In addition, if we make manufacturing
or formulation changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates
to earlier versions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
study delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates
or allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize
our product candidates.&nbsp;In addition, any delays in completing our clinical trials will increase our costs, slow down&nbsp;our&nbsp;product
candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of
these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that
cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory
approval of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and interim
results of a clinical trial do not necessarily predict final results. Further, preclinical and clinical data are often susceptible
to various interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily
in preclinical studies and clinical trials have, nonetheless, failed to obtain marketing approval.&nbsp;If the results of our
clinical studies are inconclusive or if there are safety concerns or adverse events associated with our other product candidates,
we may:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    delayed in obtaining marketing approval for our product candidates, if approved at all;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    approval for indications or patient populations that are not as broad as intended or desired;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
    approval with labeling that includes significant use or distribution restrictions or safety warnings;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    required to change the way the product is administered;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    required to perform additional clinical studies to support approval or be subject to additional post-marketing testing requirements;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">have
    regulatory authorities withdraw their approval of a product or impose restrictions on its distribution in the form of a modified
    risk evaluation and mitigation strategy;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    sued; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">experience
    damage to our reputation.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
our product candidates could potentially cause other adverse events that have not yet been predicted. The inclusion of ill patients
in our clinical studies may result in deaths or other adverse medical events due to other therapies or medications that such patients
may be using. As described above, any of these events could prevent us from achieving or maintaining market acceptance of our
product candidates and impair our ability to commercialize our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
our future pre-clinical development and future clinical Phase I/II studies are unsuccessful, we may be unable to obtain regulatory
approval of, or commercialize, our product candidates on a timely basis or at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
successful completion of pre-clinical development and multiple clinical trials is critical to the success of our future products.
If the pre-clinical development and clinical trials are unsuccessful or produce inconsistent results or unanticipated adverse
side effects, or if we are unable to collect reliable data, regulatory approval of our products could be delayed or not given
and as a result we may be unable to commercialize our products. Generally, we expect to engage third parties such as consultants,
universities or other collaboration partners to conduct clinical trials on our behalf. Incompatible practices or misapplication
of our products by these third parties could impair the success of our clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we receive regulatory approval for any of our product candidates, we may not be able to successfully commercialize the product
and the revenue that we generate from their sales, if any, may be limited.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
approved for marketing, the commercial success of our product candidates will depend upon each product&rsquo;s acceptance by the
medical community, including physicians, patients and health care payors. The degree of market acceptance for any of our product
candidates will depend on a number of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">demonstration
    of clinical safety and efficacy;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">relative
    convenience, dosing burden and ease of administration;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prevalence and severity of any adverse effects;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    willingness of physicians to prescribe our product candidates, and the target patient population to try new therapies;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">efficacy
    of our product candidates compared to competing products;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    introduction of any new products that may in the future become available targeting indications for which our product candidates
    may be approved;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">new
    procedures or therapies that may reduce the incidences of any of the indications in which our product candidates may show
    utility;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pricing
    and cost-effectiveness;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inclusion or omission of our product candidates in applicable therapeutic and vaccine guidelines;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effectiveness of our own or any future collaborators&rsquo; sales and marketing strategies;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
    or warnings contained in approved labeling from regulatory authorities;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain sufficient third-party coverage or reimbursement from government health care programs, including
    Medicare and Medicaid, private health insurers and other third-party payors or to receive the necessary pricing approvals
    from government bodies regulating the pricing and usage of therapeutics; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    willingness of patients to pay out-of-pocket in the absence of third-party coverage or reimbursement or government pricing
    approvals.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our product candidates are approved, but do not achieve an adequate level of acceptance by physicians, health care payors,
and patients, we may not generate sufficient revenues and we may not be able to achieve or sustain profitability. Our efforts
to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources
and may never be successful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, even if we obtain regulatory approvals, the timing or scope of any approvals may prohibit or reduce our ability to commercialize
our product candidates successfully. For example, if the approval process takes too long, we may miss market opportunities and
give other companies the ability to develop competing products or establish market dominance. Any regulatory approval we ultimately
obtain may be limited or subject to restrictions or post-approval commitments that render our product candidates not commercially
viable. For example, regulatory authorities may approve any of our product candidates for fewer or more limited indications than
we request, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve any of our
product candidates with a label that does not include the labeling claims necessary or desirable for the successful commercialization
for that indication. Further, the FDA or comparable foreign regulatory authorities may place conditions on approvals or require
risk management plans or a Risk Evaluation and Mitigation Strategy (&ldquo;REMS&rdquo;) to assure the safe use of the drug. If
the FDA or applicable foreign regulatory agency concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS;
the regulatory agencies will not approve the BLA without an approved REMS, if required. A REMS could include medication guides,
physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and
other risk minimization tools. The regulatory agencies may also require a REMS for an approved product when new safety information
emerges. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription
or dispensing of our product candidates. Moreover, product approvals may be withdrawn for non-compliance with regulatory standards
or if problems occur following the initial marketing of the product. Any of the foregoing scenarios could materially harm the
commercial success of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Adverse
events involving our products may lead the FDA or applicable foreign regulatory agency to delay or deny clearance for our products
or result in product recalls that could harm our reputation, business and financial results.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
a product receives regulatory clearance or approval, the agency has the authority to require the recall of commercialized products
in the event of adverse side effects, material deficiencies or defects in design or manufacture. The authority to require a recall
must be based on a regulatory finding that there is a reasonable probability that the product would cause serious injury or death.
Manufacturers may, under their own initiative, recall a product if any material deficiency in a product is found. A government-mandated
or voluntary recall by us or one of our distributors could occur as a result of adverse side effects, impurities or other product
contamination, manufacturing errors, design or labeling defects or other deficiencies and issues. Recalls of any of our products
would divert managerial and financial resources and have an adverse effect on our financial condition and results of operations.
The regulatory agencies require that certain classifications of recalls be reported to them within ten (10) working days after
the recall is initiated. Companies are required to maintain certain records of recalls, even if they are not reportable to the
regulatory agency. We may initiate voluntary recalls involving our products in the future that we determine do not require notification
of the regulatory agencies. If the regulatory agency disagrees with our determinations, they could require us to report those
actions as recalls. A future recall announcement could harm our reputation with customers and negatively affect our sales. In
addition, the regulatory agency could take enforcement action for failing to report the recalls when they were conducted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
in-licensing of technologies and the successful testing and early development of technologies in the laboratory may not be indicative
of future results and may not result in commercially viable technologies or products. Further, our future products may have to
be modified from their originally conceived versions in order to reach or be successful in the market.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Positive
results from laboratory testing and early developmental successes, may not be predictive of future successful development, commercialization
and sales results and should not be relied upon as evidence that products developed from our technologies will become commercially
viable and successful. Further, the products we plan to develop in the future may have to be significantly modified from their
originally conceived versions in order for us to control costs, compete with similar products, receive market acceptance, meet
specific development and commercialization timeframes, avoid potential infringement of the proprietary rights of others, or otherwise
succeed in developing our business and earning ongoing revenues. This can be a costly and resource draining activity. What appear
to be promising technologies when we license them may not lead to viable technologies or products, or to commercial success.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Complying with numerous regulations pertaining
to our business is an expensive and time-consuming process, and any failure to comply could result in substantial penalties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are subject to the Clinical
Laboratory Improvement Amendment of 1988, or CLIA, which is a federal law regulating clinical laboratories that perform testing on specimens
derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. Our clinical laboratory
is located in Richmond, Virginia and must be certified under CLIA in order for us to perform testing on human specimens. CLIA is intended
to ensure the quality and reliability of clinical laboratories in the United States by mandating specific standards in the areas of personnel
qualifications, administration, and participation in proficiency testing, patient test management, quality control, quality assurance
and inspections. We currently hold a CLIA certificate to perform high-complexity testing. Laboratories performing high complexity testing
are required to meet more stringent requirements than laboratories performing less complex tests. CLIA regulations require clinical laboratories
like ours to comply with various operational, personnel, facilities administration, quality, and proficiency testing requirements intended
to ensure that testing services are accurate, reliable and timely. CLIA certification is a prerequisite for reimbursement eligibility
for services provided to state and federal health care program beneficiaries. CLIA is user-fee funded. Therefore, all costs of administering
the program must be covered by the regulated facilities, including certification and survey costs. To renew this certificate, we are
subject to survey and inspection every two years. Moreover, CLIA inspectors may make periodic inspections of our clinical laboratory
outside of the renewal process. The failure to comply with CLIA requirements can result in enforcement actions, including the revocation,
suspension, or limitation of our CLIA certificate of compliance, as well as a directed plan of correction, state on-site monitoring,
civil money penalties, civil injunctive suit and/or criminal penalties. We must maintain CLIA compliance and certification to be eligible
to bill for assays provided to Medicare beneficiaries. If we were to be found out of compliance with CLIA program requirements and subjected
to sanctions, our business and reputation could be harmed. Even if it were possible for us to bring our laboratory back into compliance,
we could incur significant expenses and potentially lose revenue in doing so.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Additionally, certain states
require laboratory licenses in order to test specimens from patients in those states or received from ordering physicians in those
states. We may also be subject to regulation in foreign jurisdictions if we seek to expand international distribution of our assays
outside the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">If we were to lose our
CLIA certification or state laboratory licenses, whether as a result of a revocation, suspension or limitation, we would no longer
be able to offer our assays (including our AditxtScore&trade; platform), which would limit our revenues and harm our business.
If we were to lose, or fail to obtain, a license in any other state where we are required to hold a license, we would not be able
to test specimens from those states.&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to the Company and our Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
technology is subject to licenses from LLU and Stanford, each of which are revocable in certain circumstances, including in the
event we do not achieve certain payments and milestone deadlines. Without these licenses, we may not be able to continue to develop
our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
LLU License Agreement may be terminated by LLU in the event of a breach by us of any non-payment provision (including the provision that
requires us to meet certain deadlines for milestone events (each, a &ldquo;Milestone Deadline&rdquo;)) not cured within 90 days after
delivery of written notice by LLU. Additional Milestone Deadlines include: (i) the requirement to have regulatory approval of an IND
application to initiate first-in-human clinical trials on or before March 31, 2022, (ii) the completion of first-in-human (phase I/II)
clinical trials by March 31, 2024, (iii) the completion of Phase III clinical trials by March 31, 2026 and (iv) biologic licensing approval
(BLA) by the FDA by March 31, 2027. If the LLU License Agreement were to be terminated by LLU, we would lose our most significant asset
and may no longer be able to develop our product candidates, which would have a material adverse effect on our operations.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
February 2020 License Agreement with Stanford may be terminated by Stanford if we (i) are delinquent on any report or payments;
(ii) are not diligently developing and commercializing Licensed Product (as defined in the February 2020 License Agreement); (iii)
miss a milestone described in the agreement; (iv) are in breach of any other provision of the agreement; or (v) if we provide
a false report to Stanford. The Termination discussed above will take effect only upon 30 days written notice by Stanford unless
we remedy the breach within a 30 day cure period. If the February 2020 License Agreement were to be terminated by Stanford, we
would lose a significant asset and may no longer be able to develop our product candidates, which would have a material adverse
effect on our operations.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
results of operations will be affected by the level of royalty and milestone payments that we are required to pay to third parties.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
LLU License Agreement and February 2020 License Agreement with Stanford each require us to remit royalty payments and meet certain
performance milestones related to in-licensed intellectual property. Any failure on our part to pay royalties owed or meet milestones
could lead to us losing rights under our licenses and could thereby adversely affect our business. As our product sales increase,
we may, from time-to-time, disagree with our third-party collaborators as to the appropriate royalties owed and the resolution
of such disputes may be costly and may consume management&rsquo;s time. Furthermore, we may enter into additional license agreements
in the future, which may also include royalty payments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully
than we do.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development and commercialization of drugs is highly competitive. We compete with a variety of multinational pharmaceutical companies
and specialized biotechnology companies, as well as products and processes being developed at universities and other research
institutions. Our competitors have developed, are developing or will develop product candidates and processes competitive with
our product candidates. Competitive therapeutic treatments include those that have already been approved and accepted by the medical
community and any new treatments that may enter the market. We believe that a significant number of products are currently available,
under development, and may become commercially available in the future, for the treatment of indications for which we may try
to develop product candidates.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">More
established companies may have a competitive advantage over us due to their greater size, cash flows and institutional experience.
Compared to us, many of our competitors may have significantly greater financial, technical and human resources. As a result of
these factors, our competitors may have an advantage in marketing their approved products and may obtain regulatory approval of
their product candidates before we are able to, which may limit our ability to develop or commercialize our product candidates.
Our competitors may also develop drugs that are safer, more effective, more widely used and less expensive than ours, and may
also be more successful than us in manufacturing and marketing their products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mergers
and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among
a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly
through collaborative arrangements with large and established companies. These companies compete with us in recruiting and retaining
qualified scientific, management and commercial personnel, establishing clinical trial sites and subject registration for clinical
trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
technologies and products under development, and our business, may fail if we are not able to successfully commercialize them
and ultimately generate significant revenues as a result.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
development of technologies and our product candidates will require significant additional investment, including costs associated
with additional development, completing trials and obtaining regulatory approval, as well as the ability to manufacture or have
others manufacture our products in sufficient quantities at acceptable costs while also preserving product quality. Difficulties
often encountered in scaling up production include problems involving production yields, quality control and assurance, shortage
of qualified personnel, production costs and process controls. In addition, we are subject to inherent risks associated with new
technologies and products. These risks include the possibility that any of our technologies or future products may:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    found unsafe;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    ineffective or less effective than anticipated;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fail
    to receive necessary regulatory approvals;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    difficult to competitively price relative to alternative solutions;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    harmful to consumers or the environment;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    difficult to manufacture on an economically viable scale;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    subject to supply chain constraints for raw materials;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fail
    to be developed and accepted by the market prior to the successful marketing of alternative products by competitors;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    difficult to market because of infringement on the proprietary rights of third parties; or</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
    too expensive for commercial use.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
we may be faced with lengthy market partner or distributor evaluation and approval processes. Consequently, we may incur substantial
expenses and devote significant management effort in order to customize products for market partner or distributor acceptance,
though there can be no assurance of such acceptance. As a result, we cannot accurately predict the volume or timing of any future
sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Customers
may not adopt our products quickly, or at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Customers in the sector in which we operate can be generally cautious
in their adoption of new products and technologies. In addition, given the relative novelty of our future planned products (including
our AditxtScore&trade; platform), customers of those products may require education regarding their utility and use, which may
delay their adoption. There can be no assurance that customers will adopt our products quickly, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
significant level of competition in the markets for our products developed in the future may result in pricing pressure, reduced
margins or the inability of our future products to achieve market acceptance.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
markets for our future products are intensely competitive and rapidly changing. We may be unable to compete successfully, which
may result in price reductions, reduced margins and the inability to achieve market acceptance for our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitors may have longer operating histories, significantly greater resources, greater brand recognition and large customer
bases than we do. As a result, they may be able to devote greater resources to the manufacture, promotion or sale of their products,
receive greater resources and support from market partners and independent distributors, initiate or withstand substantial price
competition or more readily take advantage of acquisition or other opportunities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We rely on third parties for the distribution
of our current and future products, including our AditxtScore&trade; platform.&nbsp;If these parties do not distribute our products
in a satisfactory or timely manner, in sufficient quantities or at an acceptable cost, our sales and development efforts could
be delayed or otherwise negatively affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We rely on third parties
for the distribution of our current and future products, including our AditxtScore&trade; platform. Our reliance on third parties
to distribute products may present significant risks to us, including the risk that should any of these third parties fail to adequately
distribute our products and services to end consumers and other market participants, our business may be materially harmed. Additionally,
if we need to enter into agreements for the distribution of our future products with other third parties, there can be no assurance
we will be able to do so on favorable terms, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We may rely on third parties for the
production of our future products.&nbsp;If these parties do not produce our products at a satisfactory quality, in a timely manner,
in sufficient quantities or at an acceptable cost, our sales and development efforts could be delayed or otherwise negatively affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may rely on third parties
for the manufacture of our future products. Our reliance on third parties to manufacture our future products may present significant
risks to us, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced control over delivery schedules, yields and product reliability;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">price increases;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing deviations from internal and regulatory specifications;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the failure of a key manufacturer to perform as we require for technical, market or other reasons;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties in establishing additional manufacturer relationships if we are presented with the need to transfer our manufacturing process technologies to them;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">misappropriation of our intellectual property; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">other risks in potentially meeting our product development schedule or satisfying the requirements of our market partners, distributors, direct customers and end users.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If we need to enter into
agreements for the manufacturing of our future products, there can be no assurance we will be able to do so on favorable terms,
if at all.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to establish successful relations with third-party market partners or distributors, or these market partners or
distributors do not focus adequate resources on selling our products or are otherwise unsuccessful in selling them, sales of our
products may not develop.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate relying on independent market partners and distributors to distribute and assist us with the marketing and sale of
our products. Our future revenue generation and growth will depend in large part on our success in establishing and maintaining
this sales and distribution channel. If our market partners and distributors are unable to sell our products, or receive negative
feedback from end users, they may not continue to purchase or market our products. In addition, there can be no assurance that
our market partners and distributors will focus adequate resources on selling our products to end users or will be successful
in selling them. Many of our potential market partners and distributors are in the business of distributing and sometimes manufacturing
other, possibly competing, products.&nbsp;As a result, these market partners and distributors may perceive our products as a threat
to various product lines currently being distributed or manufactured by them. In addition, these market partners and distributors
may earn higher margins by selling competing products or combinations of competing products. If we are unable to establish successful
relationships with independent market partners and distributors, we will need to further develop our own sales and distribution
capabilities, which would be expensive and time-consuming and might not be successful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are not able to attract and retain highly skilled employees and contractors, we may not be able to implement our business model
successfully.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will rely upon employees and third-party consultant/contractors to effectively establish, manage and grow our business. Consequently,
we believe that our future viability will depend largely on our ability to attract and retain highly skilled personnel.&nbsp;In
order to do so, we may need to pay higher compensation, fees, and/or other incentives to our employees or consultants than we
currently expect, and such higher compensation payments would have a negative effect on our operating results. Competition for
experienced, high-quality employees, consultants and contractors is intense and we cannot assure that we will be able to recruit
and retain such personnel. We may not be able to hire or retain the necessary personnel to implement our business strategy. Our
failure to hire and retain such personnel could impair our ability to develop new products and manage our business effectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
loss of our management team or other key personnel would have an adverse impact on our future development and impair our ability
to succeed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the early stages of development, our business will be significantly dependent on the Company&rsquo;s management team and other
key personnel. Our success will be particularly dependent upon Mr. Amro Albanna and Dr. Shahrokh Shabahang. The loss of any one
of these individuals or any other future key personnel could have a material adverse effect on the Company and our ability to
further execute our intended business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
use of our products may be limited by regulations, and we may be exposed to product liability and remediation claims.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
use of our planned products may be regulated by various local, state, federal and foreign regulators.&nbsp;Even if we are able
to comply with all such regulations and obtain all necessary registrations, we cannot provide assurance that our future products
will not cause injury to the environment, people, or animals and/or otherwise have unintended adverse consequences, under all
circumstances. For example, our products may be improperly combined with other chemicals or, even when properly combined, our
products may be blamed for damage caused by those other chemicals. The costs of remediation or products liability could materially
adversely affect our results, financial condition and operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be held liable for, or incur costs to settle, liability and remediation claims if any products we develop, or any products
that use or incorporate any of our technologies, cause injury or are found unsuitable during product testing, manufacturing, marketing,
sale or use. These risks exist even with respect to products that have received, or may in the future receive, regulatory approval,
registration or clearance for commercial use. We cannot guarantee that we will be able to avoid product liability exposure.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the stage customary to do so, we expect to maintain product liability insurance at levels we believe are sufficient and consistent
with industry standards for like companies and products. However, we cannot guarantee that our product liability insurance will
be sufficient to help us avoid product liability-related losses. In the future, it is possible that meaningful insurance coverage
may not be available on commercially reasonable terms or at all. In addition, a product liability claim could result in liability
to us greater than our assets or insurance coverage. Moreover, even if we have adequate insurance coverage, product liability
claims or recalls could result in negative publicity or force us to devote significant time and attention to these matters, which
could harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
may be limitations on the effectiveness of our internal controls, and a failure of our control systems to prevent error or fraud
may materially harm our Company.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not expect that internal control over financial accounting and disclosure, even if timely and well established, will prevent
all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute,
assurance that the control system&rsquo;s objectives will be met. Further, the design of a control system must reflect the fact
that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent
limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances
of fraud, if any, have been detected. Failure of our control systems to prevent error or fraud could materially adversely affect
our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>COVID-19
may impact our operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 30, 2020 the World Health Organization declared the COVID-19 coronavirus outbreak a &ldquo;Public Health Emergency of
International Concern&rdquo; and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate
the spread of the coronavirus include restrictions on travel, and quarantines in certain areas, and forced closures for certain
types of public places and businesses. The COVID-19 coronavirus and actions taken to mitigate it have had and are expected to
continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in
which the Company operates. While it is unknown how long these conditions will last and what the complete financial effect will
be to the Company, capital raise efforts and additional development of our technologies may be negatively affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Relating to Our Intellectual Property Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
failure to obtain or maintain patents, licensing agreements and other intellectual property could materially impact our ability
to compete effectively.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order for our business to be viable and to compete effectively, we need to develop and maintain, and we will heavily rely on,
a proprietary position with respect to our technologies and intellectual property. However, there are significant risks associated
with our actual or proposed intellectual property. The risks and uncertainties that we face with respect to our rights principally
include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pending
    patent applications we have filed or will file may not result in issued patents or may take longer than we expect to result
    in issued patents;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be subject to interference proceedings;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be subject to reexamination proceedings;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be subject to post grant review proceedings;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be subject to&nbsp;<I>inter partes&nbsp;</I>review proceedings;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be subject to derivation proceedings;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be subject to opposition proceedings in the U.S. or in foreign countries;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    patents that are issued to us may not provide meaningful protection;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may not be able to develop additional proprietary technologies that are patentable;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    companies may challenge patents licensed or issued to us;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    companies may have independently developed and patented (or may in the future independently develop and patent) similar or
    alternative technologies, or duplicate our technologies;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    companies may design around technologies we have licensed or developed;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enforcement
    of patents is complex, uncertain and very expensive and we may not be able to secure,&nbsp;enforce and defend our patents;
    and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the event that we were to ever seek to enforce our patents in ligation, there is some risk that they could be deemed invalid,
    not infringed, or unenforceable.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot be certain that any patents will be issued as a result of any pending or future applications, or that any patents, once
issued, will provide us with adequate protection from competing products. For example, issued patents may be circumvented or challenged,
declared invalid or unenforceable, or narrowed in scope. In addition, since publication of discoveries in scientific or patent
literature often lags behind actual discoveries, we cannot be certain that we or our licensors were the first to invent or to
file patent applications covering them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is also possible that others may have or may obtain issued patents that could prevent us from commercializing our products or
require us to obtain licenses requiring the payment of significant fees or royalties in order to enable us to conduct our business.
There is no guarantee that such licenses will be available based on commercially reasonable terms. As to those patents that we
have licensed, our rights depend on maintaining our obligations to the licensor under the applicable license agreement, and we
may be unable to do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to obtain and maintain patent protection for our products, or if the scope of the patent protection obtained is
not sufficiently broad, competitors could develop and commercialize products similar or identical to ours, and our ability to
successfully commercialize our products could be impaired.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable
patent applications at a reasonable cost, in a timely manner, or in all jurisdictions. It is also possible that we will fail to
identify patentable aspects of our development output before it is too late to obtain patent protection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent position of life science companies generally is highly uncertain, involves complex legal and factual questions and has
in past years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the
same extent as the laws of the United States and we may fail to seek or obtain patent protection in all major markets. For example,
unlike the U.S., European patent law restricts the patentability of methods of treatment of the human body. Our pending and future
patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which
effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation
of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent
protection, even post-grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recent
patent reform legislation has increased the uncertainties and costs surrounding the prosecution of patent applications and the
enforcement or defense of issued patents. On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act,
was signed into law. The Leahy-Smith Act includes a number of significant changes to United States patent law. These include provisions
that affect the way patent applications are prosecuted and may also affect patent litigation. The U.S. Patent and Trademark Office,
or USPTO, recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive
changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective
on March 16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business.
However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of
our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect
on our business and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
we may be subject to a third-party pre-issuance submission of prior art to the USPTO, or become involved in opposition, derivation,
reexamination,&nbsp;<I>inter partes&nbsp;</I>review, post-grant review or interference proceedings challenging our patent rights
(whether licensed or otherwise held) or the patent rights of others. An adverse determination in any such submission, proceeding
or litigation could reduce the scope of, or invalidate, our patent rights (whether licensed or otherwise held), allow third parties
to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to
manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of
protection provided by our patents and patent applications (whether licensed or otherwise held) is threatened, it could dissuade
companies from collaborating with us to license, develop or commercialize current or future product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if our patent applications (whether licensed or otherwise held) result in the issuance of patents, they may not issue in a form
that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any
competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative
technologies or products in a non-infringing manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our licensed or owned patents
may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity
or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could
limit our ability to stop others from using or commercializing similar or identical products, or limit the duration of the patent
protection of our products. Given the amount of time required for the development, testing and regulatory review of new life science
product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized.
As a result, our intellectual property rights portfolio may not provide us with sufficient rights to exclude others from commercializing
products similar or identical to ours.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may become involved in lawsuits to protect or enforce our intellectual property rights, which could be expensive, time-consuming
and ultimately unsuccessful.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may infringe our intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims,
which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke these parties to assert
counterclaims against us alleging that we infringe their intellectual property or that our intellectual property is invalid or
unenforceable. In addition, in a patent infringement proceeding, a court may decide that a licensed or owned patent of ours is
invalid or unenforceable, in whole or in part, construe the patent&rsquo;s claims narrowly or refuse to stop the other party from
using the technology at issue on the grounds that our patents do not cover that technology. Moreover, lawsuits to protect or enforce
our intellectual property rights could be expensive, time-consuming and ultimately unsuccessful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Third
parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which
would be uncertain.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends upon our ability to develop, manufacture, market and sell our product candidates without infringing
the proprietary rights of third parties. There is considerable intellectual property litigation in the life sciences industry.
We cannot guarantee that our product candidates will not infringe third-party patents or other proprietary rights. We may become
party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect
to our products and technology, including&nbsp;<I>inter partes&nbsp;</I>review, interference, or derivation proceedings before
the USPTO and similar bodies in other countries. Third parties may assert infringement claims against us based on existing intellectual
property rights and intellectual property rights that may be granted in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are found to infringe a third party&rsquo;s intellectual property rights, we could be required to obtain a license from such
third party to continue developing and marketing our products. However, we may not be able to obtain any required license on commercially
reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors
access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing
technology or product. In addition, we could be found liable for monetary damages, including treble damages and attorneys&rsquo;
fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our
product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that
we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on
our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other
requirements imposed by governmental patent agencies, and our own patent protection could be reduced or eliminated for noncompliance
with these requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance fees and annuities on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages
over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of
procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent
lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are
situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial
or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse
of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time
limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might
be able to enter our markets, which could have a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property
or claiming ownership of what we regard as our own intellectual property.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
of our employees and contractors were previously employed at universities or other companies, including potential competitors.
Although we try to ensure that our employees and contractors do not use the proprietary information or know-how of others in their
work for us, we may be subject to claims that these employees or we have used or disclosed intellectual property, including trade
secrets or other proprietary information, of any such employee&rsquo;s former employer. Litigation may be necessary to defend
against these claims, and any such litigation could have an unfavorable outcome.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual
property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement
with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may
not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may
bring against us, to determine the ownership of what we regard as our intellectual property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual
property rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result
in substantial costs and adverse results, and be a distraction to management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Some
intellectual property which we own or have licensed may have been discovered through government funded programs such as, for example,
the government funded programs referenced in intellectual property licensed under the LLU License Agreement, and thus may be subject
to federal regulations such as &ldquo;march-in&rdquo; rights, certain reporting requirements, and a preference for United States
industry. Compliance with such regulations may limit our exclusive rights, subject us to expenditure of resources with respect
to reporting requirements, and limit our ability to contract with non-U.S. manufacturers.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the intellectual property rights we own or have licensed have been generated through the use of United States government funding
and may therefore be subject to certain federal regulations. As a result, the United States government may have certain rights
to intellectual property embodied in our current or future products and product candidates pursuant to the Bayh-Dole Act of 1980.
These United States government rights in certain inventions developed under a government-funded program include a non-exclusive,
non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the United States
government has the right to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions
to a third party if it determines that: (i)&nbsp;adequate steps have not been taken to commercialize the invention; (ii)&nbsp;government
action is necessary to meet public health or safety needs; or (iii)&nbsp;government action is necessary to meet requirements for
public use under federal regulations (also referred to as &ldquo;march-in rights&rdquo;). The United States government also has
the right to take title to these inventions if we fail to disclose the invention to the government and fail to file an application
to register the intellectual property within specified time limits. In addition, the United States government may acquire title
to these inventions in any country in which a patent application is not filed within specified time limits. Intellectual property
generated under a government funded program is also subject to certain reporting requirements, compliance with which may require
us to expend substantial resources. In addition, the United States government requires that any products embodying the subject
invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing
preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts
have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in
the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for United
States manufacturers may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual
property. Any exercise by the government of any of the foregoing rights could harm our competitive position, business, financial
condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Intellectual
property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur
significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition,
there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities
analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common stock.
Such litigation or proceedings could increase our operating losses and reduce the resources available for development activities
or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct
such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings
more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation
of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may spend considerable resources developing and maintaining patents, licensing agreements and other intellectual property that
may later be abandoned or may otherwise never result in products brought to market.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
all technologies and candidate products that initially show potential as the basis for future products ultimately meet the rigors
of our development process and as a result may be abandoned and/or never otherwise result in products brought to market.&nbsp;In
some cases, prior to abandonment we may be required to incur significant costs developing and maintaining intellectual property
and/or maintaining license agreements and our business could be harmed by such costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
rely on information technology, and if we are unable to protect against service interruptions, data corruption, cyber-based attacks
or network security breaches, our operations could be disrupted, and our business could be negatively affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on information technology networks and systems to process, transmit and store electronic and financial information; to coordinate
our business; and to communicate within our Company and with customers, suppliers, partners and other third-parties. These information
technology systems may be susceptible to damage, disruptions or shutdowns, hardware or software failures, power outages, computer
viruses, cyber-attacks, telecommunication failures, user errors or catastrophic events. If our information technology systems
suffer severe damage, disruption or shutdown, and our business continuity plans do not effectively resolve the issues in a timely
manner, our operations could be disrupted, and our business could be negatively affected. In addition, cyber-attacks could lead
to potential unauthorized access and disclosure of confidential information, and data loss and corruption. There is no assurance
that we will not experience these service interruptions or cyber-attacks in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are currently listed on The Nasdaq Capital Market. If we are unable to maintain listing of our securities on Nasdaq or any stock
exchange, our stock price could be adversely affected and the liquidity of our stock and our ability to obtain financing could
be impaired and it may be more difficult for our stockholders to sell their securities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
our common stock is currently listed on The Nasdaq Capital Market, we may not be able to continue to meet the exchange&rsquo;s
minimum listing requirements or those of any other national exchange. If we are unable to maintain listing on Nasdaq or if a liquid
market for our common stock does not develop or is sustained, our common stock may remain thinly traded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
listing rules of Nasdaq require listing issuers to comply with certain standards in order to remain listed on its exchange. If,
for any reason, we should fail to maintain compliance with these listing standards and Nasdaq should delist our securities from
trading on its exchange and we are unable to obtain listing on another national securities exchange, a reduction in some or all
of the following may occur, each of which could have a material adverse effect on our stockholders:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    liquidity of our common stock;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    market price of our common stock;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain financing for the continuation of our operations;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of institutional and general investors that will consider investing in our common stock;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of investors in general that will consider investing in our common stock;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of market makers in our common stock;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability of information concerning the trading prices and volume of our common stock; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of broker-dealers willing to execute trades in shares of our common stock.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I></I></B></FONT></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
do not expect to pay dividends in the foreseeable future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not intend to declare dividends for the foreseeable future, as we anticipate that we will reinvest any and all future earnings
in the development and growth of our business. Therefore, investors will not receive any funds unless they sell their securities,
and holders may be unable to sell their securities on favorable terms or at all. We cannot assure you of a positive return on
your investment or that you will not lose the entire amount of your investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Upon
dissolution of our Company, you may not recoup all or any portion of your investment.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a liquidation, dissolution or winding-up of our Company, whether voluntary or involuntary, our assets would be used
to pay all of our debts and liabilities, and only thereafter would any remaining assets be distributed to our stockholders, subject
to rights of the holders of the Preferred Stock, if any, on a&nbsp;<I>pro rata&nbsp;</I>basis. There can be no assurance that
we will have assets available from which to pay any amounts to our stockholders upon such a liquidation, dissolution or winding-up.
In such an event, you would lose all of your investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Limitation
of Liability and Indemnification of Management.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Delaware General Corporation Law and the Company&rsquo;s Amended and Restated Certificate of Incorporation provide for the limitation
of the liability of directors for monetary damages. Such provisions may discourage shareholders from bringing a lawsuit against
directors for breaches of fiduciary duty and may also have the effect of reducing the likelihood of derivative litigation against
directors and officers even though such action, if successful, might otherwise be a benefit to the Company&rsquo;s shareholders.&nbsp;In
addition, a shareholder&rsquo;s investment in the Company may be adversely affected to the extent that costs of settlement and
damage awards against the Company&rsquo;s officers or directors are paid by the Company pursuant to such provisions. Additionally,
in accordance with Delaware law and the Company&rsquo;s Amended and Restated Certificate of Incorporation, the Company shall indemnify,
hold harmless and provide advancement of expenses, to the fullest extent permitted by applicable law, directors, officers, employees,
and agents that are made a party or threatened to be made a party to legal proceedings by reason of the fact that such parties
were working at the request of the Company.&nbsp;We direct you to the Company&rsquo;s Amended and Restated Certificate of Incorporation
for more information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Anti-takeover
provisions under Delaware law could discourage, delay or prevent a change in control of our Company and could affect the trading
price of our securities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a Delaware corporation and the anti-takeover provisions of the Delaware General Corporation Law may discourage, delay or prevent
a change in control by prohibiting us from engaging in a business combination with an interested stockholder for a period of three
years after the person becomes an interested stockholder, even if a change in control would be beneficial to our existing stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
management team is required to devote substantial time to public company compliance initiatives.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a publicly reporting company, we incur significant legal, accounting and other expenses. Our management and other personnel devote
a substantial amount of time to comply with our reporting obligations. Moreover, these reporting obligations increase our legal
and financial compliance costs and make some activities more time-consuming and costly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Failure
to develop our internal controls over financial reporting as we grow could have an adverse impact on us.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
our Company matures, we will need to develop our current internal control systems and procedures to manage our growth. We are
required to establish and maintain appropriate internal controls over financial reporting. Failure to establish appropriate controls,
or any failure of those controls once established, could adversely impact our public disclosures regarding our business, financial
condition or results of operations. In addition, management&rsquo;s assessment of internal controls over financial reporting may
identify weaknesses and conditions that need to be addressed in our internal controls over financial reporting or other matters
that may raise concerns for investors. Any actual or perceived weaknesses and conditions that need to be addressed in our internal
control over financial reporting, disclosure of management&rsquo;s assessment of our internal controls over financial reporting
or disclosure of our public accounting firm&rsquo;s attestation to or report on management&rsquo;s assessment of our internal
controls over financial reporting may have an adverse impact on the price of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
could issue &ldquo;blank check&rdquo;&nbsp;preferred stock&nbsp;without stockholder approval with the effect of diluting interests
of then-current stockholders and impairing their voting rights, and provisions in our charter documents and under Delaware law
could discourage a takeover that stockholders may consider favorable.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Amended and Restated Certificate of Incorporation provides for the authorization to issue up to 3,000,000 shares of &ldquo;blank
check&rdquo;&nbsp;preferred stock&nbsp;with designations, rights and preferences as may be determined from time to time by our
board of directors. Our board of directors is empowered, without stockholder approval, to issue one or more series of preferred
stock with dividend, liquidation, conversion, voting or other rights which could dilute the interest of, or impair the voting
power of, our common stockholders. The issuance of a series of preferred stock could be used as a method of discouraging, delaying
or preventing a change in control. For example, it would be possible for our board of directors to issue preferred stock with
voting or other rights or preferences that could impede the success of any attempt to change control of our company. In addition,
advanced notice is required prior to stockholder proposals, which might further delay a change of control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
Amended and Restated Certificate of Incorporation provides that the Court of Chancery of the State of Delaware will be the sole
and exclusive forum&nbsp;for substantially all disputes between the Company and its stockholders, which could limit stockholders&rsquo;
ability to obtain a favorable judicial forum for disputes with the Company or its directors, officers or employees.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Amended and Restated Certificate of Incorporation provides that unless the Company consents in writing to the selection of an
alternative forum, the State of Delaware is the&nbsp;sole and exclusive forum for: (i) any derivative action or proceeding brought
on behalf of the Company, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other
employee of the Company to the Company or the Company&rsquo;s stockholders, (iii) any action asserting a claim against the Company,
its directors, officers or employees arising pursuant to any provision of the&nbsp;Delaware General Corporation Law&nbsp;(the
&ldquo;DGCL&rdquo;) or our Amended and Restated Certificate of Incorporation or the Company&rsquo;s Amended and Restated Bylaws,
or (iv) any action asserting a claim against the Company, its directors, officers, employees or agents governed by the internal
affairs doctrine, except for, as to each of (i) through (iv) above, any claim as to which the Court of Chancery determines that
there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not
consent to the personal jurisdiction of the Court of Chancery within ten days following such determination), which is vested in
the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for which the Court of Chancery does not have
subject matter jurisdiction. This exclusive forum provision would not apply to suits brought to enforce any liability or duty
created by the Securities Act or the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction.
To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal
jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations
thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty
or liability created by the Securities Act or the rules and regulations thereunder. However, our Amended and Restated Bylaws contain
a federal forum provision which provides that unless the Company consents in writing to the selection of an alternative forum,
the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting
a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in shares
of capital stock of the Corporation are deemed to have notice of and consented to this provision. The Supreme Court of Delaware
has held that this type of exclusive federal forum provision is enforceable. There may be uncertainty, however, as to whether
courts of other jurisdictions would enforce such a provision, if applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
choice of forum provisions may limit a stockholder&rsquo;s ability to bring a claim in a judicial forum that it finds favorable
for disputes with the Company or its directors, officers or other employees, which may discourage such lawsuits against us and
our directors, officers and other employees. Alternatively, if a court were to find our choice of forum provisions contained in
either our Amended and Restated Certificate of Incorporation or Amended and Restated Bylaws to be inapplicable or unenforceable
in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our
business, results of operations, and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are an &ldquo;emerging growth company&rdquo; and will be able to avail ourselves of reduced disclosure requirements applicable
to emerging growth companies, which could make our common stock less attractive to investors.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &ldquo;emerging growth company,&rdquo; as defined in the Jumpstart Our Business Startups Act of 2012 (the &ldquo;JOBS Act&rdquo;),
and we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public
companies that are not &ldquo;emerging growth companies&rdquo; including not being required to comply with the auditor attestation
requirements of Section&nbsp;404(b) of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute payments not previously approved. In addition, pursuant to Section&nbsp;107
of the JOBS Act, as an &ldquo;emerging growth company&rdquo; we intend to take advantage of the extended transition period provided
in Section&nbsp;7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. In other words, an &ldquo;emerging
growth company&rdquo; can delay the adoption of certain accounting standards until those standards would otherwise apply to private
companies. As a result, our financial statements may not be comparable to those of companies that comply with public company effective
dates for complying with new or revised accounting standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors
find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock
price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an &ldquo;emerging growth
company.&rdquo; We will remain an &ldquo;emerging growth company&rdquo; until the earliest of (i)&nbsp;the last day of the fiscal
year in which we have total annual gross revenues of $1.07&nbsp;billion or more; (ii)&nbsp;the last day of our fiscal year following
the fifth anniversary of the date of the completion of our initial public offering; (iii)&nbsp;the date on which we have issued
more than $1&nbsp;billion in nonconvertible debt during the previous three years; or (iv)&nbsp;the date on which we are deemed
to be a large accelerated filer under the rules of the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_004"></A>Item
1B. Unresolved Staff Comments.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_005"></A>
Item 2. Properties.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We
lease property consisting of office and laboratory space located at 2569 Wyandotte, St., Suite 101 Mountain View, CA 94043. The lease
expires on August 31, 2024, subject to extension.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_006"></A>Item
3. Legal Proceedings.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business.
However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time
to time that may harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company, Amro Albanna, our President and Chief Executive Officer, and Dr. Shahrokh Shabahang, our Chief Innovation Officer, have
been named as cross-defendants in a counterclaim filed by Christopher Sechrist in an action entitled Shahrokh Shabahang v. Christopher
Sechrist, San Bernardino County Superior Court Case No. CIVDS1831323. In a cross-complaint, Mr. Sechrist contends that he was
a partner in a dental practice with Dr. Shabahang, and that disputes arose as between those partners. Neither the Company nor
Mr. Albanna were partners in, or otherwise have an interest in, the dental practice. Notwithstanding, and seemingly based solely
on the fact that Dr. Shabahang became the Chief Innovation Officer for the Company, Mr. Sechrist has brought claims against the
Company and Mr. Albanna. Both the Company and Mr. Albanna believe that the Counterclaims filed by Mr. Sechrist have no factual
or legal merit, and they intend to vigorously defend themselves in the action and to seek a dismissal of the case as against them
as soon as possible. On May 26, 2020, Mr. Sechrist filed a request for dismissal as to the Company and Mr. Albanna with the Superior
Court of California, County of San Bernardino, San Bernardino District. The clerk of the court entered the dismissal with prejudice
on May 26, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
CEO, Amro Albanna, is a party to litigation matters unrelated to the Company or any&nbsp;of its properties. Such litigations relate
to Innovation Economy Corporation (IEC), a company in which Mr. Albanna served as the CEO and a Director from 2010 until 2017,
and its wholly-owned subsidiaries (Innovation Economy Corporation d/b/a ieCrowd). The first litigation (ieCrowd v. Kim,&nbsp;et.
al, Superior Court, Riverside County) was originally commenced by IEC and its subsidiary after Mr. Albanna was no longer affiliated
with IEC, against certain third-party defendants based upon claims related to their misconduct and mismanagement.&nbsp;Such defendants
subsequently brought a countersuit against IEC and its subsidiary, in which they named Mr. Albanna and others as defendants, alleging
that they were misled to invest in IEC and its subsidiary based upon misrepresentations by, among others,&nbsp;Mr. Albanna. The
cases have now been consolidated. Mr. Albanna believes that the counteraction commenced by the third parties against him is without
merit and intends to&nbsp;defend himself. The second matter (Calabria v. ieCrowd)&nbsp;was commenced by Calabria Ventures
(the &ldquo;Calabria Action&rdquo;) more than 2 years after Mr. Albanna was no longer affiliated with IEC, related to uncollected&nbsp;rent.&nbsp;Mr.
Albanna believes that the action commenced against him is without merit and intends to&nbsp;defend himself. IEC (either
directly or through its Director and officer insurance policy) has covered all related legal costs to date. On August 5, 2020,
the plaintiff in the Calabria Action filed a request for dismissal as to Mr. Albanna with the Superior Court of California, County
of Riverside. The clerk of the court entered the dismissal without prejudice on August 5, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_007"></A>Item
4. Mine Safety Disclosures.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_008"></A>PART
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><A NAME="a_009"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
5. Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2020, our common stock began trading on the Nasdaq Capital Market under the symbol &ldquo;ADTX.&rdquo; Prior to that
time, there was no public market for our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Holders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 24, 2021, there were approximately 135&nbsp;record holders of our common stock and no holders of our preferred stock.
The actual number of holders of our common stock is greater than this number of record holders, and includes stockholders who
are beneficial owners, but whose shares are held in street name by brokers or held by other nominees. This number of holders of
record also does not include stockholders whose shares may be held in trust by other entities.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dividend
Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never paid or declared any cash dividends on our common stock, and we do not anticipate paying any cash dividends on our
common stock in the foreseeable future. We intend to retain all available funds and any future earnings to fund the development
and expansion of our business. Any future determination to pay dividends will be at the discretion of our board of directors and
will depend upon a number of factors, including our results of operations, financial condition, future prospects, contractual
restrictions, restrictions imposed by applicable law and other factors that our board of directors deems relevant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Sales of Unregistered Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 6, 2020 the Company issued warrants to a consultant to purchase up to 120,000 shares of common stock at an exercise price
of $1.92 per share for services rendered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 31, 2020, the Company issued a consultant 650,000 shares of common stock upon completion of certain milestones included
in a consulting agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity
Compensation Plans</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information required by Item&nbsp;5 of Form&nbsp;10-K regarding equity compensation plans is incorporated herein by reference
to Item&nbsp;12 of Part&nbsp;III of this Annual Report on Form 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issuer
Purchases of Equity Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not purchase any of our registered equity securities during the period covered by this Annual Report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Use
of Proceeds from Initial Public Offering</B></FONT>&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
July 2, 2020, we completed our initial public offering (&ldquo;IPO&rdquo;). In connection therewith, we issued 1,226,668 Units
(the &ldquo;Units&rdquo;), excluding the underwriters&rsquo; option to cover overallotments, at an offering price of $9.00 per
Unit, resulting in gross proceeds of approximately $11.0 million. The Units issued in the IPO consisted of one share of common
stock, one Series A warrant, and one Series B warrant. The Series A warrants originally had an exercise price of $9.00 and a term
of 5 years. In addition, we issued a Unit Purchase Option at an exercise price of $11.25 per unit to the underwriters to purchase
up to 67,466 units, with each unit consisting of (i) one share of common stock and (ii) one Series A Warrant. On August 19, 2020
we modified the exercise price of the Series A Warrants from $9.00 per share to $4.50 per share. The term of the Series A Warrants
was not modified. The Series B warrants have an exercise price of $11.25 per share, a term of 5 years and contain a cashless exercise
option upon certain criteria being met. As of December 31, 2020, substantially all of the Series B warrants issued in the IPO have
been exercised pursuant to a cashless provision therein.</FONT>&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We
received net proceeds of $8.5 million in the IPO, after deducting underwriting discounts and commissions and issuance expenses
borne by us. No payments were made by us to directors, officers or persons owning ten percent or more of our common stock or to
their associates, or to our affiliates, other than payments in the ordinary course of business to officers for salaries and to
non-employee directors pursuant to our director compensation policy. Dawson James Securities, Inc. acted as lead book-running manager
of the offering and as representative of the underwriters&nbsp;for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">There
has been no material change in the planned use of proceeds from our IPO from that described in the final prospectus related to
the offering, dated June 29, 2020, as filed with the SEC.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_010"></A>Item
6. Selected Financial Data.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_011"></A>Item
7. Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>The
following discussion and analysis of our financial condition and results of operations should be read together with our financial
statements and the related notes and other financial information included elsewhere in this report. Some of the information contained
in this discussion and analysis or set forth elsewhere in this report, including information with respect to our plans and strategy
for our business, includes forward-looking statements that involve risks and uncertainties. See &ldquo;Cautionary Note Regarding
Forward-Looking Statements.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a life sciences company with a mission of prolonging life and enhancing its quality by improving the health of the immune
system. Our immune reprogramming technology is currently at the pre-clinical stage and designed to retrain the immune system to
induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. Our immune
monitoring technology is designed to provide a personalized comprehensive profile of the immune system and we plan to utilize
it in our upcoming clinical trials to monitor subjects&rsquo; immune response before, during and after drug administration. We
are also evaluating plans to obtain FDA approval for this monitoring tool&rsquo;s use as a clinical assay.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Developments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On January 25, 2021 (the &ldquo;Closing Date&rdquo;), we entered into a Securities Purchase Agreement (the &ldquo;Purchase
Agreement&rdquo;) with an institutional accredited investor for the offering, sale, and issuance (the &ldquo;Offering&rdquo;)
of a $6,000,000 Senior Secured Convertible Promissory Note (the &ldquo;Note&rdquo;). Concurrently with the sale of the Note, pursuant
to the Purchase Agreement, we also issued a warrant &ldquo;January 2021 Warrant&rdquo;) to the investor to purchase up to 800,000
shares (the &ldquo;January 2021 Warrant Shares&rdquo;) of the Company&rsquo;s common stock. As a result of the Offering, the Company
received aggregate gross proceeds of $5,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Note has a twenty-four month term and is convertible at the option of the investor at any time prior to maturity in shares of
Common Stock (the &ldquo;Conversion Shares&rdquo;) at an initial conversion price of $4.00 per share, subject to adjustment under
certain circumstances. The Note amortizes in nineteen (19) equal monthly installments (the &ldquo;Installment Payments&rdquo;)
starting the first day of the sixth month after the Closing Date (each, an &ldquo;Installment Date&rdquo;). At the Company&rsquo;s
option, Installment Payments may be made in cash or in shares of the Company&rsquo;s common stock. If the Company elects to repay
in cash, the amount payable shall be 105% of the applicable Installment Payment. If the Company elects to repay in shares of common
stock, the shares shall be priced at the lowest of (i) the Conversion Price then in effect, and (ii) the greater of (x) the Floor
Price (as defined in the Note) and (y) the lower of 90% of the lowest volume weighted average price (VWAP) of the common stock
for each of the five (5) Trading Days (as such term is defined in the Note) ending and including the Trading Day immediately prior
to the applicable Installment Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
Installment Payments are subject to the investor&rsquo;s right to (a) defer some or all of any Installment Payment to a subsequent
Installment Date or (b) to convert an additional Installment Payment of the Note at the then-current Installment Price until the
next Installment Date. Upon the occurrence of an Event of Default or a Change of Control (as such terms are defined in the Note),
the Note is subject to redemption by the investor. The Company is prohibited from effecting a conversion of the Note to the extent
that, as a result of such exercise, the investor, together with the its affiliates, would beneficially own more than 4.99% of
the number of shares of common stock of the Company outstanding immediately after giving effect to the issuance of the such shares,
which beneficial ownership limitation may be increased by the investor up to, but not exceeding, 9.99%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
January 2021 Warrants are immediately exercisable for a period of three (3) years at an exercise price of $4.00 per share, subject
to adjustment. After a period of one hundred eight (180) days, if a registration statement covering the resale of the shares of
common stock underlying the January 2021 Warrants is not effective, the holder may exercise the January 2021 Warrant by means
of a cashless exercise. The Company is prohibited from effecting an exercise of the January 2021 Warrants to the extent that,
as a result of such exercise, the holder of the January 2021 Warrants together with the holder&rsquo;s affiliates, would beneficially
own more than 4.99% of the number of shares of common stock of the Company outstanding immediately after giving effect to the
issuance of the such shares, which beneficial ownership limitation may be increased by the holder up to, but not exceeding, 9.99%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
until the earlier of the (i) one year anniversary the Closing Date, and (ii) such time as less than $2 million of aggregate Principal
Amount (as such term is defined in the Note) of the Note remains outstanding, the Company is prohibited from effecting or entering
into an agreement to effect any issuance of securities involving a Variable Rate Transaction (as such term is defined in the Purchase
Agreement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Immune
Reprogramming</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
discovery of immunosuppressive (anti-rejection and monoclonal) drugs over 40 years ago has made possible life-saving organ transplantation
procedures and blocking of unwanted immune responses in autoimmune diseases. However, immune suppression leads to significant
undesirable side effects, such as increased susceptibility to life-threatening infections and cancers, because it indiscriminately
and broadly suppresses immune function throughout the body. While the use of these drugs has been justifiable because they prevent
or delay organ rejection, their use for treatment of autoimmune diseases and allergies may not be acceptable because of the aforementioned
side effects. Furthermore, transplanted organs often ultimately fail despite the use of immune suppression, and about 40% of transplanted
organs survive no more than 5 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New,
focused therapeutic approaches are needed that modulate only the small portion of immune cells that are involved in rejection
of the transplanted organ, as this approach can be safer for patients than indiscriminate immune suppression. Such approaches
are referred to as immune tolerance, and when therapeutically induced, may be safer for patients and also potentially allow long-term
survival of transplanted tissues and organs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the late 1990s, academic research on these approaches was conducted at the Transplant Center in Loma Linda University (&ldquo;LLU&rdquo;)
in connection with a project that secured initial grant funding from the U.S. Department of Defense. The focus of that project
was for skin grafting for burn victims. Twenty years of research at LLU and an affiliated incubator led to a series of discoveries
that have been translated into a large patent portfolio of therapeutic approaches that may be applied to the modulation of the
immune system in order to induce tolerance to self and transplanted organs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have an exclusive worldwide license for commercializing this nucleic acid-based technology (which is currently at the pre-clinical
stage), named Apoptotic DNA Immunotherapy&trade; (ADi&trade;) from LLU, which utilizes a novel approach that mimics the way the
body naturally induces tolerance to our own tissues (&ldquo;therapeutically induced immune tolerance&rdquo;). While immune suppression
requires continuous administration to prevent rejection of a transplanted organ, induction of tolerance has the potential to retrain
the immune system to accept the organ for longer periods of time. Thus, ADi&trade; may allow patients to live with transplanted
organs with significantly reduced immune suppression. ADi&trade; is a technology platform which we believe can be engineered to
address a wide variety of indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing ADi&trade; products for organ transplantation including skin grafting, autoimmune diseases, and allergies, with
the initial focus on skin allografts and psoriasis, as we believe these indications will be most efficient in providing safety
and efficacy data in clinical trials. To submit a Biologics License Application (&ldquo;BLA&rdquo;) for a biopharmaceutical product,
clinical safety and efficacy must be demonstrated in a series of clinical studies conducted with human subjects. For products
in our class of drugs, the first-in-human trials will be a combination of Phase I (safety/tolerability) and Phase II (efficacy)
in affected subjects. To obtain approval to initiate the Phase I/IIa studies, an Investigational New Drug Application will be
submitted to compile non-clinical efficacy data as well as manufacturing and pre-clinical safety/toxicology data. To date, we
have conducted non-clinical studies in a stringent model of skin transplantation using genetically mismatched donor and recipient
animals demonstrating a 3-fold increase in the survival of the skin graft in animals that were tolerized with ADi&trade; compared
to animals that receive immune suppression alone. Prolongation of graft life was observed despite discontinuation of immune suppression
after the first 5 weeks. Additionally, in an induced non-clinical model for psoriasis, ADi&trade; treatment resulted in a 69%
reduction in skin thickness and a 38% decrease in skin flaking (two clinical parameters for assessment of psoriasis skin lesions).
The Phase I/IIa studies in psoriasis will evaluate the safety/tolerability of ADi&trade; in patients diagnosed with psoriasis.
Since the drug will be administered in subjects diagnosed with psoriasis, effectiveness of the drug to improve psoriatic lesions
will also be evaluated. In another Phase I/IIa study, patients requiring skin allografts will receive weekly intra-dermal injections
of ADi&trade; in combination with standard immune suppression to assess safety/tolerability and possibility of reducing levels
of immunosuppressive drugs as well as prolongation of graft life. Later phase trials are planned after successful completion of
these studies in preparation for submission for a BLA to regulatory agencies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Immune
Monitoring</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that understanding the status of an individual&rsquo;s immune system is key to developing and administering immunotherapies
such as ADi&trade;. We have secured an exclusive worldwide license for commercializing a technology platform named AditxtScore&trade;,
which provides a personalized comprehensive profile of the immune system. It is intended to be informative for individual immune
responses to viruses, bacterial antigens, peptides, drugs, bone marrow and solid organ transplants, and cancer. It has broad applicability
to many other agents of clinical interest impacting the immune system, including those not yet identified such as future infectious
agents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AditxtScore&trade;
is being designed to allow individuals to understand, manage and monitor their immune profiles in order to be informed about attacks
on or by their immune system. We believe AditxtScore&trade; can also assist the medical community in anticipating possible immune
responses and reactions to viruses, bacteria, allergens and transplanted organs. It can be useful in anticipating attacks on the
body by having the ability to determine its potential response and for developing a plan to deal with an undesirable reaction
by the immune system. Its advantages include the ability to provide a simple, rapid, accurate, high throughput, single platform
assay that can be multiplexed to determine the immune status with respect to several factors simultaneously, in 3-16 hours, as
well as detect antigen and antibody in a single test (i.e. infectious, recovered, immune). In addition, it can determine and differentiate
between various types of cellular and humoral immune responses (T and B cells). It also provides for simultaneous monitoring of
cell activation and levels of cytokine release (i.e., cytokine storms).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to utilize AditxtScore&trade; in our upcoming clinical trials to monitor subjects&rsquo; immune response before, during and
after ADi&trade; drug administration. We are also evaluating plans to obtain FDA approval for AditxtScore&trade;&rsquo;s use as
a clinical assay and seeking to secure manufacturing, marketing and distribution partnerships for application in the Infectious
Diseases market, by end of 2020. To obtain FDA approval to use AditxtScore&trade; as a clinical assay, we plan to conduct validation
studies comparing AditxtScore&trade; to other immunological tests to demonstrate reproducibility of data and to demonstrate the
sensitivity of the assays for use in different indications (e.g., detection of antigens present in infectious agents or antibodies
against infectious agents). We believe that these data will show AditxtScore&trade;&rsquo;s ability to multiplex in two ways using
a single assay: (i) evaluating the immune response to multiple antigens (from different infectious agents) and (ii) measuring
quantities of multiple cytokines. Furthermore, we believe that the additional validation studies will demonstrate AditxtScore&trade;&rsquo;s
ability to measure the presence of several antibody isotypes against several antigens in a single reaction. Our plan is to submit
a 510(K) application to the FDA after successful completion of these studies. We have engaged consultants for our communications
and submissions to the FDA. Beyond 2020, we plan to develop AditxtScore&trade;for applications in additional markets such as Organ
Rejection, Allergies, Drug/Vaccine Response, and Disease Susceptibility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The initial application
of the platform will be AditxtScore&trade; for COVID-19 which has been designed to provide a more complete assessment of an individual&rsquo;s
infection and immunity status with respect to the SARS-CoV-2 virus. Infection status will be determined by evaluating the presence
or absence of the virus, and immunity status by measuring levels of antibodies against viral antigens and their ability to neutralize
the virus. We will soon be expanding the panel to measure other components of the immune response such as cellular immunity. In
early 2021, we established our AditxtScore&trade; Immune Monitoring Center in Richmond, Virginia (the &ldquo;Center&rdquo;). The
Center operates as a Clinical Laboratory Improvement Amendments (CLIA) certified facility for the processing of our AditxtScore&trade;
for COVID-19 Lab Developed Test (LDT) for our prospective channel partners, including labs and hospitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License
Agreement with Loma Linda University</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 8, 2018, we entered into an Assignment Agreement (the &ldquo;Assignment Agreement&rdquo;) with Sekris Biomedical, Inc. (&ldquo;Sekris&rdquo;).
Sekris was a party to a License Agreement with Loma Linda University (&ldquo;LLU&rdquo;), entered into and made effective on May
25, 2011, and amended on June 24, 2011, July 16, 2012 and December 27, 2012 (the &ldquo;Original Agreement,&rdquo; and together
with the Assignment Agreement, the &ldquo;Sekris Agreements&rdquo;). Pursuant to the Assignment Agreement, Sekris transferred
and assigned all of its rights and obligations in and to the liabilities under the Original Agreement, of whatever kind or nature,
to us. In exchange, on March 8, 2018, we issued a warrant to Sekris to purchase up to 500,000 shares of our common stock (the
&ldquo;Sekris Warrant&rdquo;). The warrant was immediately exercisable and has an exercise price of $4.00 per share. The expiration
date of the warrant is March 8, 2023. On March 15, 2018, as amended on July 1, 2020, we entered into a LLU License Agreement directly
with Loma Linda University, which amends and restates the Sekris Agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the LLU License Agreement, we obtained the exclusive royalty-bearing worldwide license in and to all intellectual property,
including patents, technical information, trade secrets, proprietary rights, technology, know-how, data, formulas, drawings, and
specifications, owned or controlled by LLU and/or any of its affiliates (the &ldquo;LLU Patent and Technology Rights&rdquo;) and
related to therapy for immune-mediated inflammatory diseases (the ADi&trade; technology). In consideration for the LLU License
Agreement, we issued 25,000 shares of common stock to LLU.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the LLU License Agreement, we are required to pay an annual license fee to LLU. Also, we paid LLU $455,000 in July
2020 in payment of outstanding milestone payments and license fees. We are also required to pay to LLU milestone payments in connection
with certain development milestones. Specifically, we are required to make the following milestone payments: $175,000 on March
31, 2022; $100,000 on March 31, 2024; $500,000 on March 31, 2026; and $500,000 on March 31, 2027. Additionally, as consideration
for prior expenses incurred by LLU to prosecute, maintain and defend the LLU Patent and Technology Rights, we were obligated to
make the following payments to LLU:, $70,000 was paid at the end of December 2018, and a final payment of $60,000 due at
the end of March 2019. We are required to defend the LLU Patent and Technology Rights during the term of the LLU License Agreement.
Additionally, we will owe royalty payments of (i) 1.5% of Net Product Sales and Net Service Sales on any Licensed Products (defined
as any finished pharmaceutical products which utilizes the LLU Patent and Technology Rights in its development, manufacture or
supply), and (ii) 0.75% of Net Product Sales and Net Service Sales for Licensed Products and Licensed Services not covered by
a valid patent claim for technology rights and know-how for a three (3) year period beyond the expiration of all valid patent
claims. We also are required to produce a written progress report to LLU, discussing our development and commercialization efforts,
within 45 days following the end of each year. All intellectual property rights in and to LLU Patent and Technology Rights shall
remain with LLU (other than improvements developed by or on our behalf).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
LLU License Agreement shall terminate on the last day that a patent granted to us by LLU is valid and enforceable or the day
that the last patent application licensed to us is abandoned. The LLU License Agreement may be terminated by mutual agreement
or by us upon 90 days written notice to LLU. LLU may terminate the LLU License Agreement in the event of (i) non-payments or late
payments of royalty, milestone and license maintenance fees not cured within 90 days after delivery of written notice by LLU,
(ii) a breach of any non-payment provision (including the provision that requires us to meet certain deadlines for milestone events
(each, a &ldquo;Milestone Deadline&rdquo;)) not cured within 90 days after delivery of written notice by LLU and (iii) LLU delivers
notice to us of three or more actual breaches of the LLU License Agreement by us in any 12-month period. Additional Milestone
Deadlines include: (i) the requirement to have regulatory approval of an IND application to initiate a first-in-human clinical
trials on or before March 31, 2022, (ii) the completion of first-in-human (phase I/II) clinical trials by March 31, 2024, (iii)
the completion of Phase III clinical trials by March 31, 2026 and (iv) biologic licensing approval by the FDA by March 31, 2027.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License
Agreement with Leland Stanford Junior University (&ldquo;Stanford&rdquo;)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 3, 2020, we entered into an exclusive license agreement (the &ldquo;February 2020 License Agreement&rdquo;) with Stanford
with regard to a patent concerning a method for detection and measurement of specific cellular responses. Pursuant to the February
2020 License Agreement, we received an exclusive worldwide license to Stanford&rsquo;s patent with regard to use, import, offer,
and sale of Licensed Products (as defined in the agreement). The license to the patented technology is exclusive, including the
right to sublicense, beginning on the effective date of the agreement and ending when the patent expires. Under the exclusivity
agreement, we acknowledged that Stanford had already granted a non-exclusive license in the Nonexclusive Field of Use, under the
Licensed Patents in the Licensed Field of Use in the Licensed Territory (as those terms are defined in the February 2020 License
Agreement&rdquo;). However, Stanford agreed to not grant further licenses under the Licensed Patents in the Licensed Field of
Use in the Licensed Territory.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We
were obligated to pay and paid a fee of $25,000 to Stanford within 60 days of February 3, 2020. We also issued 18,750 shares of the Company&rsquo;s
common stock to Stanford. An annual licensing maintenance fee is payable by us on the first anniversary of the February 2020 License
Agreement in the amount of $40,000 for 2021 through 2024 and $60,000 starting in 2025 until the license expires upon the expiration of
the patent. The Company is required to pay and has paid $25,000 for the issuances of certain patents. The Company will pay milestone
fees of $50,000 on the first commercial sales of a licensed product and $25,000 at the beginning of any clinical study for regulatory
clearance of an&nbsp;<I>in vitro</I>&nbsp;diagnostic product developed and a potential licensed product. We are also required to: (i)
provide a listing of the management team or a schedule for the recruitment of key management positions by March 31, 2020 (which has been
completed), (ii) provide a business plan covering projected product development, markets and sales forecasts, manufacturing and operations,
and financial forecasts until at least $10,000,000 in revenue by June 30, 2020 (which has been completed), (iii) conduct validation studies
by September 30, 2020 (which has been completed), (iv) hold a pre-submission meeting with the FDA by September 30, 2020 (which has been
completed), (v) submit a 510(k) application to the FDA, Emergency Use Authorization (&ldquo;EUA&rdquo;), or a Laboratory Developed Test
(&ldquo;LDT&rdquo;) by March 31, 2021, (vi) obtain FDA approval by December 31, 2021, (vii) complete a prototype assay kit by December
31, 2021 and (viii) have a written agreement with Stanford on further development and commercialization milestones for specific fields
of use by December 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the annual license maintenance fees outlined above, we will pay Stanford royalties on Net Sales (as such term is defined
in the February 2020 License Agreement) during the of the term of the agreement as follows: 4% when Net Sales are below or equal
to $5 million annually or 6% when Net Sales are above $5 million annually. The February 2020 License Agreement may be terminated
upon our election on at least 30 days advance notice to Stanford, or by Stanford if we: (i) are delinquent on any report or payment;
(ii) are not diligently developing and commercializing Licensed Product; (iii) miss certain performance milestones; (iv) are in
breach of any provision of the February 2020 License Agreement; or (v) provide any false report to Stanford. Should any events
in the preceding sentence occur, we have a thirty (30) day cure period to remedy such violation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Team</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have assembled a team of experts from a variety of scientific fields and commercial backgrounds, with many years of collective
experience that ranges from founding startup biotech companies, to developing and marketing biopharmaceutical products, to designing
clinical trials, and to management of private and public companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Going
Concern</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We were incorporated on September 28, 2017 and has not generated
revenues to date. During the year ended December 31, 2020 we had a net loss of $9,149,227 and will require significant additional
capital in order to operate in the normal course of business and fund clinical studies in the long-term. As a result of the IPO
and the September 2020 Offering, we received net proceeds of approximately $18 million during the period. We believe that the funds
raised by the IPO and the September 2020 Offering will be sufficient to fund our operations for at least the next 12 months. As
a result, these conditions have alleviated the doubt regarding our ability to continue as a going concern beyond one year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
Results</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a limited operating history. Therefore, there is limited historical financial information upon which to base an evaluation
of our performance. Our prospects must be considered in light of the uncertainties, risks, expenses, and difficulties frequently
encountered by companies in their early stages of operations. Our financial statements as of December 31, 2020, show a net loss
of $9,149,227. We expect to incur additional net expenses over the next several years as we continue to maintain and expand our
existing operations. The amount of future losses and when, if ever, we will achieve profitability are uncertain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 2, 2020, we completed an IPO. In connection therewith, we issued 1,226,668 Units, excluding the underwriters&rsquo; overallotment,
at an offering price of $9.00 per Unit, resulting in gross proceeds of approximately $11.0 million. The Units issued in the IPO
consisted of one share of common stock, one Series A warrant, and one Series B warrant. The Series A warrants originally had an
exercise price of $9.00 and a term of 5 years. In addition, the Company issued a Unit Purchase Option at an exercise price of
$11.25 per unit to the underwriters to purchase up to 67,466 units, with each unit consisting of (i) one share of common stock
and (ii) one Series A Warrant. On August 19, 2020 the Company modified the exercise price of the Series A Warrants from $9.00
per share to $4.50 per share. The term of the Series A Warrants was not modified. The Series B warrants have an exercise price
of $11.25 per share and a term of 5 years. Substantially all of the Series B warrants issued in the IPO as part of the Units have
been exercised pursuant to a cashless provision therein.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 10, 2020, we completed a follow-on public offering (&ldquo;September 2020 Offering&rdquo;). In connection therewith,
we issued 2,400,000 units, or Follow-On Units, excluding the underwriters&rsquo; option to cover overallotments, at an offering
price of $4.00 per Follow-On Unit, resulting in gross proceeds to the Company of approximately $9.6 million. Each of the Follow-On
Units issued in the September 2020 Offering consisted of one share of common stock or Series A Preferred Stock for investors who
would own more than 4.99% of the Company if they invested in common stock, one Series A-1 warrant, and one Series B-1 warrant.
The Series A-1 warrants have an exercise price of $3.19 per share and a term of 5 years. The Series B-1 warrants have exercise
price of $5.00 per share, a term of 5 years and contain a cashless exercise option upon certain criteria being met. In addition,
the Company issued a warrant to the underwriters to purchase up to 60,000 shares of common stock at an exercise price of $5.00
per share. Subsequent to quarter end, substantially all of the Series B-1 warrants issued in the September 2020 Offering have
been exercised pursuant to a cashless provision therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results
of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Results
of operations for the year ended December 31, 2020</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2020, we incurred a loss from operations of $8,872,209. This is due to general and administrative
expenses of $7,852,256, which includes $3,188,840 in stock-based compensation, research and development of $937,966, and sales
and marketing expenses of $81,987. The $937,966 in research and development is comprised of $258,635 in licensing fees, $519,171
in product development, and $160,160 in other research and development expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2019, we incurred a loss from operations of $5,870,798. This is due to general and administrative
expenses of $5,694,806, which includes $4,221,733 in stock-based compensation, research and development of $175,441, which includes
$10,000 in stock-based compensation, and sales and marketing expenses of $551. The $175,441 in research and development is comprised
of $18,396 in licensing fees, $54,000 in product development and $103,045 in other research and development expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
increase in expenses during the year ended December 31, 2020 compared to the year ended December 31, 2019 was due to the Company
beginning to execute its business plan and incur costs of being a public company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
and Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We have incurred substantial operating losses since inception and
expect to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of December
31, 2020, we had an accumulated deficit of $20,879,178. We had working capital of $9,806,195 as of December 31, 2020. During the
year ended December 31, 2020, we paid off outstanding notes payable with a principal totaling $715,600 and accrued interest totaling
$5,842. During the year ended December 31, 2020, we paid $170,629 for the purchase of fixed assets and $58,475 on payments for
financed assets. These fixed assets were purchased to furnish our new office and laboratory. Approximately $105,000 of these purchased
fixed assets were lab equipment, approximately $55,000 was for office furniture and equipment, approximately $10,000 was for computers,
and approximately $1,000 was for other fixed assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial statements have been prepared assuming that we will continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have funded our operations from proceeds from the sale of equity and debt securities. On July 2, 2020, we completed our IPO and
raised approximately $9.5 million in net proceeds. At the time of the IPO, we believed that these funds would be sufficient to
fund our operations for the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 10, 2020, we completed a follow-on public offering. In connection therewith, we issued 2,400,000 units, or Follow-On
Units, excluding the underwriters&rsquo; option to cover overallotments, at an offering price of $4.00 per Follow-On Unit, resulting
in gross proceeds of approximately $9.6 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may need to raise significant additional capital to continue to fund our operations and the clinical trials for our product candidates.
We may seek to sell common stock, preferred stock or convertible debt securities, enter into a credit facility or another form
of third-party funding or seek other debt financing. In addition, we may seek to raise cash through collaborative agreements or
from government grants. The sale of equity and convertible debt securities may result in dilution to our stockholders and certain
of those securities may have rights senior to those of our common shares. If we raise additional funds through the issuance of
preferred stock, convertible debt securities or other debt financing, these securities or other debt could contain covenants that
would restrict our operations. Any other third-party funding arrangement could require us to relinquish valuable rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
source, timing and availability of any future financing will depend principally upon market conditions, and, more
specifically, on the progress of our clinical development program. Funding may not be available when needed, at all, or on
terms acceptable to us. Lack of necessary funds may require us to, among other things, delay, scale back or eliminate
expenses including some or all of our planned development, including our clinical trials. While we may need to raise funds in
the future, we believe the current cash reserves should be sufficient to fund our operation for the foreseeable future.
Because of these factors, we believe that this alleviates the issues about our ability to continue as a going
concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contractual
Obligations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows our contractual obligations as of December 31, 2020:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR>
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Payment&nbsp;Due&nbsp;by&nbsp;Year</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2021</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2023</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2024</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; width: 40%; padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,397,360</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">406,640</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">411,753</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">363,416</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">215,551</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financed asset</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">633,078</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">350,636</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">282,442</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total contractual obligations</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 4.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,030,438</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 4.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">757,276</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 4.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">694,195</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 4.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">363,416</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 4.5pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">215,551</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Critical
Accounting Polices and Estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation
of our financial statements and related disclosures requires us to make estimates, assumptions and judgments that affect the reported
amount of assets, liabilities, revenue, costs and expenses, and related disclosures. We believe that of our critical accounting
policies described under the heading &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Plan of Operations&mdash;Critical
Accounting Policies&rdquo; in our Prospectus, dated September 1, 2020, filed with the SEC pursuant to Rule 424(b), are critical
to fully understanding and evaluating our financial condition and results of operations. The following involve the most judgment
and complexity:</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    compensation expense</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    value of common stock</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
we believe the policies set forth above are critical to fully understanding and evaluating our financial condition and results
of operations. If actual results or events differ materially from the estimates, judgments and assumptions used by us in applying
these policies, our reported financial condition and results of operations could be materially affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Off-Balance
Sheet Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the
rules and regulations of the SEC.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JOBS
Act</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April&nbsp;5, 2012, the JOBS Act was enacted. Section&nbsp;107 of the JOBS Act provides that an &ldquo;emerging growth company&rdquo;
can take advantage of the extended transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act, for complying
with new or revised accounting standards. In other words, an &ldquo;emerging growth company&rdquo; can delay the adoption of certain
accounting standards until those standards would otherwise apply to private companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have chosen to take advantage of the extended transition periods available to emerging growth companies under the JOBS Act for
complying with new or revised accounting standards until those standards would otherwise apply to private companies provided under
the JOBS Act.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements provided by the
JOBS&nbsp;Act.&nbsp;Subject to certain conditions set forth in the JOBS Act, as an &ldquo;emerging growth company,&rdquo; we intend
to rely on certain of these exemptions, including without limitation, (i)&nbsp;providing an auditor&rsquo;s attestation report
on our system of internal controls&nbsp;over financial reporting pursuant to Section&nbsp;404(b) of the Sarbanes-Oxley Act and
(ii)&nbsp;complying with any requirement that may be adopted by the Public Company Accounting Oversight Board (&ldquo;PCAOB&rdquo;)
regarding mandatory audit firm rotation or a supplement to the auditor&rsquo;s report providing additional information about the
audit and the financial statements, known as the auditor discussion and analysis. We will remain an &ldquo;emerging growth company&rdquo;
until the earliest of (i)&nbsp;the last day of the fiscal year in which we have total annual gross revenues of $1.07&nbsp;billion
or more; (ii)&nbsp;the last day of our fiscal year following the fifth anniversary of the date of the completion of this offering;
(iii)&nbsp;the date on which we have issued more than $1&nbsp;billion in nonconvertible debt during the previous three years;
or (iv)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recently
Issued and Adopted Accounting Pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 3 - Summary of Significant Accounting Policies to the accompanying financial statements for a description of other accounting
policies and recently issued accounting pronouncements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_012"></A>Item
7A. Quantitative and Qualitative Disclosures About Market Risk.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are  not required to provide the information required by this Item as it is a &ldquo;smaller reporting company,&rdquo; as defined
in Rule 229.10(f)(1).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_013"></A>Item
8. Financial Statements and Supplementary Data.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
pages F-1 through F-17 following the Exhibit Index of this Annual Report on Form 10-K.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_014"></A>Item
9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_015"></A>Item
9A. Controls and Procedures.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Assessment
of the Effectiveness of Internal Controls over Financial Reporting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Disclosure
Controls and Procedures</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Rules 13a-15(b) and 15d-15(b) of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;),
we, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, carried out an
evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e)
and Rule 15d-15(e) of the Exchange Act) as of the end of the period covered by this Annual Report on Form 10-K. Based on the foregoing,
our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were (a) designed
to ensure that the information we are required to disclose in our reports under the Exchange Act is recorded, processed, and reported
in an accurate manner and on a timely basis and the information that we are required to disclose in our Exchange Act reports is
accumulated and communicated to management to permit timely decisions with respect to required disclosure and (b) operating in
an effective manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Change
in Internal Control Over Financial Reporting</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
change occurred in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) of the Exchange Act)
during the year ended December 31, 2020 that has materially affected, or is reasonably likely to materially affect, our
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_016"></A>Item
9B. Other Information.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_017"></A>PART
III</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_018"></A>Item&nbsp;10.
Directors, Executive Officers and Corporate Governance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
information required by this Item&nbsp;is incorporated herein by reference to the information that will be contained in our definitive
proxy statement related to the 2021 Annual Meeting of Stockholders, or the Proxy Statement, which we intend to file with the SEC
within 120&nbsp;days of the end of our fiscal&nbsp;year pursuant to General Instruction G(3)&nbsp;of Form&nbsp;10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_019"></A>Item&nbsp;11.
Executive Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
information required by this Item&nbsp;is incorporated herein by reference to the information that will be contained in our Proxy
Statement, which we intend to file with the SEC within 120&nbsp;days of the end of our fiscal&nbsp;year pursuant to General Instruction
G(3)&nbsp;of Form&nbsp;10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_020"></A>Item&nbsp;12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
information required by this Item&nbsp;is incorporated herein by reference to the information that will be contained in our Proxy
Statement, which we intend to file with the SEC within 120&nbsp;days of the end of our fiscal&nbsp;year pursuant to General Instruction
G(3)&nbsp;of Form&nbsp;10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_021"></A>Item&nbsp;13.
Certain Relationships and Related Transactions, and Director Independence</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
information required by this Item&nbsp;is incorporated herein by reference to the information that will be contained in our Proxy
Statement, which we intend to file with the SEC within 120&nbsp;days of the end of our fiscal&nbsp;year pursuant to General Instruction
G(3)&nbsp;of Form&nbsp;10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><A NAME="a_022"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item&nbsp;14.
Principal Accounting Fees and Services</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
information required by this Item&nbsp;is incorporated herein by reference to the information that will be contained in our Proxy
Statement, which we intend to file with the SEC within 120&nbsp;days of the end of our fiscal&nbsp;year pursuant to General Instruction
G(3)&nbsp;of Form&nbsp;10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_023"></A>PART
IV</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_024"></A>Item
15. Exhibits, Financial Statement Schedules.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    following documents are filed as part of this report:</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements:</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_001">Report of Independent Registered Public Accounting Firm</A></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_002">Balance Sheets</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_003">Statements of Operations</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_004">Statements of Changes in Stockholders&rsquo; Equity (Deficit)</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_005">Statements of Cash Flows</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_006">Notes to Financial Statements</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statement
    Schedules:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
financial statement schedules have been omitted because they are not applicable, not required or the information required is shown
in the financial statements or the notes thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B><BR>
EXHIBIT INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Description</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.1</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000121390020012077/ea121627ex3-1_aditxtherape.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amended and Restated Certificate of Incorporation (incorporated by reference to the Registrant&rsquo;s Registration Statement on Form S-1/A (File No. 333-235933)</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.2</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1726711/000121390020012077/ea121627ex3-2_aditxtherape.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amended and Restated Bylaws (incorporated by reference to the Registrant&rsquo;s Registration Statement on Form S-1/A (File No. 333-235933)</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.1</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="f10k2020ex4-1_aditx.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Description of Securities Registered Under Section 12 of the Exchange Act</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">23.1</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="f10k2020ex23-1_aditx.htm">Consent of dbb<I>mckennon</I>, independent registered public accounting firm</A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">31.1</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="f10k2020ex31-1_aditx.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certification of Principal Executive Officer Pursuant to Rules&nbsp;13a-14(a)&nbsp;and 15d-14(a)&nbsp;under the Securities Exchange Act of 1934, as Adopted Pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">31.2</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="f10k2020ex31-2_aditx.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certification of Principal Financial Officer Pursuant to Rules&nbsp;13a-14(a)&nbsp;and 15d-14(a)&nbsp;under the Securities Exchange Act of 1934, as Adopted Pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">31.3</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="f10k2020ex31-3_aditx.htm">Certification of Principal Accounting Officer Pursuant to Rules&nbsp;13a-14(a)&nbsp;and 15d-14(a)&nbsp;under the Securities Exchange Act of 1934, as Adopted Pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">32.1</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="f10k2020ex32-1_aditx.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certification of the Principal Executive, Financial, and Accounting Officers under Section 906 of the Sarbanes-Oxley Act of 2002</FONT></A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.INS</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL Instance Document</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.SCH</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension Schema Document</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.CAL</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension Calculation Linkbase Document</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.DEF</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension Definition Linkbase Document</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.LAB</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension Label Linkbase Document</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.PRE</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension Presentation Linkbase Document</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_025"></A>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized on this 25<SUP>th</SUP> day of March 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Aditx Therapeutics, Inc.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Amro Albanna</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amro Albanna</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>POWER
OF ATTORNEY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1934, this annual report on Form 10-K has been signed below by the following persons
on behalf of the registrant and in the capacities and on the dates indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 40%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 40%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Amro Albanna</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer, President, and Director</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 25, 2021</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amro Albanna</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal Executive Officer)</I></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Corinne Pankovcin</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
25, 2021</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corinne Pankovcin</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal Financial </I><I>Officer)</I></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Thomas J. Farley</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controller</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
25, 2021</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas J. Farley</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal Accounting Officer)</I></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Laura E. Anthony</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 25, 2021</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laura E. Anthony</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Brian Brady</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 25, 2021</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian Brady</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Namvar Kiaie</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
25, 2021</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Namvar Kiaie</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Jeffrey W. Runge, M.D.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 25, 2021</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeffrey W. Runge, M.D.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Shahrokh Shabahang</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Innovation Officer and Director</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 25, 2021</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shahrokh Shabahang</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ADITX
THERAPEUTICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FINANCIAL
STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR
THE YEARS ENDED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DECEMBER
31, 2020 AND 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_001">Report
    of Independent Registered Public Accounting Firm</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_002">Balance
    Sheets</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_003">Statements
    of Operations and Comprehensive Loss</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_004">Statements
    of Stockholders&rsquo; Equity (Deficit)</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_005">Statements
    of Cash Flows</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#b_006">Notes
    to Financial Statements</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR STYLE="clear: both"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 49; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="b_001"></A>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors and Stockholders of</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Aditx Therapeutics, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Opinion
on the Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying balance sheets of Aditx Therapeutics, Inc. (the &ldquo;Company&rdquo;) as of December 31, 2020 and
2019, the related statements of operations, stockholders&rsquo; equity (deficit), and cash flows, for the years ended December
31, 2020 and 2019, and the related notes (collectively referred to as the &ldquo;financial statements&rdquo;). In our opinion,
the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020
and 2019, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles
generally accepted in the United States of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
for Opinion</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on
the Company&rsquo;s financial statements based on our audits. We are a public accounting firm registered with the Public Company
Accounting Oversight Board (United States) (&ldquo;PCAOB&rdquo;) and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit
to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error
or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but
not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control over financial reporting.
Accordingly, we express no such opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to
error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.
We believe that our audits provide a reasonable basis for our opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
dbb<I>mckennon</I>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&rsquo;s auditor since 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Newport
Beach, California</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
25, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="b_002"></A>ADITX
THERAPEUTICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BALANCE
SHEETS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">December&nbsp;31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">December&nbsp;31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-decoration: underline; font-weight: bold; text-align: center">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">CURRENT ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">10,500,826</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,090</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">147,642</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">ROU asset - short term</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">384,685</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">TOTAL CURRENT ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,033,153</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,090</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Fixed Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">798,919</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Intangible Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">321,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Deferred offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">119,442</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">ROU asset - long term</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">871,136</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Deposits</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">72,296</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-decoration: underline; font-weight: bold; text-align: left; padding-bottom: 4pt">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">13,096,504</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">123,532</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-decoration: underline; font-weight: bold; text-align: center">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY (DEFICIT)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">CURRENT LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">241,613</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,847,458</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Accrued compensation to related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">962,651</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Notes payable - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Notes payable, net of discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">155,600</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Financing on fixed assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">587,588</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Lease liability - short term</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">391,221</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,536</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">TOTAL CURRENT LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,226,958</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,975,709</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Lease liability - long term</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">858,064</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">TOTAL LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,085,022</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,975,709</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">COMMITMENTS AND CONTINGENCIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">STOCKHOLDERS&rsquo; EQUITY (DEFICIT)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Preferred stock, $0.001 par value, 3,000,000 shares authorized, no shares issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Common stock, $0.001 par value, 27,000,000 shares authorized, 13,074,495 and 3,915,900 shares issued and 12,973,692 and 3,821,088 shares outstanding, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,078</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,916</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Treasury stock, 100,803 and 94,813 shares, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(201,605</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(189,625</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,079,187</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,063,483</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(20,879,178</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(11,729,951</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL STOCKHOLDERS&rsquo; EQUITY (DEFICIT)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">11,011,482</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,852,177</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">TOTAL LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY (DEFICIT)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">13,096,504</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">123,532</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the financial statements.<BR STYLE="clear: both"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="b_003"></A>ADITX THERAPEUTICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STATEMENTS
OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">For the Year Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">For the Year Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR>
2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR>
2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">OPERATING EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">General and administrative expenses, $3,188,840 and $4,221,733 in stock-based compensation</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7,852,256</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">5,694,806</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Research and development, includes $0 and $10,000 in stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">937,966</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">175,441</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Sales and marketing $0 and $0 in stock-based compensation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">81,987</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">551</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Total Operating Expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,872,209</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,870,798</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">LOSS FROM OPERATIONS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,872,209</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,870,798</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">OTHER INCOME (EXPENSE)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,081</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,930</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">563</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Gain on forgiveness of debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Amortization of debt discount</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(300,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Total Other Income (Expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(277,018</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,070</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">NET LOSS</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(9,149,227</TD><TD STYLE="padding-bottom: 2pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(5,827,728</TD><TD STYLE="padding-bottom: 2pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Net loss per share - basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1.33</TD><TD STYLE="padding-bottom: 2pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1.52</TD><TD STYLE="padding-bottom: 2pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Weighted average number of shares outstanding during the period - basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6,902,696</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,830,971</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="b_004"></A>ADITX
THERAPEUTICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STATEMENTS
OF STOCKHOLDERS&rsquo; EQUITY (DEFICIT)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR
THE YEARS ENDED DECEMBER 31, 2020 AND 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Preferred</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Treasury</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Additional</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Total</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Common</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Preferred</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Shares</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Shares</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Paid-in</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Accumulated</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Stockholders&rsquo;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Par</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Par</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 20%; text-align: left; padding-bottom: 4pt">Balance December 31, 2018</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; border-bottom: Black 4pt double; text-align: right">3,763,925</TD><TD STYLE="width: 1%; padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="width: 7%; border-bottom: Black 4pt double; text-align: right">3,764</TD><TD STYLE="width: 1%; padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="width: 7%; border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="white-space: nowrap; width: 7%; border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="width: 7%; border-bottom: Black 4pt double; text-align: right">4,361,725</TD><TD STYLE="width: 1%; padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="white-space: nowrap; width: 7%; border-bottom: Black 4pt double; text-align: right">(5,902,223</TD><TD STYLE="width: 1%; padding-bottom: 2pt; text-align: left">)</TD><TD STYLE="width: 1%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="width: 7%; border-bottom: Black 4pt double; text-align: right">(1,536,734</TD><TD STYLE="width: 1%; padding-bottom: 2pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of shares for cash, net of issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">131,475</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">131</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">470,046</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">470,177</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of shares for services and licenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">81,979</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Stock option and warrant compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,616,422</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,616,422</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Warrants issued with notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">533,311</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">533,311</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Treasury stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(94,813</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">(189,625</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(189,625</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right">(5,827,728</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,827,728</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Balance December 31, 2019</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,821,087</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,916</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="white-space: nowrap; border-bottom: Black 4pt double; text-align: right">(189,625</TD><TD STYLE="padding-bottom: 2pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">9,063,483</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="white-space: nowrap; border-bottom: Black 4pt double; text-align: right">(11,729,951</TD><TD STYLE="padding-bottom: 2pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(2,852,177</TD><TD STYLE="padding-bottom: 2pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Treasury stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,990</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">(11,980</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,980</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Rounding adjustment from stock split</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Exercise of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,297,703</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,300</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">206,244</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">210,544</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Stock option and warrant compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">711,406</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">711,406</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of shares for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">874,916</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">876</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,476,558</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,477,434</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of shares for intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">320,850</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">321,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of shares and warrants for the settlement of accrued compensation and accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">146,818</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">147</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,221,878</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,222,025</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of shares and warrants for IPO, net of issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,226,668</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,227</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,429,455</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,430,682</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of shares and warrants for follow-on offering, net of issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,150</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,250,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,524,376</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,526,776</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Issuance of shares and warrant for the settlement of debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">62,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">63</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">124,937</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">125,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Exercise conversion of preferred shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,250,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,250,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,250</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: right">(9,149,227</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(9,333,049</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Balance December 31, 2020</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">12,973,692</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">13,078</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="white-space: nowrap; border-bottom: Black 4pt double; text-align: right">(201,605</TD><TD STYLE="padding-bottom: 2pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">32,079,187</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="white-space: nowrap; border-bottom: Black 4pt double; text-align: right">(20,879,178</TD><TD STYLE="padding-bottom: 2pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">11,011,482</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="b_005"></A>ADITX
THERAPEUTICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STATEMENTS
OF CASH FLOWS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">For the Year Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">For the Year Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR> 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR> 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(9,149,227</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(5,827,728</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 0.25in">Adjustments to reconcile net loss to net cash used in operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,188,840</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,698,422</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Depreciation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,773</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.25in">Amortization of debt discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 0.25in">Modification of options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">533,311</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 27pt">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 0.5in">Deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(72,296</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.5in">Prepaid expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(147,642</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 0.5in">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,483,180</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">601,607</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.5in">Accrued compensation to related parties</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">124,728</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">530,036</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 45pt">Net Cash Used In Operating Activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(7,221,004</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(464,352</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">CASH FLOWS FROM INVESTING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.5in">Fixed Assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(170,629</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 45pt">Net Cash Used In Investing Activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(170,629</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Proceeds from note payable - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Proceeds from note payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">375,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Repayments of note payable - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(45,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(42,502</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Repayments of notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(670,600</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,500</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Common stock and warrants issued for cash, net of issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,500,039</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">470,177</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(423,139</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(119,442</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">Exercise of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">210,544</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Financed Asset</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(58,475</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 45pt">Net Cash Provided By Financing Activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">17,888,369</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">352,733</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">NET INCREASE (DECREASE) IN CASH</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,496,736</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(111,619</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">CASH AT BEGINNING OF PERIOD</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,090</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">115,709</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">CASH AT END OF PERIOD</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">10,500,826</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4,090</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Supplemental cash flow information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.5in">Cash paid for income taxes</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.5in">Cash paid for interest expense</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5,842</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">NONCASH INVESTING AND FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Liabilities assumed for common stock</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">11,980</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">189,625</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Issuance of Units for the settlement of notes payable</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">125,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Issuance of units for the settlement of accrued compensation and accounts payable</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,222,025</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Original issuance discount on notes payable</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">300,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Lease liability recognized from right of use asset</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,191,985</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Liability recognized for financed assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">646,063</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Shares issued for intangible assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">321,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Conversion of preferred shares</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,250</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="b_006"></A>ADITX
THERAPEUTICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
1 &ndash; ORGANIZATION AND NATURE OF BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Company
Background</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aditx
Therapeutics, Inc. (&ldquo;Aditxt&rdquo; or the &ldquo;Company&rdquo;) was incorporated in the State of Delaware on September
28, 2017 and our headquarters are located in Mountain View, CA. The Company is a Biotech Innovation company with a mission of
prolonging life and enhancing its quality by improving the health of the immune system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing biotechnologies specifically focused on improving the health of the immune system through immune reprogramming
and monitoring. Our immune reprogramming technologies are currently at the pre-clinical stage and are designed to retrain the
immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies.
Our immune monitoring technologies are designed to provide a personalized comprehensive profile of the immune system and we plan
to utilize them in our upcoming reprogramming clinical trials to monitor subjects&rsquo; immune response before, during and after
drug administration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Offerings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 2, 2020, the Company completed its initial public offering (&ldquo;IPO&rdquo;). In connection therewith, the Company issued
1,226,668 Units (the &ldquo;Units&rdquo;), excluding the underwriters&rsquo; option to cover overallotments, at an offering price
of $9.00 per Unit, resulting in gross proceeds of approximately $11.0 million. The Units issued in the IPO consisted of one share
of common stock, one Series A warrant, and one Series B warrant. The Series A warrants originally had an exercise price of $9.00
and a term of 5 years. In addition, the Company issued a Unit Purchase Option at an exercise price of $11.25 per unit to the underwriters
to purchase up to 67,466 units, with each unit consisting of (i) one share of common stock and (ii) one Series A Warrant. On August
19, 2020 the Company modified the exercise price of the Series A Warrants from $9.00 per share to $4.50 per share. The term of
the Series A Warrants was not modified. The Series B warrants have an exercise price of $11.25 per share, a term of 5 years and
contain a cashless exercise option upon certain criteria being met. As of December 31, 2020, substantially all of the Series B
warrants issued in the IPO have been exercised pursuant to a cashless provision therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 10, 2020, the Company completed a follow-on public offering (&ldquo;September 2020 Offering&rdquo;). In connection therewith,
the Company issued 2,400,000 Units (the &ldquo;Follow-On Units&rdquo;), excluding the underwriters&rsquo; option to cover overallotments,
at an offering price of $4.00 per Follow-On Unit, resulting in gross proceeds to the Company of approximately $9.6 million. The
Follow-On Units issued in the September 2020 Offering consisted of one share of common stock (or Series A Preferred Stock for
investors who would own more than 4.99% of the Company if they invested in common stock), one Series A-1 warrant, and one Series
B-1 warrant. The Series A-1 warrants have an exercise price of $3.19 per share and a term of 5 years. The Series B-1 warrants
have exercise price of $5.00 per share, a term of 5 years and contain a cashless exercise option upon certain criteria being met.
In addition, the Company issued a warrant to the underwriters to purchase up to 60,000 shares of common stock at an exercise price
of $5.00 per share. Subsequent to quarter end, substantially all of the Series B-1 warrants issued in the September 2020 Offering
have been exercised pursuant to a cashless provision therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Risks
and Uncertainties</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a limited operating history and has not generated revenue from intended operations. The Company&rsquo;s business and
operations are sensitive to general business and economic conditions in the U.S. and worldwide along with local, state, and federal
governmental policy decisions. A host of factors beyond the Company&rsquo;s control could cause fluctuations in these conditions.
Adverse conditions may include: changes in biotechnology regulatory environment, technological advances that render our technologies
obsolete, availability of resources for clinical trials, acceptance of technologies into the medical community, and competition
from larger, more well-funded companies. These adverse conditions could affect the Company&rsquo;s financial condition and the
results of its operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 30, 2020, the World Health Organization declared the COVID-19 novel coronavirus outbreak a &ldquo;Public Health Emergency
of International Concern&rdquo; and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate
the spread of the coronavirus include restrictions on travel, and quarantines in certain areas, and forced closures for certain
types of public places and businesses. The COVID-19 coronavirus and actions taken to mitigate it have had and are expected to
continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in
which the Company operates. While it is unknown how long these conditions will last and what the financial impact will be to the
Company, it is reasonably possible that future capital raise efforts and additional development of our technologies may be negatively
affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
2 &ndash; GOING CONCERN ANALYSIS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Management
Plans</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was incorporated on September 28, 2017 and has not generated revenues to date. During the year ended December 31, 2020,
the Company had a net loss of $9,149,227 and cash of $10,500,826. The Company will be conducting medical research and development,
and the time at which the Company will begin generating revenue is unknown. The Company believes, however, that the funds raised
by the IPO and the September 2020 Offering will be sufficient to fund the Company&rsquo;s operation for at least the next 12 months.
Because of these factors, the Company believes that this alleviates issues in connection with the Company&rsquo;s ability to continue
as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going
concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements included in this report do not include any adjustments to reflect the possible future effects on the recoverability
and classification of assets or the amounts and classification of liabilities that may result from the matters discussed herein.
While we believe in the viability of our strategy to generate sufficient revenue, control costs and raise additional funds when
necessary, there can be no assurances to that effect. The Company&rsquo;s ability to continue as a going concern is dependent
upon the ability to complete clinical studies and implement the business plan, generate sufficient revenues and to control operating
expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
3 &ndash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Basis
of Presentation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America (&ldquo;U.S. GAAP&rdquo;) and the rules and regulations of the Securities and Exchange Commission (&ldquo;SEC&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Use
of Estimates</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those
estimates. Significant estimates underlying the financial statements include the fair value of stock options and warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Fair
Value Measurements and Fair Value of Financial Instruments</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted Financial Accounting Standards Board (&ldquo;FASB&rdquo;) Accounting Standards Codification (&ldquo;ASC&rdquo;)
Topic 820, Fair Value Measurements. ASC Topic 820 clarifies the definition of fair value, prescribes methods for measuring fair
value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 - Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar
assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived
from or corroborated by observable market data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 - Inputs are unobservable inputs which reflect the reporting entity&rsquo;s own assumptions on what assumptions the market participants
would use in pricing the asset or liability based on the best available information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not identify any assets or liabilities that are required to be presented on the balance sheets at fair value in accordance
with ASC Topic 820.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the short-term nature of all financial assets and liabilities, their carrying value approximates their fair value as of the
balance sheet dates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Concentrations
of Credit Risk</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation.
At times, the Company may have deposits in excess of federally insured limits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cash
and Cash Equivalents</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents include short-term, liquid investments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Fixed
Assets</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Fixed assets are
stated at cost less accumulated depreciation. Cost includes expenditures for furniture, office equipment, laboratory equipment, and
other assets. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of,
the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The
costs of fixed assets are depreciated using the straight-line method over the estimated useful lives or lease life of the related
assets. Depreciation expense was $17,773 for the year ended December 31, 2020 and zero for the year ended for December 31, 2019.
Accumulated depreciation was $17,773 as of December 31, 2020 and zero as of December 31, 2019. None of the Company&rsquo;s fixed
assets serve as collateral against any loans as of December 31, 2020 and 2019, other than those subject to the financed asset liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Intangible
Assets</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets are stated at cost less accumulated amortization. For intangible assets that have definite lives, the assets are amortized
using the straight-line method over the estimated useful lives of the related assets. For intangible assets with indefinite lives,
the assets are tested periodically for impairment. Amortization expense was zero for the year ended December 31, 2020 and 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Offering
Costs</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for offering costs in accordance with ASC 340, Other Assets and Deferred Costs. Prior to the completion of an
offering, offering costs were capitalized as deferred offering costs on the balance sheet. The deferred offering costs are netted
against the proceeds of the offering in stockholders&rsquo; equity (deficit) or the related debt, as applicable. Costs related
to unsuccessful offerings are expensed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Leases</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Topic 842, adopted in 2020 with no impact related to adoption, operating lease expense is generally recognized evenly over the term
of the lease. The Company has operating leases consisting of office and laboratory space with remaining lease terms of 46 months.
Rent and Lease costs were $154,263 and $30,362 for the year ended December 31, 2020 and 2019. There was no sublease rental income
for the year ended December 31, 2020 and 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
with an initial term of twelve months or less are not recorded on the balance sheet. For lease agreements entered into or reassessed
after the adoption of Topic 842, we combine the lease and non-lease components in determining the lease liabilities and right
of use (&ldquo;ROU&rdquo;) assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
lease agreements generally do not provide an implicit borrowing rate, therefore an internal incremental borrowing rate is determined
based on information available at lease commencement date for purposes of determining the present value of lease payments. We
used the incremental borrowing rate on December 31, 2020 and 2019 for all leases that commenced prior to that date. In determining
this rate, which is used to determine the present value of future lease payments, we estimate the rate of interest we would pay
on a collateralized basis, with similar payment terms as the lease and in a similar economic environment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Lease
Costs</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<BR> December&nbsp;31,<BR> 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<BR> December&nbsp;31,<BR> 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Components of total lease costs:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left; padding-bottom: 1.5pt">Operating lease expense</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">154,263</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total lease costs</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">154,263</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Lease
Positions as of December 31, 2020</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU
lease assets and lease liabilities for our operating leases were recorded in the balance sheet as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR> 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR> 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; width: 76%; text-align: left">Right of use asset &ndash; short term</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">384,685</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Right of use asset &ndash; long term</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">871,136</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,255,821</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Operating lease liabilities &ndash; short term</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">391,221</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Operating lease liabilities &ndash; long term</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">858,064</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total lease liability</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,249,285</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Lease
Terms and Discount Rate</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: left">Weighted average remaining lease term (in years) &ndash; operating lease</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2.67</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Weighted average discount rate &ndash; operating lease</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.00</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
future annual minimum lease payments as of December 31, 2020 are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: left">2021</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">406,640</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">411,753</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">2023</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">363,416</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left">2024</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">215,551</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total future minimum lease payments</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,397,360</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: Lease imputed interest</FONT></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">148,075</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 2pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,249,285</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock-Based
Compensation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based compensation costs under the provisions of ASC 718, Compensation&mdash;Stock Compensation, which
requires the measurement and recognition of compensation expense related to the fair value of stock-based compensation awards
that are ultimately expected to vest. Stock based compensation expense recognized includes the compensation cost for all stock-based
payments granted to employees, officers, and directors based on the grant date fair value estimated in accordance with the provisions
of ASC 718. ASC. 718 is also applied to awards modified, repurchased, or cancelled during the periods reported. Stock-based compensation
is recognized as expense over the employee&rsquo;s requisite vesting period and over the nonemployee&rsquo;s period of providing
goods or services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Patents</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company incurs fees from patent licenses, which are expensed as incurred. During the year ended December 31, 2020 and 2019, the Company had a licensing fee for
the patents of $258,635 and $18,396, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incur research and development costs during the process of researching and developing our technologies and future offerings. Our
research and development costs mainly consist of licensing costs. We expense these costs as incurred unless such costs qualify
for capitalization under applicable guidance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Basic
and Diluted Net Loss per Common Share</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Basic loss per common share is computed by dividing the net loss by the
weighted average number of shares of common stock outstanding for each period. Diluted loss per share is computed by dividing the net
loss by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common
stock equivalents. The weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion
would be anti-dilutive. As of December 31, 2020, 2,143,000 stock options and 5,799,146 warrants were excluded from dilutive earnings per
share as their effects were anti-dilutive. As of December 31, 2019, 1,102,500 stock options and 1,382,478 warrants were excluded from
dilutive earnings per share as their effects were anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Recent
Accounting Pronouncements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FASB issues ASUs to amend the authoritative literature in ASC. There have been several ASUs to date, including those above, that
amend the original text of ASC. Management believes that those issued to date either (i) provide supplemental guidance, (ii) are
technical corrections, (iii) are not applicable to us or (iv) are not expected to have a significant impact our financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
4 &ndash; RELATED PARTY TRANSACTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s Chief Executive Officer (&ldquo;CEO&rdquo;) has provided certain periods of service without payment. As of December
31, 2020 and 2019, the CEO is owed $0 and $309,500, respectively, related to compensation. During the year ended December 31,
2020, the Company issued 38,055 Units consisting of one share of common stock and one Series A warrant and one Series B warrant
to settle $342,500 in accrued compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s Chief Innovation Officer (&ldquo;CIO&rdquo;) has provided certain periods of service without payment. As of December
31, 2020 and 2019, the CIO is owed $0 and $377,000, respectively, related to compensation. During the year ended December 31,
2020, the Company issued 47,222 Units consisting of one share of common stock, one Series A warrant, and one Series B warrant
to settle $425,000 in accrued compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
July 10, 2020, the Board of Directors appointed the Company&rsquo;s Chief Operating Officer (&ldquo;COO&rdquo;). Prior to the
appointment, the COO was an independent operations consultant and had provided certain periods of service without payment. As
of December 31, 2020 and 2019, the COO was owed $0 and $275,000, respectively, related to compensation. During the year ended
December 31, 2020, the Company issued 35,555 Units consisting of one share of common stock, one Series A warrant, and one Series
B warrant to settle $320,000 in accrued compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 21, 2019, the Company issued a promissory note to a related party. The note had a principal of $10,000, a maturity date
of September 21, 2019, and an interest rate of 4% per year. During the year ended December 31, 2020, this note was paid in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2020, the Company assumed $11,980 of liabilities from a related party in exchange for the return of
5,990 shares of the Company&rsquo;s common stock.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
5 &ndash; STOCKHOLDERS&rsquo; EQUITY (DEFICIT)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Common
Stock</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue 27,000,000 shares of common stock, par value $0.001 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">During the year ended December 31, 2020, the Company issued 874,916
shares of common stock and recognized expense of $2,477,434 in stock compensation for consulting services. The Company issued 150,000
shares of common stock for intangible assets valued at $320,850. The Company also issued 4,297,703 shares of common stock for the
exercise of warrants and received $210,544 for the exercise of the warrants. The Company issued 1,250,000 shares of common stock
for the exercise of 1,250,000 shares of Series A Preferred Stock. The Company issued 146,818 shares of common stock for the settlement
of accounts payable and issued 62,500 shares of common stock for the settlement of debt. The Company issued 1,226,668 shares of
common stock related to the IPO and issued 1,150,000 shares of common stock related to the September 2020 Offering. The stock compensation
for the period was valued based on prior private placements or based on management&rsquo;s estimates of value immediately prior
to the IPO and the value of the shares based on public information post IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2019, the Company issued 41,000 shares of common stock for services and recognized expense of $82,000
in stock compensation and license fees. These shares were valued based on the price which common shares were being
sold in the private placement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Reverse
Stock Split</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 29, 2020, the Company effectuated a 1-for-2 reverse stock split of its issued and outstanding shares of common stock by filing
a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of
Delaware. Accordingly, all share and per share amounts for all periods presented in the accompanying financial statements and
notes thereto have been adjusted retroactively, where applicable, to reflect this reverse stock split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Preferred
Stock</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue 3,000,000 shares of preferred stock, par value $0.001 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock-Based
Compensation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2017, our Board of Directors adopted the Aditx Therapeutics, Inc. 2017 Equity Incentive Plan (the &ldquo;2017 Plan&rdquo;).&nbsp;The
2017 Plan provides for the grant of equity awards to employees, and consultants.&nbsp;Up to 2,500,000 shares of our common stock
may be issued pursuant to awards granted under the 2017 Plan. The 2017 Plan is administered by our Board of Directors, and expires
ten years after adoption, unless terminated earlier by the Board.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2020, the Company granted 880,500 stock options with an exercise price of $1.94, $1.92 or $11.00 per
share, some of which vested immediately, and some of which vest between one and three years. The total grant date fair value was
determined to be $1,668,997.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2019, the Company granted 700,000 stock options with exercise prices of $4.00 per share vesting on
issuance. The total grant date fair value was determined to be $2,495,556. For all periods presented, the fair value of each stock
option granted was estimated using the Black-Scholes assumption ranges and or factors as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Exercise price</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.92-11.00</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 85%; text-align: left">Expected dividend yield</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">0</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Risk free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.28%-2.65</FONT></TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Expected life in years</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.70-10.00</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Expected volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">141-151</FONT></TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
risk-free interest rate assumption for options granted is based upon observed interest rates on the United States government securities
appropriate for the expected term of stock options.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expected term of stock options is calculated using either the simplified method for employee options which takes into consideration
the contractual life and vesting terms of the options, unless the options are expected to vest in which case the contractual term
of the options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined the expected volatility assumption for options granted using the historical volatility of comparable public
companies&rsquo; common stock. The Company will continue to monitor peer companies and other relevant factors used to measure
expected volatility for future stock option grants, until such time that the Company&rsquo;s common stock has enough market history
to use historical volatility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
dividend yield assumption for options granted is based on the Company&rsquo;s history and expectation of dividend payouts. The
Company has never declared or paid any cash dividends on its common stock, and the Company does not anticipate paying any cash
dividends in the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
estimated the fair value of common stock by looking at a market approach which takes into consideration past sales of stock to
third parties and Company developments to date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes stock option forfeitures as they occur as there is insufficient historical data to accurately determine future
forfeitures rates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is an analysis of the stock option grant activity under the Plan:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Stock Options</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <BR>
Average <BR>
Exercise<BR>
    Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <BR>
Average
    <BR>
Remaining<BR> Life</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left">Outstanding December 31, 2019</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,102,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">7.77</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,045,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.32</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.91</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Expired or forfeited</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.92</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Outstanding December 31, 2020</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,143,000</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3.18</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7.81</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Nonvested Options</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<BR> Average<BR> Exercise<BR> Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Nonvested at December 31, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Granted</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,045,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2.32</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Vested</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(67,500</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.93</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Expired or forfeited</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.92</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Nonvested at December 31, 2020 </TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">973,000</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2.28</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized compensation expense related to options issued and vesting of $406,880 during the year ended December 31, 2020,
which is included in general and administrative expenses in the accompanying statements of operations. The remaining value to
be expensed is $1,781,485 with a weighted average vesting term of 2.40 years as of December 31, 2020. The Company recognized compensation
expense related to options issued and vesting of $2,513,826 during the year ended December 31, 2019, which is included in general
and administrative expenses in the accompanying statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 6, 2020, the Board of Directors approved the issuance of an aggregate of 40,000 stock options as compensation for the
non-employee members of the Board of Directors under the Company&rsquo;s 2017 Equity Incentive Plan. The options are subject to
certain vesting provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Warrants</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of warrant issuances are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; border-bottom: Black 1.5pt solid"><B><I>Warrants</I></B></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<BR> Average<BR> Exercise<BR> Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<BR> Average<BR> Remaining<BR> Life</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left">Outstanding December 31, 2019</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,382,478</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">4.44</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2.84</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,906,381</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.24</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Expired or forfeited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(190,810</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.12</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Exercised</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,298,903</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7.20</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Outstanding December 31, 2020</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5,799,146</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5.05</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4.00</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Nonvested Warrants</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<BR> Average<BR> Exercise<BR> Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Nonvested at December 31, 2019</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">200,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">4.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,906,381</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.24</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Vested</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,296,668</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.14</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Expired or forfeited</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,489,713</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7.24</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Nonvested at December 31, 2020</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">320,000</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3.69</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants granted for compensation are valued using similar inputs as noted in the stock options section above, with the exception
of the expected life which is the contractual life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized compensation expense related to warrants issued and vesting of $304,526 and $1,102,596 during the year ended
December 31, 2020 and 2019, which is included in general and administrative in the accompanying Statements of Operations. The
remaining value to be expensed is $294,948 with a weighted average vesting term of 0.90 years as of December 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2020, 4,297,703 warrants were exercised for 4,298,903 shares of common stock. The Company
recognized proceeds of $210,544 related to the exercises.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2020, the Company issued 60,000 warrants to the underwriters related to the September 2020 Offering.
These warrants have an exercise price of $5.00, a term of five years, and become exercisable beginning on March 1, 2021. The value
of these warrants were both an increase and decrease to additional paid in capital as a cost of the offering for net a zero impact
on the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
6 &ndash; AGREEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 1, 2020, the Company entered into an amendment to patent and technology licensing agreement with Loma Linda University (&ldquo;LLU&rdquo;),
dated March 15, 2018. Pursuant to the amendment, the Company paid LLU $455,000 within four days of the signing of such amendment.
The amendment also updated the milestone payment dates to be $175,000 on March 31, 2022; $100,000 on March 31, 2024; $500,000
on March 31, 2026; and $500,000 on March 31, 2027.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, the Company entered into a 24-month financing agreement for lab equipment. The aggregate cost of this financing
agreement will be $467,691. The financing agreement has an interest rate of 8% per year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2020, the Company entered into an additional 24-month financing agreement for lab equipment. The aggregate cost of this
financing agreement will be $215,192. The financing agreement has an interest rate of 8% per year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Salveo
Consulting Agreement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 18, 2020, we entered into a Consulting Agreement (the &ldquo;Salveo Consulting Agreement&rdquo;) with Salveo Diagnostics,
Inc., a Delaware corporation (&ldquo;Salveo&rdquo;). Pursuant to the Salveo Consulting Agreement, Salveo agreed to establish,
setup and commence commercial operations of a licensed, College of American Pathologists accredited, and Clinical Laboratory Improvement
Amendments (CLIA) certified, independent clinical and diagnostic laboratory for us and our AditxtScore&trade; immune monitoring
technology (the &ldquo;Salveo Services&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for the Services, and upon the successful completion of certain milestones (the &ldquo;Milestones&rdquo;) described
below, we issued Salveo 650,000 shares of our common stock (the &ldquo;Salveo Shares&rdquo;) in the aggregate. The Salveo Shares
were issued to Salveo upon the completion of the following Milestones: (i) 150,000 shares upon the sale and transfer to the Company
of certain code and interpretive commenting algorithms (the &ldquo;Algorithms&rdquo;) along with related testing protocols and
all technology, codes and spreadsheets, know-how, any necessary information or tools to implement, use, and/or continue to improve
or further refine the Algorithms, and other associated intellectual property; (ii) 250,000 shares upon securing temporary laboratory
space and other related tasks in connection with the launch of the AditxtScore&trade; platform; and (iii) 250,000 shares upon
satisfaction of tasks related to the establishment of a long-term AditxtScore&trade; center in Richmond, VA. We also pay Salveo
at cost for Salveo&rsquo;s reasonable and documented purchases, general operating costs and expenses incurred in connection with
the Salveo Services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
7 &ndash; NOTES PAYABLE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 12, 2018, the Company issued an unsecured promissory note for $35,000 that accrued interest of 4% annually. The note was
due on the earlier of November 12, 2018 or in the event of default, as defined in the agreement. During the year ended December
31, 2020, this note was paid in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 10, 2018, the Company entered into a bridge loan with an investor for a principal amount of $15,600. The note was due on
the earlier of October 8, 2018 or in the event of default, as defined in the agreement. During the year ended December 31, 2020,
this note was paid in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 18, 2018, the Company entered into a bridge loan with an investor for a principal amount of $130,000. The note was due on
the earlier of October 16, 2018 or in the event of default, as defined in the agreement. During the year ended December 31, 2020,
this note was paid in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 1, 2019, the Company entered into a bridge loan with an investor for a principal amount of $50,000. This loan did not
accrue any interest. The note was due on the earlier of April 28, 2020 or in the event of default, as defined in the agreement.
The note was convertible into the same class of securities as those sold in the public offering with a conversion price of $2.00
per share. During the year ended December 31, 2020, the note was converted into securities of the Company in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 10, 2020, the Company entered into a bridge loan with an investor for a principal amount of $75,000. This Note carried
an original issue discount of $40,000. This loan did not accrue any interest. The note was due on the earlier of July 8, 2020
or in the event of default, as defined in the agreement, as amended. The note was convertible into the same class of securities
as those sold in the public offering with a conversion price of $2.00 per share. During the year ended December 31, 2020, the
note was converted into securities of the Company in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the first quarter of 2020, the Company entered into six bridge loans with investors for a total principal amount of $600,000.
These notes carried an aggregate original issue discount of $300,000. The notes were due on the earlier of April 19, 2020 or ten
days after the close of the Company&rsquo;s IPO. During the year ended December 31, 2020, these notes were paid in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
8 &ndash; INCOME TAXES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December&nbsp;31, 2020 and 2019, the Company did not record a current or deferred income tax expense or benefit
due to current and historical losses incurred by the Company. The Company&rsquo;s losses before income taxes consist solely of
losses from domestic operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 27, 2020, the United States enacted the Coronavirus Aid, Relief, and Economic Security Act (&ldquo;CARES Act&rdquo;). The
Cares Act includes provisions relating to refundable payroll tax credits, deferment of the employer portion of certain payroll
taxes, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction
limitations and technical corrections to tax depreciation methods for qualified improvement property. The CARES Act also established
a Paycheck Protection Program whereby certain small businesses are eligible for a loan to fund payroll expenses, rent, and related
costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considered the provisions under the CARES Act and elected not to take advantage of the provisions of CARES Act as the
effect of such provisions was not expected to have a material impact on the Company&rsquo;s results of operations, cash flows
and financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to income taxes as reflected
in the financial statements is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Income taxes at U.S. statutory rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">21</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">21</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">State income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Tax Credits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Permanent Differences/Others</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30.3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20.4</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(60.8</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(7.6</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total provision for income taxes</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">0</TD><TD STYLE="padding-bottom: 2pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">0</TD><TD STYLE="padding-bottom: 2pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income
tax purposes. The significant components of the Company&rsquo;s deferred tax assets and liabilities as of December&nbsp;31, 2020
and 2019 are comprised of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 8pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 8pt; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 8pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 8pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 13.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    operating loss carryforwards</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,651,932</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,044,662</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 13.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    credits carryforwards</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">116,949</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 13.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    compensation</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,350,795</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">974,644</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 13.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
    liability</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">367,029</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 13.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,920</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    deferred tax assets</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,488,625</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,019,306</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation
    allowance</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,109,685</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,019,306</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    deferred tax assets</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">378,940</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax liabilities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 13.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right
    of use assets</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(368,950</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 13.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed
    Assets</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9,990</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    deferred tax liabilities</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(378,940</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 27.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    deferred taxes</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has evaluated the positive and negative
evidence bearing upon its ability to realize its deferred tax assets, which are comprised primarily of net operating loss carryforwards
and tax credits. Management has considered the Company&rsquo;s history of cumulative net losses in the United States, estimated future
taxable income and prudent and feasible tax planning strategies and has concluded that it is more likely than not that the Company will
not realize the benefits of its U.S. federal and state deferred tax assets. Accordingly, a full valuation allowance has been established
against these net deferred tax assets as of December&nbsp;31, 2020 and 2019, respectively. The Company reevaluates the positive and negative
evidence at each reporting period. The Company&rsquo;s valuation allowance increased during 2020 by approximately $4.1&nbsp;million primarily
due to the generation of net operating loss and tax credit carryforwards and stock based compensation.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December&nbsp;31, 2020 and 2019, the Company had U.S. federal net operating loss carryforwards of $12.6 million and $3.8&nbsp;million,
respectively, which may be available to offset future income tax liabilities. The 2017 Tax Cuts and Jobs Act (&ldquo; TCJA&rdquo;)
will generally allow losses incurred after 2017 to be carried over indefinitely, but will generally limit the net operating loss
deduction to the lesser of the net operating loss carryover or 80% of a corporation&rsquo;s taxable income (subject to Section&nbsp;382
of the Internal Revenue Code of 1986, as amended). Also, there will be no carryback for losses incurred after 2017. Losses incurred
prior to 2018 will generally be deductible to the extent of the lesser of a corporation&rsquo;s net operating loss carryover or
100% of a corporation&rsquo;s taxable income and be available for twenty years from the period the loss was generated. The Company
has federal net operating losses generated following 2017 of $12.5 million, which do not expire. The federal net operating losses
generated prior to 2018 of $0.1 million will expire at various dates through 2037. The CARES Act temporarily allows the Company
to carryback net operating losses arising in 2018, 2019 and 2020 to the five prior tax years. In addition, net operating losses
generated in these years could fully offset prior year taxable income without the 80% of the taxable income limitation under the
TCJA which was enacted on December 22, 2017. The Company has been generating losses since its inception, as such the net operating
loss carryback provision under the CARES Act is not applicable to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December&nbsp;31, 2020 and 2019, the Company also had U.S. state net operating loss carryforwards of $15.2&nbsp;million and
$3.8 million, respectively, which may be available to offset future income tax liabilities and expire at various dates through
2040.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December&nbsp;31, 2020, the Company had federal tax credit carryforwards of approximately $0.1 million, available to reduce
future tax liabilities which expire at various dates through 2040. As of December&nbsp;31, 2020, the Company had state research
and development tax credit carryforwards of approximately $0.1 million available to reduce future tax liabilities which expire
at various dates through 2035. The Company did not have any federal and state tax credit carryforward as of December 31, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utilization
of the U.S. federal and state net operating loss and research and development credit carryforwards may be subject to a substantial
annual limitation under Section&nbsp;382 and Section&nbsp;383 of the Internal Revenue Code of 1986, as amended, and corresponding
provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership
changes may limit the amount of net operating loss and research and development credit carryforwards that can be utilized annually
to offset future taxable income and tax liabilities, respectively. The Company has not completed a study to assess whether a change
of ownership has occurred, or whether there have been multiple ownership changes since its formation. Any limitation may result
in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before
utilization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not, as of yet, conducted a study of research and development tax credit carryforwards. Such a study, once undertaken
by the Company, may result in an adjustment to the research and development tax credit carryforwards; however, a full valuation
allowance has been provided against the Company&rsquo;s research and development tax credits and, if an adjustment is required,
this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the balance sheet
or statement of operations if an adjustment is required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company files tax returns in the United States, California, Virginia, and New York. The Company is subject to U.S. federal and
state tax examinations by tax authorities for years 2017 through present. As of December&nbsp;31, 2020 and 2019, the Company has
recorded no liability for unrecognized tax benefits, interest, or penalties related to federal and state income tax matters and
there currently no pending tax examinations. The Company will recognize interest and penalties related to uncertain tax positions
in income tax expense</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
9 &ndash; SUBSEQUENT EVENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated subsequent events through the filing of this Annual Report on Form 10-K and has determined that there have
been no events that have occurred that would require adjustments to the Company&rsquo;s disclosures in the financial statements,
except for the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 25, 2021, the Company entered into a Securities Purchase Agreement for the sale of $6,000,000 in Convertible Notes. The
Convertible Notes have a term of 24 months, convert at $4.00 per share, and have an original issuance discount of $1,000,000.
The Company also issued 800,000 warrants to purchase shares of the Company&rsquo;s common stock. These warrants have a term of
three years, are immediately exercisable, and have an exercise price of $4.00.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During February 2021, the Company entered into
a 24 month financing agreement for lab equipment. The aggregate cost of this financing agreement will be $892,094.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Through the date of this filing, there were 1,142,306
warrants exercised for shares of the Company&rsquo;s common stock, resulting in proceeds of $3,643,956.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-17</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>f10k2020ex4-1_aditx.htm
<DESCRIPTION>DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
4.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
OF THE REGISTRANT&rsquo;S SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTERED
PURSUANT TO SECTION 12 OF THE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2020, Aditx Therapeutics, Inc. (&ldquo;the Company&rdquo;) had one class of security registered under Section&nbsp;12
of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), our common stock, par value $0.001 per share
(&ldquo;Common Stock&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description
of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description of our Common Stock is a summary and does not purport to be complete. It is<B>&nbsp;</B>subject to and qualified
in its entirety by reference to our Amended and Restated Certificate of Incorporation, as amended (the &ldquo;Certificate of Incorporation&rdquo;)
and our Amended and Restated Bylaws (the &ldquo;Bylaws&rdquo;), each of which are incorporated by reference as an exhibit to the
Annual Report on Form 10-K of which this Exhibit 4.1 is a part. We encourage you to<B>&nbsp;</B>read our Certificate of Incorporation,
Bylaws, and the applicable provisions of the Delaware General Corporation Law for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Authorized
Capital Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
authorized capital shares consist of 27,000,000 shares of common stock, $0.001 par value per share, and 3,000,000 shares of preferred
stock, $0.001 par value per share (&ldquo;Preferred Stock&rdquo;). As of December 31, 2020, there were 13,074,495 shares
of common stock issued and 12,973,692 shares of common stock outstanding. There were no shares of Preferred Stock
issued or outstanding as of December 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Voting
Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of common stock are entitled to one vote per share on all matters voted on by the stockholders, including the election of directors.
Our Certificate of Incorporation and Bylaws do not provide for cumulative voting in the election of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dividend
Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of the Company&rsquo;s common stock are entitled to receive dividends, if any, as may be declared from time to time by the board
of directors in its discretion out of funds legally available for the payment of dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidation
Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of our liquidation, the holders of our common stock will be entitled to share ratably in any distribution of our assets
after payment of all debts and other liabilities and the preferences payable to holders of shares of Preferred Stock then outstanding,
if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Applicable
Anti-Takeover Law</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is a summary of the provisions of the Certificate of Incorporation and the Bylaws that could have the effect of delaying
or preventing a change in control of the Company. The following description is only a summary and it is qualified by refence to
the Certificate of Incorporation, the Bylaws and relevant provisions of the Delaware General Corporation Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Blank
Check Preferred Stock</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Certificate of Incorporation authorizes 3,000,000 undesignated shares of Preferred Stock and permits our board of directors to
issue Preferred Stock with rights or preferences that could impede the success of any attempt to change control of the Company.
For example, our board of directors, without stockholder approval, may create or issue Preferred Stock with conversion rights
that could adversely affect the voting power of the holders of our common stock as well as rights to such Preferred Stock, in
connection with implementing a stockholder rights plan. This provision may be deemed to have a potential anti-takeover effect,
because the issuance of such Preferred Stock may delay or prevent a change of control of the Company. Furthermore, shares of Preferred
Stock, if any are issued, may have other rights, including economic rights, senior to common stock, and as a result, the issuance
thereof could depress the market price of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>No
Cumulative Voting</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Certificate of Incorporation and the Bylaws do not provide holders of our common stock cumulative voting rights in the election
of directors. The absence of cumulative voting could have the effect of preventing stockholders holding a minority of our shares
of common stock from obtaining representation on our board of directors. The absence of cumulative voting might also, under certain
circumstances, render more difficult or discourage a merger, tender offer or proxy contest favored by a majority of our stockholders,
the assumption of control by a holder of a large block of our stock or the removal of incumbent management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Advance
Notice Requirements for Stockholder Proposals and Director Nominees</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Bylaws require stockholders seeking to make nominations of candidates for election as directors or to bring other business before
a meeting of our stockholders to provide timely notice of their intent in writing. To be timely, a stockholder&rsquo;s notice
must be delivered to the Secretary at our principal executive offices not less than 90 days nor more than 120 days prior to the
first anniversary of the immediately preceding annual meeting of the stockholders; provided, however, that in the event that the
date of the annual meeting is more than 30 days before or after such anniversary date, notice by the stockholder to be timely
must be so received not later than the close of business on the tenth day following the earlier of the date on which we first
give notice or publicly announce the date of the meeting. A stockholder&rsquo;s notice must include certain information about
the stockholder and the nominee or proposal as specified in the Bylaws. These advance notice provisions may restrict the ability
of the stockholders to make nominations for directors at or bring business before a meeting of the Company&rsquo;s stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is traded on Nasdaq Capital Market under the trading symbol &ldquo;ADTX&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
Agent</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s transfer agent is VStock Transfer, LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>f10k2020ex23-1_aditx.htm
<DESCRIPTION>CONSENT OF DBBMCKENNON, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><B>Consent of Independent Registered
Public Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We consent to the incorporation by reference in the
Registration Statement on Form S-8 (File No. 333-246324) of our report dated March 25, 2021, relating to the financial statements of Aditx
Therapeutics, Inc. for the years ended December 31, 2020 and 2019, which appear in this Annual Report on Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">/s/ dbb<I>mckennon</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Newport Beach, California</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">March 25, 2021</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>f10k2020ex31-1_aditx.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0; margin-bottom: 0"><B>EXHIBIT 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I,
Amro Albanna, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I have
    reviewed this annual report on Form 10-K of Aditx Therapeutics, Inc;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based on my knowledge,
    this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
    statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
    covered by this report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based on my knowledge,
    the financial statements, and other financial information included in this report, fairly present in all material respects
    the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
    report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The registrant&rsquo;s
    other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as
    defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant,&nbsp;is made known to us by others within those entities,
    particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such internal
    control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
    to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Evaluated the effectiveness
    of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
    of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Disclosed in this
    report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
    affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
    and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
    over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
    (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
    information; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any fraud, whether
    or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal
    control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 60%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:
    March 25, 2021</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; width: 40%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/
    Amro Albanna</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amro Albanna</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief
Executive Officer</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal
Executive Officer)</FONT></P></TD></TR>
</TABLE>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>f10k2020ex31-2_aditx.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>EXHIBIT
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I,
Corinne Pankovcin, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I have
    reviewed this annual report on Form 10-K of Aditx Therapeutics, Inc;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based on my knowledge,
    this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
    statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
    covered by this report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based on my knowledge,
    the financial statements, and other financial information included in this report, fairly present in all material respects
    the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
    report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The registrant&rsquo;s
    other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as
    defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, is made known to us by others within those entities,
    particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such internal
    control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
    to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Evaluated the effectiveness
    of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
    of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Disclosed in this
    report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
    affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
    and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
    over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
    (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
    information; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any fraud, whether
    or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal
    control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 60%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:
    March 25, 2021</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; width: 40%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/
    Corinne Pankovcin</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Corinne Pankovcin</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief
Financial Officer</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal
Financial Officer)</FONT></P></TD></TR>
</TABLE>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.3
<SEQUENCE>6
<FILENAME>f10k2020ex31-3_aditx.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>EXHIBIT
31.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I,
Thomas J. Farley, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I have
    reviewed this annual report on Form 10-K of Aditx Therapeutics, Inc;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based on my knowledge,
    this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
    statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
    covered by this report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based on my knowledge,
    the financial statements, and other financial information included in this report, fairly present in all material respects
    the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
    report;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The registrant&rsquo;s
    other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as
    defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly
    during the period in which this report is being prepared;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such internal
    control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
    to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Evaluated the effectiveness
    of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
    of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Disclosed in this
    report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
    affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
    and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
    over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
    (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
    information; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any fraud, whether
    or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal
    control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 60%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:
    March 25, 2021</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; width: 40%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/
    Thomas J. Farley</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Thomas J. Farley</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Controller</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal
Accounting Officer)</FONT></P></TD></TR>
</TABLE>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>f10k2020ex32-1_aditx.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>EXHIBIT
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CERTIFICATIONS
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>AS
ENACTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
connection with the Annual Report of Aditx Therapeutics, Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the period ending December
31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), each of Amro Albanna,
Chief Executive Officer of the Company, Corinne Pankovcin, Chief Financial Officer of the Company, and Thomas J. Farley,
Controller of the Company, certify, pursuant to 18 U.S.C. &sect; 1350, as enacted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></TD>
</TR></TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; width: 60%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 25, 2021</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; width: 40%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/
    Amro Albanna</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amro Albanna</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 25, 2021</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/
    Corinne Pankovcin</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Corinne Pankovcin</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Financial Officer)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 25, 2021</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Thomas J. Farley</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Thomas J. Farley</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Controller</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Accounting Officer)</FONT></TD></TR>
</TABLE>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>adtx-20201231.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 25 16:57:49 EDT 2021 -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:adtx="http://www.aditxt.com./20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:compsci="http://compsciresources.com" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="adtx-20201231.xsd"/>
  <context id="c0_From1Jan2020To31Dec2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c1_AsOf24Mar2021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
    </entity>
    <period>
      <instant>2021-03-24</instant>
    </period>
  </context>
  <context id="c2_AsOf30Jun2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
    </entity>
    <period>
      <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="c3_AsOf31Dec2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c4_AsOf31Dec2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c5_From1Jan2019To31Dec2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c6_From1Jan2020To31Dec2020_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c7_From1Jan2019To31Dec2019_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c8_From1Jan2020To31Dec2020_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c9_From1Jan2019To31Dec2019_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c10_From1Jan2020To31Dec2020_SellingAndMarketingExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c11_From1Jan2019To31Dec2019_SellingAndMarketingExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c12_AsOf31Dec2018_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c13_AsOf31Dec2018_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c14_AsOf31Dec2018_TreasuryStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c15_AsOf31Dec2018_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c16_AsOf31Dec2018_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c17_AsOf31Dec2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c18_From1Jan2019To31Dec2019_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c19_From1Jan2019To31Dec2019_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c20_From1Jan2019To31Dec2019_TreasuryStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c21_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c22_From1Jan2019To31Dec2019_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c23_AsOf31Dec2019_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c24_AsOf31Dec2019_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c25_AsOf31Dec2019_TreasuryStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c26_AsOf31Dec2019_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c27_AsOf31Dec2019_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c28_From1Jan2020To31Dec2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c29_From1Jan2020To31Dec2020_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c30_From1Jan2020To31Dec2020_TreasuryStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c31_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c32_From1Jan2020To31Dec2020_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c33_AsOf31Dec2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c34_AsOf31Dec2020_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c35_AsOf31Dec2020_TreasuryStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c36_AsOf31Dec2020_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c37_AsOf31Dec2020_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c38_From1Jul2020To2Jul2020_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-07-01</startDate>
      <endDate>2020-07-02</endDate>
    </period>
  </context>
  <context id="c39_AsOf2Jul2020_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-07-02</instant>
    </period>
  </context>
  <context id="c40_AsOf2Jul2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
    </entity>
    <period>
      <instant>2020-07-02</instant>
    </period>
  </context>
  <context id="c41_From1Jul2020To2Jul2020_SeriesAMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-07-01</startDate>
      <endDate>2020-07-02</endDate>
    </period>
  </context>
  <context id="c42_AsOf2Jul2020_OverAllotmentOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-07-02</instant>
    </period>
  </context>
  <context id="c43_From1Aug2020To19Aug2020_MaximumMember_SeriesAMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-08-01</startDate>
      <endDate>2020-08-19</endDate>
    </period>
  </context>
  <context id="c44_From1Aug2020To19Aug2020_MinimumMember_SeriesAMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-08-01</startDate>
      <endDate>2020-08-19</endDate>
    </period>
  </context>
  <context id="c45_AsOf31Dec2020_SeriesBMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c46_AsOf10Sep2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
    </entity>
    <period>
      <instant>2020-09-10</instant>
    </period>
  </context>
  <context id="c47_AsOf10Sep2020_SeriesAMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-09-10</instant>
    </period>
  </context>
  <context id="c48_AsOf10Sep2020_SeriesA1WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">adtx:SeriesA1WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-09-10</instant>
    </period>
  </context>
  <context id="c49_From1Sep2020To10Sep2020_SeriesA1WarrantMember_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">adtx:SeriesA1WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-09-01</startDate>
      <endDate>2020-09-10</endDate>
    </period>
  </context>
  <context id="c50_From1Sep2020To10Sep2020_SeriesB1WarrantMember_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">adtx:SeriesB1WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-09-01</startDate>
      <endDate>2020-09-10</endDate>
    </period>
  </context>
  <context id="c51_AsOf31Dec2020_ChiefExecutiveOfficerMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c52_AsOf31Dec2019_ChiefExecutiveOfficerMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c53_From1Jan2020To31Dec2020_ChiefExecutiveOfficerMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c54_AsOf31Dec2020_ChiefInnovationOfficerMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adtx:ChiefInnovationOfficerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c55_AsOf31Dec2019_ChiefInnovationOfficerMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adtx:ChiefInnovationOfficerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c56_From1Jan2020To31Dec2020_ChiefInnovationOfficerMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adtx:ChiefInnovationOfficerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c57_AsOf31Dec2020_ChiefOperatingOfficerMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c58_AsOf31Dec2019_ChiefOperatingOfficerMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c59_From1Jan2020To31Dec2020_ChiefOperatingOfficerMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c60_AsOf21Mar2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
    </entity>
    <period>
      <instant>2019-03-21</instant>
    </period>
  </context>
  <context id="c61_From1Mar2019To21Mar2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
    </entity>
    <period>
      <startDate>2019-03-01</startDate>
      <endDate>2019-03-21</endDate>
    </period>
  </context>
  <context id="c62_From1Jan2020To31Dec2020_StockOptionMember_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c63_From1Jan2020To31Dec2020_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c64_From1Jan2020To31Dec2020_September2020OfferingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:September2020OfferingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c65_From1Jun2020To29Jun2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2020-06-29</endDate>
    </period>
  </context>
  <context id="c66_From2Oct2017To31Oct2017_TwoZeroOneSevenEquityIncentivePlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adtx:TwoZeroOneSevenEquityIncentivePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-10-02</startDate>
      <endDate>2017-10-31</endDate>
    </period>
  </context>
  <context id="c67_From1Jan2020To31Dec2020_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c68_From1Jan2020To31Dec2020_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c69_From1Jan2020To31Dec2020_StockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c70_From1Oct2020To6Oct2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
    </entity>
    <period>
      <startDate>2020-10-01</startDate>
      <endDate>2020-10-06</endDate>
    </period>
  </context>
  <context id="c71_From1Jan2020To31Dec2020_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c72_From1Jan2019To31Dec2019_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c73_AsOf31Dec2019_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c74_AsOf31Dec2019_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c75_From1Jan2019To31Dec2019_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c76_From1Jan2019To31Dec2019_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c77_AsOf31Dec2019_StockOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:StockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c78_From1Jan2020To31Dec2020_StockOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:StockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c79_AsOf31Dec2020_StockOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:StockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c80_AsOf31Dec2019_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c81_AsOf31Dec2020_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c82_AsOf31Dec2019_NonvestedOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:NonvestedOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c83_From1Jan2020To31Dec2020_NonvestedOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:NonvestedOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c84_AsOf31Dec2020_NonvestedOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">adtx:NonvestedOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c85_AsOf31Dec2019_NonvestedWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">adtx:NonvestedWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c86_From1Jan2020To31Dec2020_NonvestedWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">adtx:NonvestedWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c87_AsOf31Dec2020_NonvestedWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">adtx:NonvestedWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c88_From1Oct2020To31Oct2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
    </entity>
    <period>
      <startDate>2020-10-01</startDate>
      <endDate>2020-10-31</endDate>
    </period>
  </context>
  <context id="c89_AsOf31Oct2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
    </entity>
    <period>
      <instant>2020-10-31</instant>
    </period>
  </context>
  <context id="c90_From1Nov2020To30Nov2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
    </entity>
    <period>
      <startDate>2020-11-01</startDate>
      <endDate>2020-11-30</endDate>
    </period>
  </context>
  <context id="c91_AsOf30Nov2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
    </entity>
    <period>
      <instant>2020-11-30</instant>
    </period>
  </context>
  <context id="c92_From1Jan2020To31Dec2020_SalveoConsultingAgreementMember_SalveoDiagnosticsIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="adtx:TypeOfAgreementAxis">adtx:SalveoConsultingAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adtx:SalveoDiagnosticsIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c93_AsOf12Apr2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
    </entity>
    <period>
      <instant>2018-04-12</instant>
    </period>
  </context>
  <context id="c94_From2Apr2018To12Apr2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
    </entity>
    <period>
      <startDate>2018-04-02</startDate>
      <endDate>2018-04-12</endDate>
    </period>
  </context>
  <context id="c95_AsOf10Jul2018_BridgeLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-07-10</instant>
    </period>
  </context>
  <context id="c96_From2Jul2018To10Jul2018_BridgeLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-07-02</startDate>
      <endDate>2018-07-10</endDate>
    </period>
  </context>
  <context id="c97_AsOf18Jul2018_BridgeLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-07-18</instant>
    </period>
  </context>
  <context id="c98_From2Jul2018To18Jul2018_BridgeLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-07-02</startDate>
      <endDate>2018-07-18</endDate>
    </period>
  </context>
  <context id="c99_AsOf1Nov2019_BridgeLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-11-01</instant>
    </period>
  </context>
  <context id="c100_AsOf10Jan2020_BridgeLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-01-10</instant>
    </period>
  </context>
  <context id="c101_AsOf31Mar2020_SixBridgeLoansMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adtx:SixBridgeLoansMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="c102_From1Jan2020To31Mar2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c103_AsOf31Dec2020_USFederalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">adtx:USFederalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c104_AsOf31Dec2019_USFederalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">adtx:USFederalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c105_AsOf31Dec2020_USStateMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">adtx:USStateMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c106_AsOf31Dec2019_USStateMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">adtx:USStateMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c107_From13Jan2021To25Jan2021_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-13</startDate>
      <endDate>2021-01-25</endDate>
    </period>
  </context>
  <context id="c108_AsOf25Jan2021_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-01-25</instant>
    </period>
  </context>
  <context id="c109_From1Feb2021To28Feb2021_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001726711</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-02-01</startDate>
      <endDate>2021-02-28</endDate>
    </period>
  </context>
  <unit id="shares">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="usd">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="usdPershares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="pure">
    <measure>xbrli:pure</measure>
  </unit>
  <dei:EntityExTransitionPeriod contextRef="c0_From1Jan2020To31Dec2020">false</dei:EntityExTransitionPeriod>
  <dei:AmendmentFlag contextRef="c0_From1Jan2020To31Dec2020">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="c0_From1Jan2020To31Dec2020">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="c0_From1Jan2020To31Dec2020">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="c0_From1Jan2020To31Dec2020">2020</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="c0_From1Jan2020To31Dec2020">2020-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="c0_From1Jan2020To31Dec2020">10-K</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="c0_From1Jan2020To31Dec2020">0001726711</dei:EntityCentralIndexKey>
  <dei:EntityCurrentReportingStatus contextRef="c0_From1Jan2020To31Dec2020">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityEmergingGrowthCompany contextRef="c0_From1Jan2020To31Dec2020">true</dei:EntityEmergingGrowthCompany>
  <dei:EntityFileNumber contextRef="c0_From1Jan2020To31Dec2020">001-39336</dei:EntityFileNumber>
  <dei:EntityFilerCategory contextRef="c0_From1Jan2020To31Dec2020">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityIncorporationStateCountryCode contextRef="c0_From1Jan2020To31Dec2020">DE</dei:EntityIncorporationStateCountryCode>
  <dei:EntityInteractiveDataCurrent contextRef="c0_From1Jan2020To31Dec2020">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityRegistrantName contextRef="c0_From1Jan2020To31Dec2020">Aditx Therapeutics, Inc.</dei:EntityRegistrantName>
  <dei:EntityShellCompany contextRef="c0_From1Jan2020To31Dec2020">false</dei:EntityShellCompany>
  <dei:EntitySmallBusiness contextRef="c0_From1Jan2020To31Dec2020">true</dei:EntitySmallBusiness>
  <dei:EntityVoluntaryFilers contextRef="c0_From1Jan2020To31Dec2020">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="c0_From1Jan2020To31Dec2020">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityCommonStockSharesOutstanding unitRef="shares" contextRef="c1_AsOf24Mar2021" decimals="INF">14124498</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityPublicFloat unitRef="usd" contextRef="c2_AsOf30Jun2020" decimals="0">20079659</dei:EntityPublicFloat>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">10500826</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">4090</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PrepaidExpenseCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">147642</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PrepaidExpenseCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <adtx:ROUAssetShortTerm unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">384685</adtx:ROUAssetShortTerm>
  <adtx:ROUAssetShortTerm unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">11033153</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">4090</us-gaap:AssetsCurrent>
  <adtx:FixedAssets unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">798919</adtx:FixedAssets>
  <adtx:FixedAssets unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:OtherIntangibleAssetsNet unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">321000</us-gaap:OtherIntangibleAssetsNet>
  <us-gaap:OtherIntangibleAssetsNet unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:DeferredCosts unitRef="usd" contextRef="c3_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:DeferredCosts unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">119442</us-gaap:DeferredCosts>
  <adtx:RightOfUseAssetLongTerm unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">871136</adtx:RightOfUseAssetLongTerm>
  <adtx:RightOfUseAssetLongTerm unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:DepositsAssetsNoncurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">72296</us-gaap:DepositsAssetsNoncurrent>
  <us-gaap:DepositsAssetsNoncurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:Assets unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">13096504</us-gaap:Assets>
  <us-gaap:Assets unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">123532</us-gaap:Assets>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">241613</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">1847458</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">962651</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
  <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">10000</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
  <us-gaap:NotesPayableCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:NotesPayableCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">155600</us-gaap:NotesPayableCurrent>
  <adtx:FinancingOnFixedAssets unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">587588</adtx:FinancingOnFixedAssets>
  <us-gaap:OperatingLeaseLiabilityCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">391221</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:OperatingLeaseLiabilityCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:OtherLiabilitiesCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">6536</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">1226958</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">2975709</us-gaap:LiabilitiesCurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">858064</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:Liabilities unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">2085022</us-gaap:Liabilities>
  <us-gaap:Liabilities unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">2975709</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies unitRef="usd" contextRef="c3_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:CommitmentsAndContingencies unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:PreferredStockValue unitRef="usd" contextRef="c3_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:PreferredStockValue unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">13078</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">3916</us-gaap:CommonStockValue>
  <us-gaap:TreasuryStockValue unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">201605</us-gaap:TreasuryStockValue>
  <us-gaap:TreasuryStockValue unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">189625</us-gaap:TreasuryStockValue>
  <us-gaap:AdditionalPaidInCapital unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">32079187</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">9063483</us-gaap:AdditionalPaidInCapital>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">-20879178</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">-11729951</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">11011482</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">-2852177</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">13096504</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">123532</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c3_AsOf31Dec2020" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c4_AsOf31Dec2019" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">3000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c4_AsOf31Dec2019" decimals="INF">3000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c3_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:PreferredStockSharesOutstanding unitRef="shares" contextRef="c3_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:PreferredStockSharesOutstanding unitRef="shares" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c3_AsOf31Dec2020" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c4_AsOf31Dec2019" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">27000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c4_AsOf31Dec2019" decimals="INF">27000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">13074495</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c4_AsOf31Dec2019" decimals="INF">3915900</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">12973692</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" contextRef="c4_AsOf31Dec2019" decimals="INF">3821088</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:TreasuryStockShares unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">100803</us-gaap:TreasuryStockShares>
  <us-gaap:TreasuryStockShares unitRef="shares" contextRef="c4_AsOf31Dec2019" decimals="INF">94813</us-gaap:TreasuryStockShares>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">7852256</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">5694806</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">937966</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">175441</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">81987</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">551</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">8872209</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">5870798</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-8872209</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">-5870798</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestExpenseOther unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">10081</us-gaap:InterestExpenseOther>
  <us-gaap:InterestExpenseOther unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">1930</us-gaap:InterestExpenseOther>
  <us-gaap:InvestmentIncomeInterest unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">563</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">32500</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">45000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:AmortizationOfDebtDiscountPremium unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">300000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AmortizationOfDebtDiscountPremium unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:NonoperatingIncomeExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-277018</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">43070</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-9149227</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">-5827728</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">-1.33</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPershares" contextRef="c5_From1Jan2019To31Dec2019" decimals="2">-1.52</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">6902696</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted unitRef="shares" contextRef="c5_From1Jan2019To31Dec2019" decimals="INF">3830971</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c6_From1Jan2020To31Dec2020_GeneralAndAdministrativeExpenseMember" decimals="0">3188840</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c7_From1Jan2019To31Dec2019_GeneralAndAdministrativeExpenseMember" decimals="0">4221733</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c8_From1Jan2020To31Dec2020_ResearchAndDevelopmentExpenseMember" decimals="0">0</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c9_From1Jan2019To31Dec2019_ResearchAndDevelopmentExpenseMember" decimals="0">10000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c10_From1Jan2020To31Dec2020_SellingAndMarketingExpenseMember" decimals="0">0</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c11_From1Jan2019To31Dec2019_SellingAndMarketingExpenseMember" decimals="0">0</us-gaap:ShareBasedCompensation>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c12_AsOf31Dec2018_CommonStockMember" decimals="INF">3763925</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c12_AsOf31Dec2018_CommonStockMember" decimals="0">3764</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c13_AsOf31Dec2018_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c13_AsOf31Dec2018_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c14_AsOf31Dec2018_TreasuryStockMember" xs:nil="true"/>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c15_AsOf31Dec2018_AdditionalPaidInCapitalMember" decimals="0">4361725</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c16_AsOf31Dec2018_RetainedEarningsMember" decimals="0">-5902223</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c17_AsOf31Dec2018" decimals="0">-1536734</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c18_From1Jan2019To31Dec2019_CommonStockMember" decimals="INF">131475</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c18_From1Jan2019To31Dec2019_CommonStockMember" decimals="0">131</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c19_From1Jan2019To31Dec2019_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c19_From1Jan2019To31Dec2019_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c20_From1Jan2019To31Dec2019_TreasuryStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c21_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" decimals="0">470046</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c22_From1Jan2019To31Dec2019_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">470177</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices unitRef="shares" contextRef="c18_From1Jan2019To31Dec2019_CommonStockMember" decimals="INF">20500</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c18_From1Jan2019To31Dec2019_CommonStockMember" decimals="0">21</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices unitRef="shares" contextRef="c19_From1Jan2019To31Dec2019_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c19_From1Jan2019To31Dec2019_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c20_From1Jan2019To31Dec2019_TreasuryStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c21_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" decimals="0">81979</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c22_From1Jan2019To31Dec2019_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">82000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions unitRef="usd" contextRef="c18_From1Jan2019To31Dec2019_CommonStockMember" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions unitRef="usd" contextRef="c19_From1Jan2019To31Dec2019_PreferredStockMember" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions unitRef="usd" contextRef="c20_From1Jan2019To31Dec2019_TreasuryStockMember" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions unitRef="usd" contextRef="c21_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" decimals="0">3616422</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions unitRef="usd" contextRef="c22_From1Jan2019To31Dec2019_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">3616422</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits unitRef="usd" contextRef="c18_From1Jan2019To31Dec2019_CommonStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits unitRef="usd" contextRef="c19_From1Jan2019To31Dec2019_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits unitRef="usd" contextRef="c20_From1Jan2019To31Dec2019_TreasuryStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits unitRef="usd" contextRef="c21_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" decimals="0">533311</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits unitRef="usd" contextRef="c22_From1Jan2019To31Dec2019_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">533311</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
  <us-gaap:TreasuryStockSharesAcquired unitRef="shares" contextRef="c18_From1Jan2019To31Dec2019_CommonStockMember" decimals="INF">-94813</us-gaap:TreasuryStockSharesAcquired>
  <us-gaap:TreasuryStockValueAcquiredCostMethod unitRef="usd" contextRef="c18_From1Jan2019To31Dec2019_CommonStockMember" xs:nil="true"/>
  <us-gaap:TreasuryStockSharesAcquired unitRef="shares" contextRef="c19_From1Jan2019To31Dec2019_PreferredStockMember" xs:nil="true"/>
  <us-gaap:TreasuryStockValueAcquiredCostMethod unitRef="usd" contextRef="c19_From1Jan2019To31Dec2019_PreferredStockMember" xs:nil="true"/>
  <us-gaap:TreasuryStockValueAcquiredCostMethod unitRef="usd" contextRef="c20_From1Jan2019To31Dec2019_TreasuryStockMember" decimals="0">189625</us-gaap:TreasuryStockValueAcquiredCostMethod>
  <us-gaap:TreasuryStockValueAcquiredCostMethod unitRef="usd" contextRef="c21_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:TreasuryStockValueAcquiredCostMethod unitRef="usd" contextRef="c22_From1Jan2019To31Dec2019_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:TreasuryStockValueAcquiredCostMethod unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">189625</us-gaap:TreasuryStockValueAcquiredCostMethod>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c18_From1Jan2019To31Dec2019_CommonStockMember" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c19_From1Jan2019To31Dec2019_PreferredStockMember" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c20_From1Jan2019To31Dec2019_TreasuryStockMember" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c21_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c22_From1Jan2019To31Dec2019_RetainedEarningsMember" decimals="0">-5827728</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">-5827728</us-gaap:ProfitLoss>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c23_AsOf31Dec2019_CommonStockMember" decimals="INF">3821087</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c23_AsOf31Dec2019_CommonStockMember" decimals="0">3916</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c24_AsOf31Dec2019_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c24_AsOf31Dec2019_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c25_AsOf31Dec2019_TreasuryStockMember" decimals="0">-189625</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c26_AsOf31Dec2019_AdditionalPaidInCapitalMember" decimals="0">9063483</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c27_AsOf31Dec2019_RetainedEarningsMember" decimals="0">-11729951</us-gaap:StockholdersEquity>
  <us-gaap:TreasuryStockSharesAcquired unitRef="shares" contextRef="c28_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">-5990</us-gaap:TreasuryStockSharesAcquired>
  <us-gaap:TreasuryStockValueAcquiredCostMethod unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_CommonStockMember" xs:nil="true"/>
  <us-gaap:TreasuryStockSharesAcquired unitRef="shares" contextRef="c29_From1Jan2020To31Dec2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:TreasuryStockValueAcquiredCostMethod unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:TreasuryStockValueAcquiredCostMethod unitRef="usd" contextRef="c30_From1Jan2020To31Dec2020_TreasuryStockMember" decimals="0">11980</us-gaap:TreasuryStockValueAcquiredCostMethod>
  <us-gaap:TreasuryStockValueAcquiredCostMethod unitRef="usd" contextRef="c31_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:TreasuryStockValueAcquiredCostMethod unitRef="usd" contextRef="c32_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:TreasuryStockValueAcquiredCostMethod unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">11980</us-gaap:TreasuryStockValueAcquiredCostMethod>
  <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits unitRef="shares" contextRef="c28_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">-10</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_CommonStockMember" decimals="0">1</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
  <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits unitRef="shares" contextRef="c29_From1Jan2020To31Dec2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit unitRef="usd" contextRef="c30_From1Jan2020To31Dec2020_TreasuryStockMember" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit unitRef="usd" contextRef="c31_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit unitRef="usd" contextRef="c32_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">1</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c28_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">4297703</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <adtx:ExerciseOfWarrants unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_CommonStockMember" decimals="0">4300</adtx:ExerciseOfWarrants>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c29_From1Jan2020To31Dec2020_PreferredStockMember" xs:nil="true"/>
  <adtx:ExerciseOfWarrants unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_PreferredStockMember" xs:nil="true"/>
  <adtx:ExerciseOfWarrants unitRef="usd" contextRef="c30_From1Jan2020To31Dec2020_TreasuryStockMember" xs:nil="true"/>
  <adtx:ExerciseOfWarrants unitRef="usd" contextRef="c31_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="0">206244</adtx:ExerciseOfWarrants>
  <adtx:ExerciseOfWarrants unitRef="usd" contextRef="c32_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <adtx:ExerciseOfWarrants unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">210544</adtx:ExerciseOfWarrants>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_CommonStockMember" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions unitRef="usd" contextRef="c30_From1Jan2020To31Dec2020_TreasuryStockMember" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions unitRef="usd" contextRef="c31_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="0">711406</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions unitRef="usd" contextRef="c32_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">711406</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices unitRef="shares" contextRef="c28_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">874916</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_CommonStockMember" decimals="0">876</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices unitRef="shares" contextRef="c29_From1Jan2020To31Dec2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c30_From1Jan2020To31Dec2020_TreasuryStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c31_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="0">2476558</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c32_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">2477434</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <adtx:StockIssuedDuringPeriodSharesForIntangibleAssets unitRef="shares" contextRef="c28_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">150000</adtx:StockIssuedDuringPeriodSharesForIntangibleAssets>
  <adtx:StockIssuedDuringPeriodValueIntangibleAssets unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_CommonStockMember" decimals="0">150</adtx:StockIssuedDuringPeriodValueIntangibleAssets>
  <adtx:StockIssuedDuringPeriodSharesForIntangibleAssets unitRef="shares" contextRef="c29_From1Jan2020To31Dec2020_PreferredStockMember" xs:nil="true"/>
  <adtx:StockIssuedDuringPeriodValueIntangibleAssets unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_PreferredStockMember" xs:nil="true"/>
  <adtx:StockIssuedDuringPeriodValueIntangibleAssets unitRef="usd" contextRef="c30_From1Jan2020To31Dec2020_TreasuryStockMember" xs:nil="true"/>
  <adtx:StockIssuedDuringPeriodValueIntangibleAssets unitRef="usd" contextRef="c31_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="0">320850</adtx:StockIssuedDuringPeriodValueIntangibleAssets>
  <adtx:StockIssuedDuringPeriodValueIntangibleAssets unitRef="usd" contextRef="c32_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <adtx:StockIssuedDuringPeriodValueIntangibleAssets unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">321000</adtx:StockIssuedDuringPeriodValueIntangibleAssets>
  <adtx:IssuanceOfSharesForTheSettlementOfSharesAccruedCompensationAndAccountsPayable unitRef="shares" contextRef="c28_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">146818</adtx:IssuanceOfSharesForTheSettlementOfSharesAccruedCompensationAndAccountsPayable>
  <adtx:IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_CommonStockMember" decimals="0">147</adtx:IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable>
  <adtx:IssuanceOfSharesForTheSettlementOfSharesAccruedCompensationAndAccountsPayable unitRef="shares" contextRef="c29_From1Jan2020To31Dec2020_PreferredStockMember" xs:nil="true"/>
  <adtx:IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_PreferredStockMember" xs:nil="true"/>
  <adtx:IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable unitRef="usd" contextRef="c30_From1Jan2020To31Dec2020_TreasuryStockMember" xs:nil="true"/>
  <adtx:IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable unitRef="usd" contextRef="c31_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="0">1221878</adtx:IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable>
  <adtx:IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable unitRef="usd" contextRef="c32_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <adtx:IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">1222025</adtx:IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable>
  <adtx:IssuanceOfSharesAndWarrantsForIPONetOfSharesOfferingCosts unitRef="shares" contextRef="c28_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">1226668</adtx:IssuanceOfSharesAndWarrantsForIPONetOfSharesOfferingCosts>
  <adtx:IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_CommonStockMember" decimals="0">1227</adtx:IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts>
  <adtx:IssuanceOfSharesAndWarrantsForIPONetOfSharesOfferingCosts unitRef="shares" contextRef="c29_From1Jan2020To31Dec2020_PreferredStockMember" xs:nil="true"/>
  <adtx:IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_PreferredStockMember" xs:nil="true"/>
  <adtx:IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts unitRef="usd" contextRef="c30_From1Jan2020To31Dec2020_TreasuryStockMember" xs:nil="true"/>
  <adtx:IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts unitRef="usd" contextRef="c31_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="0">9429455</adtx:IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts>
  <adtx:IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts unitRef="usd" contextRef="c32_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <adtx:IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">9430682</adtx:IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts>
  <adtx:StockIssuedDuringPeriodSharesForCashNetOfOfferingCosts unitRef="shares" contextRef="c28_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">1150000</adtx:StockIssuedDuringPeriodSharesForCashNetOfOfferingCosts>
  <adtx:StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts unitRef="shares" contextRef="c28_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">1150</adtx:StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts>
  <adtx:StockIssuedDuringPeriodSharesForCashNetOfOfferingCosts unitRef="shares" contextRef="c29_From1Jan2020To31Dec2020_PreferredStockMember" decimals="INF">1250000</adtx:StockIssuedDuringPeriodSharesForCashNetOfOfferingCosts>
  <adtx:StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts unitRef="shares" contextRef="c29_From1Jan2020To31Dec2020_PreferredStockMember" decimals="INF">1250</adtx:StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts>
  <adtx:StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts unitRef="shares" contextRef="c30_From1Jan2020To31Dec2020_TreasuryStockMember" xs:nil="true"/>
  <adtx:StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts unitRef="shares" contextRef="c31_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="INF">8524376</adtx:StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts>
  <adtx:StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts unitRef="shares" contextRef="c32_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <adtx:StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">8526776</adtx:StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts>
  <adtx:IssuanceOfSharesForTheSettlementOfSharesDebtinShares unitRef="shares" contextRef="c28_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">62500</adtx:IssuanceOfSharesForTheSettlementOfSharesDebtinShares>
  <adtx:IssuanceOfSharesForTheSettlementOfDebt unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_CommonStockMember" decimals="0">63</adtx:IssuanceOfSharesForTheSettlementOfDebt>
  <adtx:IssuanceOfSharesForTheSettlementOfSharesDebtinShares unitRef="shares" contextRef="c29_From1Jan2020To31Dec2020_PreferredStockMember" xs:nil="true"/>
  <adtx:IssuanceOfSharesForTheSettlementOfDebt unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_PreferredStockMember" xs:nil="true"/>
  <adtx:IssuanceOfSharesForTheSettlementOfDebt unitRef="usd" contextRef="c30_From1Jan2020To31Dec2020_TreasuryStockMember" xs:nil="true"/>
  <adtx:IssuanceOfSharesForTheSettlementOfDebt unitRef="usd" contextRef="c31_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="0">124937</adtx:IssuanceOfSharesForTheSettlementOfDebt>
  <adtx:IssuanceOfSharesForTheSettlementOfDebt unitRef="usd" contextRef="c32_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <adtx:IssuanceOfSharesForTheSettlementOfDebt unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">125000</adtx:IssuanceOfSharesForTheSettlementOfDebt>
  <adtx:ExerciseConversionOfSharesPreferredShares unitRef="shares" contextRef="c28_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">1250000</adtx:ExerciseConversionOfSharesPreferredShares>
  <adtx:ExerciseConversionOfPreferredShares unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_CommonStockMember" decimals="0">1250</adtx:ExerciseConversionOfPreferredShares>
  <adtx:ExerciseConversionOfSharesPreferredShares unitRef="shares" contextRef="c29_From1Jan2020To31Dec2020_PreferredStockMember" decimals="INF">-1250000</adtx:ExerciseConversionOfSharesPreferredShares>
  <adtx:ExerciseConversionOfPreferredShares unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_PreferredStockMember" decimals="0">-1250</adtx:ExerciseConversionOfPreferredShares>
  <adtx:ExerciseConversionOfPreferredShares unitRef="usd" contextRef="c30_From1Jan2020To31Dec2020_TreasuryStockMember" xs:nil="true"/>
  <adtx:ExerciseConversionOfPreferredShares unitRef="usd" contextRef="c31_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <adtx:ExerciseConversionOfPreferredShares unitRef="usd" contextRef="c32_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <adtx:ExerciseConversionOfPreferredShares unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_CommonStockMember" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c29_From1Jan2020To31Dec2020_PreferredStockMember" xs:nil="true"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbshkMkzTNOwKi/SY5wisaUmNZUHQSzNMHSWLwfjT7WpDTxNyESoEbcePgflNnDx4+Cpe7iGVGde/DRQguZdZo5KjpAUGAQNyOkDD76ahIjQccKEsvf9/Xj3++QLucVobcn305z1bCg1mi6xUZr+oBVMyyqaM/+TOgNX7+t44hIrWlYUwPKsqCr5vXiF6x03y9mUm4tdk3foBWSlnM9aNsq] CSR-->
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c31_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c32_From1Jan2020To31Dec2020_RetainedEarningsMember" decimals="0">-9149227</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-9333049</us-gaap:ProfitLoss>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c33_AsOf31Dec2020_CommonStockMember" decimals="INF">12973692</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c33_AsOf31Dec2020_CommonStockMember" decimals="0">13078</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c34_AsOf31Dec2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c34_AsOf31Dec2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c35_AsOf31Dec2020_TreasuryStockMember" decimals="0">-201605</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c36_AsOf31Dec2020_AdditionalPaidInCapitalMember" decimals="0">32079187</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c37_AsOf31Dec2020_RetainedEarningsMember" decimals="0">-20879178</us-gaap:StockholdersEquity>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">3188840</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">3698422</us-gaap:ShareBasedCompensation>
  <us-gaap:DepreciationNonproduction unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">17773</us-gaap:DepreciationNonproduction>
  <us-gaap:DepreciationNonproduction unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <adtx:ModificationOfOptions unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <adtx:ModificationOfOptions unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">533311</adtx:ModificationOfOptions>
  <us-gaap:IncreaseDecreaseInDepositOtherAssets unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">72296</us-gaap:IncreaseDecreaseInDepositOtherAssets>
  <us-gaap:IncreaseDecreaseInDepositOtherAssets unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:IncreaseDecreaseInPrepaidExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">147642</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInPrepaidExpense unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-1483180</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">601607</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <adtx:IncreaseDecreaseInAccruedCompensationToRelatedParties unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">124728</adtx:IncreaseDecreaseInAccruedCompensationToRelatedParties>
  <adtx:IncreaseDecreaseInAccruedCompensationToRelatedParties unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">530036</adtx:IncreaseDecreaseInAccruedCompensationToRelatedParties>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-7221004</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">-464352</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsForProceedsFromProductiveAssets unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">170629</us-gaap:PaymentsForProceedsFromProductiveAssets>
  <us-gaap:PaymentsForProceedsFromProductiveAssets unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-170629</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:ProceedsFromRelatedPartyDebt unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:ProceedsFromRelatedPartyDebt unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">10000</us-gaap:ProceedsFromRelatedPartyDebt>
  <us-gaap:ProceedsFromNotesPayable unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">375000</us-gaap:ProceedsFromNotesPayable>
  <us-gaap:ProceedsFromNotesPayable unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">50000</us-gaap:ProceedsFromNotesPayable>
  <us-gaap:RepaymentsOfRelatedPartyDebt unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">45000</us-gaap:RepaymentsOfRelatedPartyDebt>
  <us-gaap:RepaymentsOfRelatedPartyDebt unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">42502</us-gaap:RepaymentsOfRelatedPartyDebt>
  <us-gaap:RepaymentsOfNotesPayable unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">670600</us-gaap:RepaymentsOfNotesPayable>
  <us-gaap:RepaymentsOfNotesPayable unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">15500</us-gaap:RepaymentsOfNotesPayable>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">18500039</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">470177</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:PaymentsOfStockIssuanceCosts unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">423139</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">119442</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ProceedsFromWarrantExercises unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">210544</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromWarrantExercises unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:IncreaseDecreaseInReceivables unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">58475</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">17888369</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">352733</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">10496736</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">-111619</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c17_AsOf31Dec2018" decimals="0">115709</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:IncomeTaxesPaid unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:IncomeTaxesPaid unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:InterestPaidNet unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">5842</us-gaap:InterestPaidNet>
  <us-gaap:InterestPaidNet unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <adtx:LiabilitiesAssumedForCommonStock unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">11980</adtx:LiabilitiesAssumedForCommonStock>
  <adtx:LiabilitiesAssumedForCommonStock unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">189625</adtx:LiabilitiesAssumedForCommonStock>
  <us-gaap:StockIssued1 unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">125000</us-gaap:StockIssued1>
  <us-gaap:StockIssued1 unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <adtx:IssuanceOfUnitsForTheSettlementOfAccruedCompensationAndAccountsPayable unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">1222025</adtx:IssuanceOfUnitsForTheSettlementOfAccruedCompensationAndAccountsPayable>
  <adtx:IssuanceOfUnitsForTheSettlementOfAccruedCompensationAndAccountsPayable unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <adtx:OriginalIssuanceDiscountOnNotesPayable unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">300000</adtx:OriginalIssuanceDiscountOnNotesPayable>
  <adtx:OriginalIssuanceDiscountOnNotesPayable unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">1191985</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
  <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <adtx:LiabilityRecognizedForFinancedAssets unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">646063</adtx:LiabilityRecognizedForFinancedAssets>
  <adtx:LiabilityRecognizedForFinancedAssets unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <adtx:SharesIssuedForIntangibleAssets unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">321000</adtx:SharesIssuedForIntangibleAssets>
  <adtx:SharesIssuedForIntangibleAssets unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <adtx:ConversionOfPreferredShares unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">1250</adtx:ConversionOfPreferredShares>
  <adtx:ConversionOfPreferredShares unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;NOTE
1 &amp;#x2013; ORGANIZATION AND NATURE OF BUSINESS&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Company
Background&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;Overview&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Aditx
Therapeutics, Inc. (&amp;#x201c;Aditxt&amp;#x201d; or the &amp;#x201c;Company&amp;#x201d;) was incorporated in the State of Delaware on September
28, 2017 and our headquarters are located in Mountain View, CA. The Company is a Biotech Innovation company with a mission of
prolonging life and enhancing its quality by improving the health of the immune system.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;We
are developing biotechnologies specifically focused on improving the health of the immune system through immune reprogramming
and monitoring. Our immune reprogramming technologies are currently at the pre-clinical stage and are designed to retrain the
immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies.
Our immune monitoring technologies are designed to provide a personalized comprehensive profile of the immune system and we plan
to utilize them in our upcoming reprogramming clinical trials to monitor subjects&amp;#x2019; immune response before, during and after
drug administration.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;Offerings&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;On
July 2, 2020, the Company completed its initial public offering (&amp;#x201c;IPO&amp;#x201d;). In connection therewith, the Company issued
1,226,668 Units (the &amp;#x201c;Units&amp;#x201d;), excluding the underwriters&amp;#x2019; option to cover overallotments, at an offering price
of $9.00 per Unit, resulting in gross proceeds of approximately $11.0 million. The Units issued in the IPO consisted of one share
of common stock, one Series A warrant, and one Series B warrant. The Series A warrants originally had an exercise price of $9.00
and a term of 5 years. In addition, the Company issued a Unit Purchase Option at an exercise price of $11.25 per unit to the underwriters
to purchase up to 67,466 units, with each unit consisting of (i) one share of common stock and (ii) one Series A Warrant. On August
19, 2020 the Company modified the exercise price of the Series A Warrants from $9.00 per share to $4.50 per share. The term of
the Series A Warrants was not modified. The Series B warrants have an exercise price of $11.25 per share, a term of 5 years and
contain a cashless exercise option upon certain criteria being met. As of December 31, 2020, substantially all of the Series B
warrants issued in the IPO have been exercised pursuant to a cashless provision therein.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;On
September 10, 2020, the Company completed a follow-on public offering (&amp;#x201c;September 2020 Offering&amp;#x201d;). In connection therewith,
the Company issued 2,400,000 Units (the &amp;#x201c;Follow-On Units&amp;#x201d;), excluding the underwriters&amp;#x2019; option to cover overallotments,
at an offering price of $4.00 per Follow-On Unit, resulting in gross proceeds to the Company of approximately $9.6 million. The
Follow-On Units issued in the September 2020 Offering consisted of one share of common stock (or Series A Preferred Stock for
investors who would own more than 4.99% of the Company if they invested in common stock), one Series A-1 warrant, and one Series
B-1 warrant. The Series A-1 warrants have an exercise price of $3.19 per share and a term of 5 years. The Series B-1 warrants
have exercise price of $5.00 per share, a term of 5 years and contain a cashless exercise option upon certain criteria being met.
In addition, the Company issued a warrant to the underwriters to purchase up to 60,000 shares of common stock at an exercise price
of $5.00 per share. Subsequent to quarter end, substantially all of the Series B-1 warrants issued in the September 2020 Offering
have been exercised pursuant to a cashless provision therein.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Risks
and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company has a limited operating history and has not generated revenue from intended operations. The Company&amp;#x2019;s business and
operations are sensitive to general business and economic conditions in the U.S. and worldwide along with local, state, and federal
governmental policy decisions. A host of factors beyond the Company&amp;#x2019;s control could cause fluctuations in these conditions.
Adverse conditions may include: changes in biotechnology regulatory environment, technological advances that render our technologies
obsolete, availability of resources for clinical trials, acceptance of technologies into the medical community, and competition
from larger, more well-funded companies. These adverse conditions could affect the Company&amp;#x2019;s financial condition and the
results of its operations.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;On
January 30, 2020, the World Health Organization declared the COVID-19 novel coronavirus outbreak a &amp;#x201c;Public Health Emergency
of International Concern&amp;#x201d; and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate
the spread of the coronavirus include restrictions on travel, and quarantines in certain areas, and forced closures for certain
types of public places and businesses. The COVID-19 coronavirus and actions taken to mitigate it have had and are expected to
continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in
which the Company operates. While it is unknown how long these conditions will last and what the financial impact will be to the
Company, it is reasonably possible that future capital raise efforts and additional development of our technologies may be negatively
affected.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <adtx:StockUnitIssued unitRef="usd" contextRef="c38_From1Jul2020To2Jul2020_IPOMember" decimals="0">1226668</adtx:StockUnitIssued>
  <adtx:CommonUnitIssuedPerUnit unitRef="usdPershares" contextRef="c39_AsOf2Jul2020_IPOMember" decimals="2">9.00</adtx:CommonUnitIssuedPerUnit>
  <adtx:OfferingPriceOfShares unitRef="shares" contextRef="c39_AsOf2Jul2020_IPOMember" decimals="-5">11000000</adtx:OfferingPriceOfShares>
  <us-gaap:VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure unitRef="usd" contextRef="c40_AsOf2Jul2020" decimals="2">9.00</us-gaap:VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure>
  <us-gaap:DebtInstrumentTerm contextRef="c41_From1Jul2020To2Jul2020_SeriesAMember">P5Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure unitRef="usd" contextRef="c42_AsOf2Jul2020_OverAllotmentOptionMember" decimals="2">11.25</us-gaap:VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure>
  <adtx:PurchaseOfEquityShares unitRef="shares" contextRef="c40_AsOf2Jul2020" decimals="INF">67466</adtx:PurchaseOfEquityShares>
  <us-gaap:WarrantExercisePriceIncrease unitRef="usdPershares" contextRef="c43_From1Aug2020To19Aug2020_MaximumMember_SeriesAMember" decimals="2">9.00</us-gaap:WarrantExercisePriceIncrease>
  <us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPPredecessorEntityIesToBusinessCombination contextRef="c44_From1Aug2020To19Aug2020_MinimumMember_SeriesAMember">$4.50</us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPPredecessorEntityIesToBusinessCombination>
  <us-gaap:VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure unitRef="usd" contextRef="c45_AsOf31Dec2020_SeriesBMember" decimals="2">11.25</us-gaap:VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure>
  <us-gaap:DebtInstrumentTerm contextRef="c0_From1Jan2020To31Dec2020">P5Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:CommonUnitIssued unitRef="shares" contextRef="c46_AsOf10Sep2020" decimals="INF">2400000</us-gaap:CommonUnitIssued>
  <adtx:CommonUnitIssuedPerUnit unitRef="usdPershares" contextRef="c46_AsOf10Sep2020" decimals="2">4.00</adtx:CommonUnitIssuedPerUnit>
  <adtx:OfferingPriceOfShares unitRef="shares" contextRef="c46_AsOf10Sep2020" decimals="-5">9600000</adtx:OfferingPriceOfShares>
  <adtx:CommonStockVotingRightsPercentage unitRef="pure" contextRef="c47_AsOf10Sep2020_SeriesAMember" decimals="4">0.0499</adtx:CommonStockVotingRightsPercentage>
  <us-gaap:VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure unitRef="usd" contextRef="c48_AsOf10Sep2020_SeriesA1WarrantMember" decimals="2">3.19</us-gaap:VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure>
  <us-gaap:DebtInstrumentTerm contextRef="c49_From1Sep2020To10Sep2020_SeriesA1WarrantMember_IPOMember">P5Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:WarrantExercisePriceIncrease unitRef="usdPershares" contextRef="c50_From1Sep2020To10Sep2020_SeriesB1WarrantMember_IPOMember" decimals="2">5.00</us-gaap:WarrantExercisePriceIncrease>
  <us-gaap:DebtInstrumentTerm contextRef="c50_From1Sep2020To10Sep2020_SeriesB1WarrantMember_IPOMember">P5Y</us-gaap:DebtInstrumentTerm>
  <adtx:PurchaseOfCommonStock unitRef="shares" contextRef="c46_AsOf10Sep2020" decimals="INF">60000</adtx:PurchaseOfCommonStock>
  <adtx:CommonStockExercisePricePerShare unitRef="usdPershares" contextRef="c46_AsOf10Sep2020" decimals="2">5.00</adtx:CommonStockExercisePricePerShare>
  <adtx:GoingConcernDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;NOTE
2 &amp;#x2013; GOING CONCERN ANALYSIS&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Management
Plans&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company was incorporated on September 28, 2017 and has not generated revenues to date. During the year ended December 31, 2020,
the Company had a net loss of $9,149,227 and cash of $10,500,826. The Company will be conducting medical research and development,
and the time at which the Company will begin generating revenue is unknown. The Company believes, however, that the funds raised
by the IPO and the September 2020 Offering will be sufficient to fund the Company&amp;#x2019;s operation for at least the next 12 months.
Because of these factors, the Company believes that this alleviates issues in connection with the Company&amp;#x2019;s ability to continue
as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going
concern.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
financial statements included in this report do not include any adjustments to reflect the possible future effects on the recoverability
and classification of assets or the amounts and classification of liabilities that may result from the matters discussed herein.
While we believe in the viability of our strategy to generate sufficient revenue, control costs and raise additional funds when
necessary, there can be no assurances to that effect. The Company&amp;#x2019;s ability to continue as a going concern is dependent
upon the ability to complete clinical studies and implement the business plan, generate sufficient revenues and to control operating
expenses.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;</adtx:GoingConcernDisclosureTextBlock>
  <us-gaap:Cash unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">10500826</us-gaap:Cash>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;NOTE
3 &amp;#x2013; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Basis
of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company&amp;#x2019;s financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America (&amp;#x201c;U.S. GAAP&amp;#x201d;) and the rules and regulations of the Securities and Exchange Commission (&amp;#x201c;SEC&amp;#x201d;).&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Use
of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those
estimates. Significant estimates underlying the financial statements include the fair value of stock options and warrants.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Fair
Value Measurements and Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company adopted Financial Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;) Accounting Standards Codification (&amp;#x201c;ASC&amp;#x201d;)
Topic 820, Fair Value Measurements. ASC Topic 820 clarifies the definition of fair value, prescribes methods for measuring fair
value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Level
1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Level
2 - Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar
assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived
from or corroborated by observable market data.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Level
3 - Inputs are unobservable inputs which reflect the reporting entity&amp;#x2019;s own assumptions on what assumptions the market participants
would use in pricing the asset or liability based on the best available information.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company did not identify any assets or liabilities that are required to be presented on the balance sheets at fair value in accordance
with ASC Topic 820.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Due
to the short-term nature of all financial assets and liabilities, their carrying value approximates their fair value as of the
balance sheet dates.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Concentrations
of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation.
At times, the Company may have deposits in excess of federally insured limits.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Cash
and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Cash
and cash equivalents include short-term, liquid investments.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Fixed
Assets&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;Fixed assets are
stated at cost less accumulated depreciation. Cost includes expenditures for furniture, office equipment, laboratory equipment, and
other assets. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of,
the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The
costs of fixed assets are depreciated using the straight-line method over the estimated useful lives or lease life of the related
assets. Depreciation expense was $17,773 for the year ended December 31, 2020 and zero for the year ended for December 31, 2019.
Accumulated depreciation was $17,773 as of December 31, 2020 and zero as of December 31, 2019. None of the Company&amp;#x2019;s fixed
assets serve as collateral against any loans as of December 31, 2020 and 2019, other than those subject to the financed asset liability.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Intangible
Assets&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Intangible
assets are stated at cost less accumulated amortization. For intangible assets that have definite lives, the assets are amortized
using the straight-line method over the estimated useful lives of the related assets. For intangible assets with indefinite lives,
the assets are tested periodically for impairment. Amortization expense was zero for the year ended December 31, 2020 and 2019.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Offering
Costs&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company accounts for offering costs in accordance with ASC 340, Other Assets and Deferred Costs. Prior to the completion of an
offering, offering costs were capitalized as deferred offering costs on the balance sheet. The deferred offering costs are netted
against the proceeds of the offering in stockholders&amp;#x2019; equity (deficit) or the related debt, as applicable. Costs related
to unsuccessful offerings are expensed.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Under
Topic 842, adopted in 2020 with no impact related to adoption, operating lease expense is generally recognized evenly over the term
of the lease. The Company has operating leases consisting of office and laboratory space with remaining lease terms of 46 months.
Rent and Lease costs were $154,263 and $30,362 for the year ended December 31, 2020 and 2019. There was no sublease rental income
for the year ended December 31, 2020 and 2019.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Leases
with an initial term of twelve months or less are not recorded on the balance sheet. For lease agreements entered into or reassessed
after the adoption of Topic 842, we combine the lease and non-lease components in determining the lease liabilities and right
of use (&amp;#x201c;ROU&amp;#x201d;) assets.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Our
lease agreements generally do not provide an implicit borrowing rate, therefore an internal incremental borrowing rate is determined
based on information available at lease commencement date for purposes of determining the present value of lease payments. We
used the incremental borrowing rate on December 31, 2020 and 2019 for all leases that commenced prior to that date. In determining
this rate, which is used to determine the present value of future lease payments, we estimate the rate of interest we would pay
on a collateralized basis, with similar payment terms as the lease and in a similar economic environment.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;i&gt;Lease
Costs&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Year Ended&lt;br/&gt; December&amp;#xa0;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Year Ended&lt;br/&gt; December&amp;#xa0;31,&lt;br/&gt; 2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Components of total lease costs:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left; padding-bottom: 1.5pt&quot;&gt;Operating lease expense&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;154,263&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;Total lease costs&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;154,263&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;i&gt;Lease
Positions as of December 31, 2020&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;ROU
lease assets and lease liabilities for our operating leases were recorded in the balance sheet as follows:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December&amp;#xa0;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December&amp;#xa0;31,&lt;br/&gt; 2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Assets&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; width: 76%; text-align: left&quot;&gt;Right of use asset &amp;#x2013; short term&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;384,685&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Right of use asset &amp;#x2013; long term&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;871,136&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;Total assets&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,255,821&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Liabilities&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left&quot;&gt;Operating lease liabilities &amp;#x2013; short term&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;391,221&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Operating lease liabilities &amp;#x2013; long term&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;858,064&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;Total lease liability&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,249,285&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;i&gt;Lease
Terms and Discount Rate&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: left&quot;&gt;Weighted average remaining lease term (in years) &amp;#x2013; operating lease&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;2.67&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Weighted average discount rate &amp;#x2013; operating lease&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.00&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
future annual minimum lease payments as of December 31, 2020 are as follows:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: left&quot;&gt;2021&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;406,640&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;2022&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;411,753&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;2023&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;363,416&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left&quot;&gt;2024&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;215,551&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Total future minimum lease payments&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,397,360&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Less: Lease imputed interest&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;148,075&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 2pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,249,285&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Stock-Based
Compensation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company accounts for stock-based compensation costs under the provisions of ASC 718, Compensation&amp;#x2014;Stock Compensation, which
requires the measurement and recognition of compensation expense related to the fair value of stock-based compensation awards
that are ultimately expected to vest. Stock based compensation expense recognized includes the compensation cost for all stock-based
payments granted to employees, officers, and directors based on the grant date fair value estimated in accordance with the provisions
of ASC 718. ASC. 718 is also applied to awards modified, repurchased, or cancelled during the periods reported. Stock-based compensation
is recognized as expense over the employee&amp;#x2019;s requisite vesting period and over the nonemployee&amp;#x2019;s period of providing
goods or services.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Patents&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company incurs fees from patent licenses, which are expensed as incurred. During the year ended December 31, 2020 and 2019, the Company had a licensing fee for
the patents of $258,635 and $18,396, respectively.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Research
and Development&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;We
incur research and development costs during the process of researching and developing our technologies and future offerings. Our
research and development costs mainly consist of licensing costs. We expense these costs as incurred unless such costs qualify
for capitalization under applicable guidance.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Basic
and Diluted Net Loss per Common Share&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;Basic loss per common share is computed by dividing the net loss by the
weighted average number of shares of common stock outstanding for each period. Diluted loss per share is computed by dividing the net
loss by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common
stock equivalents. The weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion
would be anti-dilutive. As of December 31, 2020, 2,143,000 stock options and 5,799,146 warrants were excluded from dilutive earnings per
share as their effects were anti-dilutive. As of December 31, 2019, 1,102,500 stock options and 1,382,478 warrants were excluded from
dilutive earnings per share as their effects were anti-dilutive.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Recent
Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
FASB issues ASUs to amend the authoritative literature in ASC. There have been several ASUs to date, including those above, that
amend the original text of ASC. Management believes that those issued to date either (i) provide supplemental guidance, (ii) are
technical corrections, (iii) are not applicable to us or (iv) are not expected to have a significant impact our financial statements.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Basis
of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company&amp;#x2019;s financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America (&amp;#x201c;U.S. GAAP&amp;#x201d;) and the rules and regulations of the Securities and Exchange Commission (&amp;#x201c;SEC&amp;#x201d;).&lt;/font&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:UseOfEstimates contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Use
of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those
estimates. Significant estimates underlying the financial statements include the fair value of stock options and warrants.&lt;/font&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Fair
Value Measurements and Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company adopted Financial Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;) Accounting Standards Codification (&amp;#x201c;ASC&amp;#x201d;)
Topic 820, Fair Value Measurements. ASC Topic 820 clarifies the definition of fair value, prescribes methods for measuring fair
value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Level
1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Level
2 - Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar
assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived
from or corroborated by observable market data.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Level
3 - Inputs are unobservable inputs which reflect the reporting entity&amp;#x2019;s own assumptions on what assumptions the market participants
would use in pricing the asset or liability based on the best available information.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company did not identify any assets or liabilities that are required to be presented on the balance sheets at fair value in accordance
with ASC Topic 820.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Due
to the short-term nature of all financial assets and liabilities, their carrying value approximates their fair value as of the
balance sheet dates.&lt;/font&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Concentrations
of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation.
At times, the Company may have deposits in excess of federally insured limits.&lt;/font&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Cash
and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Cash
and cash equivalents include short-term, liquid investments.&lt;/font&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <adtx:FixedAssetPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Fixed
Assets&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;Fixed assets are
stated at cost less accumulated depreciation. Cost includes expenditures for furniture, office equipment, laboratory equipment, and
other assets. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of,
the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The
costs of fixed assets are depreciated using the straight-line method over the estimated useful lives or lease life of the related
assets. Depreciation expense was $17,773 for the year ended December 31, 2020 and zero for the year ended for December 31, 2019.
Accumulated depreciation was $17,773 as of December 31, 2020 and zero as of December 31, 2019. None of the Company&amp;#x2019;s fixed
assets serve as collateral against any loans as of December 31, 2020 and 2019, other than those subject to the financed asset liability.&lt;/p&gt;</adtx:FixedAssetPolicyTextBlock>
  <us-gaap:Depreciation unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">17773</us-gaap:Depreciation>
  <us-gaap:Depreciation unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">0</us-gaap:Depreciation>
  <adtx:AccumulatedDepreciation unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">17773</adtx:AccumulatedDepreciation>
  <adtx:AccumulatedDepreciation unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">0</adtx:AccumulatedDepreciation>
  <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Intangible
Assets&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Intangible
assets are stated at cost less accumulated amortization. For intangible assets that have definite lives, the assets are amortized
using the straight-line method over the estimated useful lives of the related assets. For intangible assets with indefinite lives,
the assets are tested periodically for impairment. Amortization expense was zero for the year ended December 31, 2020 and 2019.&lt;/font&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
  <adtx:OfferingCostsPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Offering
Costs&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company accounts for offering costs in accordance with ASC 340, Other Assets and Deferred Costs. Prior to the completion of an
offering, offering costs were capitalized as deferred offering costs on the balance sheet. The deferred offering costs are netted
against the proceeds of the offering in stockholders&amp;#x2019; equity (deficit) or the related debt, as applicable. Costs related
to unsuccessful offerings are expensed.&lt;/font&gt;&lt;/p&gt;</adtx:OfferingCostsPolicyTextBlock>
  <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Under
Topic 842, adopted in 2020 with no impact related to adoption, operating lease expense is generally recognized evenly over the term
of the lease. The Company has operating leases consisting of office and laboratory space with remaining lease terms of 46 months.
Rent and Lease costs were $154,263 and $30,362 for the year ended December 31, 2020 and 2019. There was no sublease rental income
for the year ended December 31, 2020 and 2019.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Leases
with an initial term of twelve months or less are not recorded on the balance sheet. For lease agreements entered into or reassessed
after the adoption of Topic 842, we combine the lease and non-lease components in determining the lease liabilities and right
of use (&amp;#x201c;ROU&amp;#x201d;) assets.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Our
lease agreements generally do not provide an implicit borrowing rate, therefore an internal incremental borrowing rate is determined
based on information available at lease commencement date for purposes of determining the present value of lease payments. We
used the incremental borrowing rate on December 31, 2020 and 2019 for all leases that commenced prior to that date. In determining
this rate, which is used to determine the present value of future lease payments, we estimate the rate of interest we would pay
on a collateralized basis, with similar payment terms as the lease and in a similar economic environment.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;i&gt;Lease
Costs&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Year Ended&lt;br/&gt; December&amp;#xa0;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Year Ended&lt;br/&gt; December&amp;#xa0;31,&lt;br/&gt; 2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Components of total lease costs:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left; padding-bottom: 1.5pt&quot;&gt;Operating lease expense&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;154,263&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;Total lease costs&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;154,263&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;i&gt;Lease
Positions as of December 31, 2020&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;ROU
lease assets and lease liabilities for our operating leases were recorded in the balance sheet as follows:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December&amp;#xa0;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December&amp;#xa0;31,&lt;br/&gt; 2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Assets&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; width: 76%; text-align: left&quot;&gt;Right of use asset &amp;#x2013; short term&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;384,685&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Right of use asset &amp;#x2013; long term&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;871,136&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;Total assets&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,255,821&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Liabilities&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left&quot;&gt;Operating lease liabilities &amp;#x2013; short term&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;391,221&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Operating lease liabilities &amp;#x2013; long term&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;858,064&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;Total lease liability&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,249,285&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;i&gt;Lease
Terms and Discount Rate&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: left&quot;&gt;Weighted average remaining lease term (in years) &amp;#x2013; operating lease&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;2.67&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Weighted average discount rate &amp;#x2013; operating lease&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.00&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
future annual minimum lease payments as of December 31, 2020 are as follows:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: left&quot;&gt;2021&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;406,640&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;2022&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;411,753&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;2023&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;363,416&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left&quot;&gt;2024&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;215,551&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Total future minimum lease payments&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,397,360&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Less: Lease imputed interest&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;148,075&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 2pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,249,285&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
  <us-gaap:DirectCostsOfLeasedAndRentedPropertyOrEquipment unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">154263</us-gaap:DirectCostsOfLeasedAndRentedPropertyOrEquipment>
  <us-gaap:DirectCostsOfLeasedAndRentedPropertyOrEquipment unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">30362</us-gaap:DirectCostsOfLeasedAndRentedPropertyOrEquipment>
  <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Stock-Based
Compensation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company accounts for stock-based compensation costs under the provisions of ASC 718, Compensation&amp;#x2014;Stock Compensation, which
requires the measurement and recognition of compensation expense related to the fair value of stock-based compensation awards
that are ultimately expected to vest. Stock based compensation expense recognized includes the compensation cost for all stock-based
payments granted to employees, officers, and directors based on the grant date fair value estimated in accordance with the provisions
of ASC 718. ASC. 718 is also applied to awards modified, repurchased, or cancelled during the periods reported. Stock-based compensation
is recognized as expense over the employee&amp;#x2019;s requisite vesting period and over the nonemployee&amp;#x2019;s period of providing
goods or services.&lt;/font&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
  <adtx:PatentsPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Patents&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company incurs fees from patent licenses, which are expensed as incurred. During the year ended December 31, 2020 and 2019, the Company had a licensing fee for
the patents of $258,635 and $18,396, respectively.&lt;/font&gt;&lt;/p&gt;</adtx:PatentsPolicyTextBlock>
  <adtx:LicensingFeeForPatents unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">258635</adtx:LicensingFeeForPatents>
  <adtx:LicensingFeeForPatents unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">18396</adtx:LicensingFeeForPatents>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Research
and Development&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;We
incur research and development costs during the process of researching and developing our technologies and future offerings. Our
research and development costs mainly consist of licensing costs. We expense these costs as incurred unless such costs qualify
for capitalization under applicable guidance.&lt;/font&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Basic
and Diluted Net Loss per Common Share&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;Basic loss per common share is computed by dividing the net loss by the
weighted average number of shares of common stock outstanding for each period. Diluted loss per share is computed by dividing the net
loss by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common
stock equivalents. The weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion
would be anti-dilutive. As of December 31, 2020, 2,143,000 stock options and 5,799,146 warrants were excluded from dilutive earnings per
share as their effects were anti-dilutive. As of December 31, 2019, 1,102,500 stock options and 1,382,478 warrants were excluded from
dilutive earnings per share as their effects were anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <adtx:WarrantsOfStockOption unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">2143000</adtx:WarrantsOfStockOption>
  <adtx:DilutiveEarningsShares unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">5799146</adtx:DilutiveEarningsShares>
  <adtx:WarrantsOfStockOption unitRef="shares" contextRef="c5_From1Jan2019To31Dec2019" decimals="INF">1102500</adtx:WarrantsOfStockOption>
  <adtx:DilutiveEarningsShares unitRef="shares" contextRef="c5_From1Jan2019To31Dec2019" decimals="INF">1382478</adtx:DilutiveEarningsShares>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Recent
Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
FASB issues ASUs to amend the authoritative literature in ASC. There have been several ASUs to date, including those above, that
amend the original text of ASC. Management believes that those issued to date either (i) provide supplemental guidance, (ii) are
technical corrections, (iii) are not applicable to us or (iv) are not expected to have a significant impact our financial statements.&lt;/font&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:LeaseCostTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Year Ended&lt;br/&gt; December&amp;#xa0;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Year Ended&lt;br/&gt; December&amp;#xa0;31,&lt;br/&gt; 2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Components of total lease costs:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left; padding-bottom: 1.5pt&quot;&gt;Operating lease expense&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;154,263&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;Total lease costs&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;154,263&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
  <us-gaap:OperatingLeaseCost unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">154263</us-gaap:OperatingLeaseCost>
  <us-gaap:OperatingLeaseCost unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:LeaseCost unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">154263</us-gaap:LeaseCost>
  <us-gaap:LeaseCost unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:ScheduleOfCapitalLeasedAsssetsTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December&amp;#xa0;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December&amp;#xa0;31,&lt;br/&gt; 2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Assets&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; width: 76%; text-align: left&quot;&gt;Right of use asset &amp;#x2013; short term&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;384,685&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Right of use asset &amp;#x2013; long term&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;871,136&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;Total assets&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,255,821&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Liabilities&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left&quot;&gt;Operating lease liabilities &amp;#x2013; short term&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;391,221&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Operating lease liabilities &amp;#x2013; long term&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;858,064&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;Total lease liability&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,249,285&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfCapitalLeasedAsssetsTableTextBlock>
  <adtx:RightOfUseAssetShortTerm unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">384685</adtx:RightOfUseAssetShortTerm>
  <adtx:RightOfUseAssetShortTerm unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:OperatingLeaseRightOfUseAsset unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">1255821</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseRightOfUseAsset unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:OperatingLeaseLiability unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">1249285</us-gaap:OperatingLeaseLiability>
  <us-gaap:OperatingLeaseLiability unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: left&quot;&gt;Weighted average remaining lease term (in years) &amp;#x2013; operating lease&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;2.67&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Weighted average discount rate &amp;#x2013; operating lease&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.00&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
  <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c3_AsOf31Dec2020">P2Y244D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
  <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent unitRef="pure" contextRef="c3_AsOf31Dec2020" decimals="4">0.0800</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: left&quot;&gt;2021&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;406,640&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;2022&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;411,753&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;2023&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;363,416&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left&quot;&gt;2024&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;215,551&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Total future minimum lease payments&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,397,360&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Less: Lease imputed interest&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;148,075&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 2pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,249,285&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">406640</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">411753</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">363416</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">215551</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">1397360</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
  <us-gaap:ReceivableWithImputedInterestNetAmount unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">148075</us-gaap:ReceivableWithImputedInterestNetAmount>
  <adtx:LesseeOperatingLeaseLiability unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">1249285</adtx:LesseeOperatingLeaseLiability>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;NOTE
4 &amp;#x2013; RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company&amp;#x2019;s Chief Executive Officer (&amp;#x201c;CEO&amp;#x201d;) has provided certain periods of service without payment. As of December
31, 2020 and 2019, the CEO is owed $0 and $309,500, respectively, related to compensation. During the year ended December 31,
2020, the Company issued 38,055 Units consisting of one share of common stock and one Series A warrant and one Series B warrant
to settle $342,500 in accrued compensation.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company&amp;#x2019;s Chief Innovation Officer (&amp;#x201c;CIO&amp;#x201d;) has provided certain periods of service without payment. As of December
31, 2020 and 2019, the CIO is owed $0 and $377,000, respectively, related to compensation. During the year ended December 31,
2020, the Company issued 47,222 Units consisting of one share of common stock, one Series A warrant, and one Series B warrant
to settle $425,000 in accrued compensation.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Effective
July 10, 2020, the Board of Directors appointed the Company&amp;#x2019;s Chief Operating Officer (&amp;#x201c;COO&amp;#x201d;). Prior to the
appointment, the COO was an independent operations consultant and had provided certain periods of service without payment. As
of December 31, 2020 and 2019, the COO was owed $0 and $275,000, respectively, related to compensation. During the year ended
December 31, 2020, the Company issued 35,555 Units consisting of one share of common stock, one Series A warrant, and one Series
B warrant to settle $320,000 in accrued compensation.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;On
March 21, 2019, the Company issued a promissory note to a related party. The note had a principal of $10,000, a maturity date
of September 21, 2019, and an interest rate of 4% per year. During the year ended December 31, 2020, this note was paid in full.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;During
the year ended December 31, 2020, the Company assumed $11,980 of liabilities from a related party in exchange for the return of
5,990 shares of the Company&amp;#x2019;s common stock.&amp;#xa0;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:DueFromOfficersOrStockholders unitRef="usd" contextRef="c51_AsOf31Dec2020_ChiefExecutiveOfficerMember" decimals="0">0</us-gaap:DueFromOfficersOrStockholders>
  <us-gaap:DueFromOfficersOrStockholders unitRef="usd" contextRef="c52_AsOf31Dec2019_ChiefExecutiveOfficerMember" decimals="0">309500</us-gaap:DueFromOfficersOrStockholders>
  <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c53_From1Jan2020To31Dec2020_ChiefExecutiveOfficerMember">During the year ended December 31, 2020, the Company issued 38,055 Units consisting of one share of common stock and one Series A warrant and one Series B warrant to settle $342,500 in accrued compensation.</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
  <adtx:AccruedCompensationForRelatedParty unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">342500</adtx:AccruedCompensationForRelatedParty>
  <us-gaap:DueFromOfficersOrStockholders unitRef="usd" contextRef="c54_AsOf31Dec2020_ChiefInnovationOfficerMember" decimals="0">0</us-gaap:DueFromOfficersOrStockholders>
  <us-gaap:DueFromOfficersOrStockholders unitRef="usd" contextRef="c55_AsOf31Dec2019_ChiefInnovationOfficerMember" decimals="0">377000</us-gaap:DueFromOfficersOrStockholders>
  <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c56_From1Jan2020To31Dec2020_ChiefInnovationOfficerMember">During the year ended December 31, 2020, the Company issued 47,222 Units consisting of one share of common stock, one Series A warrant, and one Series B warrant to settle $425,000 in accrued compensation.</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
  <adtx:AccruedCompensationForRelatedParty unitRef="usd" contextRef="c56_From1Jan2020To31Dec2020_ChiefInnovationOfficerMember" decimals="0">425000</adtx:AccruedCompensationForRelatedParty>
  <us-gaap:DueFromOfficersOrStockholders unitRef="usd" contextRef="c57_AsOf31Dec2020_ChiefOperatingOfficerMember" decimals="0">0</us-gaap:DueFromOfficersOrStockholders>
  <us-gaap:DueFromOfficersOrStockholders unitRef="usd" contextRef="c58_AsOf31Dec2019_ChiefOperatingOfficerMember" decimals="0">275000</us-gaap:DueFromOfficersOrStockholders>
  <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="c59_From1Jan2020To31Dec2020_ChiefOperatingOfficerMember">During the year ended December 31, 2020, the Company issued 35,555 Units consisting of one share of common stock, one Series A warrant, and one Series B warrant to settle $320,000 in accrued compensation.</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
  <adtx:AccruedCompensationForRelatedParty unitRef="usd" contextRef="c59_From1Jan2020To31Dec2020_ChiefOperatingOfficerMember" decimals="0">320000</adtx:AccruedCompensationForRelatedParty>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c60_AsOf21Mar2019" decimals="0">10000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentInterestRateDuringPeriod unitRef="pure" contextRef="c61_From1Mar2019To21Mar2019" decimals="2">0.04</us-gaap:DebtInstrumentInterestRateDuringPeriod>
  <adtx:StockIssuedDuringPeriodValueNewIssued unitRef="usd" contextRef="c28_From1Jan2020To31Dec2020_CommonStockMember" decimals="0">11980</adtx:StockIssuedDuringPeriodValueNewIssued>
  <adtx:StocksIssuedDuringPeriodSharesIssues unitRef="shares" contextRef="c28_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">5990</adtx:StocksIssuedDuringPeriodSharesIssues>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;NOTE
5 &amp;#x2013; STOCKHOLDERS&amp;#x2019; EQUITY (DEFICIT)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company is authorized to issue 27,000,000 shares of common stock, par value $0.001 per share.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;During the year ended December 31, 2020, the Company issued 874,916
shares of common stock and recognized expense of $2,477,434 in stock compensation for consulting services. The Company issued 150,000
shares of common stock for intangible assets valued at $320,850. The Company also issued 4,297,703 shares of common stock for the
exercise of warrants and received $210,544 for the exercise of the warrants. The Company issued 1,250,000 shares of common stock
for the exercise of 1,250,000 shares of Series A Preferred Stock. The Company issued 146,818 shares of common stock for the settlement
of accounts payable and issued 62,500 shares of common stock for the settlement of debt. The Company issued 1,226,668 shares of
common stock related to the IPO and issued 1,150,000 shares of common stock related to the September 2020 Offering. The stock compensation
for the period was valued based on prior private placements or based on management&amp;#x2019;s estimates of value immediately prior
to the IPO and the value of the shares based on public information post IPO.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;During
the year ended December 31, 2019, the Company issued 41,000 shares of common stock for services and recognized expense of $82,000
in stock compensation and license fees. These shares were valued based on the price which common shares were being
sold in the private placement.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;i&gt;Reverse
Stock Split&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;On
June 29, 2020, the Company effectuated a 1-for-2 reverse stock split of its issued and outstanding shares of common stock by filing
a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of
Delaware. Accordingly, all share and per share amounts for all periods presented in the accompanying financial statements and
notes thereto have been adjusted retroactively, where applicable, to reflect this reverse stock split.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Preferred
Stock&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company is authorized to issue 3,000,000 shares of preferred stock, par value $0.001 per share.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Stock-Based
Compensation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;In
October 2017, our Board of Directors adopted the Aditx Therapeutics, Inc. 2017 Equity Incentive Plan (the &amp;#x201c;2017 Plan&amp;#x201d;).&amp;#xa0;The
2017 Plan provides for the grant of equity awards to employees, and consultants.&amp;#xa0;Up to 2,500,000 shares of our common stock
may be issued pursuant to awards granted under the 2017 Plan. The 2017 Plan is administered by our Board of Directors, and expires
ten years after adoption, unless terminated earlier by the Board.&amp;#xa0;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;During
the year ended December 31, 2020, the Company granted 880,500 stock options with an exercise price of $1.94, $1.92 or $11.00 per
share, some of which vested immediately, and some of which vest between one and three years. The total grant date fair value was
determined to be $1,668,997.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;During
the year ended December 31, 2019, the Company granted 700,000 stock options with exercise prices of $4.00 per share vesting on
issuance. The total grant date fair value was determined to be $2,495,556. For all periods presented, the fair value of each stock
option granted was estimated using the Black-Scholes assumption ranges and or factors as follows:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Exercise price&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;1.92-11.00&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 85%; text-align: left&quot;&gt;Expected dividend yield&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 12%; text-align: right&quot;&gt;0&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;0.28%-2.65&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Expected life in years&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;2.70-10.00&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;141-151&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
risk-free interest rate assumption for options granted is based upon observed interest rates on the United States government securities
appropriate for the expected term of stock options.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
expected term of stock options is calculated using either the simplified method for employee options which takes into consideration
the contractual life and vesting terms of the options, unless the options are expected to vest in which case the contractual term
of the options.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company determined the expected volatility assumption for options granted using the historical volatility of comparable public
companies&amp;#x2019; common stock. The Company will continue to monitor peer companies and other relevant factors used to measure
expected volatility for future stock option grants, until such time that the Company&amp;#x2019;s common stock has enough market history
to use historical volatility.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
dividend yield assumption for options granted is based on the Company&amp;#x2019;s history and expectation of dividend payouts. The
Company has never declared or paid any cash dividends on its common stock, and the Company does not anticipate paying any cash
dividends in the foreseeable future.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Management
estimated the fair value of common stock by looking at a market approach which takes into consideration past sales of stock to
third parties and Company developments to date.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company recognizes stock option forfeitures as they occur as there is insufficient historical data to accurately determine future
forfeitures rates.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
following is an analysis of the stock option grant activity under the Plan:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left&quot;&gt;Stock Options&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Number&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted &lt;br/&gt;
Average &lt;br/&gt;
Exercise&lt;br/&gt;
    Price&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted &lt;br/&gt;
Average
    &lt;br/&gt;
Remaining&lt;br/&gt; Life&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left&quot;&gt;Outstanding December 31, 2019&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,102,500&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;4.00&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;7.77&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,045,500&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.32&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.91&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Expired or forfeited&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(5,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;1.92&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;Outstanding December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2,143,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;3.18&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;7.81&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left&quot;&gt;Nonvested Options&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Shares&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Nonvested at December 31, 2019&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left&quot;&gt;Granted&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,045,500&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;2.32&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Vested&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(67,500&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.93&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Expired or forfeited&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(5,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;1.92&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;Nonvested at December 31, 2020 &lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;973,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2.28&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company recognized compensation expense related to options issued and vesting of $406,880 during the year ended December 31, 2020,
which is included in general and administrative expenses in the accompanying statements of operations. The remaining value to
be expensed is $1,781,485 with a weighted average vesting term of 2.40 years as of December 31, 2020. The Company recognized compensation
expense related to options issued and vesting of $2,513,826 during the year ended December 31, 2019, which is included in general
and administrative expenses in the accompanying statements of operations.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;On
October 6, 2020, the Board of Directors approved the issuance of an aggregate of 40,000 stock options as compensation for the
non-employee members of the Board of Directors under the Company&amp;#x2019;s 2017 Equity Incentive Plan. The options are subject to
certain vesting provisions.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;A
summary of warrant issuances are as follows:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Number&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Life&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left&quot;&gt;Outstanding December 31, 2019&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,382,478&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;4.44&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;2.84&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8,906,381&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.24&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.00&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Expired or forfeited&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(190,810&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.12&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Exercised&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(4,298,903&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;7.20&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;Outstanding December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;5,799,146&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;5.05&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;4.00&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left&quot;&gt;Nonvested Warrants&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Shares&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left&quot;&gt;Nonvested at December 31, 2019&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;200,000&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;4.00&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8,906,381&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.24&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Vested&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(4,296,668&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.14&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Expired or forfeited&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(4,489,713&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;7.24&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;Nonvested at December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;320,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;3.69&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
warrants granted for compensation are valued using similar inputs as noted in the stock options section above, with the exception
of the expected life which is the contractual life.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company recognized compensation expense related to warrants issued and vesting of $304,526 and $1,102,596 during the year ended
December 31, 2020 and 2019, which is included in general and administrative in the accompanying Statements of Operations. The
remaining value to be expensed is $294,948 with a weighted average vesting term of 0.90 years as of December 31, 2020.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;During
the year ended December 31, 2020, 4,297,703 warrants were exercised for 4,298,903 shares of common stock. The Company
recognized proceeds of $210,544 related to the exercises.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;During
the year ended December 31, 2020, the Company issued 60,000 warrants to the underwriters related to the September 2020 Offering.
These warrants have an exercise price of $5.00, a term of five years, and become exercisable beginning on March 1, 2021. The value
of these warrants were both an increase and decrease to additional paid in capital as a cost of the offering for net a zero impact
on the financial statements.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:CommonUnitIssued unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">874916</us-gaap:CommonUnitIssued>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">2477434</us-gaap:AllocatedShareBasedCompensationExpense>
  <adtx:StockIssuedDuringPeriodSharesIntangibleAssets unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">150000</adtx:StockIssuedDuringPeriodSharesIntangibleAssets>
  <us-gaap:IntangibleAssetsCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">320850</us-gaap:IntangibleAssetsCurrent>
  <us-gaap:ExcessStockSharesIssued unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">4297703</us-gaap:ExcessStockSharesIssued>
  <adtx:CommonStockIssuedForPreferredShares unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">1250000</adtx:CommonStockIssuedForPreferredShares>
  <adtx:PreferredStockExercise unitRef="shares" contextRef="c62_From1Jan2020To31Dec2020_StockOptionMember_SeriesAPreferredStockMember" decimals="INF">1250000</adtx:PreferredStockExercise>
  <adtx:SettlementOfAccountsPayableShares unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">146818</adtx:SettlementOfAccountsPayableShares>
  <adtx:StockIssuedSettlementOfDebt unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">62500</adtx:StockIssuedSettlementOfDebt>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c63_From1Jan2020To31Dec2020_IPOMember" decimals="INF">1226668</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c64_From1Jan2020To31Dec2020_September2020OfferingMember" decimals="INF">1150000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <adtx:StockIssuedDuringPeriodSharesIssuedForService unitRef="shares" contextRef="c5_From1Jan2019To31Dec2019" decimals="INF">41000</adtx:StockIssuedDuringPeriodSharesIssuedForService>
  <us-gaap:StockholdersEquityReverseStockSplit contextRef="c65_From1Jun2020To29Jun2020">On June 29, 2020, the Company effectuated a 1-for-2 reverse stock split of its issued and outstanding shares of common stock by filing a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware.</us-gaap:StockholdersEquityReverseStockSplit>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation unitRef="shares" contextRef="c66_From2Oct2017To31Oct2017_TwoZeroOneSevenEquityIncentivePlanMember" decimals="INF">2500000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">880500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">1.94</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c67_From1Jan2020To31Dec2020_MinimumMember" decimals="2">1.92</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c68_From1Jan2020To31Dec2020_MaximumMember" decimals="2">11.00</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
  <adtx:TotalGrantFairValue unitRef="usd" contextRef="c69_From1Jan2020To31Dec2020_StockOptionMember" decimals="0">1668997</adtx:TotalGrantFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted unitRef="shares" contextRef="c5_From1Jan2019To31Dec2019" decimals="INF">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
  <adtx:StockOptionexercisePrice unitRef="usdPershares" contextRef="c5_From1Jan2019To31Dec2019" decimals="2">4.00</adtx:StockOptionexercisePrice>
  <adtx:TotalGrantFairValue unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">2495556</adtx:TotalGrantFairValue>
  <us-gaap:StockOptionPlanExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">406880</us-gaap:StockOptionPlanExpense>
  <adtx:ShareBasedPaymentRemnainingExpenses unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">1781485</adtx:ShareBasedPaymentRemnainingExpenses>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c0_From1Jan2020To31Dec2020">P2Y146D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">2513826</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan unitRef="shares" contextRef="c70_From1Oct2020To6Oct2020" decimals="INF">40000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
  <adtx:WarrantsIssuedAndVesting unitRef="usd" contextRef="c71_From1Jan2020To31Dec2020_WarrantMember" decimals="0">304526</adtx:WarrantsIssuedAndVesting>
  <adtx:WarrantsIssuedAndVesting unitRef="usd" contextRef="c72_From1Jan2019To31Dec2019_WarrantMember" decimals="0">1102596</adtx:WarrantsIssuedAndVesting>
  <adtx:ShareBasedPaymentRemnainingExpenses unitRef="usd" contextRef="c71_From1Jan2020To31Dec2020_WarrantMember" decimals="0">294948</adtx:ShareBasedPaymentRemnainingExpenses>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c71_From1Jan2020To31Dec2020_WarrantMember">P328D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
  <adtx:WarrantsExercised unitRef="shares" contextRef="c71_From1Jan2020To31Dec2020_WarrantMember" decimals="INF">4297703</adtx:WarrantsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesOther unitRef="shares" contextRef="c71_From1Jan2020To31Dec2020_WarrantMember" decimals="INF">4298903</us-gaap:StockIssuedDuringPeriodSharesOther>
  <us-gaap:ProceedsFromStockOptionsExercised unitRef="usd" contextRef="c71_From1Jan2020To31Dec2020_WarrantMember" decimals="0">210544</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">60000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 unitRef="usdPershares" contextRef="c3_AsOf31Dec2020" decimals="2">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Exercise price&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;1.92-11.00&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 85%; text-align: left&quot;&gt;Expected dividend yield&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 12%; text-align: right&quot;&gt;0&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;0.28%-2.65&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Expected life in years&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;2.70-10.00&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;141-151&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice unitRef="usdPershares" contextRef="c73_AsOf31Dec2019_MinimumMember" decimals="2">1.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice unitRef="usdPershares" contextRef="c74_AsOf31Dec2019_MaximumMember" decimals="2">11.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c5_From1Jan2019To31Dec2019" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c75_From1Jan2019To31Dec2019_MinimumMember" decimals="4">0.0028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c76_From1Jan2019To31Dec2019_MaximumMember" decimals="4">0.0265</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c75_From1Jan2019To31Dec2019_MinimumMember">P2Y255D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c76_From1Jan2019To31Dec2019_MaximumMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c75_From1Jan2019To31Dec2019_MinimumMember" decimals="2">1.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c76_From1Jan2019To31Dec2019_MaximumMember" decimals="2">1.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <adtx:ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left&quot;&gt;Stock Options&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Number&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted &lt;br/&gt;
Average &lt;br/&gt;
Exercise&lt;br/&gt;
    Price&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted &lt;br/&gt;
Average
    &lt;br/&gt;
Remaining&lt;br/&gt; Life&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left&quot;&gt;Outstanding December 31, 2019&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,102,500&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;4.00&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;7.77&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,045,500&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.32&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.91&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Expired or forfeited&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(5,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;1.92&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;Outstanding December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2,143,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;3.18&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;7.81&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Number&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Life&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left&quot;&gt;Outstanding December 31, 2019&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,382,478&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;4.44&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;2.84&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8,906,381&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.24&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.00&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Expired or forfeited&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(190,810&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.12&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Exercised&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(4,298,903&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;7.20&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;Outstanding December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;5,799,146&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;5.05&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;4.00&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</adtx:ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber unitRef="shares" contextRef="c77_AsOf31Dec2019_StockOptionsMember" decimals="INF">1102500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <adtx:WeightedAverageExercisePriceOutstanding unitRef="usdPershares" contextRef="c77_AsOf31Dec2019_StockOptionsMember" decimals="2">4.00</adtx:WeightedAverageExercisePriceOutstanding>
  <adtx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3 contextRef="c78_From1Jan2020To31Dec2020_StockOptionsMember">P7Y281D</adtx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod unitRef="shares" contextRef="c78_From1Jan2020To31Dec2020_StockOptionsMember" decimals="INF">1045500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c78_From1Jan2020To31Dec2020_StockOptionsMember" decimals="2">2.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <adtx:WeightedAverageRemainingLifeGranted contextRef="c78_From1Jan2020To31Dec2020_StockOptionsMember">P8Y332D</adtx:WeightedAverageRemainingLifeGranted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod unitRef="shares" contextRef="c78_From1Jan2020To31Dec2020_StockOptionsMember" decimals="INF">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c78_From1Jan2020To31Dec2020_StockOptionsMember" decimals="2">1.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <adtx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingLifeExpiredOrForfeited contextRef="c78_From1Jan2020To31Dec2020_StockOptionsMember" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber unitRef="shares" contextRef="c79_AsOf31Dec2020_StockOptionsMember" decimals="INF">2143000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <adtx:WeightedAverageExercisePriceOutstanding unitRef="usdPershares" contextRef="c79_AsOf31Dec2020_StockOptionsMember" decimals="2">3.18</adtx:WeightedAverageExercisePriceOutstanding>
  <adtx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c78_From1Jan2020To31Dec2020_StockOptionsMember">P7Y295D</adtx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber unitRef="shares" contextRef="c80_AsOf31Dec2019_WarrantMember" decimals="INF">1382478</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <adtx:WeightedAverageExercisePriceOutstanding unitRef="usdPershares" contextRef="c80_AsOf31Dec2019_WarrantMember" decimals="2">4.44</adtx:WeightedAverageExercisePriceOutstanding>
  <adtx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3 contextRef="c71_From1Jan2020To31Dec2020_WarrantMember">P2Y306D</adtx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod unitRef="shares" contextRef="c71_From1Jan2020To31Dec2020_WarrantMember" decimals="INF">8906381</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c71_From1Jan2020To31Dec2020_WarrantMember" decimals="2">6.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <adtx:WeightedAverageRemainingLifeGranted contextRef="c71_From1Jan2020To31Dec2020_WarrantMember">P5Y</adtx:WeightedAverageRemainingLifeGranted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod unitRef="shares" contextRef="c71_From1Jan2020To31Dec2020_WarrantMember" decimals="INF">190810</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c71_From1Jan2020To31Dec2020_WarrantMember" decimals="2">8.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <adtx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingLifeExpiredOrForfeited contextRef="c71_From1Jan2020To31Dec2020_WarrantMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c71_From1Jan2020To31Dec2020_WarrantMember" decimals="INF">4298903</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c71_From1Jan2020To31Dec2020_WarrantMember" decimals="2">7.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <adtx:ShareBasedPaymentsWeightedAverageRemainingLifeExercised contextRef="c71_From1Jan2020To31Dec2020_WarrantMember" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber unitRef="shares" contextRef="c81_AsOf31Dec2020_WarrantMember" decimals="INF">5799146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <adtx:WeightedAverageExercisePriceOutstanding unitRef="usdPershares" contextRef="c81_AsOf31Dec2020_WarrantMember" decimals="2">5.05</adtx:WeightedAverageExercisePriceOutstanding>
  <adtx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c71_From1Jan2020To31Dec2020_WarrantMember">P4Y</adtx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left&quot;&gt;Nonvested Options&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Shares&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Nonvested at December 31, 2019&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left&quot;&gt;Granted&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,045,500&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;2.32&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Vested&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(67,500&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.93&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Expired or forfeited&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(5,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;1.92&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;Nonvested at December 31, 2020 &lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;973,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2.28&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left&quot;&gt;Nonvested Warrants&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Shares&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left&quot;&gt;Nonvested at December 31, 2019&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;200,000&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;4.00&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8,906,381&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.24&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Vested&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(4,296,668&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.14&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Expired or forfeited&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(4,489,713&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;7.24&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;Nonvested at December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;320,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;3.69&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c82_AsOf31Dec2019_NonvestedOptionsMember" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c82_AsOf31Dec2019_NonvestedOptionsMember" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c83_From1Jan2020To31Dec2020_NonvestedOptionsMember" decimals="INF">1045500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <adtx:WeightedAverageExercisePriceGranted unitRef="usdPershares" contextRef="c83_From1Jan2020To31Dec2020_NonvestedOptionsMember" decimals="2">2.32</adtx:WeightedAverageExercisePriceGranted>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares unitRef="shares" contextRef="c83_From1Jan2020To31Dec2020_NonvestedOptionsMember" decimals="INF">67500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
  <adtx:WeightedAverageExercisePriceVested unitRef="shares" contextRef="c83_From1Jan2020To31Dec2020_NonvestedOptionsMember" decimals="INF">2.93</adtx:WeightedAverageExercisePriceVested>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod unitRef="shares" contextRef="c83_From1Jan2020To31Dec2020_NonvestedOptionsMember" decimals="INF">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <adtx:WeightedAverageExercisePriceForfeited unitRef="usdPershares" contextRef="c83_From1Jan2020To31Dec2020_NonvestedOptionsMember" decimals="2">1.92</adtx:WeightedAverageExercisePriceForfeited>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c84_AsOf31Dec2020_NonvestedOptionsMember" decimals="INF">973000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c84_AsOf31Dec2020_NonvestedOptionsMember" decimals="2">2.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c85_AsOf31Dec2019_NonvestedWarrantsMember" decimals="INF">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c85_AsOf31Dec2019_NonvestedWarrantsMember" decimals="2">4.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c86_From1Jan2020To31Dec2020_NonvestedWarrantsMember" decimals="INF">8906381</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <adtx:WeightedAverageExercisePriceGranted unitRef="usdPershares" contextRef="c86_From1Jan2020To31Dec2020_NonvestedWarrantsMember" decimals="2">6.24</adtx:WeightedAverageExercisePriceGranted>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares unitRef="shares" contextRef="c86_From1Jan2020To31Dec2020_NonvestedWarrantsMember" decimals="INF">4296668</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
  <adtx:WeightedAverageExercisePriceVested unitRef="shares" contextRef="c86_From1Jan2020To31Dec2020_NonvestedWarrantsMember" decimals="INF">5.14</adtx:WeightedAverageExercisePriceVested>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod unitRef="shares" contextRef="c86_From1Jan2020To31Dec2020_NonvestedWarrantsMember" decimals="INF">4489713</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <adtx:WeightedAverageExercisePriceForfeited unitRef="usdPershares" contextRef="c86_From1Jan2020To31Dec2020_NonvestedWarrantsMember" decimals="2">7.24</adtx:WeightedAverageExercisePriceForfeited>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c87_AsOf31Dec2020_NonvestedWarrantsMember" decimals="INF">320000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c87_AsOf31Dec2020_NonvestedWarrantsMember" decimals="2">3.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <adtx:AgreementsDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;NOTE
6 &amp;#x2013; AGREEMENTS&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;On
July 1, 2020, the Company entered into an amendment to patent and technology licensing agreement with Loma Linda University (&amp;#x201c;LLU&amp;#x201d;),
dated March 15, 2018. Pursuant to the amendment, the Company paid LLU $455,000 within four days of the signing of such amendment.
The amendment also updated the milestone payment dates to be $175,000 on March 31, 2022; $100,000 on March 31, 2024; $500,000
on March 31, 2026; and $500,000 on March 31, 2027.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;In
October 2020, the Company entered into a 24-month financing agreement for lab equipment. The aggregate cost of this financing
agreement will be $467,691. The financing agreement has an interest rate of 8% per year.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;In
November 2020, the Company entered into an additional 24-month financing agreement for lab equipment. The aggregate cost of this
financing agreement will be $215,192. The financing agreement has an interest rate of 8% per year.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;i&gt;Salveo
Consulting Agreement&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;On
November 18, 2020, we entered into a Consulting Agreement (the &amp;#x201c;Salveo Consulting Agreement&amp;#x201d;) with Salveo Diagnostics,
Inc., a Delaware corporation (&amp;#x201c;Salveo&amp;#x201d;). Pursuant to the Salveo Consulting Agreement, Salveo agreed to establish,
setup and commence commercial operations of a licensed, College of American Pathologists accredited, and Clinical Laboratory Improvement
Amendments (CLIA) certified, independent clinical and diagnostic laboratory for us and our AditxtScore&amp;#x2122; immune monitoring
technology (the &amp;#x201c;Salveo Services&amp;#x201d;).&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;In
consideration for the Services, and upon the successful completion of certain milestones (the &amp;#x201c;Milestones&amp;#x201d;) described
below, we issued Salveo 650,000 shares of our common stock (the &amp;#x201c;Salveo Shares&amp;#x201d;) in the aggregate. The Salveo Shares
were issued to Salveo upon the completion of the following Milestones: (i) 150,000 shares upon the sale and transfer to the Company
of certain code and interpretive commenting algorithms (the &amp;#x201c;Algorithms&amp;#x201d;) along with related testing protocols and
all technology, codes and spreadsheets, know-how, any necessary information or tools to implement, use, and/or continue to improve
or further refine the Algorithms, and other associated intellectual property; (ii) 250,000 shares upon securing temporary laboratory
space and other related tasks in connection with the launch of the AditxtScore&amp;#x2122; platform; and (iii) 250,000 shares upon
satisfaction of tasks related to the establishment of a long-term AditxtScore&amp;#x2122; center in Richmond, VA. We also pay Salveo
at cost for Salveo&amp;#x2019;s reasonable and documented purchases, general operating costs and expenses incurred in connection with
the Salveo Services.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;</adtx:AgreementsDisclosureTextBlock>
  <us-gaap:BroadcastersLicenseAgreementCommitmentsDescription contextRef="c0_From1Jan2020To31Dec2020">On July 1, 2020, the Company entered into an amendment to patent and technology licensing agreement with Loma Linda University (&amp;#x201c;LLU&amp;#x201d;), dated March 15, 2018. Pursuant to the amendment, the Company paid LLU $455,000 within four days of the signing of such amendment. The amendment also updated the milestone payment dates to be $175,000 on March 31, 2022; $100,000 on March 31, 2024; $500,000 on March 31, 2026; and $500,000 on March 31, 2027</us-gaap:BroadcastersLicenseAgreementCommitmentsDescription>
  <adtx:FinanceArrangementCost unitRef="usd" contextRef="c88_From1Oct2020To31Oct2020" decimals="0">467691</adtx:FinanceArrangementCost>
  <us-gaap:DebtInstrumentInterestRateEffectivePercentage unitRef="pure" contextRef="c89_AsOf31Oct2020" decimals="2">0.08</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
  <adtx:FinanceArrangementCost unitRef="usd" contextRef="c90_From1Nov2020To30Nov2020" decimals="0">215192</adtx:FinanceArrangementCost>
  <us-gaap:DebtInstrumentInterestRateEffectivePercentage unitRef="pure" contextRef="c91_AsOf30Nov2020" decimals="2">0.08</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
  <us-gaap:StockIssuedDuringPeriodSharesOther unitRef="shares" contextRef="c92_From1Jan2020To31Dec2020_SalveoConsultingAgreementMember_SalveoDiagnosticsIncMember" decimals="INF">650000</us-gaap:StockIssuedDuringPeriodSharesOther>
  <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="c92_From1Jan2020To31Dec2020_SalveoConsultingAgreementMember_SalveoDiagnosticsIncMember">The Salveo Shares were issued to Salveo upon the completion of the following Milestones: (i) 150,000 shares upon the sale and transfer to the Company of certain code and interpretive commenting algorithms (the &amp;#x201c;Algorithms&amp;#x201d;) along with related testing protocols and all technology, codes and spreadsheets, know-how, any necessary information or tools to implement, use, and/or continue to improve or further refine the Algorithms, and other associated intellectual property; (ii) 250,000 shares upon securing temporary laboratory space and other related tasks in connection with the launch of the AditxtScore&amp;#x2122; platform; and (iii) 250,000 shares upon satisfaction of tasks related to the establishment of a long-term AditxtScore&amp;#x2122; center in Richmond, VA. We also pay Salveo at cost for Salveo&amp;#x2019;s reasonable and documented purchases, general operating costs and expenses incurred in connection with the Salveo Services.</us-gaap:SaleOfStockDescriptionOfTransaction>
  <us-gaap:DebtDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;NOTE
7 &amp;#x2013; NOTES PAYABLE&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;On
April 12, 2018, the Company issued an unsecured promissory note for $35,000 that accrued interest of 4% annually. The note was
due on the earlier of November 12, 2018 or in the event of default, as defined in the agreement. During the year ended December
31, 2020, this note was paid in full.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;On
July 10, 2018, the Company entered into a bridge loan with an investor for a principal amount of $15,600. The note was due on
the earlier of October 8, 2018 or in the event of default, as defined in the agreement. During the year ended December 31, 2020,
this note was paid in full.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;On
July 18, 2018, the Company entered into a bridge loan with an investor for a principal amount of $130,000. The note was due on
the earlier of October 16, 2018 or in the event of default, as defined in the agreement. During the year ended December 31, 2020,
this note was paid in full.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;On
November 1, 2019, the Company entered into a bridge loan with an investor for a principal amount of $50,000. This loan did not
accrue any interest. The note was due on the earlier of April 28, 2020 or in the event of default, as defined in the agreement.
The note was convertible into the same class of securities as those sold in the public offering with a conversion price of $2.00
per share. During the year ended December 31, 2020, the note was converted into securities of the Company in full.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;On
January 10, 2020, the Company entered into a bridge loan with an investor for a principal amount of $75,000. This Note carried
an original issue discount of $40,000. This loan did not accrue any interest. The note was due on the earlier of July 8, 2020
or in the event of default, as defined in the agreement, as amended. The note was convertible into the same class of securities
as those sold in the public offering with a conversion price of $2.00 per share. During the year ended December 31, 2020, the
note was converted into securities of the Company in full.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;During
the first quarter of 2020, the Company entered into six bridge loans with investors for a total principal amount of $600,000.
These notes carried an aggregate original issue discount of $300,000. The notes were due on the earlier of April 19, 2020 or ten
days after the close of the Company&amp;#x2019;s IPO. During the year ended December 31, 2020, these notes were paid in full.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:UnsecuredDebt unitRef="usd" contextRef="c93_AsOf12Apr2018" decimals="0">35000</us-gaap:UnsecuredDebt>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage unitRef="pure" contextRef="c93_AsOf12Apr2018" decimals="2">0.04</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentMaturityDateDescription contextRef="c94_From2Apr2018To12Apr2018">The note was due on the earlier of November 12, 2018 or in the event of default, as defined in the agreement.</us-gaap:DebtInstrumentMaturityDateDescription>
  <us-gaap:BridgeLoan unitRef="usd" contextRef="c95_AsOf10Jul2018_BridgeLoanMember" decimals="0">15600</us-gaap:BridgeLoan>
  <us-gaap:ShortTermDebtDescription contextRef="c96_From2Jul2018To10Jul2018_BridgeLoanMember">The note was due on the earlier of October 8, 2018 or in the event of default, as defined in the agreement.</us-gaap:ShortTermDebtDescription>
  <us-gaap:BridgeLoan unitRef="usd" contextRef="c97_AsOf18Jul2018_BridgeLoanMember" decimals="0">130000</us-gaap:BridgeLoan>
  <us-gaap:ShortTermDebtDescription contextRef="c98_From2Jul2018To18Jul2018_BridgeLoanMember">The note was due on the earlier of October 16, 2018 or in the event of default, as defined in the agreement.</us-gaap:ShortTermDebtDescription>
  <us-gaap:ShortTermBorrowings unitRef="usd" contextRef="c99_AsOf1Nov2019_BridgeLoanMember" decimals="0">50000</us-gaap:ShortTermBorrowings>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 unitRef="usdPershares" contextRef="c99_AsOf1Nov2019_BridgeLoanMember" decimals="2">2.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:ShortTermBorrowings unitRef="usd" contextRef="c100_AsOf10Jan2020_BridgeLoanMember" decimals="0">75000</us-gaap:ShortTermBorrowings>
  <adtx:OriginalIssueDiscount unitRef="usd" contextRef="c100_AsOf10Jan2020_BridgeLoanMember" decimals="0">40000</adtx:OriginalIssueDiscount>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 unitRef="usdPershares" contextRef="c100_AsOf10Jan2020_BridgeLoanMember" decimals="2">2.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtInstrumentCarryingAmount unitRef="usd" contextRef="c101_AsOf31Mar2020_SixBridgeLoansMember" decimals="0">600000</us-gaap:DebtInstrumentCarryingAmount>
  <adtx:OriginalIssueDiscount unitRef="usd" contextRef="c101_AsOf31Mar2020_SixBridgeLoansMember" decimals="0">300000</adtx:OriginalIssueDiscount>
  <us-gaap:DebtInstrumentMaturityDateDescription contextRef="c102_From1Jan2020To31Mar2020">The notes were due on the earlier of April 19, 2020 or ten days after the close of the Company&amp;#x2019;s IPO.</us-gaap:DebtInstrumentMaturityDateDescription>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;NOTE
8 &amp;#x2013; INCOME TAXES&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;For
the years ended December&amp;#xa0;31, 2020 and 2019, the Company did not record a current or deferred income tax expense or benefit
due to current and historical losses incurred by the Company. The Company&amp;#x2019;s losses before income taxes consist solely of
losses from domestic operations.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;On
March 27, 2020, the United States enacted the Coronavirus Aid, Relief, and Economic Security Act (&amp;#x201c;CARES Act&amp;#x201d;). The
Cares Act includes provisions relating to refundable payroll tax credits, deferment of the employer portion of certain payroll
taxes, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction
limitations and technical corrections to tax depreciation methods for qualified improvement property. The CARES Act also established
a Paycheck Protection Program whereby certain small businesses are eligible for a loan to fund payroll expenses, rent, and related
costs.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company considered the provisions under the CARES Act and elected not to take advantage of the provisions of CARES Act as the
effect of such provisions was not expected to have a material impact on the Company&amp;#x2019;s results of operations, cash flows
and financial statements.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;A
reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to income taxes as reflected
in the financial statements is as follows:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left&quot;&gt;Income taxes at U.S. statutory rate&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;21&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;%&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;21&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;State income taxes&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.2&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7.0&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Tax Credits&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.3&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Permanent Differences/Others&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;30.3&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(20.4&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Change in valuation allowance&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(60.8&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(7.6&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;Total provision for income taxes&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;0&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;%&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;0&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Deferred
taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income
tax purposes. The significant components of the Company&amp;#x2019;s deferred tax assets and liabilities as of December&amp;#xa0;31, 2020
and 2019 are comprised of the following:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Year
    Ended December 31,&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-size: 8pt; font-weight: bold&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-size: 8pt; font-weight: bold; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-size: 8pt; font-weight: bold&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-size: 8pt; font-weight: bold&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Deferred tax assets&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; padding-left: 13.7pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Net
    operating loss carryforwards&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;3,651,932&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;1,044,662&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 13.7pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Tax
    credits carryforwards&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;116,949&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 13.7pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Stock-based
    compensation&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;2,350,795&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;974,644&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 13.7pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Lease
    liability&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;367,029&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; padding-left: 13.7pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Other&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;1,920&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 27.35pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Total
    deferred tax assets&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;6,488,625&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;2,019,306&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Valuation
    allowance&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;(6,109,685&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;(2,019,306&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; padding-left: 27.35pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Net
    deferred tax assets&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;378,940&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x2014;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Deferred tax liabilities&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 13.7pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Right
    of use assets&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;(368,950&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 13.7pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Fixed
    Assets&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;(9,990&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 27.35pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Total
    deferred tax liabilities&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;(378,940&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x2014;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; padding-left: 27.35pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Net
    deferred taxes&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x2014;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x2014;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify&quot;&gt;The Company has evaluated the positive and negative
evidence bearing upon its ability to realize its deferred tax assets, which are comprised primarily of net operating loss carryforwards
and tax credits. Management has considered the Company&amp;#x2019;s history of cumulative net losses in the United States, estimated future
taxable income and prudent and feasible tax planning strategies and has concluded that it is more likely than not that the Company will
not realize the benefits of its U.S. federal and state deferred tax assets. Accordingly, a full valuation allowance has been established
against these net deferred tax assets as of December&amp;#xa0;31, 2020 and 2019, respectively. The Company reevaluates the positive and negative
evidence at each reporting period. The Company&amp;#x2019;s valuation allowance increased during 2020 by approximately $4.1&amp;#xa0;million primarily
due to the generation of net operating loss and tax credit carryforwards and stock based compensation.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;As
of December&amp;#xa0;31, 2020 and 2019, the Company had U.S. federal net operating loss carryforwards of $12.6 million and $3.8&amp;#xa0;million,
respectively, which may be available to offset future income tax liabilities. The 2017 Tax Cuts and Jobs Act (&amp;#x201c; TCJA&amp;#x201d;)
will generally allow losses incurred after 2017 to be carried over indefinitely, but will generally limit the net operating loss
deduction to the lesser of the net operating loss carryover or 80% of a corporation&amp;#x2019;s taxable income (subject to Section&amp;#xa0;382
of the Internal Revenue Code of 1986, as amended). Also, there will be no carryback for losses incurred after 2017. Losses incurred
prior to 2018 will generally be deductible to the extent of the lesser of a corporation&amp;#x2019;s net operating loss carryover or
100% of a corporation&amp;#x2019;s taxable income and be available for twenty years from the period the loss was generated. The Company
has federal net operating losses generated following 2017 of $12.5 million, which do not expire. The federal net operating losses
generated prior to 2018 of $0.1 million will expire at various dates through 2037. The CARES Act temporarily allows the Company
to carryback net operating losses arising in 2018, 2019 and 2020 to the five prior tax years. In addition, net operating losses
generated in these years could fully offset prior year taxable income without the 80% of the taxable income limitation under the
TCJA which was enacted on December 22, 2017. The Company has been generating losses since its inception, as such the net operating
loss carryback provision under the CARES Act is not applicable to the Company.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;As
of December&amp;#xa0;31, 2020 and 2019, the Company also had U.S. state net operating loss carryforwards of $15.2&amp;#xa0;million and
$3.8 million, respectively, which may be available to offset future income tax liabilities and expire at various dates through
2040.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;As
of December&amp;#xa0;31, 2020, the Company had federal tax credit carryforwards of approximately $0.1 million, available to reduce
future tax liabilities which expire at various dates through 2040. As of December&amp;#xa0;31, 2020, the Company had state research
and development tax credit carryforwards of approximately $0.1 million available to reduce future tax liabilities which expire
at various dates through 2035. The Company did not have any federal and state tax credit carryforward as of December 31, 2019.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Utilization
of the U.S. federal and state net operating loss and research and development credit carryforwards may be subject to a substantial
annual limitation under Section&amp;#xa0;382 and Section&amp;#xa0;383 of the Internal Revenue Code of 1986, as amended, and corresponding
provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership
changes may limit the amount of net operating loss and research and development credit carryforwards that can be utilized annually
to offset future taxable income and tax liabilities, respectively. The Company has not completed a study to assess whether a change
of ownership has occurred, or whether there have been multiple ownership changes since its formation. Any limitation may result
in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before
utilization.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company has not, as of yet, conducted a study of research and development tax credit carryforwards. Such a study, once undertaken
by the Company, may result in an adjustment to the research and development tax credit carryforwards; however, a full valuation
allowance has been provided against the Company&amp;#x2019;s research and development tax credits and, if an adjustment is required,
this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the balance sheet
or statement of operations if an adjustment is required.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company files tax returns in the United States, California, Virginia, and New York. The Company is subject to U.S. federal and
state tax examinations by tax authorities for years 2017 through present. As of December&amp;#xa0;31, 2020 and 2019, the Company has
recorded no liability for unrecognized tax benefits, interest, or penalties related to federal and state income tax matters and
there currently no pending tax examinations. The Company will recognize interest and penalties related to uncertain tax positions
in income tax expense&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-5">4100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:OperatingLossCarryforwards unitRef="usd" contextRef="c103_AsOf31Dec2020_USFederalMember" decimals="-5">12600000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards unitRef="usd" contextRef="c104_AsOf31Dec2019_USFederalMember" decimals="-5">3800000</us-gaap:OperatingLossCarryforwards>
  <adtx:NetOperatingLossPercentage unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">0.80</adtx:NetOperatingLossPercentage>
  <adtx:CorporationsTaxableIncomePercentage unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">1.00</adtx:CorporationsTaxableIncomePercentage>
  <us-gaap:OperatingLossCarryforwardsLimitationsOnUse contextRef="c0_From1Jan2020To31Dec2020">The Company has federal net operating losses generated following 2017 of $12.5 million, which do not expire. The federal net operating losses generated prior to 2018 of $0.1 million will expire at various dates through 2037. The CARES Act temporarily allows the Company to carryback net operating losses arising in 2018, 2019 and 2020 to the five prior tax years. In addition, net operating losses generated in these years could fully offset prior year taxable income without the 80% of the taxable income limitation under the TCJA which was enacted on December 22, 2017.</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
  <us-gaap:OperatingLossCarryforwards unitRef="usd" contextRef="c105_AsOf31Dec2020_USStateMember" decimals="-5">15200000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards unitRef="usd" contextRef="c106_AsOf31Dec2019_USStateMember" decimals="-5">3800000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:TaxCreditCarryforwardAmount unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-5">100000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="-5">100000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left&quot;&gt;Income taxes at U.S. statutory rate&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;21&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;%&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;21&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;State income taxes&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8.2&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7.0&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Tax Credits&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.3&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Permanent Differences/Others&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;30.3&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(20.4&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Change in valuation allowance&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(60.8&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(7.6&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;Total provision for income taxes&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;0&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;%&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;0&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate unitRef="pure" contextRef="c5_From1Jan2019To31Dec2019" decimals="2">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="3">0.082</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes unitRef="pure" contextRef="c5_From1Jan2019To31Dec2019" decimals="3">0.070</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="3">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits unitRef="pure" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="3">0.303</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate unitRef="pure" contextRef="c5_From1Jan2019To31Dec2019" decimals="3">-0.204</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="3">0.608</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance unitRef="pure" contextRef="c5_From1Jan2019To31Dec2019" decimals="3">0.076</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations unitRef="pure" contextRef="c5_From1Jan2019To31Dec2019" decimals="2">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Year
    Ended December 31,&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-size: 8pt; font-weight: bold&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-size: 8pt; font-weight: bold; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-size: 8pt; font-weight: bold&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-size: 8pt; font-weight: bold&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Deferred tax assets&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; padding-left: 13.7pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Net
    operating loss carryforwards&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;3,651,932&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;1,044,662&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 13.7pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Tax
    credits carryforwards&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;116,949&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 13.7pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Stock-based
    compensation&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;2,350,795&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;974,644&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 13.7pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Lease
    liability&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;367,029&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; padding-left: 13.7pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Other&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;1,920&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 27.35pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Total
    deferred tax assets&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;6,488,625&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;2,019,306&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Valuation
    allowance&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;(6,109,685&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;(2,019,306&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; padding-left: 27.35pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Net
    deferred tax assets&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;378,940&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x2014;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Deferred tax liabilities&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 13.7pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Right
    of use assets&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;(368,950&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 13.7pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Fixed
    Assets&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;(9,990&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 27.35pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Total
    deferred tax liabilities&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;(378,940&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x2014;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 4pt; padding-left: 27.35pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Net
    deferred taxes&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x2014;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x2014;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">3651932</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">1044662</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">116949</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">2350795</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">974644</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <adtx:DeferredTaxAssetsLeaseLiability unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">367029</adtx:DeferredTaxAssetsLeaseLiability>
  <us-gaap:DeferredTaxAssetsOther unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">1920</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsOther unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:DeferredTaxAssetsGross unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">6488625</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">2019306</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsValuationAllowance unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">6109685</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">2019306</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsNet unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">378940</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsNet unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <adtx:DeferredTaxLiabilitiesRightOfUseAssets unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">368950</adtx:DeferredTaxLiabilitiesRightOfUseAssets>
  <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">9990</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
  <us-gaap:DeferredIncomeTaxLiabilities unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">378940</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:DeferredIncomeTaxLiabilities unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet unitRef="usd" contextRef="c3_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:SubsequentEventsTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;NOTE
9 &amp;#x2013; SUBSEQUENT EVENTS&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The
Company has evaluated subsequent events through the filing of this Annual Report on Form 10-K and has determined that there have
been no events that have occurred that would require adjustments to the Company&amp;#x2019;s disclosures in the financial statements,
except for the following:&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;On
January 25, 2021, the Company entered into a Securities Purchase Agreement for the sale of $6,000,000 in Convertible Notes. The
Convertible Notes have a term of 24 months, convert at $4.00 per share, and have an original issuance discount of $1,000,000.
The Company also issued 800,000 warrants to purchase shares of the Company&amp;#x2019;s common stock. These warrants have a term of
three years, are immediately exercisable, and have an exercise price of $4.00.&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify&quot;&gt;During February 2021, the Company entered into
a 24 month financing agreement for lab equipment. The aggregate cost of this financing agreement will be $892,094.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify&quot;&gt;Through the date of this filing, there were 1,142,306
warrants exercised for shares of the Company&amp;#x2019;s common stock, resulting in proceeds of $3,643,956.&amp;#xa0;&lt;/p&gt;&lt;br/&gt;</us-gaap:SubsequentEventsTextBlock>
  <adtx:SaleOfConvertableNote unitRef="usd" contextRef="c107_From13Jan2021To25Jan2021_SubsequentEventMember" decimals="0">6000000</adtx:SaleOfConvertableNote>
  <us-gaap:DebtInstrumentTerm contextRef="c107_From13Jan2021To25Jan2021_SubsequentEventMember">P24M</us-gaap:DebtInstrumentTerm>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 unitRef="usdPershares" contextRef="c108_AsOf25Jan2021_SubsequentEventMember" decimals="2">4.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtInstrumentUnamortizedDiscount unitRef="usd" contextRef="c108_AsOf25Jan2021_SubsequentEventMember" decimals="0">1000000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:ProceedsFromIssuanceOfWarrants unitRef="usd" contextRef="c107_From13Jan2021To25Jan2021_SubsequentEventMember" decimals="0">800000</us-gaap:ProceedsFromIssuanceOfWarrants>
  <adtx:InvestmentWarrantsExpirationPeriod contextRef="c107_From13Jan2021To25Jan2021_SubsequentEventMember">P3Y</adtx:InvestmentWarrantsExpirationPeriod>
  <adtx:InvestmentWarrantsExercisePrice unitRef="usdPershares" contextRef="c107_From13Jan2021To25Jan2021_SubsequentEventMember" decimals="2">4.00</adtx:InvestmentWarrantsExercisePrice>
  <adtx:FinancingAgreementTerm contextRef="c109_From1Feb2021To28Feb2021_SubsequentEventMember">P24Y</adtx:FinancingAgreementTerm>
  <adtx:CostOfFinancingAgreement unitRef="usd" contextRef="c109_From1Feb2021To28Feb2021_SubsequentEventMember" decimals="0">892094</adtx:CostOfFinancingAgreement>
  <adtx:WarrantsExercisedForShares unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">1142306</adtx:WarrantsExercisedForShares>
  <adtx:ProceedsFormWarrantsIssued unitRef="usd" contextRef="c71_From1Jan2020To31Dec2020_WarrantMember" decimals="0">3643956</adtx:ProceedsFormWarrantsIssued>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>adtx-20201231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 25 16:57:49 EDT 2021 -->
<xs:schema elementFormDefault="qualified" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" targetNamespace="http://www.aditxt.com./20201231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:adtx="http://www.aditxt.com./20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="adtx-20201231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="adtx-20201231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="adtx-20201231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="adtx-20201231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.aditxt.com./role/ConsolidatedBalanceSheet" id="adtx_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/ConsolidatedBalanceSheet_Parentheticals" id="adtx_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/ConsolidatedIncomeStatement" id="adtx_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/ConsolidatedIncomeStatement_Parentheticals" id="adtx_r_ConsolidatedIncomeStatement_Parentheticals">
        <link:definition>004 - Statement - Statements of Operations (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/ShareholdersEquityType2or3" id="adtx_r_ShareholdersEquityType2or3">
        <link:definition>005 - Statement - Statements of Stockholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/ConsolidatedCashFlow" id="adtx_r_ConsolidatedCashFlow">
        <link:definition>006 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/OrganizationandNatureofBusiness" id="adtx_r_OrganizationandNatureofBusiness">
        <link:definition>007 - Disclosure - Organization and Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/GoingConcernAnalysis" id="adtx_r_GoingConcernAnalysis">
        <link:definition>008 - Disclosure - Going Concern Analysis</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/SummaryofSignificantAccountingPolicies" id="adtx_r_SummaryofSignificantAccountingPolicies">
        <link:definition>009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/RelatedPartyTransactions" id="adtx_r_RelatedPartyTransactions">
        <link:definition>010 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/StockholdersEquityDeficit" id="adtx_r_StockholdersEquityDeficit">
        <link:definition>011 - Disclosure - Stockholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/Agreements" id="adtx_r_Agreements">
        <link:definition>012 - Disclosure - Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/NotesPayable" id="adtx_r_NotesPayable">
        <link:definition>013 - Disclosure - Notes Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/IncomeTaxes" id="adtx_r_IncomeTaxes">
        <link:definition>014 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/SubsequentEvents" id="adtx_r_SubsequentEvents">
        <link:definition>015 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/AccountingPoliciesByPolicy" id="adtx_r_AccountingPoliciesByPolicy">
        <link:definition>016 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesTables" id="adtx_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>017 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/StockholdersEquityDeficitTables" id="adtx_r_StockholdersEquityDeficitTables">
        <link:definition>018 - Disclosure - Stockholders&#8217; Equity (Deficit) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/IncomeTaxesTables" id="adtx_r_IncomeTaxesTables">
        <link:definition>019 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails" id="adtx_r_OrganizationandNatureofBusinessDetails">
        <link:definition>020 - Disclosure - Organization and Nature of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/GoingConcernAnalysisDetails" id="adtx_r_GoingConcernAnalysisDetails">
        <link:definition>021 - Disclosure - Going Concern Analysis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesDetails" id="adtx_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>022 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/ScheduleofleasecostsTable" id="adtx_r_ScheduleofleasecostsTable">
        <link:definition>023 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of lease costs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/ScheduleofrightofuseassetleaseassetsandleaseliabilitiesTable" id="adtx_r_ScheduleofrightofuseassetleaseassetsandleaseliabilitiesTable">
        <link:definition>024 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of right of use asset lease assets and lease liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/ScheduleofleasetermsanddiscountTable" id="adtx_r_ScheduleofleasetermsanddiscountTable">
        <link:definition>025 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of lease terms and discount</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/SchedulefutureminimumleasepaymentsundertheleasesTable" id="adtx_r_SchedulefutureminimumleasepaymentsundertheleasesTable">
        <link:definition>026 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule future minimum lease payments under the leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/RelatedPartyTransactionsDetails" id="adtx_r_RelatedPartyTransactionsDetails">
        <link:definition>027 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/StockholdersEquityDeficitDetails" id="adtx_r_StockholdersEquityDeficitDetails">
        <link:definition>028 - Disclosure - Stockholders&#8217; Equity (Deficit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/ScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionTable" id="adtx_r_ScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionTable">
        <link:definition>029 - Disclosure - Stockholders&#8217; Equity (Deficit) (Details) - Schedule of stock option granted was estimated using the Black-Scholes assumption</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbshkMkzTNOwKi/SY5wisaUmNZUHQSzNMHSWLwfjT7WpDTxNyESoEbcePgflNnDx4+Cpe7iGVGde/DRQguZdZo5KjpAUGAQNyOkDD76ahIjQccKEsvf9/Xj3++QLucVobcn305z1bCg1mi6xUZr+oBVMyyqaM/+TOgNX7+t44hIrWlYUwPKsqCr5vXiF6x03y+dnPJsJWsg0ZTfzR4zGd6o] CSR-->
      <link:roleType roleURI="http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable" id="adtx_r_ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable">
        <link:definition>030 - Disclosure - Stockholders&#8217; Equity (Deficit) (Details) - Schedule of analysis of the stock option grant activity under the plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/ScheduleofnonvestedoptionTable" id="adtx_r_ScheduleofnonvestedoptionTable">
        <link:definition>031 - Disclosure - Stockholders&#8217; Equity (Deficit) (Details) - Schedule of nonvested option</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/AgreementsDetails" id="adtx_r_AgreementsDetails">
        <link:definition>032 - Disclosure - Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/NotesPayableDetails" id="adtx_r_NotesPayableDetails">
        <link:definition>033 - Disclosure - Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/IncomeTaxesDetails" id="adtx_r_IncomeTaxesDetails">
        <link:definition>034 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/ScheduleofstatutoryfederalincometaxrateTable" id="adtx_r_ScheduleofstatutoryfederalincometaxrateTable">
        <link:definition>035 - Disclosure - Income Taxes (Details) - Schedule of statutory federal income tax rate</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/ScheduleofdeferredtaxassetsandliabilitiesTable" id="adtx_r_ScheduleofdeferredtaxassetsandliabilitiesTable">
        <link:definition>036 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets and liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/SubsequentEventsDetails" id="adtx_r_SubsequentEventsDetails">
        <link:definition>037 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.aditxt.com./role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd"/>
  <xs:element name="GoingConcernDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_GoingConcernDisclosureAbstract"/>
  <xs:element name="ScheduleOfLeaseCostsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ScheduleOfLeaseCostsAbstract"/>
  <xs:element name="ScheduleOfRightOfUseAssetLeaseAssetsAndLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ScheduleOfRightOfUseAssetLeaseAssetsAndLeaseLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfLeaseTermsAndDiscountAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ScheduleOfLeaseTermsAndDiscountAbstract"/>
  <xs:element name="ScheduleFutureMinimumLeasePaymentsUnderTheLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ScheduleFutureMinimumLeasePaymentsUnderTheLeasesAbstract"/>
  <xs:element name="ScheduleOfStockOptionGrantedWasEstimatedUsingTheBlackScholesAssumptionAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ScheduleOfStockOptionGrantedWasEstimatedUsingTheBlackScholesAssumptionAbstract"/>
  <xs:element name="ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanAbstract"/>
  <xs:element name="ScheduleOfNonvestedOptionAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ScheduleOfNonvestedOptionAbstract"/>
  <xs:element name="AgreementsDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_AgreementsDisclosureAbstract"/>
  <xs:element name="ScheduleOfStatutoryFederalIncomeTaxRateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ScheduleOfStatutoryFederalIncomeTaxRateAbstract"/>
  <xs:element name="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
  <xs:element name="AssetsAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_AssetsAbstract0"/>
  <xs:element name="DeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_DeferredTaxAssetsAbstract"/>
  <xs:element name="ROUAssetShortTerm" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_ROUAssetShortTerm"/>
  <xs:element name="FixedAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_FixedAssets"/>
  <xs:element name="RightOfUseAssetLongTerm" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_RightOfUseAssetLongTerm"/>
  <xs:element name="FinancingOnFixedAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_FinancingOnFixedAssets"/>
  <xs:element name="ExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_ExerciseOfWarrants"/>
  <xs:element name="StockIssuedDuringPeriodValueIntangibleAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_StockIssuedDuringPeriodValueIntangibleAssets"/>
  <xs:element name="StockIssuedDuringPeriodSharesForIntangibleAssets" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_StockIssuedDuringPeriodSharesForIntangibleAssets"/>
  <xs:element name="IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable"/>
  <xs:element name="IssuanceOfSharesForTheSettlementOfSharesAccruedCompensationAndAccountsPayable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_IssuanceOfSharesForTheSettlementOfSharesAccruedCompensationAndAccountsPayable"/>
  <xs:element name="IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts"/>
  <xs:element name="IssuanceOfSharesAndWarrantsForIPONetOfSharesOfferingCosts" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_IssuanceOfSharesAndWarrantsForIPONetOfSharesOfferingCosts"/>
  <xs:element name="StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts"/>
  <xs:element name="StockIssuedDuringPeriodSharesForCashNetOfOfferingCosts" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_StockIssuedDuringPeriodSharesForCashNetOfOfferingCosts"/>
  <xs:element name="IssuanceOfSharesForTheSettlementOfDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_IssuanceOfSharesForTheSettlementOfDebt"/>
  <xs:element name="IssuanceOfSharesForTheSettlementOfSharesDebtinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_IssuanceOfSharesForTheSettlementOfSharesDebtinShares"/>
  <xs:element name="ExerciseConversionOfPreferredShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_ExerciseConversionOfPreferredShares"/>
  <xs:element name="ExerciseConversionOfSharesPreferredShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ExerciseConversionOfSharesPreferredShares"/>
  <xs:element name="ModificationOfOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_ModificationOfOptions"/>
  <xs:element name="IncreaseDecreaseInAccruedCompensationToRelatedParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_IncreaseDecreaseInAccruedCompensationToRelatedParties"/>
  <xs:element name="LiabilitiesAssumedForCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_LiabilitiesAssumedForCommonStock"/>
  <xs:element name="IssuanceOfUnitsForTheSettlementOfAccruedCompensationAndAccountsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_IssuanceOfUnitsForTheSettlementOfAccruedCompensationAndAccountsPayable"/>
  <xs:element name="OriginalIssuanceDiscountOnNotesPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_OriginalIssuanceDiscountOnNotesPayable"/>
  <xs:element name="LiabilityRecognizedForFinancedAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_LiabilityRecognizedForFinancedAssets"/>
  <xs:element name="SharesIssuedForIntangibleAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_SharesIssuedForIntangibleAssets"/>
  <xs:element name="ConversionOfPreferredShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_ConversionOfPreferredShares"/>
  <xs:element name="GoingConcernDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_GoingConcernDisclosureTextBlock"/>
  <xs:element name="AgreementsDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_AgreementsDisclosureTextBlock"/>
  <xs:element name="FixedAssetPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_FixedAssetPolicyTextBlock"/>
  <xs:element name="OfferingCostsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_OfferingCostsPolicyTextBlock"/>
  <xs:element name="PatentsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_PatentsPolicyTextBlock"/>
  <xs:element name="ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock"/>
  <xs:element name="RightOfUseAssetShortTerm" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_RightOfUseAssetShortTerm"/>
  <xs:element name="LesseeOperatingLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_LesseeOperatingLeaseLiability"/>
  <xs:element name="StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionTable"/>
  <xs:element name="StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionLineItems"/>
  <xs:element name="StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"/>
  <xs:element name="StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems"/>
  <xs:element name="WeightedAverageExercisePriceOutstanding" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="adtx_WeightedAverageExercisePriceOutstanding"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3"/>
  <xs:element name="WeightedAverageRemainingLifeGranted" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_WeightedAverageRemainingLifeGranted"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingLifeExpiredOrForfeited" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingLifeExpiredOrForfeited"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1"/>
  <xs:element name="ShareBasedPaymentsWeightedAverageRemainingLifeExercised" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ShareBasedPaymentsWeightedAverageRemainingLifeExercised"/>
  <xs:element name="StockholdersEquityDeficitDetailsScheduleofnonvestedoptionTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionTable"/>
  <xs:element name="StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems"/>
  <xs:element name="WeightedAverageExercisePriceGranted" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_WeightedAverageExercisePriceGranted"/>
  <xs:element name="WeightedAverageExercisePriceVested" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_WeightedAverageExercisePriceVested"/>
  <xs:element name="WeightedAverageExercisePriceForfeited" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_WeightedAverageExercisePriceForfeited"/>
  <xs:element name="DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_DeferredTaxAssetsLeaseLiability"/>
  <xs:element name="DeferredTaxLiabilitiesRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_DeferredTaxLiabilitiesRightOfUseAssets"/>
  <xs:element name="OrganizationandNatureofBusinessDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="adtx_OrganizationandNatureofBusinessDetailsTable"/>
  <xs:element name="OrganizationandNatureofBusinessDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_OrganizationandNatureofBusinessDetailsLineItems"/>
  <xs:element name="StockUnitIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_StockUnitIssued"/>
  <xs:element name="CommonUnitIssuedPerUnit" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="adtx_CommonUnitIssuedPerUnit"/>
  <xs:element name="OfferingPriceOfShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="adtx_OfferingPriceOfShares"/>
  <xs:element name="PurchaseOfEquityShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="adtx_PurchaseOfEquityShares"/>
  <xs:element name="CommonStockVotingRightsPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="adtx_CommonStockVotingRightsPercentage"/>
  <xs:element name="PurchaseOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="adtx_PurchaseOfCommonStock"/>
  <xs:element name="CommonStockExercisePricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="adtx_CommonStockExercisePricePerShare"/>
  <xs:element name="AccumulatedDepreciation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_AccumulatedDepreciation"/>
  <xs:element name="LicensingFeeForPatents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_LicensingFeeForPatents"/>
  <xs:element name="WarrantsOfStockOption" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_WarrantsOfStockOption"/>
  <xs:element name="DilutiveEarningsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_DilutiveEarningsShares"/>
  <xs:element name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="adtx_RelatedPartyTransactionsDetailsTable"/>
  <xs:element name="RelatedPartyTransactionsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_RelatedPartyTransactionsDetailsLineItems"/>
  <xs:element name="AccruedCompensationForRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_AccruedCompensationForRelatedParty"/>
  <xs:element name="StockIssuedDuringPeriodValueNewIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_StockIssuedDuringPeriodValueNewIssued"/>
  <xs:element name="StocksIssuedDuringPeriodSharesIssues" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_StocksIssuedDuringPeriodSharesIssues"/>
  <xs:element name="StockholdersEquityDeficitDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="adtx_StockholdersEquityDeficitDetailsTable"/>
  <xs:element name="StockholdersEquityDeficitDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_StockholdersEquityDeficitDetailsLineItems"/>
  <xs:element name="StockIssuedDuringPeriodSharesIntangibleAssets" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_StockIssuedDuringPeriodSharesIntangibleAssets"/>
  <xs:element name="CommonStockIssuedForPreferredShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_CommonStockIssuedForPreferredShares"/>
  <xs:element name="PreferredStockExercise" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_PreferredStockExercise"/>
  <xs:element name="SettlementOfAccountsPayableShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_SettlementOfAccountsPayableShares"/>
  <xs:element name="StockIssuedSettlementOfDebt" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_StockIssuedSettlementOfDebt"/>
  <xs:element name="StockIssuedDuringPeriodSharesIssuedForService" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_StockIssuedDuringPeriodSharesIssuedForService"/>
  <xs:element name="TotalGrantFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_TotalGrantFairValue"/>
  <xs:element name="StockOptionexercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_StockOptionexercisePrice"/>
  <xs:element name="ShareBasedPaymentRemnainingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_ShareBasedPaymentRemnainingExpenses"/>
  <xs:element name="WarrantsIssuedAndVesting" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_WarrantsIssuedAndVesting"/>
  <xs:element name="WarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_WarrantsExercised"/>
  <xs:element name="TypeOfAgreementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_TypeOfAgreementDomain"/>
  <xs:element name="AgreementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="adtx_AgreementsDetailsTable"/>
  <xs:element name="AgreementsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_AgreementsDetailsLineItems"/>
  <xs:element name="FinanceArrangementCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_FinanceArrangementCost"/>
  <xs:element name="NotesPayableDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="adtx_NotesPayableDetailsTable"/>
  <xs:element name="NotesPayableDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_NotesPayableDetailsLineItems"/>
  <xs:element name="OriginalIssueDiscount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_OriginalIssueDiscount"/>
  <xs:element name="IncomeTaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="adtx_IncomeTaxesDetailsTable"/>
  <xs:element name="IncomeTaxesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_IncomeTaxesDetailsLineItems"/>
  <xs:element name="NetOperatingLossPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_NetOperatingLossPercentage"/>
  <xs:element name="CorporationsTaxableIncomePercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_CorporationsTaxableIncomePercentage"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="adtx_SubsequentEventsDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_SubsequentEventsDetailsLineItems"/>
  <xs:element name="SaleOfConvertableNote" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="adtx_SaleOfConvertableNote"/>
  <xs:element name="InvestmentWarrantsExpirationPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_InvestmentWarrantsExpirationPeriod"/>
  <xs:element name="InvestmentWarrantsExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_InvestmentWarrantsExercisePrice"/>
  <xs:element name="FinancingAgreementTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_FinancingAgreementTerm"/>
  <xs:element name="CostOfFinancingAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_CostOfFinancingAgreement"/>
  <xs:element name="WarrantsExercisedForShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="adtx_WarrantsExercisedForShares"/>
  <xs:element name="ProceedsFormWarrantsIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="adtx_ProceedsFormWarrantsIssued"/>
  <xs:element name="TypeOfAgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="adtx_TypeOfAgreementAxis"/>
  <xs:element name="ChiefInnovationOfficerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_ChiefInnovationOfficerMember"/>
  <xs:element name="NonvestedOptionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_NonvestedOptionsMember"/>
  <xs:element name="NonvestedWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_NonvestedWarrantsMember"/>
  <xs:element name="SalveoConsultingAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_SalveoConsultingAgreementMember"/>
  <xs:element name="SalveoDiagnosticsIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_SalveoDiagnosticsIncMember"/>
  <xs:element name="September2020OfferingMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_September2020OfferingMember"/>
  <xs:element name="SeriesA1WarrantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_SeriesA1WarrantMember"/>
  <xs:element name="SeriesB1WarrantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_SeriesB1WarrantMember"/>
  <xs:element name="SixBridgeLoansMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_SixBridgeLoansMember"/>
  <xs:element name="StockOptionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_StockOptionsMember"/>
  <xs:element name="TwoZeroOneSevenEquityIncentivePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_TwoZeroOneSevenEquityIncentivePlanMember"/>
  <xs:element name="USFederalMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_USFederalMember"/>
  <xs:element name="USStateMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_USStateMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="adtx_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>adtx-20201231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 25 16:57:49 EDT 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ConsolidatedBalanceSheet" roleURI="http://www.aditxt.com./role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ConsolidatedIncomeStatement" roleURI="http://www.aditxt.com./role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ConsolidatedCashFlow" roleURI="http://www.aditxt.com./role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ScheduleofleasecostsTable" roleURI="http://www.aditxt.com./role/ScheduleofleasecostsTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ScheduleofrightofuseassetleaseassetsandleaseliabilitiesTable" roleURI="http://www.aditxt.com./role/ScheduleofrightofuseassetleaseassetsandleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_SchedulefutureminimumleasepaymentsundertheleasesTable" roleURI="http://www.aditxt.com./role/SchedulefutureminimumleasepaymentsundertheleasesTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="adtx_ROUAssetShortTerm" xlink:href="adtx-20201231.xsd#adtx_ROUAssetShortTerm"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="adtx_ROUAssetShortTerm" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="adtx_FixedAssets" xlink:href="adtx-20201231.xsd#adtx_FixedAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="adtx_FixedAssets" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherIntangibleAssetsNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredCosts" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="adtx_RightOfUseAssetLongTerm" xlink:href="adtx-20201231.xsd#adtx_RightOfUseAssetLongTerm"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="adtx_RightOfUseAssetLongTerm" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="adtx_FinancingOnFixedAssets" xlink:href="adtx-20201231.xsd#adtx_FinancingOnFixedAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="adtx_FinancingOnFixedAssets" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockValue" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseOther" order="3" weight="-1"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbshkMkzTNOwKi/SY5wisaUmNZUHQSzNMHSWLwfjT7WpDTxNyESoEbcePgflNnDx4+Cpe7iGVGde/DRQguZdZo5KjpAUGAQNyOkDD76ahIjQccKEsvf9/Xj3++QLucVobcn305z1bCg1mi6xUZr+oBVMyyqaM/+TOgNX7+t44hIrWlYUwPKsqCr5vXiF6x03y9kPPu5SKrGeJm1M5EWPhrW] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationNonproduction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationNonproduction"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationNonproduction" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="adtx_ModificationOfOptions" xlink:href="adtx-20201231.xsd#adtx_ModificationOfOptions"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="adtx_ModificationOfOptions" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="adtx_IncreaseDecreaseInAccruedCompensationToRelatedParties" xlink:href="adtx-20201231.xsd#adtx_IncreaseDecreaseInAccruedCompensationToRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="adtx_IncreaseDecreaseInAccruedCompensationToRelatedParties" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromProductiveAssets" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromNotesPayable" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofleasecostsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="1" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofrightofuseassetleaseassetsandleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <loc xlink:type="locator" xlink:label="adtx_RightOfUseAssetShortTerm" xlink:href="adtx-20201231.xsd#adtx_RightOfUseAssetShortTerm"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="adtx_RightOfUseAssetShortTerm" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="adtx_RightOfUseAssetLongTerm" xlink:href="adtx-20201231.xsd#adtx_RightOfUseAssetLongTerm"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="adtx_RightOfUseAssetLongTerm" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/SchedulefutureminimumleasepaymentsundertheleasesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="adtx_LesseeOperatingLeaseLiability" xlink:href="adtx-20201231.xsd#adtx_LesseeOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="adtx_LesseeOperatingLeaseLiability" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableWithImputedInterestNetAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableWithImputedInterestNetAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="adtx_LesseeOperatingLeaseLiability" xlink:to="us-gaap_ReceivableWithImputedInterestNetAmount" order="2" weight="-1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>adtx-20201231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 25 16:57:49 EDT 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ConsolidatedBalanceSheet" roleURI="http://www.aditxt.com./role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.aditxt.com./role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ConsolidatedIncomeStatement" roleURI="http://www.aditxt.com./role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.aditxt.com./role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ShareholdersEquityType2or3" roleURI="http://www.aditxt.com./role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ConsolidatedCashFlow" roleURI="http://www.aditxt.com./role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_OrganizationandNatureofBusiness" roleURI="http://www.aditxt.com./role/OrganizationandNatureofBusiness"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_GoingConcernAnalysis" roleURI="http://www.aditxt.com./role/GoingConcernAnalysis"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.aditxt.com./role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_RelatedPartyTransactions" roleURI="http://www.aditxt.com./role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_StockholdersEquityDeficit" roleURI="http://www.aditxt.com./role/StockholdersEquityDeficit"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_Agreements" roleURI="http://www.aditxt.com./role/Agreements"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_NotesPayable" roleURI="http://www.aditxt.com./role/NotesPayable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_IncomeTaxes" roleURI="http://www.aditxt.com./role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_SubsequentEvents" roleURI="http://www.aditxt.com./role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_AccountingPoliciesByPolicy" roleURI="http://www.aditxt.com./role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_StockholdersEquityDeficitTables" roleURI="http://www.aditxt.com./role/StockholdersEquityDeficitTables"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_IncomeTaxesTables" roleURI="http://www.aditxt.com./role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ScheduleofleasecostsTable" roleURI="http://www.aditxt.com./role/ScheduleofleasecostsTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ScheduleofrightofuseassetleaseassetsandleaseliabilitiesTable" roleURI="http://www.aditxt.com./role/ScheduleofrightofuseassetleaseassetsandleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ScheduleofleasetermsanddiscountTable" roleURI="http://www.aditxt.com./role/ScheduleofleasetermsanddiscountTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_SchedulefutureminimumleasepaymentsundertheleasesTable" roleURI="http://www.aditxt.com./role/SchedulefutureminimumleasepaymentsundertheleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionTable" roleURI="http://www.aditxt.com./role/ScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable" roleURI="http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ScheduleofnonvestedoptionTable" roleURI="http://www.aditxt.com./role/ScheduleofnonvestedoptionTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ScheduleofstatutoryfederalincometaxrateTable" roleURI="http://www.aditxt.com./role/ScheduleofstatutoryfederalincometaxrateTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ScheduleofdeferredtaxassetsandliabilitiesTable" roleURI="http://www.aditxt.com./role/ScheduleofdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_OrganizationandNatureofBusinessDetails" roleURI="http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_GoingConcernAnalysisDetails" roleURI="http://www.aditxt.com./role/GoingConcernAnalysisDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_RelatedPartyTransactionsDetails" roleURI="http://www.aditxt.com./role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_StockholdersEquityDeficitDetails" roleURI="http://www.aditxt.com./role/StockholdersEquityDeficitDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_AgreementsDetails" roleURI="http://www.aditxt.com./role/AgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_NotesPayableDetails" roleURI="http://www.aditxt.com./role/NotesPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_IncomeTaxesDetails" roleURI="http://www.aditxt.com./role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_SubsequentEventsDetails" roleURI="http://www.aditxt.com./role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#DocumentAndEntityInformation" roleURI="http://www.aditxt.com./role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_ROUAssetShortTerm" xlink:href="adtx-20201231.xsd#adtx_ROUAssetShortTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="adtx_ROUAssetShortTerm" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_FixedAssets" xlink:href="adtx-20201231.xsd#adtx_FixedAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrent" xlink:to="adtx_FixedAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherIntangibleAssetsNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DeferredCosts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_RightOfUseAssetLongTerm" xlink:href="adtx-20201231.xsd#adtx_RightOfUseAssetLongTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrent" xlink:to="adtx_RightOfUseAssetLongTerm" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_FinancingOnFixedAssets" xlink:href="adtx-20201231.xsd#adtx_FinancingOnFixedAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="adtx_FinancingOnFixedAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TreasuryStockShares" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_OperatingExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseOther" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_StockIssuedDuringPeriodValueIntangibleAssets" xlink:href="adtx-20201231.xsd#adtx_StockIssuedDuringPeriodValueIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_StockIssuedDuringPeriodValueIntangibleAssets" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_StockIssuedDuringPeriodSharesForIntangibleAssets" xlink:href="adtx-20201231.xsd#adtx_StockIssuedDuringPeriodSharesForIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_StockIssuedDuringPeriodSharesForIntangibleAssets" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable" xlink:href="adtx-20201231.xsd#adtx_IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_IssuanceOfSharesForTheSettlementOfSharesAccruedCompensationAndAccountsPayable" xlink:href="adtx-20201231.xsd#adtx_IssuanceOfSharesForTheSettlementOfSharesAccruedCompensationAndAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_IssuanceOfSharesForTheSettlementOfSharesAccruedCompensationAndAccountsPayable" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts" xlink:href="adtx-20201231.xsd#adtx_IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_IssuanceOfSharesAndWarrantsForIPONetOfSharesOfferingCosts" xlink:href="adtx-20201231.xsd#adtx_IssuanceOfSharesAndWarrantsForIPONetOfSharesOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_IssuanceOfSharesAndWarrantsForIPONetOfSharesOfferingCosts" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts" xlink:href="adtx-20201231.xsd#adtx_StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_StockIssuedDuringPeriodSharesForCashNetOfOfferingCosts" xlink:href="adtx-20201231.xsd#adtx_StockIssuedDuringPeriodSharesForCashNetOfOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_StockIssuedDuringPeriodSharesForCashNetOfOfferingCosts" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_IssuanceOfSharesForTheSettlementOfDebt" xlink:href="adtx-20201231.xsd#adtx_IssuanceOfSharesForTheSettlementOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_IssuanceOfSharesForTheSettlementOfDebt" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_IssuanceOfSharesForTheSettlementOfSharesDebtinShares" xlink:href="adtx-20201231.xsd#adtx_IssuanceOfSharesForTheSettlementOfSharesDebtinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_IssuanceOfSharesForTheSettlementOfSharesDebtinShares" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_ExerciseConversionOfPreferredShares" xlink:href="adtx-20201231.xsd#adtx_ExerciseConversionOfPreferredShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_ExerciseConversionOfPreferredShares" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_ExerciseConversionOfSharesPreferredShares" xlink:href="adtx-20201231.xsd#adtx_ExerciseConversionOfSharesPreferredShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_ExerciseConversionOfSharesPreferredShares" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockSharesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockSharesAcquired" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_ExerciseOfWarrants" xlink:href="adtx-20201231.xsd#adtx_ExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="adtx_ExerciseOfWarrants" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="27" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationNonproduction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationNonproduction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationNonproduction" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_ModificationOfOptions" xlink:href="adtx-20201231.xsd#adtx_ModificationOfOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="adtx_ModificationOfOptions" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_IncreaseDecreaseInAccruedCompensationToRelatedParties" xlink:href="adtx-20201231.xsd#adtx_IncreaseDecreaseInAccruedCompensationToRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="adtx_IncreaseDecreaseInAccruedCompensationToRelatedParties" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromProductiveAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_LiabilitiesAssumedForCommonStock" xlink:href="adtx-20201231.xsd#adtx_LiabilitiesAssumedForCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="adtx_LiabilitiesAssumedForCommonStock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_StockIssued1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_IssuanceOfUnitsForTheSettlementOfAccruedCompensationAndAccountsPayable" xlink:href="adtx-20201231.xsd#adtx_IssuanceOfUnitsForTheSettlementOfAccruedCompensationAndAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="adtx_IssuanceOfUnitsForTheSettlementOfAccruedCompensationAndAccountsPayable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_OriginalIssuanceDiscountOnNotesPayable" xlink:href="adtx-20201231.xsd#adtx_OriginalIssuanceDiscountOnNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="adtx_OriginalIssuanceDiscountOnNotesPayable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_LiabilityRecognizedForFinancedAssets" xlink:href="adtx-20201231.xsd#adtx_LiabilityRecognizedForFinancedAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="adtx_LiabilityRecognizedForFinancedAssets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_SharesIssuedForIntangibleAssets" xlink:href="adtx-20201231.xsd#adtx_SharesIssuedForIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="adtx_SharesIssuedForIntangibleAssets" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_ConversionOfPreferredShares" xlink:href="adtx-20201231.xsd#adtx_ConversionOfPreferredShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="adtx_ConversionOfPreferredShares" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/OrganizationandNatureofBusiness">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/GoingConcernAnalysis">
    <loc xlink:type="locator" xlink:label="adtx_GoingConcernDisclosureAbstract" xlink:href="adtx-20201231.xsd#adtx_GoingConcernDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="adtx_GoingConcernDisclosureTextBlock" xlink:href="adtx-20201231.xsd#adtx_GoingConcernDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_GoingConcernDisclosureAbstract" xlink:to="adtx_GoingConcernDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/StockholdersEquityDeficit">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/Agreements">
    <loc xlink:type="locator" xlink:label="adtx_AgreementsDisclosureAbstract" xlink:href="adtx-20201231.xsd#adtx_AgreementsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="adtx_AgreementsDisclosureTextBlock" xlink:href="adtx-20201231.xsd#adtx_AgreementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_AgreementsDisclosureAbstract" xlink:to="adtx_AgreementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/NotesPayable">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_FixedAssetPolicyTextBlock" xlink:href="adtx-20201231.xsd#adtx_FixedAssetPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adtx_FixedAssetPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_OfferingCostsPolicyTextBlock" xlink:href="adtx-20201231.xsd#adtx_OfferingCostsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adtx_OfferingCostsPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_PatentsPolicyTextBlock" xlink:href="adtx-20201231.xsd#adtx_PatentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adtx_PatentsPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/StockholdersEquityDeficitTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock" xlink:href="adtx-20201231.xsd#adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofleasecostsTable">
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfLeaseCostsAbstract" xlink:href="adtx-20201231.xsd#adtx_ScheduleOfLeaseCostsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfLeaseCostsAbstract" xlink:to="us-gaap_LeaseCostAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofrightofuseassetleaseassetsandleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfRightOfUseAssetLeaseAssetsAndLeaseLiabilitiesAbstract" xlink:href="adtx-20201231.xsd#adtx_ScheduleOfRightOfUseAssetLeaseAssetsAndLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="adtx_AssetsAbstract0" xlink:href="adtx-20201231.xsd#adtx_AssetsAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfRightOfUseAssetLeaseAssetsAndLeaseLiabilitiesAbstract" xlink:to="adtx_AssetsAbstract0" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_RightOfUseAssetShortTerm" xlink:href="adtx-20201231.xsd#adtx_RightOfUseAssetShortTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_AssetsAbstract0" xlink:to="adtx_RightOfUseAssetShortTerm" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_RightOfUseAssetLongTerm" xlink:href="adtx-20201231.xsd#adtx_RightOfUseAssetLongTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_AssetsAbstract0" xlink:to="adtx_RightOfUseAssetLongTerm" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfRightOfUseAssetLeaseAssetsAndLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfRightOfUseAssetLeaseAssetsAndLeaseLiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfRightOfUseAssetLeaseAssetsAndLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofleasetermsanddiscountTable">
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfLeaseTermsAndDiscountAbstract" xlink:href="adtx-20201231.xsd#adtx_ScheduleOfLeaseTermsAndDiscountAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfLeaseTermsAndDiscountAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfLeaseTermsAndDiscountAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/SchedulefutureminimumleasepaymentsundertheleasesTable">
    <loc xlink:type="locator" xlink:label="adtx_ScheduleFutureMinimumLeasePaymentsUnderTheLeasesAbstract" xlink:href="adtx-20201231.xsd#adtx_ScheduleFutureMinimumLeasePaymentsUnderTheLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleFutureMinimumLeasePaymentsUnderTheLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleFutureMinimumLeasePaymentsUnderTheLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleFutureMinimumLeasePaymentsUnderTheLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleFutureMinimumLeasePaymentsUnderTheLeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableWithImputedInterestNetAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableWithImputedInterestNetAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_ReceivableWithImputedInterestNetAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_LesseeOperatingLeaseLiability" xlink:href="adtx-20201231.xsd#adtx_LesseeOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="adtx_LesseeOperatingLeaseLiability" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionTable">
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionLineItems" xlink:href="adtx-20201231.xsd#adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionLineItems"/>
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionTable" xlink:href="adtx-20201231.xsd#adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionLineItems" xlink:to="adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable">
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:href="adtx-20201231.xsd#adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems"/>
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable" xlink:href="adtx-20201231.xsd#adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_StockOptionsMember" xlink:href="adtx-20201231.xsd#adtx_StockOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="adtx_StockOptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1" xbrldt:closed="true"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbshkMkzTNOwKi/SY5wisaUmNZUHQSzNMHSWLwfjT7WpDTxNyESoEbcePgflNnDx4+Cpe7iGVGde/DRQguZdZo5KjpAUGAQNyOkDD76ahIjQccKEsvf9/Xj3++QLucVobcn305z1bCg1mi6xUZr+oBVMyyqaM/+TOgNX7+t44hIrWlYUwPKsqCr5vXiF6x03y9RKMySLwbpvuXZqM2i2E3k] CSR-->
    <loc xlink:type="locator" xlink:label="adtx_WeightedAverageExercisePriceOutstanding" xlink:href="adtx-20201231.xsd#adtx_WeightedAverageExercisePriceOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="adtx_WeightedAverageExercisePriceOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:href="adtx-20201231.xsd#adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_WeightedAverageRemainingLifeGranted" xlink:href="adtx-20201231.xsd#adtx_WeightedAverageRemainingLifeGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="adtx_WeightedAverageRemainingLifeGranted" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingLifeExpiredOrForfeited" xlink:href="adtx-20201231.xsd#adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingLifeExpiredOrForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingLifeExpiredOrForfeited" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_ShareBasedPaymentsWeightedAverageRemainingLifeExercised" xlink:href="adtx-20201231.xsd#adtx_ShareBasedPaymentsWeightedAverageRemainingLifeExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="adtx_ShareBasedPaymentsWeightedAverageRemainingLifeExercised" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="adtx-20201231.xsd#adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofnonvestedoptionTable">
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems" xlink:href="adtx-20201231.xsd#adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems"/>
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionTable" xlink:href="adtx-20201231.xsd#adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems" xlink:to="adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_NonvestedWarrantsMember" xlink:href="adtx-20201231.xsd#adtx_NonvestedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="adtx_NonvestedWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_NonvestedOptionsMember" xlink:href="adtx-20201231.xsd#adtx_NonvestedOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="adtx_NonvestedOptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_WeightedAverageExercisePriceGranted" xlink:href="adtx-20201231.xsd#adtx_WeightedAverageExercisePriceGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems" xlink:to="adtx_WeightedAverageExercisePriceGranted" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_WeightedAverageExercisePriceVested" xlink:href="adtx-20201231.xsd#adtx_WeightedAverageExercisePriceVested"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems" xlink:to="adtx_WeightedAverageExercisePriceVested" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_WeightedAverageExercisePriceForfeited" xlink:href="adtx-20201231.xsd#adtx_WeightedAverageExercisePriceForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems" xlink:to="adtx_WeightedAverageExercisePriceForfeited" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofstatutoryfederalincometaxrateTable">
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfStatutoryFederalIncomeTaxRateAbstract" xlink:href="adtx-20201231.xsd#adtx_ScheduleOfStatutoryFederalIncomeTaxRateAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfStatutoryFederalIncomeTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfStatutoryFederalIncomeTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfStatutoryFederalIncomeTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfStatutoryFederalIncomeTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfStatutoryFederalIncomeTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofdeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="adtx-20201231.xsd#adtx_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="adtx_DeferredTaxAssetsAbstract" xlink:href="adtx-20201231.xsd#adtx_DeferredTaxAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="adtx_DeferredTaxAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_DeferredTaxAssetsLeaseLiability" xlink:href="adtx-20201231.xsd#adtx_DeferredTaxAssetsLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_DeferredTaxAssetsAbstract" xlink:to="adtx_DeferredTaxAssetsLeaseLiability" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:href="adtx-20201231.xsd#adtx_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="adtx_DeferredTaxLiabilitiesRightOfUseAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails">
    <loc xlink:type="locator" xlink:label="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:href="adtx-20201231.xsd#adtx_OrganizationandNatureofBusinessDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="adtx_OrganizationandNatureofBusinessDetailsTable" xlink:href="adtx-20201231.xsd#adtx_OrganizationandNatureofBusinessDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="adtx_OrganizationandNatureofBusinessDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_OrganizationandNatureofBusinessDetailsTable" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_OrganizationandNatureofBusinessDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_OrganizationandNatureofBusinessDetailsTable" xlink:to="srt_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:to="us-gaap_SeriesAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:to="us-gaap_SeriesBMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_SeriesA1WarrantMember" xlink:href="adtx-20201231.xsd#adtx_SeriesA1WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:to="adtx_SeriesA1WarrantMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_SeriesB1WarrantMember" xlink:href="adtx-20201231.xsd#adtx_SeriesB1WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:to="adtx_SeriesB1WarrantMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_StockUnitIssued" xlink:href="adtx-20201231.xsd#adtx_StockUnitIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="adtx_StockUnitIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_CommonUnitIssuedPerUnit" xlink:href="adtx-20201231.xsd#adtx_CommonUnitIssuedPerUnit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="adtx_CommonUnitIssuedPerUnit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_OfferingPriceOfShares" xlink:href="adtx-20201231.xsd#adtx_OfferingPriceOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="adtx_OfferingPriceOfShares" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="us-gaap_VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_PurchaseOfEquityShares" xlink:href="adtx-20201231.xsd#adtx_PurchaseOfEquityShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="adtx_PurchaseOfEquityShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceIncrease" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPPredecessorEntityIesToBusinessCombination" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPPredecessorEntityIesToBusinessCombination"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPPredecessorEntityIesToBusinessCombination" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonUnitIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonUnitIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="us-gaap_CommonUnitIssued" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_CommonStockVotingRightsPercentage" xlink:href="adtx-20201231.xsd#adtx_CommonStockVotingRightsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="adtx_CommonStockVotingRightsPercentage" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_PurchaseOfCommonStock" xlink:href="adtx-20201231.xsd#adtx_PurchaseOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="adtx_PurchaseOfCommonStock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_CommonStockExercisePricePerShare" xlink:href="adtx-20201231.xsd#adtx_CommonStockExercisePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="adtx_CommonStockExercisePricePerShare" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/GoingConcernAnalysisDetails">
    <loc xlink:type="locator" xlink:label="adtx_GoingConcernDisclosureAbstract" xlink:href="adtx-20201231.xsd#adtx_GoingConcernDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_GoingConcernDisclosureAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_GoingConcernDisclosureAbstract" xlink:to="us-gaap_Cash" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_AccumulatedDepreciation" xlink:href="adtx-20201231.xsd#adtx_AccumulatedDepreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adtx_AccumulatedDepreciation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_LicensingFeeForPatents" xlink:href="adtx-20201231.xsd#adtx_LicensingFeeForPatents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adtx_LicensingFeeForPatents" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_WarrantsOfStockOption" xlink:href="adtx-20201231.xsd#adtx_WarrantsOfStockOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adtx_WarrantsOfStockOption" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_DilutiveEarningsShares" xlink:href="adtx-20201231.xsd#adtx_DilutiveEarningsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adtx_DilutiveEarningsShares" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="adtx_RelatedPartyTransactionsDetailsLineItems" xlink:href="adtx-20201231.xsd#adtx_RelatedPartyTransactionsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="adtx_RelatedPartyTransactionsDetailsTable" xlink:href="adtx-20201231.xsd#adtx_RelatedPartyTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adtx_RelatedPartyTransactionsDetailsLineItems" xlink:to="adtx_RelatedPartyTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_RelatedPartyTransactionsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_ChiefInnovationOfficerMember" xlink:href="adtx-20201231.xsd#adtx_ChiefInnovationOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="adtx_ChiefInnovationOfficerMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefOperatingOfficerMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefOperatingOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefOperatingOfficerMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromOfficersOrStockholders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromOfficersOrStockholders"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DueFromOfficersOrStockholders" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_AccruedCompensationForRelatedParty" xlink:href="adtx-20201231.xsd#adtx_AccruedCompensationForRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_RelatedPartyTransactionsDetailsLineItems" xlink:to="adtx_AccruedCompensationForRelatedParty" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_StockIssuedDuringPeriodValueNewIssued" xlink:href="adtx-20201231.xsd#adtx_StockIssuedDuringPeriodValueNewIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_RelatedPartyTransactionsDetailsLineItems" xlink:to="adtx_StockIssuedDuringPeriodValueNewIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_StocksIssuedDuringPeriodSharesIssues" xlink:href="adtx-20201231.xsd#adtx_StocksIssuedDuringPeriodSharesIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_RelatedPartyTransactionsDetailsLineItems" xlink:to="adtx_StocksIssuedDuringPeriodSharesIssues" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/StockholdersEquityDeficitDetails">
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:href="adtx-20201231.xsd#adtx_StockholdersEquityDeficitDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDeficitDetailsTable" xlink:href="adtx-20201231.xsd#adtx_StockholdersEquityDeficitDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="adtx_StockholdersEquityDeficitDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_StockholdersEquityDeficitDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_StockholdersEquityDeficitDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_StockholdersEquityDeficitDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_StockholdersEquityDeficitDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_StockholdersEquityDeficitDetailsTable" xlink:to="srt_RangeAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_StockholdersEquityDeficitDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_TwoZeroOneSevenEquityIncentivePlanMember" xlink:href="adtx-20201231.xsd#adtx_TwoZeroOneSevenEquityIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="adtx_TwoZeroOneSevenEquityIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_September2020OfferingMember" xlink:href="adtx-20201231.xsd#adtx_September2020OfferingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="adtx_September2020OfferingMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonUnitIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonUnitIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_CommonUnitIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_StockIssuedDuringPeriodSharesIntangibleAssets" xlink:href="adtx-20201231.xsd#adtx_StockIssuedDuringPeriodSharesIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="adtx_StockIssuedDuringPeriodSharesIntangibleAssets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_IntangibleAssetsCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExcessStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_CommonStockIssuedForPreferredShares" xlink:href="adtx-20201231.xsd#adtx_CommonStockIssuedForPreferredShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="adtx_CommonStockIssuedForPreferredShares" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_PreferredStockExercise" xlink:href="adtx-20201231.xsd#adtx_PreferredStockExercise"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="adtx_PreferredStockExercise" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_SettlementOfAccountsPayableShares" xlink:href="adtx-20201231.xsd#adtx_SettlementOfAccountsPayableShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="adtx_SettlementOfAccountsPayableShares" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_StockIssuedSettlementOfDebt" xlink:href="adtx-20201231.xsd#adtx_StockIssuedSettlementOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="adtx_StockIssuedSettlementOfDebt" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_StockIssuedDuringPeriodSharesIssuedForService" xlink:href="adtx-20201231.xsd#adtx_StockIssuedDuringPeriodSharesIssuedForService"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="adtx_StockIssuedDuringPeriodSharesIssuedForService" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_TotalGrantFairValue" xlink:href="adtx-20201231.xsd#adtx_TotalGrantFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="adtx_TotalGrantFairValue" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_StockOptionexercisePrice" xlink:href="adtx-20201231.xsd#adtx_StockOptionexercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="adtx_StockOptionexercisePrice" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionPlanExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_StockOptionPlanExpense" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_ShareBasedPaymentRemnainingExpenses" xlink:href="adtx-20201231.xsd#adtx_ShareBasedPaymentRemnainingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="adtx_ShareBasedPaymentRemnainingExpenses" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_WarrantsIssuedAndVesting" xlink:href="adtx-20201231.xsd#adtx_WarrantsIssuedAndVesting"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="adtx_WarrantsIssuedAndVesting" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_WarrantsExercised" xlink:href="adtx-20201231.xsd#adtx_WarrantsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="adtx_WarrantsExercised" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="35" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/AgreementsDetails">
    <loc xlink:type="locator" xlink:label="adtx_AgreementsDetailsLineItems" xlink:href="adtx-20201231.xsd#adtx_AgreementsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="adtx_AgreementsDetailsTable" xlink:href="adtx-20201231.xsd#adtx_AgreementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adtx_AgreementsDetailsLineItems" xlink:to="adtx_AgreementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_AgreementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_TypeOfAgreementAxis" xlink:href="adtx-20201231.xsd#adtx_TypeOfAgreementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_AgreementsDetailsTable" xlink:to="adtx_TypeOfAgreementAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_TypeOfAgreementDomain" xlink:href="adtx-20201231.xsd#adtx_TypeOfAgreementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="adtx_TypeOfAgreementAxis" xlink:to="adtx_TypeOfAgreementDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_TypeOfAgreementDomain_0" xlink:href="adtx-20201231.xsd#adtx_TypeOfAgreementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="adtx_TypeOfAgreementAxis" xlink:to="adtx_TypeOfAgreementDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_SalveoDiagnosticsIncMember" xlink:href="adtx-20201231.xsd#adtx_SalveoDiagnosticsIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="adtx_SalveoDiagnosticsIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_SalveoConsultingAgreementMember" xlink:href="adtx-20201231.xsd#adtx_SalveoConsultingAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_TypeOfAgreementDomain" xlink:to="adtx_SalveoConsultingAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BroadcastersLicenseAgreementCommitmentsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_AgreementsDetailsLineItems" xlink:to="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_FinanceArrangementCost" xlink:href="adtx-20201231.xsd#adtx_FinanceArrangementCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_AgreementsDetailsLineItems" xlink:to="adtx_FinanceArrangementCost" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_AgreementsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_AgreementsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_AgreementsDetailsLineItems" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/NotesPayableDetails">
    <loc xlink:type="locator" xlink:label="adtx_NotesPayableDetailsLineItems" xlink:href="adtx-20201231.xsd#adtx_NotesPayableDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="adtx_NotesPayableDetailsTable" xlink:href="adtx-20201231.xsd#adtx_NotesPayableDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="adtx_NotesPayableDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_NotesPayableDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_NotesPayableDetailsTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_SixBridgeLoansMember" xlink:href="adtx-20201231.xsd#adtx_SixBridgeLoansMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="adtx_SixBridgeLoansMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BridgeLoanMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_BridgeLoanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnsecuredDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="us-gaap_UnsecuredDebt" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BridgeLoan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="us-gaap_BridgeLoan" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="us-gaap_ShortTermDebtDescription" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="us-gaap_ShortTermBorrowings" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_OriginalIssueDiscount" xlink:href="adtx-20201231.xsd#adtx_OriginalIssueDiscount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="adtx_OriginalIssueDiscount" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="adtx_IncomeTaxesDetailsLineItems" xlink:href="adtx-20201231.xsd#adtx_IncomeTaxesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="adtx_IncomeTaxesDetailsTable" xlink:href="adtx-20201231.xsd#adtx_IncomeTaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adtx_IncomeTaxesDetailsLineItems" xlink:to="adtx_IncomeTaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_USFederalMember" xlink:href="adtx-20201231.xsd#adtx_USFederalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="adtx_USFederalMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_USStateMember" xlink:href="adtx-20201231.xsd#adtx_USStateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="adtx_USStateMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_NetOperatingLossPercentage" xlink:href="adtx-20201231.xsd#adtx_NetOperatingLossPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_IncomeTaxesDetailsLineItems" xlink:to="adtx_NetOperatingLossPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_CorporationsTaxableIncomePercentage" xlink:href="adtx-20201231.xsd#adtx_CorporationsTaxableIncomePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_IncomeTaxesDetailsLineItems" xlink:to="adtx_CorporationsTaxableIncomePercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="adtx_SubsequentEventsDetailsLineItems" xlink:href="adtx-20201231.xsd#adtx_SubsequentEventsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="adtx_SubsequentEventsDetailsTable" xlink:href="adtx-20201231.xsd#adtx_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="adtx_SubsequentEventsDetailsLineItems" xlink:to="adtx_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="adtx_SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_SaleOfConvertableNote" xlink:href="adtx-20201231.xsd#adtx_SaleOfConvertableNote"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_SubsequentEventsDetailsLineItems" xlink:to="adtx_SaleOfConvertableNote" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_InvestmentWarrantsExpirationPeriod" xlink:href="adtx-20201231.xsd#adtx_InvestmentWarrantsExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_SubsequentEventsDetailsLineItems" xlink:to="adtx_InvestmentWarrantsExpirationPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_InvestmentWarrantsExercisePrice" xlink:href="adtx-20201231.xsd#adtx_InvestmentWarrantsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_SubsequentEventsDetailsLineItems" xlink:to="adtx_InvestmentWarrantsExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_FinancingAgreementTerm" xlink:href="adtx-20201231.xsd#adtx_FinancingAgreementTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_SubsequentEventsDetailsLineItems" xlink:to="adtx_FinancingAgreementTerm" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_CostOfFinancingAgreement" xlink:href="adtx-20201231.xsd#adtx_CostOfFinancingAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_SubsequentEventsDetailsLineItems" xlink:to="adtx_CostOfFinancingAgreement" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_WarrantsExercisedForShares" xlink:href="adtx-20201231.xsd#adtx_WarrantsExercisedForShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_SubsequentEventsDetailsLineItems" xlink:to="adtx_WarrantsExercisedForShares" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="adtx_ProceedsFormWarrantsIssued" xlink:href="adtx-20201231.xsd#adtx_ProceedsFormWarrantsIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="adtx_SubsequentEventsDetailsLineItems" xlink:to="adtx_ProceedsFormWarrantsIssued" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="21" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>adtx-20201231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 25 16:57:49 EDT 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">TOTAL CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">TOTAL CURRENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL STOCKHOLDERS&#8217; EQUITY (DEFICIT)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">LOSS FROM OPERATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total Other Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Used In Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Used In Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided By Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">CASH AT BEGINNING OF PERIOD</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">CASH AT END OF PERIOD</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_GoingConcernDisclosureAbstract" xlink:href="adtx-20201231.xsd#adtx_GoingConcernDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_GoingConcernDisclosureAbstract_lbl" xml:lang="en-US">Going Concern Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_GoingConcernDisclosureAbstract" xlink:to="adtx_GoingConcernDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfLeaseCostsAbstract" xlink:href="adtx-20201231.xsd#adtx_ScheduleOfLeaseCostsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ScheduleOfLeaseCostsAbstract_lbl" xml:lang="en-US">Schedule of lease costs [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ScheduleOfLeaseCostsAbstract" xlink:to="adtx_ScheduleOfLeaseCostsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfRightOfUseAssetLeaseAssetsAndLeaseLiabilitiesAbstract" xlink:href="adtx-20201231.xsd#adtx_ScheduleOfRightOfUseAssetLeaseAssetsAndLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ScheduleOfRightOfUseAssetLeaseAssetsAndLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of right of use asset lease assets and lease liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ScheduleOfRightOfUseAssetLeaseAssetsAndLeaseLiabilitiesAbstract" xlink:to="adtx_ScheduleOfRightOfUseAssetLeaseAssetsAndLeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfLeaseTermsAndDiscountAbstract" xlink:href="adtx-20201231.xsd#adtx_ScheduleOfLeaseTermsAndDiscountAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ScheduleOfLeaseTermsAndDiscountAbstract_lbl" xml:lang="en-US">Schedule of lease terms and discount [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ScheduleOfLeaseTermsAndDiscountAbstract" xlink:to="adtx_ScheduleOfLeaseTermsAndDiscountAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ScheduleFutureMinimumLeasePaymentsUnderTheLeasesAbstract" xlink:href="adtx-20201231.xsd#adtx_ScheduleFutureMinimumLeasePaymentsUnderTheLeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ScheduleFutureMinimumLeasePaymentsUnderTheLeasesAbstract_lbl" xml:lang="en-US">Schedule future minimum lease payments under the leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ScheduleFutureMinimumLeasePaymentsUnderTheLeasesAbstract" xlink:to="adtx_ScheduleFutureMinimumLeasePaymentsUnderTheLeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total future minimum lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_LesseeOperatingLeaseLiability" xlink:href="adtx-20201231.xsd#adtx_LesseeOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="adtx_LesseeOperatingLeaseLiability_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_LesseeOperatingLeaseLiability" xlink:to="adtx_LesseeOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfStockOptionGrantedWasEstimatedUsingTheBlackScholesAssumptionAbstract" xlink:href="adtx-20201231.xsd#adtx_ScheduleOfStockOptionGrantedWasEstimatedUsingTheBlackScholesAssumptionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ScheduleOfStockOptionGrantedWasEstimatedUsingTheBlackScholesAssumptionAbstract_lbl" xml:lang="en-US">Schedule of stock option granted was estimated using the Black-Scholes assumption [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ScheduleOfStockOptionGrantedWasEstimatedUsingTheBlackScholesAssumptionAbstract" xlink:to="adtx_ScheduleOfStockOptionGrantedWasEstimatedUsingTheBlackScholesAssumptionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanAbstract" xlink:href="adtx-20201231.xsd#adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanAbstract_lbl" xml:lang="en-US">Schedule of analysis of the stock option grant activity under the plan [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanAbstract" xlink:to="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number, Outstanding beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0" xml:lang="en-US">Number, Outstanding ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="adtx_WeightedAverageExercisePriceOutstanding" xlink:href="adtx-20201231.xsd#adtx_WeightedAverageExercisePriceOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="adtx_WeightedAverageExercisePriceOutstanding_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageExercisePriceOutstanding" xlink:to="adtx_WeightedAverageExercisePriceOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="adtx_WeightedAverageExercisePriceOutstanding_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Outstanding ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageExercisePriceOutstanding" xlink:to="adtx_WeightedAverageExercisePriceOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfNonvestedOptionAbstract" xlink:href="adtx-20201231.xsd#adtx_ScheduleOfNonvestedOptionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ScheduleOfNonvestedOptionAbstract_lbl" xml:lang="en-US">Schedule of nonvested option [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ScheduleOfNonvestedOptionAbstract" xlink:to="adtx_ScheduleOfNonvestedOptionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Shares, Nonvested at beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Shares, Nonvested at ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- Average Exercise Price, Outstanding beginning balance (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted- Average Exercise Price, Outstanding ending balance (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_AgreementsDisclosureAbstract" xlink:href="adtx-20201231.xsd#adtx_AgreementsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_AgreementsDisclosureAbstract_lbl" xml:lang="en-US">Agreements Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_AgreementsDisclosureAbstract" xlink:to="adtx_AgreementsDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfStatutoryFederalIncomeTaxRateAbstract" xlink:href="adtx-20201231.xsd#adtx_ScheduleOfStatutoryFederalIncomeTaxRateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ScheduleOfStatutoryFederalIncomeTaxRateAbstract_lbl" xml:lang="en-US">Schedule of statutory federal income tax rate [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ScheduleOfStatutoryFederalIncomeTaxRateAbstract" xlink:to="adtx_ScheduleOfStatutoryFederalIncomeTaxRateAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="adtx-20201231.xsd#adtx_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of deferred tax assets and liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="adtx_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ROUAssetShortTerm" xlink:href="adtx-20201231.xsd#adtx_ROUAssetShortTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_ROUAssetShortTerm_lbl" xml:lang="en-US">ROU asset - short term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ROUAssetShortTerm" xlink:to="adtx_ROUAssetShortTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_FixedAssets" xlink:href="adtx-20201231.xsd#adtx_FixedAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_FixedAssets_lbl" xml:lang="en-US">Fixed Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FixedAssets" xlink:to="adtx_FixedAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIntangibleAssetsNet_lbl" xml:lang="en-US">Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIntangibleAssetsNet" xlink:to="us-gaap_OtherIntangibleAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCosts_lbl" xml:lang="en-US">Deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_RightOfUseAssetLongTerm" xlink:href="adtx-20201231.xsd#adtx_RightOfUseAssetLongTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_RightOfUseAssetLongTerm_lbl" xml:lang="en-US">ROU asset - long term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RightOfUseAssetLongTerm" xlink:to="adtx_RightOfUseAssetLongTerm_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="adtx_RightOfUseAssetLongTerm_lbl0" xml:lang="en-US">Right of use asset &#8211; long term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RightOfUseAssetLongTerm" xlink:to="adtx_RightOfUseAssetLongTerm_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued compensation to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl" xml:lang="en-US">Notes payable - related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes payable, net of discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_FinancingOnFixedAssets" xlink:href="adtx-20201231.xsd#adtx_FinancingOnFixedAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_FinancingOnFixedAssets_lbl" xml:lang="en-US">Financing on fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FinancingOnFixedAssets" xlink:to="adtx_FinancingOnFixedAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Lease liability - short term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating lease liabilities &#8211; short term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease liability - long term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating lease liabilities &#8211; long term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value, 3,000,000 shares authorized, no shares issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value, 27,000,000 shares authorized, 13,074,495 and 3,915,900 shares issued and 12,973,692 and 3,821,088 shares outstanding, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockShares_lbl" xml:lang="en-US">Treasury stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses, $3,188,840 and $4,221,733 in stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development, includes $0 and $10,000 in stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Sales and marketing $0 and $0 in stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">OTHER INCOME (EXPENSE)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain on forgiveness of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share - basic and diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of shares outstanding during the period - basic and diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of shares for cash, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of shares for cash, net of issuance costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of shares for services and licenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0" xml:lang="en-US">Common stock for services and recognized expense (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of shares for services and licenses (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl" xml:lang="en-US">Stock option and warrant compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Warrants issued with notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockSharesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockSharesAcquired_lbl" xml:lang="en-US">Treasury stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockSharesAcquired" xlink:to="us-gaap_TreasuryStockSharesAcquired_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Rounding adjustment from stock split (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ExerciseOfWarrants" xlink:href="adtx-20201231.xsd#adtx_ExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_ExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ExerciseOfWarrants" xlink:to="adtx_ExerciseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of warrants (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Number, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <loc xlink:type="locator" xlink:label="adtx_StockIssuedDuringPeriodValueIntangibleAssets" xlink:href="adtx-20201231.xsd#adtx_StockIssuedDuringPeriodValueIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_StockIssuedDuringPeriodValueIntangibleAssets_lbl" xml:lang="en-US">Issuance of shares for intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockIssuedDuringPeriodValueIntangibleAssets" xlink:to="adtx_StockIssuedDuringPeriodValueIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StockIssuedDuringPeriodSharesForIntangibleAssets" xlink:href="adtx-20201231.xsd#adtx_StockIssuedDuringPeriodSharesForIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_StockIssuedDuringPeriodSharesForIntangibleAssets_lbl" xml:lang="en-US">Issuance of shares for intangible assets (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockIssuedDuringPeriodSharesForIntangibleAssets" xlink:to="adtx_StockIssuedDuringPeriodSharesForIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable" xlink:href="adtx-20201231.xsd#adtx_IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable_lbl" xml:lang="en-US">Issuance of shares and warrants for the settlement of accrued compensation and accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable" xlink:to="adtx_IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_IssuanceOfSharesForTheSettlementOfSharesAccruedCompensationAndAccountsPayable" xlink:href="adtx-20201231.xsd#adtx_IssuanceOfSharesForTheSettlementOfSharesAccruedCompensationAndAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_IssuanceOfSharesForTheSettlementOfSharesAccruedCompensationAndAccountsPayable_lbl" xml:lang="en-US">Issuance of shares and warrants for the settlement of accrued compensation and accounts payable (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesForTheSettlementOfSharesAccruedCompensationAndAccountsPayable" xlink:to="adtx_IssuanceOfSharesForTheSettlementOfSharesAccruedCompensationAndAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts" xlink:href="adtx-20201231.xsd#adtx_IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts_lbl" xml:lang="en-US">Issuance of shares and warrants for IPO, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts" xlink:to="adtx_IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_IssuanceOfSharesAndWarrantsForIPONetOfSharesOfferingCosts" xlink:href="adtx-20201231.xsd#adtx_IssuanceOfSharesAndWarrantsForIPONetOfSharesOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_IssuanceOfSharesAndWarrantsForIPONetOfSharesOfferingCosts_lbl" xml:lang="en-US">Issuance of shares and warrants for IPO, net of issuance costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesAndWarrantsForIPONetOfSharesOfferingCosts" xlink:to="adtx_IssuanceOfSharesAndWarrantsForIPONetOfSharesOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts" xlink:href="adtx-20201231.xsd#adtx_StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts_lbl" xml:lang="en-US">Issuance of shares and warrants for follow-on offering, net of issuance costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts" xlink:to="adtx_StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StockIssuedDuringPeriodSharesForCashNetOfOfferingCosts" xlink:href="adtx-20201231.xsd#adtx_StockIssuedDuringPeriodSharesForCashNetOfOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_StockIssuedDuringPeriodSharesForCashNetOfOfferingCosts_lbl" xml:lang="en-US">Issuance of shares and warrants for follow-on offering, net of issuance costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockIssuedDuringPeriodSharesForCashNetOfOfferingCosts" xlink:to="adtx_StockIssuedDuringPeriodSharesForCashNetOfOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_IssuanceOfSharesForTheSettlementOfDebt" xlink:href="adtx-20201231.xsd#adtx_IssuanceOfSharesForTheSettlementOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_IssuanceOfSharesForTheSettlementOfDebt_lbl" xml:lang="en-US">Issuance of shares and warrant for the settlement of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesForTheSettlementOfDebt" xlink:to="adtx_IssuanceOfSharesForTheSettlementOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_IssuanceOfSharesForTheSettlementOfSharesDebtinShares" xlink:href="adtx-20201231.xsd#adtx_IssuanceOfSharesForTheSettlementOfSharesDebtinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_IssuanceOfSharesForTheSettlementOfSharesDebtinShares_lbl" xml:lang="en-US">Issuance of shares and warrant for the settlement of debt (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesForTheSettlementOfSharesDebtinShares" xlink:to="adtx_IssuanceOfSharesForTheSettlementOfSharesDebtinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ExerciseConversionOfPreferredShares" xlink:href="adtx-20201231.xsd#adtx_ExerciseConversionOfPreferredShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_ExerciseConversionOfPreferredShares_lbl" xml:lang="en-US">Exercise conversion of preferred shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ExerciseConversionOfPreferredShares" xlink:to="adtx_ExerciseConversionOfPreferredShares_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ExerciseConversionOfSharesPreferredShares" xlink:href="adtx-20201231.xsd#adtx_ExerciseConversionOfSharesPreferredShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_ExerciseConversionOfSharesPreferredShares_lbl" xml:lang="en-US">Exercise conversion of preferred shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ExerciseConversionOfSharesPreferredShares" xlink:to="adtx_ExerciseConversionOfSharesPreferredShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationNonproduction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationNonproduction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationNonproduction_lbl" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationNonproduction" xlink:to="us-gaap_DepreciationNonproduction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl0" xml:lang="en-US">Amortization of debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl0"/>
    <loc xlink:type="locator" xlink:label="adtx_ModificationOfOptions" xlink:href="adtx-20201231.xsd#adtx_ModificationOfOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_ModificationOfOptions_lbl" xml:lang="en-US">Modification of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ModificationOfOptions" xlink:to="adtx_ModificationOfOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_IncreaseDecreaseInAccruedCompensationToRelatedParties" xlink:href="adtx-20201231.xsd#adtx_IncreaseDecreaseInAccruedCompensationToRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_IncreaseDecreaseInAccruedCompensationToRelatedParties_lbl" xml:lang="en-US">Accrued compensation to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IncreaseDecreaseInAccruedCompensationToRelatedParties" xlink:to="adtx_IncreaseDecreaseInAccruedCompensationToRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Proceeds from note payable - related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Common stock and warrants issued for cash, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl0" xml:lang="en-US">Exercise of warrants and received (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Cash paid for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">NONCASH INVESTING AND FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_LiabilitiesAssumedForCommonStock" xlink:href="adtx-20201231.xsd#adtx_LiabilitiesAssumedForCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_LiabilitiesAssumedForCommonStock_lbl" xml:lang="en-US">Liabilities assumed for common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_LiabilitiesAssumedForCommonStock" xlink:to="adtx_LiabilitiesAssumedForCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Issuance of Units for the settlement of notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_IssuanceOfUnitsForTheSettlementOfAccruedCompensationAndAccountsPayable" xlink:href="adtx-20201231.xsd#adtx_IssuanceOfUnitsForTheSettlementOfAccruedCompensationAndAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_IssuanceOfUnitsForTheSettlementOfAccruedCompensationAndAccountsPayable_lbl" xml:lang="en-US">Issuance of units for the settlement of accrued compensation and accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfUnitsForTheSettlementOfAccruedCompensationAndAccountsPayable" xlink:to="adtx_IssuanceOfUnitsForTheSettlementOfAccruedCompensationAndAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_OriginalIssuanceDiscountOnNotesPayable" xlink:href="adtx-20201231.xsd#adtx_OriginalIssuanceDiscountOnNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_OriginalIssuanceDiscountOnNotesPayable_lbl" xml:lang="en-US">Original issuance discount on notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OriginalIssuanceDiscountOnNotesPayable" xlink:to="adtx_OriginalIssuanceDiscountOnNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Lease liability recognized from right of use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_LiabilityRecognizedForFinancedAssets" xlink:href="adtx-20201231.xsd#adtx_LiabilityRecognizedForFinancedAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_LiabilityRecognizedForFinancedAssets_lbl" xml:lang="en-US">Liability recognized for financed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_LiabilityRecognizedForFinancedAssets" xlink:to="adtx_LiabilityRecognizedForFinancedAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_SharesIssuedForIntangibleAssets" xlink:href="adtx-20201231.xsd#adtx_SharesIssuedForIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_SharesIssuedForIntangibleAssets_lbl" xml:lang="en-US">Shares issued for intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SharesIssuedForIntangibleAssets" xlink:to="adtx_SharesIssuedForIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ConversionOfPreferredShares" xlink:href="adtx-20201231.xsd#adtx_ConversionOfPreferredShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_ConversionOfPreferredShares_lbl" xml:lang="en-US">Conversion of preferred shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ConversionOfPreferredShares" xlink:to="adtx_ConversionOfPreferredShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury stock, 100,803 and 94,813 shares, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseOther_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl" xml:lang="en-US">Treasury stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" xml:lang="en-US">Rounding adjustment from stock split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xml:lang="en-US">Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets_lbl" xml:lang="en-US">Fixed Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:to="us-gaap_PaymentsForProceedsFromProductiveAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Repayments of note payable - related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayments of notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US">Financed Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xml:lang="en-US">Sales and marketing [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockMember_lbl" xml:lang="en-US">Treasury Shares Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND NATURE OF BUSINESS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_GoingConcernDisclosureTextBlock" xlink:href="adtx-20201231.xsd#adtx_GoingConcernDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_GoingConcernDisclosureTextBlock_lbl" xml:lang="en-US">GOING CONCERN ANALYSIS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_GoingConcernDisclosureTextBlock" xlink:to="adtx_GoingConcernDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of lease costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Components of total lease costs:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of right of use asset lease assets and lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_AssetsAbstract0" xlink:href="adtx-20201231.xsd#adtx_AssetsAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_AssetsAbstract0_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_AssetsAbstract0" xlink:to="adtx_AssetsAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_RightOfUseAssetShortTerm" xlink:href="adtx-20201231.xsd#adtx_RightOfUseAssetShortTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_RightOfUseAssetShortTerm_lbl" xml:lang="en-US">Right of use asset &#8211; short term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RightOfUseAssetShortTerm" xlink:to="adtx_RightOfUseAssetShortTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of lease terms and discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term (in years) &#8211; operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate &#8211; operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule future minimum lease payments under the leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableWithImputedInterestNetAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableWithImputedInterestNetAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivableWithImputedInterestNetAmount_lbl" xml:lang="en-US">Less: Lease imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableWithImputedInterestNetAmount" xlink:to="us-gaap_ReceivableWithImputedInterestNetAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of stock option granted was estimated using the Black-Scholes assumption</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life in years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock" xlink:href="adtx-20201231.xsd#adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock_lbl" xml:lang="en-US">Schedule of analysis of the stock option grant activity under the plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock" xlink:to="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:href="adtx-20201231.xsd#adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_lbl" xml:lang="en-US">Weighted Average Remaining Life, Outstanding beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:to="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_WeightedAverageRemainingLifeGranted" xlink:href="adtx-20201231.xsd#adtx_WeightedAverageRemainingLifeGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_WeightedAverageRemainingLifeGranted_lbl" xml:lang="en-US">Weighted Average Remaining Life, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageRemainingLifeGranted" xlink:to="adtx_WeightedAverageRemainingLifeGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired or forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingLifeExpiredOrForfeited" xlink:href="adtx-20201231.xsd#adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingLifeExpiredOrForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingLifeExpiredOrForfeited_lbl" xml:lang="en-US">Weighted Average Remaining Life, Expired or forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingLifeExpiredOrForfeited" xlink:to="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingLifeExpiredOrForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="adtx-20201231.xsd#adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Life, Outstanding ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ShareBasedPaymentsWeightedAverageRemainingLifeExercised" xlink:href="adtx-20201231.xsd#adtx_ShareBasedPaymentsWeightedAverageRemainingLifeExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_ShareBasedPaymentsWeightedAverageRemainingLifeExercised_lbl" xml:lang="en-US">Weighted Average Remaining Life, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ShareBasedPaymentsWeightedAverageRemainingLifeExercised" xlink:to="adtx_ShareBasedPaymentsWeightedAverageRemainingLifeExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of nonvested option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Shares, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_WeightedAverageExercisePriceGranted" xlink:href="adtx-20201231.xsd#adtx_WeightedAverageExercisePriceGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_WeightedAverageExercisePriceGranted_lbl" xml:lang="en-US">Weighted- Average Exercise Price, Granted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageExercisePriceGranted" xlink:to="adtx_WeightedAverageExercisePriceGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_WeightedAverageExercisePriceVested" xlink:href="adtx-20201231.xsd#adtx_WeightedAverageExercisePriceVested"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_WeightedAverageExercisePriceVested_lbl" xml:lang="en-US">Weighted- Average Exercise Price, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageExercisePriceVested" xlink:to="adtx_WeightedAverageExercisePriceVested_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_WeightedAverageExercisePriceForfeited" xlink:href="adtx-20201231.xsd#adtx_WeightedAverageExercisePriceForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_WeightedAverageExercisePriceForfeited_lbl" xml:lang="en-US">Weighted- Average Exercise Price, Expired or forfeited	(in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageExercisePriceForfeited" xlink:to="adtx_WeightedAverageExercisePriceForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_AgreementsDisclosureTextBlock" xlink:href="adtx-20201231.xsd#adtx_AgreementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_AgreementsDisclosureTextBlock_lbl" xml:lang="en-US">AGREEMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_AgreementsDisclosureTextBlock" xlink:to="adtx_AgreementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">NOTES PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of statutory federal income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Income taxes at U.S. statutory rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US">Tax Credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Permanent Differences/Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Total provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_DeferredTaxAssetsAbstract" xlink:href="adtx-20201231.xsd#adtx_DeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_DeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DeferredTaxAssetsAbstract" xlink:to="adtx_DeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US">Tax credits carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_DeferredTaxAssetsLeaseLiability" xlink:href="adtx-20201231.xsd#adtx_DeferredTaxAssetsLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DeferredTaxAssetsLeaseLiability" xlink:to="adtx_DeferredTaxAssetsLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number, Expired or forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Shares, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Shares, Expired or forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:href="adtx-20201231.xsd#adtx_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="adtx_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xml:lang="en-US">Right of use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="adtx_DeferredTaxLiabilitiesRightOfUseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Fixed Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StockOptionsMember" xlink:href="adtx-20201231.xsd#adtx_StockOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_StockOptionsMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockOptionsMember" xlink:to="adtx_StockOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="adtx_NonvestedOptionsMember" xlink:href="adtx-20201231.xsd#adtx_NonvestedOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_NonvestedOptionsMember_lbl" xml:lang="en-US">Nonvested Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NonvestedOptionsMember" xlink:to="adtx_NonvestedOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_NonvestedWarrantsMember" xlink:href="adtx-20201231.xsd#adtx_NonvestedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_NonvestedWarrantsMember_lbl" xml:lang="en-US">Nonvested Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NonvestedWarrantsMember" xlink:to="adtx_NonvestedWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_lbl" xml:lang="en-US">Auction Market Preferred Securities, Stock Series [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_TypeOfAgreementAxis" xlink:href="adtx-20201231.xsd#adtx_TypeOfAgreementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_TypeOfAgreementAxis_lbl" xml:lang="en-US">Type Of Agreement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_TypeOfAgreementAxis" xlink:to="adtx_TypeOfAgreementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StockUnitIssued" xlink:href="adtx-20201231.xsd#adtx_StockUnitIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_StockUnitIssued_lbl" xml:lang="en-US">Common stock unit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockUnitIssued" xlink:to="adtx_StockUnitIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_CommonUnitIssuedPerUnit" xlink:href="adtx-20201231.xsd#adtx_CommonUnitIssuedPerUnit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_CommonUnitIssuedPerUnit_lbl" xml:lang="en-US">Company issued per unit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CommonUnitIssuedPerUnit" xlink:to="adtx_CommonUnitIssuedPerUnit_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_OfferingPriceOfShares" xlink:href="adtx-20201231.xsd#adtx_OfferingPriceOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_OfferingPriceOfShares_lbl" xml:lang="en-US">Total offering price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OfferingPriceOfShares" xlink:to="adtx_OfferingPriceOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure_lbl" xml:lang="en-US">Exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure" xlink:to="us-gaap_VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Exercise price term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl0" xml:lang="en-US">Convertible term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl0"/>
    <loc xlink:type="locator" xlink:label="adtx_PurchaseOfEquityShares" xlink:href="adtx-20201231.xsd#adtx_PurchaseOfEquityShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_PurchaseOfEquityShares_lbl" xml:lang="en-US">Purchase of equity shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PurchaseOfEquityShares" xlink:to="adtx_PurchaseOfEquityShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl" xml:lang="en-US">Exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPPredecessorEntityIesToBusinessCombination" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPPredecessorEntityIesToBusinessCombination"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPPredecessorEntityIesToBusinessCombination_lbl" xml:lang="en-US">Exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPPredecessorEntityIesToBusinessCombination" xlink:to="us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPPredecessorEntityIesToBusinessCombination_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonUnitIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonUnitIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonUnitIssued_lbl" xml:lang="en-US">Company issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonUnitIssued" xlink:to="us-gaap_CommonUnitIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonUnitIssued_lbl0" xml:lang="en-US">Common stock issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonUnitIssued" xlink:to="us-gaap_CommonUnitIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="adtx_CommonStockVotingRightsPercentage" xlink:href="adtx-20201231.xsd#adtx_CommonStockVotingRightsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_CommonStockVotingRightsPercentage_lbl" xml:lang="en-US">Common stock voting rights percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CommonStockVotingRightsPercentage" xlink:to="adtx_CommonStockVotingRightsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_PurchaseOfCommonStock" xlink:href="adtx-20201231.xsd#adtx_PurchaseOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_PurchaseOfCommonStock_lbl" xml:lang="en-US">Purchase of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PurchaseOfCommonStock" xlink:to="adtx_PurchaseOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_CommonStockExercisePricePerShare" xlink:href="adtx-20201231.xsd#adtx_CommonStockExercisePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_CommonStockExercisePricePerShare_lbl" xml:lang="en-US">Common stock exercise price, per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CommonStockExercisePricePerShare" xlink:to="adtx_CommonStockExercisePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_AccumulatedDepreciation" xlink:href="adtx-20201231.xsd#adtx_AccumulatedDepreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_AccumulatedDepreciation_lbl" xml:lang="en-US">Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_AccumulatedDepreciation" xlink:to="adtx_AccumulatedDepreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment_lbl" xml:lang="en-US">Rent and Lease costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment" xlink:to="us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_LicensingFeeForPatents" xlink:href="adtx-20201231.xsd#adtx_LicensingFeeForPatents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_LicensingFeeForPatents_lbl" xml:lang="en-US">Licensing fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_LicensingFeeForPatents" xlink:to="adtx_LicensingFeeForPatents_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_WarrantsOfStockOption" xlink:href="adtx-20201231.xsd#adtx_WarrantsOfStockOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_WarrantsOfStockOption_lbl" xml:lang="en-US">Warrants of stock option (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WarrantsOfStockOption" xlink:to="adtx_WarrantsOfStockOption_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_DilutiveEarningsShares" xlink:href="adtx-20201231.xsd#adtx_DilutiveEarningsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_DilutiveEarningsShares_lbl" xml:lang="en-US">Dilutive earnings share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DilutiveEarningsShares" xlink:to="adtx_DilutiveEarningsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromOfficersOrStockholders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromOfficersOrStockholders"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueFromOfficersOrStockholders_lbl" xml:lang="en-US">Owed amount of related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromOfficersOrStockholders" xlink:to="us-gaap_DueFromOfficersOrStockholders_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl" xml:lang="en-US">Description of related party transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_AccruedCompensationForRelatedParty" xlink:href="adtx-20201231.xsd#adtx_AccruedCompensationForRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_AccruedCompensationForRelatedParty_lbl" xml:lang="en-US">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_AccruedCompensationForRelatedParty" xlink:to="adtx_AccruedCompensationForRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StockIssuedDuringPeriodValueNewIssued" xlink:href="adtx-20201231.xsd#adtx_StockIssuedDuringPeriodValueNewIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_StockIssuedDuringPeriodValueNewIssued_lbl" xml:lang="en-US">Amount of liabilities from related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockIssuedDuringPeriodValueNewIssued" xlink:to="adtx_StockIssuedDuringPeriodValueNewIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StocksIssuedDuringPeriodSharesIssues" xlink:href="adtx-20201231.xsd#adtx_StocksIssuedDuringPeriodSharesIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_StocksIssuedDuringPeriodSharesIssues_lbl" xml:lang="en-US">Shares of liabilities from related party (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StocksIssuedDuringPeriodSharesIssues" xlink:to="adtx_StocksIssuedDuringPeriodSharesIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock compensation for consulting services (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StockIssuedDuringPeriodSharesIntangibleAssets" xlink:href="adtx-20201231.xsd#adtx_StockIssuedDuringPeriodSharesIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_StockIssuedDuringPeriodSharesIntangibleAssets_lbl" xml:lang="en-US">Shares issued for intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockIssuedDuringPeriodSharesIntangibleAssets" xlink:to="adtx_StockIssuedDuringPeriodSharesIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsCurrent_lbl" xml:lang="en-US">Intangible assets valued (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsCurrent" xlink:to="us-gaap_IntangibleAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExcessStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExcessStockSharesIssued_lbl" xml:lang="en-US">Issue of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_CommonStockIssuedForPreferredShares" xlink:href="adtx-20201231.xsd#adtx_CommonStockIssuedForPreferredShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_CommonStockIssuedForPreferredShares_lbl" xml:lang="en-US">Common stock issued for preferred shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CommonStockIssuedForPreferredShares" xlink:to="adtx_CommonStockIssuedForPreferredShares_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_PreferredStockExercise" xlink:href="adtx-20201231.xsd#adtx_PreferredStockExercise"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_PreferredStockExercise_lbl" xml:lang="en-US">Preferred stock shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PreferredStockExercise" xlink:to="adtx_PreferredStockExercise_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_SettlementOfAccountsPayableShares" xlink:href="adtx-20201231.xsd#adtx_SettlementOfAccountsPayableShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_SettlementOfAccountsPayableShares_lbl" xml:lang="en-US">Settlement of accounts payable Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SettlementOfAccountsPayableShares" xlink:to="adtx_SettlementOfAccountsPayableShares_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StockIssuedSettlementOfDebt" xlink:href="adtx-20201231.xsd#adtx_StockIssuedSettlementOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_StockIssuedSettlementOfDebt_lbl" xml:lang="en-US">Settlement of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockIssuedSettlementOfDebt" xlink:to="adtx_StockIssuedSettlementOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StockIssuedDuringPeriodSharesIssuedForService" xlink:href="adtx-20201231.xsd#adtx_StockIssuedDuringPeriodSharesIssuedForService"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_StockIssuedDuringPeriodSharesIssuedForService_lbl" xml:lang="en-US">Common stock issued for service</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockIssuedDuringPeriodSharesIssuedForService" xlink:to="adtx_StockIssuedDuringPeriodSharesIssuedForService_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Share issued for stock based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Granted stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Exercise prices (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_TotalGrantFairValue" xlink:href="adtx-20201231.xsd#adtx_TotalGrantFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_TotalGrantFairValue_lbl" xml:lang="en-US">Total grant fair value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_TotalGrantFairValue" xlink:to="adtx_TotalGrantFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StockOptionexercisePrice" xlink:href="adtx-20201231.xsd#adtx_StockOptionexercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_StockOptionexercisePrice_lbl" xml:lang="en-US">Stock option exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockOptionexercisePrice" xlink:to="adtx_StockOptionexercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionPlanExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionPlanExpense_lbl" xml:lang="en-US">Compensation expense (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionPlanExpense" xlink:to="us-gaap_StockOptionPlanExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ShareBasedPaymentRemnainingExpenses" xlink:href="adtx-20201231.xsd#adtx_ShareBasedPaymentRemnainingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_ShareBasedPaymentRemnainingExpenses_lbl" xml:lang="en-US">Share based payment remaining expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ShareBasedPaymentRemnainingExpenses" xlink:to="adtx_ShareBasedPaymentRemnainingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Weighted average vesting term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense_lbl" xml:lang="en-US">Compensation expense related to options issued and vesting (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl" xml:lang="en-US">Issue of aggregate stock option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_WarrantsIssuedAndVesting" xlink:href="adtx-20201231.xsd#adtx_WarrantsIssuedAndVesting"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_WarrantsIssuedAndVesting_lbl" xml:lang="en-US">Warrants issued and vesting (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WarrantsIssuedAndVesting" xlink:to="adtx_WarrantsIssuedAndVesting_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xml:lang="en-US">Weighted average vesting term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_WarrantsExercised" xlink:href="adtx-20201231.xsd#adtx_WarrantsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_WarrantsExercised_lbl" xml:lang="en-US">Warrants exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WarrantsExercised" xlink:to="adtx_WarrantsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Issue of salveo shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercised (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Warrant issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrant exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BroadcastersLicenseAgreementCommitmentsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription_lbl" xml:lang="en-US">License agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription" xlink:to="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_FinanceArrangementCost" xlink:href="adtx-20201231.xsd#adtx_FinanceArrangementCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_FinanceArrangementCost_lbl" xml:lang="en-US">Finance arrangement cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FinanceArrangementCost" xlink:to="adtx_FinanceArrangementCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xml:lang="en-US">Share issued description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnsecuredDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnsecuredDebt_lbl" xml:lang="en-US">Unsecured promissory note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebt" xlink:to="us-gaap_UnsecuredDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Accrued interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xml:lang="en-US">Maturity date, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BridgeLoan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BridgeLoan_lbl" xml:lang="en-US">Bridge loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BridgeLoan" xlink:to="us-gaap_BridgeLoan_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtDescription_lbl" xml:lang="en-US">Bridge loan, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtDescription" xlink:to="us-gaap_ShortTermDebtDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0" xml:lang="en-US">Convertible price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0"/>
    <loc xlink:type="locator" xlink:label="adtx_OriginalIssueDiscount" xlink:href="adtx-20201231.xsd#adtx_OriginalIssueDiscount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_OriginalIssueDiscount_lbl" xml:lang="en-US">Original issue discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OriginalIssueDiscount" xlink:to="adtx_OriginalIssueDiscount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Total principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation allowance increased amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_NetOperatingLossPercentage" xlink:href="adtx-20201231.xsd#adtx_NetOperatingLossPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_NetOperatingLossPercentage_lbl" xml:lang="en-US">Net operating loss percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NetOperatingLossPercentage" xlink:to="adtx_NetOperatingLossPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_CorporationsTaxableIncomePercentage" xlink:href="adtx-20201231.xsd#adtx_CorporationsTaxableIncomePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_CorporationsTaxableIncomePercentage_lbl" xml:lang="en-US">Net operating loss carryover or corporation&#8217;s taxable income percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CorporationsTaxableIncomePercentage" xlink:to="adtx_CorporationsTaxableIncomePercentage_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbshkMkzTNOwKi/SY5wisaUmNZUHQSzNMHSWLwfjT7WpDTxNyESoEbcePgflNnDx4+Cpe7iGVGde/DRQguZdZo5KjpAUGAQNyOkDD76ahIjQccKEsvf9/Xj3++QLucVobcn305z1bCg1mi6xUZr+oBVMyyqaM/+TOgNX7+t44hIrWlYUwPKsqCr5vXiF6x03y9mCrDT1DUK0BHxnobWpUaa] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xml:lang="en-US">Operating loss carryforwards, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Federal tax credit carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research and development tax credit carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_SaleOfConvertableNote" xlink:href="adtx-20201231.xsd#adtx_SaleOfConvertableNote"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_SaleOfConvertableNote_lbl" xml:lang="en-US">Sale of convertible note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SaleOfConvertableNote" xlink:to="adtx_SaleOfConvertableNote_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Original issuance discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Warrants to purchase shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_InvestmentWarrantsExpirationPeriod" xlink:href="adtx-20201231.xsd#adtx_InvestmentWarrantsExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_InvestmentWarrantsExpirationPeriod_lbl" xml:lang="en-US">Warrant term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_InvestmentWarrantsExpirationPeriod" xlink:to="adtx_InvestmentWarrantsExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_InvestmentWarrantsExercisePrice" xlink:href="adtx-20201231.xsd#adtx_InvestmentWarrantsExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_InvestmentWarrantsExercisePrice_lbl" xml:lang="en-US">Warrants exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_InvestmentWarrantsExercisePrice" xlink:to="adtx_InvestmentWarrantsExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_FinancingAgreementTerm" xlink:href="adtx-20201231.xsd#adtx_FinancingAgreementTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_FinancingAgreementTerm_lbl" xml:lang="en-US">Term of financing agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FinancingAgreementTerm" xlink:to="adtx_FinancingAgreementTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_CostOfFinancingAgreement" xlink:href="adtx-20201231.xsd#adtx_CostOfFinancingAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_CostOfFinancingAgreement_lbl" xml:lang="en-US">Cost of financing agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CostOfFinancingAgreement" xlink:to="adtx_CostOfFinancingAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_WarrantsExercisedForShares" xlink:href="adtx-20201231.xsd#adtx_WarrantsExercisedForShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_WarrantsExercisedForShares_lbl" xml:lang="en-US">Warrants exercised for shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WarrantsExercisedForShares" xlink:to="adtx_WarrantsExercisedForShares_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ProceedsFormWarrantsIssued" xlink:href="adtx-20201231.xsd#adtx_ProceedsFormWarrantsIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_ProceedsFormWarrantsIssued_lbl" xml:lang="en-US">Proceeds form warrants issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ProceedsFormWarrantsIssued" xlink:to="adtx_ProceedsFormWarrantsIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements and Fair Value of Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_FixedAssetPolicyTextBlock" xlink:href="adtx-20201231.xsd#adtx_FixedAssetPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_FixedAssetPolicyTextBlock_lbl" xml:lang="en-US">Fixed Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FixedAssetPolicyTextBlock" xlink:to="adtx_FixedAssetPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_OfferingCostsPolicyTextBlock" xlink:href="adtx-20201231.xsd#adtx_OfferingCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_OfferingCostsPolicyTextBlock_lbl" xml:lang="en-US">Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OfferingCostsPolicyTextBlock" xlink:to="adtx_OfferingCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_PatentsPolicyTextBlock" xlink:href="adtx-20201231.xsd#adtx_PatentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_PatentsPolicyTextBlock_lbl" xml:lang="en-US">Patents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PatentsPolicyTextBlock" xlink:to="adtx_PatentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Net Loss per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAMember_lbl" xml:lang="en-US">Series A warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAMember" xlink:to="us-gaap_SeriesAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBMember_lbl" xml:lang="en-US">Series B warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBMember" xlink:to="us-gaap_SeriesBMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_SeriesA1WarrantMember" xlink:href="adtx-20201231.xsd#adtx_SeriesA1WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_SeriesA1WarrantMember_lbl" xml:lang="en-US">Series A-1 warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SeriesA1WarrantMember" xlink:to="adtx_SeriesA1WarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_SeriesB1WarrantMember" xlink:href="adtx-20201231.xsd#adtx_SeriesB1WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_SeriesB1WarrantMember_lbl" xml:lang="en-US">Series B-1 warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SeriesB1WarrantMember" xlink:to="adtx_SeriesB1WarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_ChiefInnovationOfficerMember" xlink:href="adtx-20201231.xsd#adtx_ChiefInnovationOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_ChiefInnovationOfficerMember_lbl" xml:lang="en-US">Chief Innovation Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ChiefInnovationOfficerMember" xlink:to="adtx_ChiefInnovationOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefOperatingOfficerMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefOperatingOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefOperatingOfficerMember_lbl" xml:lang="en-US">Chief Operating Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefOperatingOfficerMember" xlink:to="srt_ChiefOperatingOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock option [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_September2020OfferingMember" xlink:href="adtx-20201231.xsd#adtx_September2020OfferingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_September2020OfferingMember_lbl" xml:lang="en-US">September 2020 Offering [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_September2020OfferingMember" xlink:to="adtx_September2020OfferingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_TwoZeroOneSevenEquityIncentivePlanMember" xlink:href="adtx-20201231.xsd#adtx_TwoZeroOneSevenEquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_TwoZeroOneSevenEquityIncentivePlanMember_lbl" xml:lang="en-US">2017 Equity Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_TwoZeroOneSevenEquityIncentivePlanMember" xlink:to="adtx_TwoZeroOneSevenEquityIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_SalveoConsultingAgreementMember" xlink:href="adtx-20201231.xsd#adtx_SalveoConsultingAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_SalveoConsultingAgreementMember_lbl" xml:lang="en-US">Salveo Consulting Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SalveoConsultingAgreementMember" xlink:to="adtx_SalveoConsultingAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_SalveoDiagnosticsIncMember" xlink:href="adtx-20201231.xsd#adtx_SalveoDiagnosticsIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_SalveoDiagnosticsIncMember_lbl" xml:lang="en-US">Salveo Diagnostics, Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SalveoDiagnosticsIncMember" xlink:to="adtx_SalveoDiagnosticsIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BridgeLoanMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BridgeLoanMember_lbl" xml:lang="en-US">Bridge Loan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BridgeLoanMember" xlink:to="us-gaap_BridgeLoanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_SixBridgeLoansMember" xlink:href="adtx-20201231.xsd#adtx_SixBridgeLoansMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_SixBridgeLoansMember_lbl" xml:lang="en-US">Six bridge loans [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SixBridgeLoansMember" xlink:to="adtx_SixBridgeLoansMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_USFederalMember" xlink:href="adtx-20201231.xsd#adtx_USFederalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_USFederalMember_lbl" xml:lang="en-US">U.S. federal [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_USFederalMember" xlink:to="adtx_USFederalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_USStateMember" xlink:href="adtx-20201231.xsd#adtx_USStateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adtx_USStateMember_lbl" xml:lang="en-US">U.S.state [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_USStateMember" xlink:to="adtx_USStateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionTable" xlink:href="adtx-20201231.xsd#adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionTable_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Deficit) (Details) - Schedule of stock option granted was estimated using the Black-Scholes assumption [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionTable" xlink:to="adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionTable_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionLineItems" xlink:href="adtx-20201231.xsd#adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionLineItems_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Deficit) (Details) - Schedule of stock option granted was estimated using the Black-Scholes assumption [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionLineItems" xlink:to="adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable" xlink:href="adtx-20201231.xsd#adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Deficit) (Details) - Schedule of analysis of the stock option grant activity under the plan [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable" xlink:to="adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:href="adtx-20201231.xsd#adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Deficit) (Details) - Schedule of analysis of the stock option grant activity under the plan [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Financial Instruments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionTable" xlink:href="adtx-20201231.xsd#adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionTable_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Deficit) (Details) - Schedule of nonvested option [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionTable" xlink:to="adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionTable_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems" xlink:href="adtx-20201231.xsd#adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Deficit) (Details) - Schedule of nonvested option [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems" xlink:to="adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_lbl" xml:lang="en-US">Auction Market Preferred Securities, Stock Series, Title [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_OrganizationandNatureofBusinessDetailsTable" xlink:href="adtx-20201231.xsd#adtx_OrganizationandNatureofBusinessDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_OrganizationandNatureofBusinessDetailsTable_lbl" xml:lang="en-US">Organization and Nature of Business (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OrganizationandNatureofBusinessDetailsTable" xlink:to="adtx_OrganizationandNatureofBusinessDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:href="adtx-20201231.xsd#adtx_OrganizationandNatureofBusinessDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_OrganizationandNatureofBusinessDetailsLineItems_lbl" xml:lang="en-US">Organization and Nature of Business (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OrganizationandNatureofBusinessDetailsLineItems" xlink:to="adtx_OrganizationandNatureofBusinessDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_RelatedPartyTransactionsDetailsTable" xlink:href="adtx-20201231.xsd#adtx_RelatedPartyTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_RelatedPartyTransactionsDetailsTable_lbl" xml:lang="en-US">Related Party Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RelatedPartyTransactionsDetailsTable" xlink:to="adtx_RelatedPartyTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_RelatedPartyTransactionsDetailsLineItems" xlink:href="adtx-20201231.xsd#adtx_RelatedPartyTransactionsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_RelatedPartyTransactionsDetailsLineItems_lbl" xml:lang="en-US">Related Party Transactions (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RelatedPartyTransactionsDetailsLineItems" xlink:to="adtx_RelatedPartyTransactionsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDeficitDetailsTable" xlink:href="adtx-20201231.xsd#adtx_StockholdersEquityDeficitDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StockholdersEquityDeficitDetailsTable_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Deficit) (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockholdersEquityDeficitDetailsTable" xlink:to="adtx_StockholdersEquityDeficitDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:href="adtx-20201231.xsd#adtx_StockholdersEquityDeficitDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StockholdersEquityDeficitDetailsLineItems_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Deficit) (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockholdersEquityDeficitDetailsLineItems" xlink:to="adtx_StockholdersEquityDeficitDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_TypeOfAgreementDomain" xlink:href="adtx-20201231.xsd#adtx_TypeOfAgreementDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_TypeOfAgreementDomain_lbl" xml:lang="en-US">TypeOfAgreement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_TypeOfAgreementDomain" xlink:to="adtx_TypeOfAgreementDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_AgreementsDetailsTable" xlink:href="adtx-20201231.xsd#adtx_AgreementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_AgreementsDetailsTable_lbl" xml:lang="en-US">Agreements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_AgreementsDetailsTable" xlink:to="adtx_AgreementsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_AgreementsDetailsLineItems" xlink:href="adtx-20201231.xsd#adtx_AgreementsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_AgreementsDetailsLineItems_lbl" xml:lang="en-US">Agreements (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_AgreementsDetailsLineItems" xlink:to="adtx_AgreementsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US">Long-term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_NotesPayableDetailsTable" xlink:href="adtx-20201231.xsd#adtx_NotesPayableDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_NotesPayableDetailsTable_lbl" xml:lang="en-US">Notes Payable (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NotesPayableDetailsTable" xlink:to="adtx_NotesPayableDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_NotesPayableDetailsLineItems" xlink:href="adtx-20201231.xsd#adtx_NotesPayableDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_NotesPayableDetailsLineItems_lbl" xml:lang="en-US">Notes Payable (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NotesPayableDetailsLineItems" xlink:to="adtx_NotesPayableDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_IncomeTaxesDetailsTable" xlink:href="adtx-20201231.xsd#adtx_IncomeTaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_IncomeTaxesDetailsTable_lbl" xml:lang="en-US">Income Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IncomeTaxesDetailsTable" xlink:to="adtx_IncomeTaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_IncomeTaxesDetailsLineItems" xlink:href="adtx-20201231.xsd#adtx_IncomeTaxesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_IncomeTaxesDetailsLineItems_lbl" xml:lang="en-US">Income Taxes (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IncomeTaxesDetailsLineItems" xlink:to="adtx_IncomeTaxesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_SubsequentEventsDetailsTable" xlink:href="adtx-20201231.xsd#adtx_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SubsequentEventsDetailsTable" xlink:to="adtx_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="adtx_SubsequentEventsDetailsLineItems" xlink:href="adtx-20201231.xsd#adtx_SubsequentEventsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_SubsequentEventsDetailsLineItems_lbl" xml:lang="en-US">Subsequent Events (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SubsequentEventsDetailsLineItems" xlink:to="adtx_SubsequentEventsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_AccruedCompensationForRelatedParty_lbl0" xml:lang="en-US">The amount represents accrued compensation for related paty.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_AccruedCompensationForRelatedParty" xlink:to="adtx_AccruedCompensationForRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_AccumulatedDepreciation_lbl0" xml:lang="en-US">Amount of accumulated depreciation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_AccumulatedDepreciation" xlink:to="adtx_AccumulatedDepreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_AgreementsDisclosureTextBlock_lbl0" xml:lang="en-US">Agreements disclosure text block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_AgreementsDisclosureTextBlock" xlink:to="adtx_AgreementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_CommonStockExercisePricePerShare_lbl0" xml:lang="en-US">Common stock exercise price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CommonStockExercisePricePerShare" xlink:to="adtx_CommonStockExercisePricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_CommonStockIssuedForPreferredShares_lbl0" xml:lang="en-US">Common stock issued for preferred shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CommonStockIssuedForPreferredShares" xlink:to="adtx_CommonStockIssuedForPreferredShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_CommonStockVotingRightsPercentage_lbl0" xml:lang="en-US">Common stock voting rights percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CommonStockVotingRightsPercentage" xlink:to="adtx_CommonStockVotingRightsPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_CorporationsTaxableIncomePercentage_lbl0" xml:lang="en-US">Corporation&#8217;s taxable income Percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CorporationsTaxableIncomePercentage" xlink:to="adtx_CorporationsTaxableIncomePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_CostOfFinancingAgreement_lbl0" xml:lang="en-US">Cost of financing agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CostOfFinancingAgreement" xlink:to="adtx_CostOfFinancingAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_DeferredTaxAssetsLeaseLiability_lbl0" xml:lang="en-US">Lease liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DeferredTaxAssetsLeaseLiability" xlink:to="adtx_DeferredTaxAssetsLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_DeferredTaxLiabilitiesRightOfUseAssets_lbl0" xml:lang="en-US">Deferred Tax Liabilities Right of use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="adtx_DeferredTaxLiabilitiesRightOfUseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_ExerciseConversionOfPreferredShares_lbl0" xml:lang="en-US">Exercise conversion of preferred shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ExerciseConversionOfPreferredShares" xlink:to="adtx_ExerciseConversionOfPreferredShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_ExerciseConversionOfSharesPreferredShares_lbl0" xml:lang="en-US">Exercise conversion of preferred shares,shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ExerciseConversionOfSharesPreferredShares" xlink:to="adtx_ExerciseConversionOfSharesPreferredShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_ExerciseOfWarrants_lbl0" xml:lang="en-US">Exercise of warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ExerciseOfWarrants" xlink:to="adtx_ExerciseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_FinanceArrangementCost_lbl0" xml:lang="en-US">Finance Arrangement Cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FinanceArrangementCost" xlink:to="adtx_FinanceArrangementCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_FinancingAgreementTerm_lbl0" xml:lang="en-US">Term of financing agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FinancingAgreementTerm" xlink:to="adtx_FinancingAgreementTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_FinancingOnFixedAssets_lbl0" xml:lang="en-US">Financing on fixed assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FinancingOnFixedAssets" xlink:to="adtx_FinancingOnFixedAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_IncreaseDecreaseInAccruedCompensationToRelatedParties_lbl0" xml:lang="en-US">Accrued compensation to related parties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IncreaseDecreaseInAccruedCompensationToRelatedParties" xlink:to="adtx_IncreaseDecreaseInAccruedCompensationToRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts_lbl0" xml:lang="en-US">Issuance of shares and warrants for IPO, net of offering costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts" xlink:to="adtx_IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_IssuanceOfSharesAndWarrantsForIPONetOfSharesOfferingCosts_lbl0" xml:lang="en-US">Issuance of shares and warrants for IPO, net of offering costs,shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesAndWarrantsForIPONetOfSharesOfferingCosts" xlink:to="adtx_IssuanceOfSharesAndWarrantsForIPONetOfSharesOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable_lbl0" xml:lang="en-US">Issuance of shares for the settlement of accrued compensation and accounts payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable" xlink:to="adtx_IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_IssuanceOfSharesForTheSettlementOfDebt_lbl0" xml:lang="en-US">Issuance of shares for the settlement of debt.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesForTheSettlementOfDebt" xlink:to="adtx_IssuanceOfSharesForTheSettlementOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_IssuanceOfSharesForTheSettlementOfSharesAccruedCompensationAndAccountsPayable_lbl0" xml:lang="en-US">Issuance of shares for the settlement of accrued compensation and accounts payable,share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesForTheSettlementOfSharesAccruedCompensationAndAccountsPayable" xlink:to="adtx_IssuanceOfSharesForTheSettlementOfSharesAccruedCompensationAndAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_IssuanceOfSharesForTheSettlementOfSharesDebtinShares_lbl0" xml:lang="en-US">Issuance of shares for the settlement of debt Shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesForTheSettlementOfSharesDebtinShares" xlink:to="adtx_IssuanceOfSharesForTheSettlementOfSharesDebtinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_IssuanceOfUnitsForTheSettlementOfAccruedCompensationAndAccountsPayable_lbl0" xml:lang="en-US">Issuance of units for the settlement of accrued compensation and accounts payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfUnitsForTheSettlementOfAccruedCompensationAndAccountsPayable" xlink:to="adtx_IssuanceOfUnitsForTheSettlementOfAccruedCompensationAndAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_LesseeOperatingLeaseLiability_lbl0" xml:lang="en-US">Total Lease Liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_LesseeOperatingLeaseLiability" xlink:to="adtx_LesseeOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_LiabilitiesAssumedForCommonStock_lbl0" xml:lang="en-US">Liabilities assumed for common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_LiabilitiesAssumedForCommonStock" xlink:to="adtx_LiabilitiesAssumedForCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_LicensingFeeForPatents_lbl0" xml:lang="en-US">Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_LicensingFeeForPatents" xlink:to="adtx_LicensingFeeForPatents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_NetOperatingLossPercentage_lbl0" xml:lang="en-US">Net Operating Loss Percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NetOperatingLossPercentage" xlink:to="adtx_NetOperatingLossPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_OfferingCostsPolicyTextBlock_lbl0" xml:lang="en-US">Offering Costs Policy Text Block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OfferingCostsPolicyTextBlock" xlink:to="adtx_OfferingCostsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_OriginalIssuanceDiscountOnNotesPayable_lbl0" xml:lang="en-US">Original issuance discount on notes payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OriginalIssuanceDiscountOnNotesPayable" xlink:to="adtx_OriginalIssuanceDiscountOnNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_PatentsPolicyTextBlock_lbl0" xml:lang="en-US">Patents Policy Text Block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PatentsPolicyTextBlock" xlink:to="adtx_PatentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_PreferredStockExercise_lbl0" xml:lang="en-US">Preferred stock exercise.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PreferredStockExercise" xlink:to="adtx_PreferredStockExercise_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_ProceedsFormWarrantsIssued_lbl0" xml:lang="en-US">Proceeds form warrants issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ProceedsFormWarrantsIssued" xlink:to="adtx_ProceedsFormWarrantsIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_PurchaseOfCommonStock_lbl0" xml:lang="en-US">Purchase of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PurchaseOfCommonStock" xlink:to="adtx_PurchaseOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_PurchaseOfEquityShares_lbl0" xml:lang="en-US">Purchase of equity shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PurchaseOfEquityShares" xlink:to="adtx_PurchaseOfEquityShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_RightOfUseAssetLongTerm_lbl1" xml:lang="en-US">Right of use asset &#8211; long term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RightOfUseAssetLongTerm" xlink:to="adtx_RightOfUseAssetLongTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_RightOfUseAssetShortTerm_lbl0" xml:lang="en-US">Right of use asset &#8211; short term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RightOfUseAssetShortTerm" xlink:to="adtx_RightOfUseAssetShortTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_SettlementOfAccountsPayableShares_lbl0" xml:lang="en-US">Settlement of accounts payable shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SettlementOfAccountsPayableShares" xlink:to="adtx_SettlementOfAccountsPayableShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_ShareBasedPaymentRemnainingExpenses_lbl0" xml:lang="en-US">Share based payment remnaining expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ShareBasedPaymentRemnainingExpenses" xlink:to="adtx_ShareBasedPaymentRemnainingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_ShareBasedPaymentsWeightedAverageRemainingLifeExercised_lbl0" xml:lang="en-US">Weighted Average Remaining Life, Exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ShareBasedPaymentsWeightedAverageRemainingLifeExercised" xlink:to="adtx_ShareBasedPaymentsWeightedAverageRemainingLifeExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_lbl0" xml:lang="en-US">Weighted Average Remaining Life, Outstanding beginning balance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:to="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingLifeExpiredOrForfeited_lbl0" xml:lang="en-US">Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingLifeExpiredOrForfeited" xlink:to="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingLifeExpiredOrForfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts_lbl0" xml:lang="en-US">Issuance of shares and warrants for follow-on offering, net of issuance costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts" xlink:to="adtx_StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_StockIssuedDuringPeriodSharesForCashNetOfOfferingCosts_lbl0" xml:lang="en-US">Issuance of shares for cash, net of offering costs (in Shares).&#xd;
..</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockIssuedDuringPeriodSharesForCashNetOfOfferingCosts" xlink:to="adtx_StockIssuedDuringPeriodSharesForCashNetOfOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_StockIssuedDuringPeriodSharesForIntangibleAssets_lbl0" xml:lang="en-US">Issuance of shares for intangible assets (in Shares).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockIssuedDuringPeriodSharesForIntangibleAssets" xlink:to="adtx_StockIssuedDuringPeriodSharesForIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_StockIssuedDuringPeriodSharesIntangibleAssets_lbl0" xml:lang="en-US">Number of shares issued for intangible assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockIssuedDuringPeriodSharesIntangibleAssets" xlink:to="adtx_StockIssuedDuringPeriodSharesIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_StockIssuedDuringPeriodSharesIssuedForService_lbl0" xml:lang="en-US">Stock issued during period shares issued for service.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockIssuedDuringPeriodSharesIssuedForService" xlink:to="adtx_StockIssuedDuringPeriodSharesIssuedForService_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_StockIssuedDuringPeriodValueIntangibleAssets_lbl0" xml:lang="en-US">Issuance of shares for intangible assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockIssuedDuringPeriodValueIntangibleAssets" xlink:to="adtx_StockIssuedDuringPeriodValueIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_StockIssuedDuringPeriodValueNewIssued_lbl0" xml:lang="en-US">Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockIssuedDuringPeriodValueNewIssued" xlink:to="adtx_StockIssuedDuringPeriodValueNewIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_StockIssuedSettlementOfDebt_lbl0" xml:lang="en-US">Stock issued settlement of debt.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockIssuedSettlementOfDebt" xlink:to="adtx_StockIssuedSettlementOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_StockOptionexercisePrice_lbl0" xml:lang="en-US">Stock option exercise price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockOptionexercisePrice" xlink:to="adtx_StockOptionexercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_StockUnitIssued_lbl0" xml:lang="en-US">Stock Unit Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockUnitIssued" xlink:to="adtx_StockUnitIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_StocksIssuedDuringPeriodSharesIssues_lbl0" xml:lang="en-US">Number of new stock issued during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StocksIssuedDuringPeriodSharesIssues" xlink:to="adtx_StocksIssuedDuringPeriodSharesIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_WarrantsExercised_lbl0" xml:lang="en-US">Warrants Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WarrantsExercised" xlink:to="adtx_WarrantsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_WarrantsExercisedForShares_lbl0" xml:lang="en-US">Warrants exercised for shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WarrantsExercisedForShares" xlink:to="adtx_WarrantsExercisedForShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_WeightedAverageExercisePriceForfeited_lbl0" xml:lang="en-US">Weighted- Average Exercise Price, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageExercisePriceForfeited" xlink:to="adtx_WeightedAverageExercisePriceForfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_WeightedAverageExercisePriceOutstanding_lbl1" xml:lang="en-US">Weighted Average Exercise Price, Outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageExercisePriceOutstanding" xlink:to="adtx_WeightedAverageExercisePriceOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_TypeOfAgreementAxis_lbl0" xml:lang="en-US">Salveo Consulting Agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_TypeOfAgreementAxis" xlink:to="adtx_TypeOfAgreementAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_SalveoConsultingAgreementMember_lbl0" xml:lang="en-US">Salveo Consulting Agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SalveoConsultingAgreementMember" xlink:to="adtx_SalveoConsultingAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_SalveoDiagnosticsIncMember_lbl0" xml:lang="en-US">Salveo Diagnostics, Inc..</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SalveoDiagnosticsIncMember" xlink:to="adtx_SalveoDiagnosticsIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_USFederalMember_lbl0" xml:lang="en-US">U.S. Federal.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_USFederalMember" xlink:to="adtx_USFederalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adtx_USStateMember_lbl0" xml:lang="en-US">U.S.State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_USStateMember" xlink:to="adtx_USStateMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_FixedAssets_lbl0" xml:lang="en-US">FixedAssets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FixedAssets" xlink:to="adtx_FixedAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_LesseeOperatingLeaseLiability_lbl1" xml:lang="en-US">LesseeOperatingLeaseLiability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_LesseeOperatingLeaseLiability" xlink:to="adtx_LesseeOperatingLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_WarrantsExercised_lbl1" xml:lang="en-US">WarrantsExercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WarrantsExercised" xlink:to="adtx_WarrantsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_InvestmentWarrantsExercisePrice_lbl0" xml:lang="en-US">InvestmentWarrantsExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_InvestmentWarrantsExercisePrice" xlink:to="adtx_InvestmentWarrantsExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_AgreementsDisclosureTextBlock_lbl1" xml:lang="en-US">AgreementsDisclosureTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_AgreementsDisclosureTextBlock" xlink:to="adtx_AgreementsDisclosureTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_SalveoConsultingAgreementMember_lbl1" xml:lang="en-US">SalveoConsultingAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SalveoConsultingAgreementMember" xlink:to="adtx_SalveoConsultingAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_NetOperatingLossPercentage_lbl1" xml:lang="en-US">NetOperatingLossPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NetOperatingLossPercentage" xlink:to="adtx_NetOperatingLossPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_IssuanceOfSharesForTheSettlementOfSharesDebtinShares_lbl1" xml:lang="en-US">IssuanceOfSharesForTheSettlementOfSharesDebtinShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesForTheSettlementOfSharesDebtinShares" xlink:to="adtx_IssuanceOfSharesForTheSettlementOfSharesDebtinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StockIssuedDuringPeriodSharesIntangibleAssets_lbl1" xml:lang="en-US">StockIssuedDuringPeriodSharesIntangibleAssets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockIssuedDuringPeriodSharesIntangibleAssets" xlink:to="adtx_StockIssuedDuringPeriodSharesIntangibleAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_SeriesA1WarrantMember_lbl0" xml:lang="en-US">SeriesA1WarrantMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SeriesA1WarrantMember" xlink:to="adtx_SeriesA1WarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_IssuanceOfUnitsForTheSettlementOfAccruedCompensationAndAccountsPayable_lbl1" xml:lang="en-US">IssuanceOfUnitsForTheSettlementOfAccruedCompensationAndAccountsPayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfUnitsForTheSettlementOfAccruedCompensationAndAccountsPayable" xlink:to="adtx_IssuanceOfUnitsForTheSettlementOfAccruedCompensationAndAccountsPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_NonvestedWarrantsMember_lbl0" xml:lang="en-US">NonvestedWarrantsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NonvestedWarrantsMember" xlink:to="adtx_NonvestedWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_WeightedAverageExercisePriceForfeited_lbl1" xml:lang="en-US">WeightedAverageExercisePriceForfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageExercisePriceForfeited" xlink:to="adtx_WeightedAverageExercisePriceForfeited_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_WeightedAverageExercisePriceVested_lbl0" xml:lang="en-US">WeightedAverageExercisePriceVested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageExercisePriceVested" xlink:to="adtx_WeightedAverageExercisePriceVested_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts_lbl1" xml:lang="en-US">StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts" xlink:to="adtx_StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_OriginalIssuanceDiscountOnNotesPayable_lbl1" xml:lang="en-US">OriginalIssuanceDiscountOnNotesPayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OriginalIssuanceDiscountOnNotesPayable" xlink:to="adtx_OriginalIssuanceDiscountOnNotesPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_IssuanceOfSharesForTheSettlementOfDebt_lbl1" xml:lang="en-US">IssuanceOfSharesForTheSettlementOfDebt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesForTheSettlementOfDebt" xlink:to="adtx_IssuanceOfSharesForTheSettlementOfDebt_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ConversionOfPreferredShares_lbl0" xml:lang="en-US">ConversionOfPreferredShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ConversionOfPreferredShares" xlink:to="adtx_ConversionOfPreferredShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ExerciseConversionOfPreferredShares_lbl1" xml:lang="en-US">ExerciseConversionOfPreferredShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ExerciseConversionOfPreferredShares" xlink:to="adtx_ExerciseConversionOfPreferredShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_WarrantsExercisedForShares_lbl1" xml:lang="en-US">WarrantsExercisedForShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WarrantsExercisedForShares" xlink:to="adtx_WarrantsExercisedForShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_OfferingPriceOfShares_lbl0" xml:lang="en-US">OfferingPriceOfShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OfferingPriceOfShares" xlink:to="adtx_OfferingPriceOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_SharesIssuedForIntangibleAssets_lbl0" xml:lang="en-US">SharesIssuedForIntangibleAssets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SharesIssuedForIntangibleAssets" xlink:to="adtx_SharesIssuedForIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_DilutiveEarningsShares_lbl0" xml:lang="en-US">DilutiveEarningsShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DilutiveEarningsShares" xlink:to="adtx_DilutiveEarningsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_TypeOfAgreementAxis_lbl1" xml:lang="en-US">TypeOfAgreementAxis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_TypeOfAgreementAxis" xlink:to="adtx_TypeOfAgreementAxis_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_OriginalIssueDiscount_lbl0" xml:lang="en-US">OriginalIssueDiscount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OriginalIssueDiscount" xlink:to="adtx_OriginalIssueDiscount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_lbl1" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:to="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_WarrantsOfStockOption_lbl0" xml:lang="en-US">WarrantsOfStockOption</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WarrantsOfStockOption" xlink:to="adtx_WarrantsOfStockOption_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_FixedAssetPolicyTextBlock_lbl0" xml:lang="en-US">FixedAssetPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FixedAssetPolicyTextBlock" xlink:to="adtx_FixedAssetPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_PurchaseOfCommonStock_lbl1" xml:lang="en-US">PurchaseOfCommonStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PurchaseOfCommonStock" xlink:to="adtx_PurchaseOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ChiefInnovationOfficerMember_lbl0" xml:lang="en-US">ChiefInnovationOfficerMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ChiefInnovationOfficerMember" xlink:to="adtx_ChiefInnovationOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_September2020OfferingMember_lbl0" xml:lang="en-US">September2020OfferingMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_September2020OfferingMember" xlink:to="adtx_September2020OfferingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_LiabilityRecognizedForFinancedAssets_lbl0" xml:lang="en-US">LiabilityRecognizedForFinancedAssets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_LiabilityRecognizedForFinancedAssets" xlink:to="adtx_LiabilityRecognizedForFinancedAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StockIssuedDuringPeriodSharesForCashNetOfOfferingCosts_lbl1" xml:lang="en-US">StockIssuedDuringPeriodSharesForCashNetOfOfferingCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockIssuedDuringPeriodSharesForCashNetOfOfferingCosts" xlink:to="adtx_StockIssuedDuringPeriodSharesForCashNetOfOfferingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_PatentsPolicyTextBlock_lbl1" xml:lang="en-US">PatentsPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PatentsPolicyTextBlock" xlink:to="adtx_PatentsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_SalveoDiagnosticsIncMember_lbl1" xml:lang="en-US">SalveoDiagnosticsIncMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SalveoDiagnosticsIncMember" xlink:to="adtx_SalveoDiagnosticsIncMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ShareBasedPaymentRemnainingExpenses_lbl1" xml:lang="en-US">ShareBasedPaymentRemnainingExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ShareBasedPaymentRemnainingExpenses" xlink:to="adtx_ShareBasedPaymentRemnainingExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ShareBasedPaymentsWeightedAverageRemainingLifeExercised_lbl1" xml:lang="en-US">ShareBasedPaymentsWeightedAverageRemainingLifeExercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ShareBasedPaymentsWeightedAverageRemainingLifeExercised" xlink:to="adtx_ShareBasedPaymentsWeightedAverageRemainingLifeExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable_lbl1" xml:lang="en-US">IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable" xlink:to="adtx_IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_CommonStockIssuedForPreferredShares_lbl1" xml:lang="en-US">CommonStockIssuedForPreferredShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CommonStockIssuedForPreferredShares" xlink:to="adtx_CommonStockIssuedForPreferredShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_SettlementOfAccountsPayableShares_lbl1" xml:lang="en-US">SettlementOfAccountsPayableShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SettlementOfAccountsPayableShares" xlink:to="adtx_SettlementOfAccountsPayableShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_NonvestedOptionsMember_lbl0" xml:lang="en-US">NonvestedOptionsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_NonvestedOptionsMember" xlink:to="adtx_NonvestedOptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_CommonStockExercisePricePerShare_lbl1" xml:lang="en-US">CommonStockExercisePricePerShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CommonStockExercisePricePerShare" xlink:to="adtx_CommonStockExercisePricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_CommonUnitIssuedPerUnit_lbl0" xml:lang="en-US">CommonUnitIssuedPerUnit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CommonUnitIssuedPerUnit" xlink:to="adtx_CommonUnitIssuedPerUnit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ExerciseOfWarrants_lbl1" xml:lang="en-US">ExerciseOfWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ExerciseOfWarrants" xlink:to="adtx_ExerciseOfWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_PurchaseOfEquityShares_lbl1" xml:lang="en-US">PurchaseOfEquityShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PurchaseOfEquityShares" xlink:to="adtx_PurchaseOfEquityShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_DeferredTaxAssetsLeaseLiability_lbl1" xml:lang="en-US">DeferredTaxAssetsLeaseLiability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DeferredTaxAssetsLeaseLiability" xlink:to="adtx_DeferredTaxAssetsLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_USStateMember_lbl1" xml:lang="en-US">USStateMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_USStateMember" xlink:to="adtx_USStateMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StockOptionsMember_lbl0" xml:lang="en-US">StockOptionsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockOptionsMember" xlink:to="adtx_StockOptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_FinancingAgreementTerm_lbl1" xml:lang="en-US">FinancingAgreementTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FinancingAgreementTerm" xlink:to="adtx_FinancingAgreementTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ProceedsFormWarrantsIssued_lbl1" xml:lang="en-US">ProceedsFormWarrantsIssued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ProceedsFormWarrantsIssued" xlink:to="adtx_ProceedsFormWarrantsIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ROUAssetShortTerm_lbl0" xml:lang="en-US">ROUAssetShortTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ROUAssetShortTerm" xlink:to="adtx_ROUAssetShortTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_AccumulatedDepreciation_lbl1" xml:lang="en-US">AccumulatedDepreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_AccumulatedDepreciation" xlink:to="adtx_AccumulatedDepreciation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_DeferredTaxAssetsAbstract_lbl0" xml:lang="en-US">DeferredTaxAssetsAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DeferredTaxAssetsAbstract" xlink:to="adtx_DeferredTaxAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_RightOfUseAssetLongTerm_lbl2" xml:lang="en-US">RightOfUseAssetLongTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RightOfUseAssetLongTerm" xlink:to="adtx_RightOfUseAssetLongTerm_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_USFederalMember_lbl1" xml:lang="en-US">USFederalMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_USFederalMember" xlink:to="adtx_USFederalMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_AccruedCompensationForRelatedParty_lbl1" xml:lang="en-US">AccruedCompensationForRelatedParty</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_AccruedCompensationForRelatedParty" xlink:to="adtx_AccruedCompensationForRelatedParty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_CommonStockVotingRightsPercentage_lbl1" xml:lang="en-US">CommonStockVotingRightsPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CommonStockVotingRightsPercentage" xlink:to="adtx_CommonStockVotingRightsPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingLifeExpiredOrForfeited_lbl1" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingLifeExpiredOrForfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingLifeExpiredOrForfeited" xlink:to="adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingLifeExpiredOrForfeited_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock_lbl0" xml:lang="en-US">ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock" xlink:to="adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_WeightedAverageExercisePriceGranted_lbl0" xml:lang="en-US">WeightedAverageExercisePriceGranted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageExercisePriceGranted" xlink:to="adtx_WeightedAverageExercisePriceGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_DeferredTaxLiabilitiesRightOfUseAssets_lbl1" xml:lang="en-US">DeferredTaxLiabilitiesRightOfUseAssets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="adtx_DeferredTaxLiabilitiesRightOfUseAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_WeightedAverageExercisePriceOutstanding_lbl2" xml:lang="en-US">WeightedAverageExercisePriceOutstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageExercisePriceOutstanding" xlink:to="adtx_WeightedAverageExercisePriceOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_IssuanceOfSharesForTheSettlementOfSharesAccruedCompensationAndAccountsPayable_lbl1" xml:lang="en-US">IssuanceOfSharesForTheSettlementOfSharesAccruedCompensationAndAccountsPayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesForTheSettlementOfSharesAccruedCompensationAndAccountsPayable" xlink:to="adtx_IssuanceOfSharesForTheSettlementOfSharesAccruedCompensationAndAccountsPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_PreferredStockExercise_lbl1" xml:lang="en-US">PreferredStockExercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_PreferredStockExercise" xlink:to="adtx_PreferredStockExercise_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_TotalGrantFairValue_lbl0" xml:lang="en-US">TotalGrantFairValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_TotalGrantFairValue" xlink:to="adtx_TotalGrantFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_AssetsAbstract0_lbl0" xml:lang="en-US">AssetsAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_AssetsAbstract0" xlink:to="adtx_AssetsAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StockOptionexercisePrice_lbl1" xml:lang="en-US">StockOptionexercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockOptionexercisePrice" xlink:to="adtx_StockOptionexercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_OfferingCostsPolicyTextBlock_lbl1" xml:lang="en-US">OfferingCostsPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_OfferingCostsPolicyTextBlock" xlink:to="adtx_OfferingCostsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_SaleOfConvertableNote_lbl0" xml:lang="en-US">SaleOfConvertableNote</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SaleOfConvertableNote" xlink:to="adtx_SaleOfConvertableNote_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_GoingConcernDisclosureTextBlock_lbl0" xml:lang="en-US">GoingConcernDisclosureTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_GoingConcernDisclosureTextBlock" xlink:to="adtx_GoingConcernDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StockIssuedDuringPeriodValueNewIssued_lbl1" xml:lang="en-US">StockIssuedDuringPeriodValueNewIssued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockIssuedDuringPeriodValueNewIssued" xlink:to="adtx_StockIssuedDuringPeriodValueNewIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_CostOfFinancingAgreement_lbl1" xml:lang="en-US">CostOfFinancingAgreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CostOfFinancingAgreement" xlink:to="adtx_CostOfFinancingAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StockUnitIssued_lbl1" xml:lang="en-US">StockUnitIssued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockUnitIssued" xlink:to="adtx_StockUnitIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_WeightedAverageRemainingLifeGranted_lbl0" xml:lang="en-US">WeightedAverageRemainingLifeGranted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WeightedAverageRemainingLifeGranted" xlink:to="adtx_WeightedAverageRemainingLifeGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_WarrantsIssuedAndVesting_lbl0" xml:lang="en-US">WarrantsIssuedAndVesting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_WarrantsIssuedAndVesting" xlink:to="adtx_WarrantsIssuedAndVesting_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts_lbl1" xml:lang="en-US">IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts" xlink:to="adtx_IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_IncreaseDecreaseInAccruedCompensationToRelatedParties_lbl1" xml:lang="en-US">IncreaseDecreaseInAccruedCompensationToRelatedParties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IncreaseDecreaseInAccruedCompensationToRelatedParties" xlink:to="adtx_IncreaseDecreaseInAccruedCompensationToRelatedParties_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StockIssuedDuringPeriodSharesForIntangibleAssets_lbl1" xml:lang="en-US">StockIssuedDuringPeriodSharesForIntangibleAssets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockIssuedDuringPeriodSharesForIntangibleAssets" xlink:to="adtx_StockIssuedDuringPeriodSharesForIntangibleAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_InvestmentWarrantsExpirationPeriod_lbl0" xml:lang="en-US">InvestmentWarrantsExpirationPeriod</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_InvestmentWarrantsExpirationPeriod" xlink:to="adtx_InvestmentWarrantsExpirationPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_LiabilitiesAssumedForCommonStock_lbl1" xml:lang="en-US">LiabilitiesAssumedForCommonStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_LiabilitiesAssumedForCommonStock" xlink:to="adtx_LiabilitiesAssumedForCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_FinancingOnFixedAssets_lbl1" xml:lang="en-US">FinancingOnFixedAssets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FinancingOnFixedAssets" xlink:to="adtx_FinancingOnFixedAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_TwoZeroOneSevenEquityIncentivePlanMember_lbl0" xml:lang="en-US">TwoZeroOneSevenEquityIncentivePlanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_TwoZeroOneSevenEquityIncentivePlanMember" xlink:to="adtx_TwoZeroOneSevenEquityIncentivePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StocksIssuedDuringPeriodSharesIssues_lbl1" xml:lang="en-US">StocksIssuedDuringPeriodSharesIssues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StocksIssuedDuringPeriodSharesIssues" xlink:to="adtx_StocksIssuedDuringPeriodSharesIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_CorporationsTaxableIncomePercentage_lbl1" xml:lang="en-US">CorporationsTaxableIncomePercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_CorporationsTaxableIncomePercentage" xlink:to="adtx_CorporationsTaxableIncomePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StockIssuedSettlementOfDebt_lbl1" xml:lang="en-US">StockIssuedSettlementOfDebt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockIssuedSettlementOfDebt" xlink:to="adtx_StockIssuedSettlementOfDebt_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_LicensingFeeForPatents_lbl1" xml:lang="en-US">LicensingFeeForPatents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_LicensingFeeForPatents" xlink:to="adtx_LicensingFeeForPatents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StockIssuedDuringPeriodSharesIssuedForService_lbl1" xml:lang="en-US">StockIssuedDuringPeriodSharesIssuedForService</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockIssuedDuringPeriodSharesIssuedForService" xlink:to="adtx_StockIssuedDuringPeriodSharesIssuedForService_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_FinanceArrangementCost_lbl1" xml:lang="en-US">FinanceArrangementCost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_FinanceArrangementCost" xlink:to="adtx_FinanceArrangementCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ModificationOfOptions_lbl0" xml:lang="en-US">ModificationOfOptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ModificationOfOptions" xlink:to="adtx_ModificationOfOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_IssuanceOfSharesAndWarrantsForIPONetOfSharesOfferingCosts_lbl1" xml:lang="en-US">IssuanceOfSharesAndWarrantsForIPONetOfSharesOfferingCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_IssuanceOfSharesAndWarrantsForIPONetOfSharesOfferingCosts" xlink:to="adtx_IssuanceOfSharesAndWarrantsForIPONetOfSharesOfferingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_RightOfUseAssetShortTerm_lbl1" xml:lang="en-US">RightOfUseAssetShortTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_RightOfUseAssetShortTerm" xlink:to="adtx_RightOfUseAssetShortTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_SeriesB1WarrantMember_lbl0" xml:lang="en-US">SeriesB1WarrantMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SeriesB1WarrantMember" xlink:to="adtx_SeriesB1WarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_StockIssuedDuringPeriodValueIntangibleAssets_lbl1" xml:lang="en-US">StockIssuedDuringPeriodValueIntangibleAssets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_StockIssuedDuringPeriodValueIntangibleAssets" xlink:to="adtx_StockIssuedDuringPeriodValueIntangibleAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_ExerciseConversionOfSharesPreferredShares_lbl1" xml:lang="en-US">ExerciseConversionOfSharesPreferredShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_ExerciseConversionOfSharesPreferredShares" xlink:to="adtx_ExerciseConversionOfSharesPreferredShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adtx_SixBridgeLoansMember_lbl0" xml:lang="en-US">SixBridgeLoansMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adtx_SixBridgeLoansMember" xlink:to="adtx_SixBridgeLoansMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAMember_lbl0" xml:lang="en-US">Series A [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAMember" xlink:to="us-gaap_SeriesAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceIncrease_lbl0" xml:lang="en-US">Warrant, Exercise Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceIncrease" xlink:to="us-gaap_WarrantExercisePriceIncrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefOperatingOfficerMember_lbl0" xml:lang="en-US">Chief Operating Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefOperatingOfficerMember" xlink:to="srt_ChiefOperatingOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCosts_lbl0" xml:lang="en-US">Deferred Costs, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockMember_lbl0" xml:lang="en-US">Treasury Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl0" xml:lang="en-US">Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl1" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl0" xml:lang="en-US">Increase (Decrease) in Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl0" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl0" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl0" xml:lang="en-US">Proceeds from Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnsecuredDebt_lbl0" xml:lang="en-US">Unsecured Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebt" xlink:to="us-gaap_UnsecuredDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets_lbl0" xml:lang="en-US">Payments for (Proceeds from) Productive Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:to="us-gaap_PaymentsForProceedsFromProductiveAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl0" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl0" xml:lang="en-US">Operating Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl0" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription_lbl0" xml:lang="en-US">Debt Instrument, Maturity Date, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsCurrent_lbl0" xml:lang="en-US">Intangible Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsCurrent" xlink:to="us-gaap_IntangibleAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl0" xml:lang="en-US">APIC, Share-based Payment Arrangement, Recognition and Exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl0" xml:lang="en-US">Stock Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivableWithImputedInterestNetAmount_lbl0" xml:lang="en-US">Receivable with Imputed Interest, Net Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableWithImputedInterestNetAmount" xlink:to="us-gaap_ReceivableWithImputedInterestNetAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl0" xml:lang="en-US">Related Party Transaction, Description of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate During Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl0" xml:lang="en-US">Selling and Marketing Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtDescription_lbl0" xml:lang="en-US">Short-term Debt, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtDescription" xlink:to="us-gaap_ShortTermDebtDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BridgeLoanMember_lbl0" xml:lang="en-US">Bridge Loan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BridgeLoanMember" xlink:to="us-gaap_BridgeLoanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl0" xml:lang="en-US">Deposits Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl0" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessStockSharesIssued_lbl0" xml:lang="en-US">Excess Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl0" xml:lang="en-US">Short-term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Deposit Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl0" xml:lang="en-US">Lease, Cost [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction_lbl0" xml:lang="en-US">Sale of Stock, Description of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl0" xml:lang="en-US">Operating Loss Carryforwards, Limitations on Use</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense_lbl0" xml:lang="en-US">Stock Issued, Value, Stock Options Exercised, Net of Tax Benefit (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl0" xml:lang="en-US">Income Taxes Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl1" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Disclosure [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl0" xml:lang="en-US">Repayments of Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl0" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockSharesAcquired_lbl0" xml:lang="en-US">Treasury Stock, Shares, Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockSharesAcquired" xlink:to="us-gaap_TreasuryStockSharesAcquired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPPredecessorEntityIesToBusinessCombination_lbl0" xml:lang="en-US">Limited Liability Company (LLC) or Limited Partnership (LP), Predecessor Entity(ies) to Business Combination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPPredecessorEntityIesToBusinessCombination" xlink:to="us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPPredecessorEntityIesToBusinessCombination_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl0" xml:lang="en-US">Stockholders&apos; Equity, Reverse Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl1" xml:lang="en-US">Debt Instrument, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl0" xml:lang="en-US">Investment Income, Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl0" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl0" xml:lang="en-US">Notes Payable, Related Parties, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription_lbl0" xml:lang="en-US">Broadcasters License Agreement Commitments, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription" xlink:to="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl0" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl0" xml:lang="en-US">Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment_lbl0" xml:lang="en-US">Direct Costs of Leased and Rented Property or Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment" xlink:to="us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_lbl0" xml:lang="en-US">Treasury Stock, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl1" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl0" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonUnitIssued_lbl1" xml:lang="en-US">Common Unit, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonUnitIssued" xlink:to="us-gaap_CommonUnitIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl0" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl0" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIntangibleAssetsNet_lbl0" xml:lang="en-US">Other Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIntangibleAssetsNet" xlink:to="us-gaap_OtherIntangibleAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromOfficersOrStockholders_lbl0" xml:lang="en-US">Due from Officers or Stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromOfficersOrStockholders" xlink:to="us-gaap_DueFromOfficersOrStockholders_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Other Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl2" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockShares_lbl0" xml:lang="en-US">Treasury Stock, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl0" xml:lang="en-US">Notes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BridgeLoan_lbl0" xml:lang="en-US">Bridge Loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BridgeLoan" xlink:to="us-gaap_BridgeLoan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionPlanExpense_lbl0" xml:lang="en-US">Stock or Unit Option Plan Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionPlanExpense" xlink:to="us-gaap_StockOptionPlanExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Ownership Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl0" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure_lbl0" xml:lang="en-US">Variable Interest Entity, Nonconsolidated, Comparison of Carrying Amount of Assets and Liabilities to Maximum Loss Exposure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure" xlink:to="us-gaap_VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationNonproduction_lbl0" xml:lang="en-US">Depreciation, Nonproduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationNonproduction" xlink:to="us-gaap_DepreciationNonproduction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl0" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl0" xml:lang="en-US">Proceeds from Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBMember_lbl0" xml:lang="en-US">Series B [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBMember" xlink:to="us-gaap_SeriesBMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseOther_lbl0" xml:lang="en-US">Interest Expense, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl0" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl0" xml:lang="en-US">Repayments of Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl0" xml:lang="en-US">Long-term Debt, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Stock Splits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl1" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl0" xml:lang="en-US">Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl0" xml:lang="en-US">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Capital Leased Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>adtx-20201231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 25 16:57:49 EDT 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ConsolidatedBalanceSheet" roleURI="http://www.aditxt.com./role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.aditxt.com./role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ConsolidatedIncomeStatement" roleURI="http://www.aditxt.com./role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.aditxt.com./role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ShareholdersEquityType2or3" roleURI="http://www.aditxt.com./role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ConsolidatedCashFlow" roleURI="http://www.aditxt.com./role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_OrganizationandNatureofBusiness" roleURI="http://www.aditxt.com./role/OrganizationandNatureofBusiness"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_GoingConcernAnalysis" roleURI="http://www.aditxt.com./role/GoingConcernAnalysis"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.aditxt.com./role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_RelatedPartyTransactions" roleURI="http://www.aditxt.com./role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_StockholdersEquityDeficit" roleURI="http://www.aditxt.com./role/StockholdersEquityDeficit"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_Agreements" roleURI="http://www.aditxt.com./role/Agreements"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_NotesPayable" roleURI="http://www.aditxt.com./role/NotesPayable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_IncomeTaxes" roleURI="http://www.aditxt.com./role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_SubsequentEvents" roleURI="http://www.aditxt.com./role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_AccountingPoliciesByPolicy" roleURI="http://www.aditxt.com./role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_StockholdersEquityDeficitTables" roleURI="http://www.aditxt.com./role/StockholdersEquityDeficitTables"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_IncomeTaxesTables" roleURI="http://www.aditxt.com./role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ScheduleofleasecostsTable" roleURI="http://www.aditxt.com./role/ScheduleofleasecostsTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ScheduleofrightofuseassetleaseassetsandleaseliabilitiesTable" roleURI="http://www.aditxt.com./role/ScheduleofrightofuseassetleaseassetsandleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ScheduleofleasetermsanddiscountTable" roleURI="http://www.aditxt.com./role/ScheduleofleasetermsanddiscountTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_SchedulefutureminimumleasepaymentsundertheleasesTable" roleURI="http://www.aditxt.com./role/SchedulefutureminimumleasepaymentsundertheleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionTable" roleURI="http://www.aditxt.com./role/ScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable" roleURI="http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ScheduleofnonvestedoptionTable" roleURI="http://www.aditxt.com./role/ScheduleofnonvestedoptionTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ScheduleofstatutoryfederalincometaxrateTable" roleURI="http://www.aditxt.com./role/ScheduleofstatutoryfederalincometaxrateTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_ScheduleofdeferredtaxassetsandliabilitiesTable" roleURI="http://www.aditxt.com./role/ScheduleofdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_OrganizationandNatureofBusinessDetails" roleURI="http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_GoingConcernAnalysisDetails" roleURI="http://www.aditxt.com./role/GoingConcernAnalysisDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_RelatedPartyTransactionsDetails" roleURI="http://www.aditxt.com./role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_StockholdersEquityDeficitDetails" roleURI="http://www.aditxt.com./role/StockholdersEquityDeficitDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_AgreementsDetails" roleURI="http://www.aditxt.com./role/AgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_NotesPayableDetails" roleURI="http://www.aditxt.com./role/NotesPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_IncomeTaxesDetails" roleURI="http://www.aditxt.com./role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#adtx_r_SubsequentEventsDetails" roleURI="http://www.aditxt.com./role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="adtx-20201231.xsd#DocumentAndEntityInformation" roleURI="http://www.aditxt.com./role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ROUAssetShortTerm" xlink:href="adtx-20201231.xsd#adtx_ROUAssetShortTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="ROUAssetShortTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="FixedAssets" xlink:href="adtx-20201231.xsd#adtx_FixedAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrent" xlink:to="FixedAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherIntangibleAssetsNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DeferredCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightOfUseAssetLongTerm" xlink:href="adtx-20201231.xsd#adtx_RightOfUseAssetLongTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrent" xlink:to="RightOfUseAssetLongTerm" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinancingOnFixedAssets" xlink:href="adtx-20201231.xsd#adtx_FinancingOnFixedAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="FinancingOnFixedAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TreasuryStockShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_OperatingExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseOther" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_SellingAndMarketingExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_TreasuryStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="5.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueIntangibleAssets" xlink:href="adtx-20201231.xsd#adtx_StockIssuedDuringPeriodValueIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueIntangibleAssets" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesForIntangibleAssets" xlink:href="adtx-20201231.xsd#adtx_StockIssuedDuringPeriodSharesForIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesForIntangibleAssets" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable" xlink:href="adtx-20201231.xsd#adtx_IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfSharesForTheSettlementOfSharesAccruedCompensationAndAccountsPayable" xlink:href="adtx-20201231.xsd#adtx_IssuanceOfSharesForTheSettlementOfSharesAccruedCompensationAndAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfSharesForTheSettlementOfSharesAccruedCompensationAndAccountsPayable" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts" xlink:href="adtx-20201231.xsd#adtx_IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfSharesAndWarrantsForIPONetOfSharesOfferingCosts" xlink:href="adtx-20201231.xsd#adtx_IssuanceOfSharesAndWarrantsForIPONetOfSharesOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfSharesAndWarrantsForIPONetOfSharesOfferingCosts" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts" xlink:href="adtx-20201231.xsd#adtx_StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesForCashNetOfOfferingCosts" xlink:href="adtx-20201231.xsd#adtx_StockIssuedDuringPeriodSharesForCashNetOfOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesForCashNetOfOfferingCosts" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfSharesForTheSettlementOfDebt" xlink:href="adtx-20201231.xsd#adtx_IssuanceOfSharesForTheSettlementOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfSharesForTheSettlementOfDebt" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfSharesForTheSettlementOfSharesDebtinShares" xlink:href="adtx-20201231.xsd#adtx_IssuanceOfSharesForTheSettlementOfSharesDebtinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfSharesForTheSettlementOfSharesDebtinShares" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseConversionOfPreferredShares" xlink:href="adtx-20201231.xsd#adtx_ExerciseConversionOfPreferredShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ExerciseConversionOfPreferredShares" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseConversionOfSharesPreferredShares" xlink:href="adtx-20201231.xsd#adtx_ExerciseConversionOfSharesPreferredShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ExerciseConversionOfSharesPreferredShares" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod" order="20.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockSharesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockSharesAcquired" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" order="22.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfWarrants" xlink:href="adtx-20201231.xsd#adtx_ExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ExerciseOfWarrants" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationNonproduction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationNonproduction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationNonproduction" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ModificationOfOptions" xlink:href="adtx-20201231.xsd#adtx_ModificationOfOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ModificationOfOptions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInAccruedCompensationToRelatedParties" xlink:href="adtx-20201231.xsd#adtx_IncreaseDecreaseInAccruedCompensationToRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccruedCompensationToRelatedParties" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromProductiveAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LiabilitiesAssumedForCommonStock" xlink:href="adtx-20201231.xsd#adtx_LiabilitiesAssumedForCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="LiabilitiesAssumedForCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_StockIssued1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfUnitsForTheSettlementOfAccruedCompensationAndAccountsPayable" xlink:href="adtx-20201231.xsd#adtx_IssuanceOfUnitsForTheSettlementOfAccruedCompensationAndAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="IssuanceOfUnitsForTheSettlementOfAccruedCompensationAndAccountsPayable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginalIssuanceDiscountOnNotesPayable" xlink:href="adtx-20201231.xsd#adtx_OriginalIssuanceDiscountOnNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="OriginalIssuanceDiscountOnNotesPayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LiabilityRecognizedForFinancedAssets" xlink:href="adtx-20201231.xsd#adtx_LiabilityRecognizedForFinancedAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="LiabilityRecognizedForFinancedAssets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesIssuedForIntangibleAssets" xlink:href="adtx-20201231.xsd#adtx_SharesIssuedForIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="SharesIssuedForIntangibleAssets" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfPreferredShares" xlink:href="adtx-20201231.xsd#adtx_ConversionOfPreferredShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="ConversionOfPreferredShares" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/OrganizationandNatureofBusiness">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/GoingConcernAnalysis">
    <loc xlink:type="locator" xlink:label="GoingConcernDisclosureAbstract" xlink:href="adtx-20201231.xsd#adtx_GoingConcernDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="GoingConcernDisclosureTextBlock" xlink:href="adtx-20201231.xsd#adtx_GoingConcernDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernDisclosureAbstract" xlink:to="GoingConcernDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/StockholdersEquityDeficit">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/Agreements">
    <loc xlink:type="locator" xlink:label="AgreementsDisclosureAbstract" xlink:href="adtx-20201231.xsd#adtx_AgreementsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="AgreementsDisclosureTextBlock" xlink:href="adtx-20201231.xsd#adtx_AgreementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementsDisclosureAbstract" xlink:to="AgreementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/NotesPayable">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FixedAssetPolicyTextBlock" xlink:href="adtx-20201231.xsd#adtx_FixedAssetPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="FixedAssetPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfferingCostsPolicyTextBlock" xlink:href="adtx-20201231.xsd#adtx_OfferingCostsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="OfferingCostsPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PatentsPolicyTextBlock" xlink:href="adtx-20201231.xsd#adtx_PatentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PatentsPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/StockholdersEquityDeficitTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock" xlink:href="adtx-20201231.xsd#adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofleasecostsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfLeaseCostsAbstract" xlink:href="adtx-20201231.xsd#adtx_ScheduleOfLeaseCostsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseCostsAbstract" xlink:to="us-gaap_LeaseCostAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofrightofuseassetleaseassetsandleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRightOfUseAssetLeaseAssetsAndLeaseLiabilitiesAbstract" xlink:href="adtx-20201231.xsd#adtx_ScheduleOfRightOfUseAssetLeaseAssetsAndLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="AssetsAbstract0" xlink:href="adtx-20201231.xsd#adtx_AssetsAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRightOfUseAssetLeaseAssetsAndLeaseLiabilitiesAbstract" xlink:to="AssetsAbstract0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightOfUseAssetShortTerm" xlink:href="adtx-20201231.xsd#adtx_RightOfUseAssetShortTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract0" xlink:to="RightOfUseAssetShortTerm" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightOfUseAssetLongTerm" xlink:href="adtx-20201231.xsd#adtx_RightOfUseAssetLongTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract0" xlink:to="RightOfUseAssetLongTerm" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRightOfUseAssetLeaseAssetsAndLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRightOfUseAssetLeaseAssetsAndLeaseLiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRightOfUseAssetLeaseAssetsAndLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofleasetermsanddiscountTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfLeaseTermsAndDiscountAbstract" xlink:href="adtx-20201231.xsd#adtx_ScheduleOfLeaseTermsAndDiscountAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseTermsAndDiscountAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseTermsAndDiscountAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/SchedulefutureminimumleasepaymentsundertheleasesTable">
    <loc xlink:type="locator" xlink:label="ScheduleFutureMinimumLeasePaymentsUnderTheLeasesAbstract" xlink:href="adtx-20201231.xsd#adtx_ScheduleFutureMinimumLeasePaymentsUnderTheLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleFutureMinimumLeasePaymentsUnderTheLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleFutureMinimumLeasePaymentsUnderTheLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleFutureMinimumLeasePaymentsUnderTheLeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleFutureMinimumLeasePaymentsUnderTheLeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivableWithImputedInterestNetAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableWithImputedInterestNetAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_ReceivableWithImputedInterestNetAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LesseeOperatingLeaseLiability" xlink:href="adtx-20201231.xsd#adtx_LesseeOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="LesseeOperatingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionGrantedWasEstimatedUsingTheBlackScholesAssumptionAbstract" xlink:href="adtx-20201231.xsd#adtx_ScheduleOfStockOptionGrantedWasEstimatedUsingTheBlackScholesAssumptionAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionTable" xlink:href="adtx-20201231.xsd#adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionTable"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionLineItems" xlink:href="adtx-20201231.xsd#adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionGrantedWasEstimatedUsingTheBlackScholesAssumptionAbstract" xlink:to="StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionTable" xlink:to="StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanAbstract" xlink:href="adtx-20201231.xsd#adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable" xlink:href="adtx-20201231.xsd#adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:href="adtx-20201231.xsd#adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanAbstract" xlink:to="StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbshkMkzTNOwKi/SY5wisaUmNZUHQSzNMHSWLwfjT7WpDTxNyESoEbcePgflNnDx4+Cpe7iGVGde/DRQguZdZo5KjpAUGAQNyOkDD76ahIjQccKEsvf9/Xj3++QLucVobcn305z1bCg1mi6xUZr+oBVMyyqaM/+TOgNX7+t44hIrWlYUwPKsqCr5vXiF6x03y9f1z9dAS815Q/8GkmXy44q] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="StockOptionsMember" xlink:href="adtx-20201231.xsd#adtx_StockOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="StockOptionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanTable" xlink:to="StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceOutstanding" xlink:href="adtx-20201231.xsd#adtx_WeightedAverageExercisePriceOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="WeightedAverageExercisePriceOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:href="adtx-20201231.xsd#adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingLifeGranted" xlink:href="adtx-20201231.xsd#adtx_WeightedAverageRemainingLifeGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="WeightedAverageRemainingLifeGranted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingLifeExpiredOrForfeited" xlink:href="adtx-20201231.xsd#adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingLifeExpiredOrForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingLifeExpiredOrForfeited" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentsWeightedAverageRemainingLifeExercised" xlink:href="adtx-20201231.xsd#adtx_ShareBasedPaymentsWeightedAverageRemainingLifeExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="ShareBasedPaymentsWeightedAverageRemainingLifeExercised" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceOutstanding_0" xlink:href="adtx-20201231.xsd#adtx_WeightedAverageExercisePriceOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="WeightedAverageExercisePriceOutstanding_0" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="adtx-20201231.xsd#adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofnonvestedoptionTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfNonvestedOptionAbstract" xlink:href="adtx-20201231.xsd#adtx_ScheduleOfNonvestedOptionAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDeficitDetailsScheduleofnonvestedoptionTable" xlink:href="adtx-20201231.xsd#adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionTable"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems" xlink:href="adtx-20201231.xsd#adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNonvestedOptionAbstract" xlink:to="StockholdersEquityDeficitDetailsScheduleofnonvestedoptionTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofnonvestedoptionTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NonvestedOptionsMember" xlink:href="adtx-20201231.xsd#adtx_NonvestedOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="NonvestedOptionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofnonvestedoptionTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NonvestedWarrantsMember" xlink:href="adtx-20201231.xsd#adtx_NonvestedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="NonvestedWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofnonvestedoptionTable" xlink:to="StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceGranted" xlink:href="adtx-20201231.xsd#adtx_WeightedAverageExercisePriceGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems" xlink:to="WeightedAverageExercisePriceGranted" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceVested" xlink:href="adtx-20201231.xsd#adtx_WeightedAverageExercisePriceVested"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems" xlink:to="WeightedAverageExercisePriceVested" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceForfeited" xlink:href="adtx-20201231.xsd#adtx_WeightedAverageExercisePriceForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems" xlink:to="WeightedAverageExercisePriceForfeited" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofstatutoryfederalincometaxrateTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStatutoryFederalIncomeTaxRateAbstract" xlink:href="adtx-20201231.xsd#adtx_ScheduleOfStatutoryFederalIncomeTaxRateAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatutoryFederalIncomeTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatutoryFederalIncomeTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatutoryFederalIncomeTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatutoryFederalIncomeTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatutoryFederalIncomeTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/ScheduleofdeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="adtx-20201231.xsd#adtx_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsAbstract" xlink:href="adtx-20201231.xsd#adtx_DeferredTaxAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsLeaseLiability" xlink:href="adtx-20201231.xsd#adtx_DeferredTaxAssetsLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxLiabilitiesRightOfUseAssets" xlink:href="adtx-20201231.xsd#adtx_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="DeferredTaxLiabilitiesRightOfUseAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="OrganizationandNatureofBusinessDetailsTable" xlink:href="adtx-20201231.xsd#adtx_OrganizationandNatureofBusinessDetailsTable"/>
    <loc xlink:type="locator" xlink:label="OrganizationandNatureofBusinessDetailsLineItems" xlink:href="adtx-20201231.xsd#adtx_OrganizationandNatureofBusinessDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="OrganizationandNatureofBusinessDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsTable" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:to="us-gaap_SeriesAMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:to="us-gaap_SeriesBMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesA1WarrantMember" xlink:href="adtx-20201231.xsd#adtx_SeriesA1WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:to="SeriesA1WarrantMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesB1WarrantMember" xlink:href="adtx-20201231.xsd#adtx_SeriesB1WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:to="SeriesB1WarrantMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsTable" xlink:to="OrganizationandNatureofBusinessDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="StockUnitIssued" xlink:href="adtx-20201231.xsd#adtx_StockUnitIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsLineItems" xlink:to="StockUnitIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonUnitIssuedPerUnit" xlink:href="adtx-20201231.xsd#adtx_CommonUnitIssuedPerUnit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsLineItems" xlink:to="CommonUnitIssuedPerUnit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfferingPriceOfShares" xlink:href="adtx-20201231.xsd#adtx_OfferingPriceOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsLineItems" xlink:to="OfferingPriceOfShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsLineItems" xlink:to="us-gaap_VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOfEquityShares" xlink:href="adtx-20201231.xsd#adtx_PurchaseOfEquityShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsLineItems" xlink:to="PurchaseOfEquityShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantExercisePriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceIncrease" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPPredecessorEntityIesToBusinessCombination" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPPredecessorEntityIesToBusinessCombination"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsLineItems" xlink:to="us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPPredecessorEntityIesToBusinessCombination" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonUnitIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonUnitIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsLineItems" xlink:to="us-gaap_CommonUnitIssued" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockVotingRightsPercentage" xlink:href="adtx-20201231.xsd#adtx_CommonStockVotingRightsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsLineItems" xlink:to="CommonStockVotingRightsPercentage" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOfCommonStock" xlink:href="adtx-20201231.xsd#adtx_PurchaseOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsLineItems" xlink:to="PurchaseOfCommonStock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockExercisePricePerShare" xlink:href="adtx-20201231.xsd#adtx_CommonStockExercisePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofBusinessDetailsLineItems" xlink:to="CommonStockExercisePricePerShare" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/GoingConcernAnalysisDetails">
    <loc xlink:type="locator" xlink:label="GoingConcernDisclosureAbstract" xlink:href="adtx-20201231.xsd#adtx_GoingConcernDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernDisclosureAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoingConcernDisclosureAbstract" xlink:to="us-gaap_Cash" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccumulatedDepreciation" xlink:href="adtx-20201231.xsd#adtx_AccumulatedDepreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="AccumulatedDepreciation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LicensingFeeForPatents" xlink:href="adtx-20201231.xsd#adtx_LicensingFeeForPatents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LicensingFeeForPatents" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsOfStockOption" xlink:href="adtx-20201231.xsd#adtx_WarrantsOfStockOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="WarrantsOfStockOption" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DilutiveEarningsShares" xlink:href="adtx-20201231.xsd#adtx_DilutiveEarningsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DilutiveEarningsShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsTable" xlink:href="adtx-20201231.xsd#adtx_RelatedPartyTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsLineItems" xlink:href="adtx-20201231.xsd#adtx_RelatedPartyTransactionsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefExecutiveOfficerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChiefInnovationOfficerMember" xlink:href="adtx-20201231.xsd#adtx_ChiefInnovationOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="ChiefInnovationOfficerMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefOperatingOfficerMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefOperatingOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefOperatingOfficerMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="RelatedPartyTransactionsDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromOfficersOrStockholders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromOfficersOrStockholders"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DueFromOfficersOrStockholders" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionDescriptionOfTransaction" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedCompensationForRelatedParty" xlink:href="adtx-20201231.xsd#adtx_AccruedCompensationForRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="AccruedCompensationForRelatedParty" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueNewIssued" xlink:href="adtx-20201231.xsd#adtx_StockIssuedDuringPeriodValueNewIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="StockIssuedDuringPeriodValueNewIssued" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StocksIssuedDuringPeriodSharesIssues" xlink:href="adtx-20201231.xsd#adtx_StocksIssuedDuringPeriodSharesIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="StocksIssuedDuringPeriodSharesIssues" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/StockholdersEquityDeficitDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDeficitDetailsTable" xlink:href="adtx-20201231.xsd#adtx_StockholdersEquityDeficitDetailsTable"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDeficitDetailsLineItems" xlink:href="adtx-20201231.xsd#adtx_StockholdersEquityDeficitDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="StockholdersEquityDeficitDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="September2020OfferingMember" xlink:href="adtx-20201231.xsd#adtx_September2020OfferingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="September2020OfferingMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoZeroOneSevenEquityIncentivePlanMember" xlink:href="adtx-20201231.xsd#adtx_TwoZeroOneSevenEquityIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoZeroOneSevenEquityIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsTable" xlink:to="srt_RangeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsTable" xlink:to="StockholdersEquityDeficitDetailsLineItems" order="7.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonUnitIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonUnitIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_CommonUnitIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesIntangibleAssets" xlink:href="adtx-20201231.xsd#adtx_StockIssuedDuringPeriodSharesIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="StockIssuedDuringPeriodSharesIntangibleAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_IntangibleAssetsCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExcessStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedForPreferredShares" xlink:href="adtx-20201231.xsd#adtx_CommonStockIssuedForPreferredShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="CommonStockIssuedForPreferredShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreferredStockExercise" xlink:href="adtx-20201231.xsd#adtx_PreferredStockExercise"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="PreferredStockExercise" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SettlementOfAccountsPayableShares" xlink:href="adtx-20201231.xsd#adtx_SettlementOfAccountsPayableShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="SettlementOfAccountsPayableShares" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedSettlementOfDebt" xlink:href="adtx-20201231.xsd#adtx_StockIssuedSettlementOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="StockIssuedSettlementOfDebt" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesIssuedForService" xlink:href="adtx-20201231.xsd#adtx_StockIssuedDuringPeriodSharesIssuedForService"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="StockIssuedDuringPeriodSharesIssuedForService" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalGrantFairValue" xlink:href="adtx-20201231.xsd#adtx_TotalGrantFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="TotalGrantFairValue" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptionexercisePrice" xlink:href="adtx-20201231.xsd#adtx_StockOptionexercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="StockOptionexercisePrice" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionPlanExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionPlanExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_StockOptionPlanExpense" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentRemnainingExpenses" xlink:href="adtx-20201231.xsd#adtx_ShareBasedPaymentRemnainingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="ShareBasedPaymentRemnainingExpenses" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsIssuedAndVesting" xlink:href="adtx-20201231.xsd#adtx_WarrantsIssuedAndVesting"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="WarrantsIssuedAndVesting" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsExercised" xlink:href="adtx-20201231.xsd#adtx_WarrantsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="WarrantsExercised" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDeficitDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/AgreementsDetails">
    <loc xlink:type="locator" xlink:label="AgreementsDisclosureAbstract" xlink:href="adtx-20201231.xsd#adtx_AgreementsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="AgreementsDetailsTable" xlink:href="adtx-20201231.xsd#adtx_AgreementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="AgreementsDetailsLineItems" xlink:href="adtx-20201231.xsd#adtx_AgreementsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementsDisclosureAbstract" xlink:to="AgreementsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SalveoDiagnosticsIncMember" xlink:href="adtx-20201231.xsd#adtx_SalveoDiagnosticsIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="SalveoDiagnosticsIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TypeOfAgreementAxis" xlink:href="adtx-20201231.xsd#adtx_TypeOfAgreementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementsDetailsTable" xlink:to="TypeOfAgreementAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TypeOfAgreementDomain" xlink:href="adtx-20201231.xsd#adtx_TypeOfAgreementDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfAgreementAxis" xlink:to="TypeOfAgreementDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SalveoConsultingAgreementMember" xlink:href="adtx-20201231.xsd#adtx_SalveoConsultingAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfAgreementAxis" xlink:to="SalveoConsultingAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementsDetailsTable" xlink:to="AgreementsDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BroadcastersLicenseAgreementCommitmentsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementsDetailsLineItems" xlink:to="us-gaap_BroadcastersLicenseAgreementCommitmentsDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceArrangementCost" xlink:href="adtx-20201231.xsd#adtx_FinanceArrangementCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementsDetailsLineItems" xlink:to="FinanceArrangementCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AgreementsDetailsLineItems" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/NotesPayableDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="NotesPayableDetailsTable" xlink:href="adtx-20201231.xsd#adtx_NotesPayableDetailsTable"/>
    <loc xlink:type="locator" xlink:label="NotesPayableDetailsLineItems" xlink:href="adtx-20201231.xsd#adtx_NotesPayableDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="NotesPayableDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BridgeLoanMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_BridgeLoanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SixBridgeLoansMember" xlink:href="adtx-20201231.xsd#adtx_SixBridgeLoansMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="SixBridgeLoansMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="NotesPayableDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnsecuredDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_UnsecuredDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BridgeLoan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_BridgeLoan" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_ShortTermDebtDescription" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_ShortTermBorrowings" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginalIssueDiscount" xlink:href="adtx-20201231.xsd#adtx_OriginalIssueDiscount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="OriginalIssueDiscount" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsTable" xlink:href="adtx-20201231.xsd#adtx_IncomeTaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsLineItems" xlink:href="adtx-20201231.xsd#adtx_IncomeTaxesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="USFederalMember" xlink:href="adtx-20201231.xsd#adtx_USFederalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="USFederalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="USStateMember" xlink:href="adtx-20201231.xsd#adtx_USStateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="USStateMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="IncomeTaxesDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetOperatingLossPercentage" xlink:href="adtx-20201231.xsd#adtx_NetOperatingLossPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="NetOperatingLossPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CorporationsTaxableIncomePercentage" xlink:href="adtx-20201231.xsd#adtx_CorporationsTaxableIncomePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="CorporationsTaxableIncomePercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="adtx-20201231.xsd#adtx_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsLineItems" xlink:href="adtx-20201231.xsd#adtx_SubsequentEventsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="SubsequentEventsDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="SaleOfConvertableNote" xlink:href="adtx-20201231.xsd#adtx_SaleOfConvertableNote"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="SaleOfConvertableNote" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentWarrantsExpirationPeriod" xlink:href="adtx-20201231.xsd#adtx_InvestmentWarrantsExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="InvestmentWarrantsExpirationPeriod" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentWarrantsExercisePrice" xlink:href="adtx-20201231.xsd#adtx_InvestmentWarrantsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="InvestmentWarrantsExercisePrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinancingAgreementTerm" xlink:href="adtx-20201231.xsd#adtx_FinancingAgreementTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="FinancingAgreementTerm" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CostOfFinancingAgreement" xlink:href="adtx-20201231.xsd#adtx_CostOfFinancingAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="CostOfFinancingAgreement" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsExercisedForShares" xlink:href="adtx-20201231.xsd#adtx_WarrantsExercisedForShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="WarrantsExercisedForShares" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFormWarrantsIssued" xlink:href="adtx-20201231.xsd#adtx_ProceedsFormWarrantsIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="ProceedsFormWarrantsIssued" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.aditxt.com./role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="adtx-20201231.xsd#adtx_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &W F4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BDS[4%@* %I*KRWT,7!;)]!4/VJ:0YC0@>I
MH O?C32Z#N*HE)GYDE 'H*!'$.K$_C0!:-S$O\5)]KC/3-5O,@3TS[T?:HQV
M6@"T+E2.A-'V@?W3587D?^S2B[3KQ0!9\]>]*)TJNMW$WI4GF1'TH F$BG^*
ME!]Q47R$<4NS'2@":DYJ++CWIX8@<T /HI P-+0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1129% "T4POZ4TECTH DS2;AZXIFW/4FD\M?>
M@!QE0=3FD\Y?2DV*.U''H* $^T+_ '32?:5_NFG8 ["DX]!185Q/M2=P12BY
MB/\ %1Q_=6F%$/510,F65#T84_.>XJFUO&>F13?(=?\ 5R8^M %['K2BL_SK
MF'[R^8/:GQ7\;'# K]: +F:6FK(C#*L#2Y]!0 M%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 44G-(QP,Y H =4;R)&,LU4K
MC4@I*0#=)4"P23?O+IBOM0!8EU#YML2ER>X[5$8IY/FGDVKZ"F-<P0#:A )]
M!UJG+>/(=H4CWS0!>S!!RH#'_:J&34<?=P/I65<74<"EKJ=80/[S=:YR_P#'
MFBV;%$WW#C^[TH%<[![V5SUJ,O,_0?C7E]Y\2;V;*64"1+V+"L.X\5ZW<$A[
MXI_N<4"YCV=I50'S)HP?<U$UY;+]ZZA'_ A7A<M_>S\RWD[?C4)DE/65R/\
M::@+GO']HV'3[;!G_>%2)>VC?=O(/^^A7@70_>)/KNI=\@Z2L/\ @5 'T"LL
M;'B:-C_LN*F7S ,@$#ZYKY[CNKF(YCNIE/L]:%OXEUJW_P!7?2_\".10.Y[N
MMU+'UJQ'J#9YKQFS^(NL6IQ<+'<#Z5TEE\2]+FP+V%[9C_=^84!<]-BO$<X)
MQ5I71QUS7(V.JV&HQAK2\C;=T!;!_*M&.>:+AB<CICI0,WL =*4$_A6?!?YQ
MYF,FKPD5NAH D!I:8<<<TOXT .HI,TM !1110 4444 %%%% !1110 444A-
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M:O$LFGSCS,9:-C706E]CY6&* -(9S3\U&CK(,@T^@8M%)2YH **** "BBB@
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M,O">PKGWD:61Y9"2Y.<^M,/3=W/:OF*V.ESZ,]VE@H\FI<O=2NM2<M-*Q3/
MZ54[8[>U ! Z_A17#4KRJ/4[J=&,%H&*,\8HHK(U"BBB@5@HHHH&%%%%%PL%
M%%% !1110 4=Z** "@\X]J**=[:DM7);>XGM)!+;L4(ZX/6NQT?Q9',4ANSM
M8\;S7$_2@D$Y(KT,/C73ZG'7PJFM$>OJZ/@H1@CKVI<__KKSS1/$DMBRPW&9
M+;H/5:[ZVN8KRW6:*161AP17T.'Q<:L3Q*U!TW8CN[-9AO0[9!R"*;8W[!C#
M.-K#@9[U;QQFJM]:"YCW*=LJ\AA7<<S-0'(R*7Z5DZ=?'=Y$I^=>.>]:P(/(
MZ4 +1110 4444 %%%% !1110 4G:EIC/MR20 .: (;NX6WB+,<8YK(LXWOYV
MNYA^Z'13396?5+ORT)\I3DD5H2LEO"-O" =!0!%=7 B0JH^8_=%<1XM\3QZ'
M:LB-OO9!@+Z&M#Q+K\>BZ>\\C#SW_P!2IKQB\O9]2NWN[EBSN?P'TH$V1SSR
MW5P]Q<2%W<YY_AJ,@$?-D@<CWH[;CT'44J)+),D<2%Y)#MC04$[DUE9W.I7T
M=C:H99Y2,;1]VO<_"/@ZU\,V@D9%DU%Q^\<]OI4?@CP=#X<TY9YD#:A*-SN?
MX<]A75XYR>:920O/3.1ZTHI*44AA0*0,&W?P[/O ]A7'ZC\0[)-8;1=#MVU3
M4\$[(SA5^I[T#2N=E7.^*/%EMX?^SV2)]IU6\.VUM0>2?4^U<Q9?$+Q1<7%]
M')X:"M8'%Q'Y@#*.N[Z5Q%[KD6L0W7B:^M+R#65F#:<P0LJ(#R!C\:!;/4T=
M>UG7P]]'XDU:6PGVYMXK+A<?CWJ6[TNYT[PWI.O:5K]]%+<2+%,[-D$DX&:3
MQ'XC\/\ B#5=&NY%N+A)4\N\A6$ADXZ_G4]AI/B'Q)H5SX=MK%K+1VN=\5[.
M?G5 <C ]:"VU8M:EX[U_2+Q_#=U) \Y*I_:T0)2-3_>_VJIZ+I&F1#Q1/?%M
M96&-=MT[;CEASCTKTS1?"NE:/HQTU(!.D@_?R2\M*W<FN7N?AD^GF^?PIJ36
M*W@_?6\G*$^U!,;=3@]*&E^(H]$T8:8L7E709F QYB9Y&:Z.*?4_"?BK5CHP
M\[P[8,OVNVD8DID9)4GTJ2#P/XRLM1T^ZMGTI)+-2HPA^?/=O>M73_AM?2W5
MY/K>LRR)>-OGMX#A&/H?:@<[/8U+[XF^&K*Q2=+IKI2@?;"I.![GI5:W^*FC
M.(C>6EW913'"23)PWTKC]<T*3PC=Q^&K>%(_#^K7*EKIAGR5[J3Z9J7QIJS/
MJT*:?:+=:=HL8#84-&SXZ''M0$8W/6M.U&TU.W%Q93QW$)'#*>?QJYG<?]CH
M1Z5X9ITEYHNBW'CFUE:RQ* VG-GRY%[[1ZU['I&JV^M:/:ZE;'$-RH;!Z@^E
M I)Q=C1 P,"E..]-W'OP:4-G/&,>M A2"<].>OO7">,_ -MKT#W5@JV]^O/
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M(8D,:<HN.AJ?M32(;N%*!24HIDB$X]\]*1V5$8NZJH&6)Z 4OOZ5POQ.UO\
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M<_A6_P#;[, %[RW7G! E7&?SKRSQ!>7]]X[N-9TRYMI4T.(?Z,7&)O[V/?%
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MGM;VYC=89[>-AAT;CMZ5[%;SQ75M#/%S'*@=3]: )N "._>FTX=.>M!H :Q
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MRV_[U8%]XUUV])Q<B%3V2N?R** N/FFFN7+SS/(QZ[C3!C'&1[444PN%%%%
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M/I,R@'= >JFO1-.U>WU"$/"P/8KW%><:CI$]A(V/GA/1O2JMI>3V,PFMI2K
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!113)7\N)WQD*,XH =D49%846NSS6INUL6^S#.7W<\>U6(]:AFFM$B4L+D;E
M/I0!K<456-S$K!#+'YG==U.DN$A&Z614 ZDG% $]'%0B:-T\Q94*'H<\4U;F
M%MP6525Z\T 6**KBX1D+1.LF/0]*:MR#;B5W2,$XR3Q0!:XI*S8=5CGU-K*+
M#[4W%P:FU*_&G637!0N%XP* +F:7BL5M8N(46:XLBD!&6?=TI-3U^+3DM)?*
M,L5RV R_PCUH V^*3(JC=:C';0PRC]XDK +COFH-:UF/18(Y)(S(9'"@#^=
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MNBRW=H8H6_C4YXH V\BCBL74M>ATPVI9"\5P>''85<N;]+:.!R-PF8*"/0T
M7N*.*R-8UJ/1TB,J%S(X48[#UK2C8.@<-E6&10!+Q1Q58SD3K#@;BN>M#74*
MLJF=,L<#F@"SQ1Q4$L\<6-\B(IZ,QZU3MM6BNKBXB38%AQ\^[@T :?%)FHFE
M10K,X53T.>M-EN88& EF5=WW030!/FC(JM)<[)(T4(?,Z9:DDO(8QN:9%!.T
M#/>@"UD4M022K%'O=U1?[Q/%1P7\%Q,8X9%? R2#F@"W12*VY0W8TM !1110
M 4444 %%%% !1110 4444 %%%% !4-T<6LW^X?Y5-3)462)T;[K#!H Y?2$U
M.;1(H(_*6!MRF3.3C/I3OL:Z?JFF6JN2L:,6/K6]:6D5E;+!%G:O3-,N+"*:
M\CNG!+Q@J /0T <W*KW%A=7-K;H(0S'S97PW'I4QMKR\ATZ]M94DD2+]Y;RG
MB3WK0/A^V(FAWR>2W\&>*E?1+=TC1'DC>)-H930!AM/%/H]] D4EO/'(#(A/
M3Z5:O(4BN=)*94N &P?O?6M0:);"V>)BQ:7&]SU.*EGT^"=[9V)S;?=]Z ,=
M\0ZKJ=M$=J>1NV@]\54MD^T)H]M)DPD%BN?O-FNB;3H);B6X.0\R;#]*B.DV
M_P!CAA)*FW;*L* *5K%!!XPE$("G[/\ ,HZ=:L>)<?V'( 2/F7^=6(-+@MKM
M[M69IV7!)J>_LHM0M'MI20IYXH BO7B71)'N,;/)Z'UQQ6'90>99:1;W*DAP
MV0W85IKHT+;1-/)(@/\ JST-7'LXI)X).GDD@"@#F999+(C1[@C>)U:V8_W,
M]*LZA(MYJ]S&8)9HXHMB;1D!B.:V;W2;?49X99T^>%LJW>I;2SBM/,:,,"[$
MDDT 9_AF\^U:3Y3[EEA;8R-U '2H;]$E\66:2-QY+?+G@UJ6^G16US<3HW,Q
MR:S[VT:X\1V[F,^6L1'F#L: *%RIAFUBWA;$/DYVYX4TRZ@%KX?L8XCCSG42
MOW(K=.DVY@F@926F&))/6I)=.MYK%;-P?+0?*WI0!EZJD5C>:=/;IME+%<+_
M !#%5;6"*YT34+JX :<ELEC]VM>WTF*"9)'D:9D^X&[4LNC6\K2X<I%+]]!W
M- ,R+906\/\ SG&TX]"*DNY6AU?5I8F+.MNIQZ5K'2K<VT,.2H@^XPZBFQ:5
M;13R3?,S2KL;/<4"N4[>PLVTNSN'D"2-M;S>Y)[50GW?9=>RQ.-O.>GO6NFB
MV\,\;F1WB3I$>@/:I#H\#)=(S'_2B-U S-FMH[*RTJ6('>SH&<GDY%4IT\V_
MU2!K=[F=W C?LM=-+812Q01AO^/<@KGV%8$,*PW%T;^VN&E9\AXB<&@#H-,M
MWM-,@@D #JN#BKG:LK0DNH[ BZ#!MQ*[CSBM44 +1110 4444 %%%% !2'I2
MTAZ&@"K>X^Q7#'G]T1C\*P-,CU.?0HX8O+6-EVE\Y.*Z22-98G1NDBX-165J
MEE:K;Q_<48YH PO(33=:L8%/[J*!MQ[GBJDN^;2KF\MK>,0@LPDD?#5T<MC!
M->1W;@EHU*8]C5*7P[:R1R0L\@A;GRP>* *3VEW<I97MK)'-.L0W6\O0@BJS
M3PSZ+=1K!)!*LH$T3-P#[5N2Z/%((C%(\)C4*,'J!1_8UL;9XF+%G8,[GJ32
M H7<*1:MI:QC:'4!U_O#%,*B"_U6V3B+RBV!V-;4NGPS2V\S9W6_W33)-+MV
MFN)2Q#3KM;Z4 8%L//;1[69B82A//<YZ&KUE%%#XPNUB"C,"DJ.QJ^^E6_V6
M&,9!M_\ 5N.HI;328;>\:[#EIF7:Q]:+@5_$IQI#$8QYBY![\U/J)BCT&8RX
M"&$X#<\XXJQ?6,=_:-;2'Y6P<^XJC_8,<FSSKB22->J$\&@#.MX1-;:3!>1[
MUDA8%>X]*@2XDM)X=(N6S-%.&B8_Q)[?2ND:RBDGAE<;6B!6,#TJ&^TBWO[F
MVN9\K-;GY"M &-?NE_JE\DD4LT<<6Q"BY -:?AR[^UZ1&C_ZV'Y'5NH],U>M
M;5+1&$0X9LM3+73X;2>YDBS^^.YOK0!G79 \41KDX^S$XSWK-L;6,>';N<[F
MD\TL"3RO/:NEEL8I+Y;L_>5"E11:7!'I\EFI)B?))[TP,BWQ?ZU:)<<HML'5
M>Q-53%%$VMK;J,!!N _AK?DTJ%TM]K%'A&U6'4T6VE6UKYY4%FF_UF>] &5?
M,/[,T=1(=I=._+5):0+?W6HF[P3&VU0W\"^M7&T.V8Q>86(B;=$,_=I]WH\5
MU.9P[1.1B0*?O4 9<L21WVEQQSF:,,0'IFGVD5RFKO)ND;S3MS_#]*V?[)M0
M]NRY58.1CN:D@TZ.V681@XN&R^32N!SCR9M]'DF+S1EBK1CDM^%:NC6DD5U=
MW0C\N*0_NT*X(%5-0L!:SVBB"22RC4C"'Y@<U/IL<YU(O;QRQV2CD2DY)I@=
M HP*=3%.><\'I3S0 4444 %%%% !1110 4444 %%%% !1110 4444 -V=.>A
MHV\CGI3J* &[10%QCGI3J* &X X]:AN;B.UMWN)F"Q1C)/I4S' K'\20I<>'
M[^,L57RCFDP+MK>07ULMQ"P9&YSGI4V\,K?,IQUP<XKSF%VTOPQI&GV<DBB^
MF"/(3SCOBM&>%_#OB*P2VN)'@N@8Y(Y#G)QUI7+43J]/U2UU-96M) PC?:Q/
M8U;+@G"D$^N:\J.I2Z3X8=8CM%S?&-V3KC-:EE<M:ZUIZZ<+J6&0;;CS,X Q
MUHY@Y#T$.&. 0/0^M&X$D C)/0]:X308[B\EU2]O=0<1VT["%0>$7UK.N]1N
M8]/;4K=K^:59 /M8QY9YZ4<P.)Z87R?3'<FESN()P0>F*X:62YU?Q?:0/<R1
MVS6H=U4_>)%5QK%[IVF:A:).7*SB&.4_P!CBCF%RG?AQU+*<9R0>E+O4@+E<
M]>37)+I5YH?E7]M>&0",F>*5N'/J*Y>TU0:CI5W?-)>/?,[&,1@[00>!1<:C
M<]5R<' P#ZU%;W(F5]J, AQAN_TK"TSQ [6=G#>6\Z74D7((Z&N4N-0U ^&M
M09+F19UO BN/X!FBX*)Z:'!4[<$CKCJ*9/<Q6\+S2$!$7<V3TKD)/-T+6=-9
M+F25;F/$H8\$[<YK,BL9-;T/5M2N+R5)&+@*#\H HN"B=[8WT.HVD=U;MNAD
M&5SWJRI!(YZ=CVKS[2YY8O\ A%8DE*HR,'5>C<<59U'5KC3_ !%K$D<I98K5
M2J'H&I\PW [?<<D#&1UJ&.Y$DDB[&4(.2?Z5RECH]\;"RU6#4'^V2[7E,C?(
M5/45G37]X;;Q.$N'62+:8B>@^E',+E/0MZE.2%XR<GG%&\ 9<J!CO7"&.;38
M]&U$W4LDURZ1S!CP016?JERMUJ>MQW]]/%<QD+:Q1YP5_"ES!R'I44\<Z%XW
M#C.,BIATK$\,0R0>';19HRDQ7+YZD^M;0Z51+'4444""BBB@ HHHH **** &
MXR,4A(&<G%+TK"O?-F\0PVXF*Q-'\ZBLW*PTC;!R.QSZ=*0-SS@G/ %<]',T
M,5Y;23LB1D;'[U%]JFAN[1E6X5'."9/XJS]L/E.@BNHYII(XV!9#AA4P;+#N
M#7/6UJL-]J4JLP<8. :/M$A\---N82;CSGWI^U'RG0Y/.<>U&0>HZ=#7/R"6
MYUFUA\UTC, 9L'[U$S>9<RQQF:X"#@(?N'WH]H+E-JYNHK54:9]H8X^M2KA@
M-O QFN6FN)+C1H3)@,DP7!Z]:ZH @+@=NE-2N)JQ''<12$JC9*<&GYY SG'4
M"L_58Q:Z;<2VZ[9",Y%9["2UL[.Z65V:38) 3ZT.=AI'0Y.5SP/>C< ,DXR>
M]8-OYT^K7K23-Y4.&1*9:QMJ-C->O.X;<=HS]W%+VH<IT#.,-D8Q2"9&.Q7!
M;O[5S3WTEQ%9BXF*1.""X[D=*;E[?3]1GB=MI8>6Q]*/:CY3J5/WN<\TI(QG
M/Y5@3;K/3X@UPWF2D'Z\5';7$T.J+"5FCC=,@24>U%RG1''0$<GB@ON)"G!'
M6N9'GMIEQ<B:0RQR';GI4\K2P"PG\QO,E(WCUH]H'*;W &3P/0T @,=Q'/2L
M0"2YOKU6E<", J :JB2<Z,+QY6$D;G'N*7M Y3ILY Z >]-89/!.3T/85SEQ
M?&?5DBF+B)80_P G?(IAO;F&UN(5WA&D B9NH!H]H'*=%/<Q0/&K-\TAP,>M
M+!.D\CJH.Y/6L"[LQ;7&FMYKL?,&<GO71!53<<!2>XJHRN)JQ*O)-.IJY[TZ
MMA!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #6S^%5[NW2
M[LIK=_NRH5-63S2;?RI- <?_ ,(M=2:,EC/=(9;:3S+21?X<=C5JWT*[NM2@
MOM5GBED@0K$L0X!]3[UTC)DDC ;'!H$>!QWZTK%<QR2^#4.DRVDDVZ3SS/"_
M]TU<M-(U3[1%)>WJLD0P$B &[ZUT6WI[=*-G/'%%@YCG+#PVEI8ZA9S2[XKQ
MV?Y>JYK+F\':G<:*-(?4U6U1@4$8P< Y^:NV*#.< _SIFT$X)_\ KT6#F,*U
MT$PZW#J?GAEBA$)C'3([U!_PB4<B:FEQ.3'=OO0KU1O45TV!E<#&>M&/4\#N
M*+!S',VWA^]DN(#JE\LT-NA2-4R"P_VO>HH/#FIV,,MC87D$=HSEP2GSID]
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83:*'#BE-%%-"0M%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '_ UL# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBD)Q0
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M/,'(?7W]M:9G'VZ#_OL4O]L:=G_C^@_[[%?)C&3 832Y/^T:LPK+LWF:7/\
MO&FI#Y#ZK.K:>%W&\@Q_OBE&J6#<K>0'_@8KYB(=[,@S2<_[1J.&25"0L\F/
M]XT[ARGT\=8TU3\U[ /^!BD_MS2O^@A;_P#?P5\IZA+-@_OY 3_M&L SS$N/
MM$V1_MFBX<I]E#7-*/34+?\ [[%*-:TL]+^W_P"^Q7QG').HYN93G_;-7H9I
M%7!GER?]LTN87(?7_P#;.F8S]NM_^^Q0-9TTCB^MS_P,5\CI+(8BIN)>>^\T
MD,DJIC[1,?\ @9HYA\A]=C5-/89%Y"?^!BG?VG8_\_</_?8KY32>=+=2+F4;
MC_>-3&\G*KBXER/]HT<X<A]2-JNGJV&O8 ?]\4AU?30>;V#/^^*^6)[IV*N9
MI?3[QJE<3R_,5N),@]=QI\PN0^LSK.F+UOH!_P #%)_;>E_\_P#;_P#?8KY$
MDN9'4$SR_P#?9J"2656_U\V/]\T<P<A]@_VYI7_00M_^^Q2'7=)'74;?_OX*
M^.3++G/VB7_OLU"[REO^/B;_ +[-','(?9HUS26Z:A;_ /?P4IUO2O\ H(6_
M_?8KXSCEE0_Z^;'^^:E:28?-]HE(_P!\TN<.0^Q_[;TH_P#,0M_^^Q2C6=,/
M2_M_^^Q7QP9)MN[[1+_WV:?#/-N_X^9<'_;-'.'(?89UK2\X^WV^?]\4#6=-
M:41_;H0QZ#S!7R!,\JG<+B7_ +[-0&2?.Y;F=6[$.<T<X<I]IJ5D&Y'!'JIS
M0,$]<D5\G^'?B/XC\,RIB[>YMP<,DASD>U?17@OQIIWC32?M5FX6XCXG@S\R
M&J4KB:L=2.G-'>@=*.],D****!A1110 4444 %%%% !1110 4444 %%%% !0
M:*0]* #-,9U4%F8*@ZDFF3SQ01/+*X6.,$NQZ 5XEXR\?76N--:Z=(8;.-MN
MX=7H!(]$UCXBZ#I'F(;CSI4_@3FN7?XWV"C/]E7##V->0%AO;:69SU8\T00/
M/+G.YA_#05RGL<7QILI.?[)N!^(IP^-%EG']EW'YUY8,1 JRX-11JNXMG&.>
M:D?*>P2?%ZTCB$C:;. ?<5%'\8[.7[NEW'YUY8[->E(P,(.IJV!' NQ0,CBJ
M#D/33\7;,#YM-G'XBHQ\8[(L?^);. /4BO,'&\[G^[4,D/VI@RJ5"]J3'RGJ
MD?QCLY&^72[C'KFEG^,=E#_S#)\^F17EWF+!'L51FJL2/-/F3D9I!RGK3?&.
MS2+S&TR<#TR*CB^-%E*3_P 2NX4?45Y-=9DE\L'@4X1O@ +G QQ0V-0/7U^+
MUDZ%AIL_'N*JR_&JRB_YA<Y_$5Y9-*8;78.&-58[=[E_EYQ4W'R'KR?&FT<9
M&E7'YBE?XTV*8SI=Q^8KRJ7$%N5(^:LNYD/E@=6-','(>O7'QWT^*X2%-)N&
M+>]77^,UDL:L=+N-S'ID5XSI5B))7G*[M@SG%6X"9KO>WW1T%/F#D1[-#\5[
M25-QTZ<'TR*J3_&:PA;;_9EQG.#R*\Z@7.]N1QQ67=Q%@.,L#S3Y@Y$>N/\
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M/NHYD]CS7R?J4'D-\RA@W6FZ1X@U3PWJ2WFFS,&CY,6?E84R7$^Q!TH KDO
MGCFQ\9:,+B-@EW$,3P]U/K76,V,>E,D=1110 4444 %%%% !1110 4AZ4M(P
MR,4 5;^\CT_3Y[R7[D*%C^%?*WB#5IO$VOW&I7$I9=Q$0SP%[5[Q\6]4;3?
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M -/&2?EKP<K'<64A)&<5[_\ #9-G@BQ4>E4B&==1113)"BBB@ HHHH ****
M$%!H%!H \N^.,IB\(P$=YJ\,C<R$<5[E\<QGPG;<9_?UX8\PAB^49.*AE1)P
ML9D!F?"BG33I-((X"=HZUF1":Z?(/X5HPJEM]X<FH9:9(RA$P>/>JXW;^N[T
MI9I@!\W"]A44+.[C:,"DD.Y8,>\;I&^8=*CG<B, <5,Q7..]1#!8A^?2@"L$
MWR =JO+;@)CM2*%!RJT'>1P::!D4GRD%5Y6F(@+^8YYJ3<RDYJ*0A3N)_"F2
M3&?RG+$9&*J+F:5I6Z4_<TGRXS3RA1-IXJA7  RG:#A:EPD0$0&<T0Q@+G.
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M* "BBB@ HHHH **** "BBB@ HHHH *3O2TAZT ?+7CJ-I/'VI$GY=]4+=29
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MBKJ2-)M:0DA1P*9+(+AMV  *F3-(Q,.[EWR\C&.*AN+9#$BH0S&MBXMXF!;
M)Q6)/'(C94XQ47-.5%"3S[9R5) ^M9EU/(Q89^\,5IW!9^,YK,DMG:X"YYJT
MS.41EO;.5"$X!]:D\CRF90-Q'>KT]J8+59"26[5!F28!<8;':K1FXF5,C9)+
M9/I3UB8(21Q6FMBD8RV"Q]:&ASA!C [4B)1*,489 ".]7H+-C(3MXQ4ZVB!
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M\U58%)+.YY/2NA\)V7VW65..$[U(STO3[?[/;*2O.T4B'=<8/3-:# );X/\
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M<>Z3+YQ4MV+B7U,80$GFJLSX!(/%+))&[$J?D7J:K/F9MP&$''UI%#HI6^Z
M.34YC620(3@U7\Q0P '/M6G:0!AN923ZTEN!+;1QJZIMX[UI^5 2 J5#%Y:=
M4YJY%(>R<5I8"8PE<(N!D=JFMT D\F08!'WJM6L"2P[FX>FM:R1R99LKVI6+
M4C0L?LNF7222MYD1/*UM:G<:7JL+BWA$1"Y7CK7-QP_:P$1U##^\:C:]2PF,
M,A#.#U'05G*G<UC(HWUDT$A2084C(JBULTK8CZ5MW]W'.D;,^6/0"G6)M#$R
MR-ANU1[,W4SGY-/EBPRL,U9ALQ,@$C&K+^1'(S2/\GJ:KQ:G"]R(;4!B3C)Z
M52B2YD\>F$?ZJ,D#N:W=+T&YN(Y)0P18QD^M9]I?S"9K=]B^XK0CU.6VW+',
M=N</CTHM8ARNC4N9%.G"WBCC96&'D(YKG;K6H[=?LT5OM(_C/>M>^FMKBP+Z
M=-A%'SYZYKDECGN[CR$A9F'>M#$T3KNJM!M$Y2'LBU1N)9Q:M*TK GN>M.?]
MQ$Z2,1(OMTJI=SM+9;7 ;T-*Q+92,T;!79SN]?6J=P<RLT8^IJN6:)MS@E :
M%F="2!N1J0A\#JLQ#=ZD:':[;*A4K++A1S5E582;2?QI#'VSE,JW4U:AB9N(
M_E(YJ$(N3@\BGK<%)"RCY2,&@"$O^_=)!D'O3K20PNT;#<AZ4VX4$J1TZYH;
M+C*\<4 2!\.0.AJC/$KLPZ&IEE^8)CFIWB5D+CJ.U-,&8+H WE]Z5H@HPIW5
M=D$<J'C:XJFR%!M4'=00R+?)#R>5]*#.9%.W@TZ1]L6"O/O4<<3-$SHA/K2Z
MCZ'TC\'=Y\#1[SG]X<5Z .:\_P#@ZQ/@6/<,8D->@#FMD9,6BBBF 4444 %%
M%% !1110 4444 %%%% !1110 4G>EI.] 'RY\09 WC;4E/3?7)-N8X7I73_$
M4_\ %;ZD!_?KGDXC QS4LM#-A&,FGNGR=:#P0#R:F90  >]*Q1! -K!VZ"IK
MBX-U(%_@%1RX'':F1I\PP>:+#1-(/NHM>C>!K%8;<S[>37 JI9T4#YSQ7K?A
MZS:UT.+(^9@,U+1=R]JEPMII[R'JPP*H6(+"V![G)J+Q#/ONH+<'*@985/IK
M%F# #'8>E2@N;SC.17.>)RSO&@KH1C9NS6#JO[Z] /04PN+9H%MHT7AC6U'G
MRU4]JQ8Y-EY%%T-;!)W-@X]*"64-4;+C/05RTY\RZ;)X%;6M7&UEC)P3UKG&
M9I9&P< =_6D:1'6Y,EP0!TK?TA 7QT(-8=D_^G*B#D]:Z+25S)(V,!6Q5HB;
M-37R(]+A7^)FK(MHPOF/ZBM/Q I:&UV\@5EVC$PR9Z TF3$EL\O,RCTJ*[!%
MIM/K26#,+F1UYXJO)<F7S%[JV,4T!M::FZ%5SVZ5FM\]Q+@=&K2M/W4L87D%
M<FJ<VQ)).>6.:3!;E5XA)<(1US@TS52LDZ(>D2U+&Q-XI4 BJ&HG<UU)GGIB
MD6BQ=.%T%)(_6K5W+YW@96'WMW6LMR3X6!'K5^WS+X"F4#+*P(H0I')%05^?
MKBK5E*)M-N(&/S(/EJF8Y&0!AM)%26J>6_'\0YJK!?0H+\T+(>67FD@F6:V>
M-QR*E*;;A_0FLV9S#=, ?E-,FXUW>-"JG %9MP[$<]:NW;_)E#FJ,F73<HSC
MK0%RDMQ@DC@]ZDVJ_P ZGD]:J3Q,)2W0>@ID<[QGDX6E8EEJ;*D%,Y'6I[.Z
M!RK]:KK,LG1NM12H4.Y:$(FU"/=&Y'/%?3_PC!_X5YIP/]VOE^.97A9)#CBO
MJ3X58'@#3\=-M6A29VU%%%,D**** "BBB@ HHHH *#0*0]* /(OV@SCP;;?]
M=Z^>$D<]%_&OH?\ :";'@ZV_Z[U\\^9@"D \RR=,T] 96&3BHE.3DU/;8+=*
M0[%D0@@ 'GUK2MP\L7V:(?,>"U5(XFD(5.O:I;B\%A"8D'[YA@UG)W+2L07\
MB1,+6/[W\1J%&8 (IXJ",%BSR<L:L1(7(!&!0AFA9+;IS)R:U(;Y(_X1BL>(
M1J=IZBI0VU@QQFF@N;'GL<LHP#TJ[:>;*G-8\,C3LH X%;4;_9U4^E6!>\UK
M<C@T27D\R_(*II>*]V<CY2*M0_('*_=- $UM)&JY*GS.^*H:E-#=R%85\ED^
M]G^.I)I-CAATQS7.7UWMNFD5N >E!29T]K=;-/WND;[.,=Q61-J(MV:1QR>@
MKF+S5KN:0"$,B]_>H_L]Y*=SS\'M4/0KF-\7$FID^9((X^PJ[:BUMUVF10?[
MPZUR8BN8@1&^5J>S+1R;IF.[/%*P<QV*1&<_NBV!_%5=IY5F,<3X8=2>]4!K
M-S)']G5@%J:RM@\H9V^IH0W(W$B"1QR,Q3=]['0UH6]R+7<T,J@D=:PKF[(Q
M#N^4=*EBC(@!WY8U=S,;>3,\+F099F^]5&0_Z("AR13K]W 5/7K5#SS'^[/W
M30V%AKNLJE6P!BJ=O*L9>)CGTJRL2RR.%XR.*SW!B)!Y9#^E0!:\@JAD5L&I
M[.1W^23MWI(2LJ*?X&ITRB,CR>&/7WI#)MH4DH<T!@QY^[WJI;O(TY#G:HZ^
M]3HVQV(/% #PX63'5.U-+LKE@/EI$82AQW%$0#1GCYA3 E1HIQG #5%YOE.?
MG '?-598YHW+J*='OE&'45# 6:2(2AED6HY)%(_=D-(.34;6:NY4G8/6JN3:
MS[2"K'C)]*$A-EG^T)).4@0;?O%A4%QJLD$3-L0 C^&JEZTBRY4_(>M1O"5M
MR7YC85:0KGTO\&9_M/@*)\8S(:]#QS7G/P5C6/P!$%Z>::]&&,UJC)BT444P
M"BBB@ HHHH **** "BBB@ HHHH **** "DQS2TF?FQ0!\J_$,?\ %<:E_OUS
MD1.0:Z+X@-O\>ZDO^W6/%;[5S4EID:J6FZ5*$!?YSTI\8V/GUI2N%8^M,HAE
MC#/3(D'G[?09J?;A>34$8Q.0.,T :VEQB?5($[[A7KP86\,49/W1S7FG@JU$
MVM^<PRJ5WU]*,NPZ5$AW,.243:K<2L<A!Q6EHTI^S,_;-87G+YDA[UM>'E\V
MPN/4&I&=(K P!^QK'N=KWP/85H1SE;%5QRHK$A=KRYF?.,# H =8YN-7><_<
M48%;V"%+=A6%8L!J1@4Y(&36IJ5P(;%F/!88H#J<KJ=R)[J1\\)Q6<)4CC)4
MYR:=>.IBV \]:I)S&OK0E<LOV=PL>H1''+5UND(5M;AV_B;BN")Q=0M_M5Z%
M8,388]<5:1$M2;5,O:H!V6LCF#17D/WB<5KW;?N"@_NUEW2XTR)/4TF)"61$
M21YZR"L=7QJEW$.N[-;.=L\"$<UA60W>);M/XN]%QG06+R-.NX_PXIMT@\XC
MO2:>ZF]*9Y6ENY-S.>X:DQ+<@MB(C([=0#6>0)X'?/\ K,TZ^N#"S>C+C%4Y
M;@P6T"C@$YI%E]DV>'Q#[U;T%@^AWEN><#(%07,J'2ED7^+BCPPY>_GMST,9
MJDB6<Y<W3S-C;M"\5#%(PE+?PBI;]3;74RC^%S5=I L;>C"J%<?? ;E=> >:
MPM05U82KRM;-[+LM+>11D=*RF83ATS@FD(J2,'C5QTQS3+9/WOE]FYIL>3%+
M&_53Q55;@GY6."M %Z:V4L0163=66"2GY5JP722+M=AFB4 GF@#G C1'YN".
ME.6ZR=K5H74:-VK+EBPQ(XH):'3A7B8AL-BOJWX1 CX<Z=DY^6ODAF(4@G-?
M6WP?.?AQIO\ NU2)9WE%%%,04444 %%%% !1110 "D/2E%(>E 'D?[0*[O!U
MM_UWKYX6/\:^B/C_ /\ (G6W_7>OGIB$3.:0"#G@"KENN .,DU7M5#MN8X4<
MU.UXB9"K]#4L:+\ETEC""#ND/3':LLM)/(9'.6-0D%V#.V2:LQD*<FIL5<E\
MLH!E?QI4=\YQ[5&]R\@"XX%:6GVH=#-*<**3&B#RF0&1SCTI]M"\_P [L54>
MM->5II2O_+-3UJ4R,5")]VA,JQIVNV+E>E7?,WKS67;L4PG6KQ.%ZXJDQ%I2
MBH#BK)N,0X!P*S"Q6,5,IS&-W2G<!MY=X3"UBE07W/S@U/J,AC88%4Q*3U'7
MK3"Y9D"W>W8B@BB/3K@Y<K\M/M8_G&WH>IK8CNE\HPFBUQ7,%XBC\'&.U:5D
M()5"RP\=S3#;EF<CD5-",0?+UI6"YHQZ=ICQEH@=X[9IJ36J(T6QM^>*IVCH
MTQ1LJWJ.E/G95G&X<KT]Z+#3*]VF9,!^?2I!.8D0%B&J*Y*./M$9Y'452%XL
MLP4\U+*-*60R2<^E5+V#]R65@3Z"I6"D@AOPJ)@V_@Y%%P*,5R=@20$.#Q]*
M@NR5DW@Y#<$58U"W;:)X\;QVJ"&\A>+RY0-QZ^QH8B&"[>UG\N0_NC]WVK1D
MG+$*PP#]UJQ[R"2%U9_FB/1O2K(\YHD;[R8^4U(%]N,;P0PZ$=Z?;LL@.3@^
MA[UB/=SQ/\YW#M[4^&^X\PL!(.@IBN:[$V\GF8(7N*G21;CYX2!Z@U6M-4MY
MU$4^-[=Z6YLY[2;S$.8VZ8I7&,N)95R,D>U0YD$88.=WH.U61,DRF"5<2?PM
M5*0O!((SU[^]%@)HV,T9$C8:IGB6]MB) !.HX/M5-7*ODCBK7FLH$D6&;N*$
M)E)[<M!@C@'!J#>%B>";A<?+FM1@TBF0<CN!VJI-'!=(R$A9 ORYJD(^AO@N
MN/ ,0SG]ZU>B 8KSKX+(\?@*-)/O"5J]%[UHC-BT444P"BBB@ HHHH ****
M"BBB@ HHHH **** "D/6EHH ^7_'=NI\;ZD^.=]8JJ1'BNE\<@?\)GJ/^_7/
M%/EX-%BHD3 ",D]:8YQ&,CBEF'R@ TR9CY(4]:18WC;Q40&) 32+(>1C&*E,
M6;-I ><T =_X"M0MC-/P236KJ\IBMI2.H&:;X2@^R>'D<]7&:JZQ)OMV;/!;
M%0QHRH1B!'?[TIX]JZ301LMYE6N?#1RWD$"G[JYQ71: ,M<J>U"0S9G*Q63'
MOLKGM-5H+9Y7Y#,2*T]:N!%I8(.&8[:SI_W5A'%NPV,TK"'Z1&1=23=78\&G
M>(;G%N(R>13-'<N_!X7K6+K=T;C5"@.0!3L'4P_M!:X=2>_%2*3]HV <566/
M=>.!V-:4:*)%>A&CV&RIY<L3$<!J] LB/L$8 ^\ :X*XE#W,<6.2:] LV"VD
M2X^ZM,R;"5L12EA]T5EW!W01 _6M"^?_ $#@\N^*SY%_TI5)^5%HL),CN'9)
MXF!&0,USV@R22Z[?W#\DYYK6OIL2EAT (K.T.(Q6]W*?O/DT6*N7]%D,E[.Y
M/(-:,Y D!ZAST]*Q/#89FE.<G<:VYBJ=1RO-#0D]3 U'/GO_ +)J&[(E@B4]
M4YJ>5UF@GG;LV*H/,&7/:H-#30F32_+]#FGZ+-Y>N(Z\!EP:73$\[3YB.BBL
M^WF6"[B<G'S8JD2QOB!=NH3X'4YKG)I6"*I.,5U7B1<W<<BGY&'-<;JF?-!3
MI3)+YF+V*QD9P:RIYA'J"E> 1C%$=VX4H>XK-NI62\&[TH$S3F0*#(.?45AS
M,!(2P.">U:L4WFQ8/I5"YMRR,P[&@+D&UEPZ&G_;G'#@YJO%,RMM-3;E8[B!
M0%QQNE/6H9)83U-6=L9 .!4;Q0N/NC- F9EP8@"4/&*^M/@__P DXT[_ ':^
M4;FU C)'%?5WP?&WX<Z:/]FJ1!WE%%%, HHHH **** "BBB@ I&Z4M(>E 'D
M7[0;;?!UJ?\ IO7SSM$K YP*^A?VA%SX.M?3SZ^>"3]U>E)@3$G/EH/E]:C<
M>7P>:<KE%PO-1DLS9:D,D2-W7<>%[4]<EN3TJ,,[+@G"#I5NUA,I 7\ZEC1:
MM+5I?F(^0=:?<3[5**3M':G27!M$%O'@AOO57=E8@ 9J2D3VH5D.>GI4J!?,
MZX'I441VC:!S4L65D^84QER*1%W;!D^]60PE W<56*C@K@>M.CERI%-"+14E
M1SQ3FE$: 'FJH+>5NS@57,N9U4G(-58+DETGF8)JLZ(B#')S5^^0+$N#S6:Q
M)"@<G- ,T(?E )^5:E,L8DXJE*6PH.<&ASL4&F27?,98V(S@TP7(6(A>3Z5%
M'=?*5QVJ 2*KG ^M%RB]'-LVD]32W3';YF<8XJ@\K-&6';I4T<QN+?:X[4@*
M=S/+;GS4P8SU':J,<P6]4H1R>E7Y$_<M&WX5CW48LY8Y!V/-)C.HN(2D*RAL
M$]JI&^,,R*Q&#5Z-ENM/24'Y<<UD7ML)$R <CI2 V;CRYHP4':N9N;1U=FCX
M;-7+/4G<"VE^1EX%/G# $YR/6E8=RA!=FXA:TG;&.F:DL;F2Q9K6Y_U;?=8]
MJADM5F)(!5EY!]:BDG,T'D7*[73HWK18399N4$;$##*>A]:IND3'GAJELKE+
MA?(E(#+]TFG7$?EMC;^-*PKE-HG0Y5O<58M]8N[4XD9G3T)J,X4_-^=#,G1E
M_&G85RX=5ANF!/R..E#7YD8++@^C=ZRI4CZH<FHC(RD @T6#F-X.5&Y6W>U.
M64H/E)7/7%8J3$='/TJ=+K(PQI-!S&W:W*QGEN&ZBH]4BB=/.A.& [5DBX9#
MD'(J99@Z."W44(J^A]+_  7D,O@"(D\B4Y->B#K7G/P4 '@&/'_/5J]%'4UH
MC)CJ***H HHHH **** "BBB@ HHHH **** "BBB@ I.]+2=Z /FWQO&#XSU'
M+?QUSDGR#%=#XZX\9ZB<_P =<X^9!3;&ABE6))/2H)GW-BE &X@GFF%2[X':
MI**^'&7/2K5L6\H[A\K' %1L,E5SUJ6(L]_;0#[OF#-(#U>T86?A^W4_Q+TK
MF];N21#;KT<Y)K;U^:.STV!=P&V,5QM]+NBMYRQ^;)I-#3+VB)YFJ37#DXB&
M![UT?AR:20WTAX7.!7,:3(PLI'QRQ./<5O\ ASFUFPW\7(I6*OH:][%YZ6\9
MZ9W'-<IK>J%;F;#82,8&*Z^]N%2T9R.0F :\FU:Y,D[+GY<Y-%A(]#\.29TE
MISQ\I.:YKS#/=3R^I/-;EDWV;P0K]'9>*YO3W)@DW=\XIH=Q+=@C/W+'K5N'
M S@YQ5,;(Y%R>G6I;63+/COTJ@N36!:75XV8 A3WKT4GRK96_O5YUI6]M35.
M^:[]R2D41/(I,ELBN6S/:Q]1G)%9%Q,[7%TP)&#@5H33!;N0D_ZM>*Q$G,DF
MW^\V6I B.]N5%M&N?F Y]Z8L_DZ(TF,%^E9M](O]I&,'@&K>KS"WTB*$C&>1
M043>$Y6\YO=JU]6E:(3./2N;\,R,&+J>_%;.JSJNDS3,WWN*"5N8+W6ZP\L$
M@EB3CO42@M&&SA1U%4GG$=LBCEB>:=+<80*K=JDTN==X5E66"ZA_V2:YO491
M'.0/X6S6OX(GS?7"$<E#6!JSA[F8+U#D51-S<U*87>DV\R]A@UR5YD2X/2M3
M1[OS[&XM&.64?(*R+DE\A_O*>:$)LHQMB\56/&:KZROEW(*\@]ZDG1DD5AWI
MEV2T8W<TR&5[*X/F;2>*OHV2R'D-6,C;7/;%:%O-D@GI0!5N;?9(2.M51*<[
M6K7N5!?<.E9T\.3G'- ,:DFUASQ4Q8$YJL0 -O.32*7C(/44A%BY),?3C%?5
M'PB_Y)UIW^[7RO)<K)![@5]4_"0Y^'>G'_9JD([FBBBF 4444 %%%% !1110
M 4'I12'I0!Y%^T&"?!MMC_GO7SN%VC-?17Q_&?!UMS_RWKYX8+MYI,"#S#OZ
M<5(6W$8J+.3@5,@"C-(99A0280\"KF\6J%4ZGI5*&0L0!P*'<M+@G.* )D!D
M)WY+GI5J*V*3 ,<C&:99M&6+8X%)YFZ5L-R3Q4E(NJ$$AY&!2JH:3<'XK-D9
MXLY;.:FAE_<#'6E8=R[*'4<-1%YB#GO5<RNP4,,"IGEQ&,'FKBK$MEQI"MOL
M?FJT842AF/%,\T%!S\U%M'Y\C#J138)DUQ,S-L4$BJHF\ICN'0U<1O()#+DY
MJM>HI#,5P3VI 3-<K(%P*CN)25'&:H02[&"-SDX%:L:\E2N0HR:3!(@MIUS\
MPP*=<E0Z[>AZU6OF7[\0P!UIB2"6+=G@4%&APJA.H-1P7"V\S1N.#TH@S(BL
M3G'2H;V(LGF+]]?UIA<L,Z,&4]^AJE=6_F6[Y&3VJ>TVW\'7$J_PU-$P4F.5
M:5QD7AZX1X6M7;##L:NW,3I+C'RUSEP[6&I+,O"$\XKJQ<1WEBLB8)(I <WJ
M\&<2Q<,/2I-/O4N8/)D'([U:NE5LJ1ANE9$?^@WG[Q?W;<&F(T)_E.P<XZ$5
M3E5;@_OEPW8BKTUN8XQ)"V^-OX:SW?YL."I%(#-N;>2";<O3L15^UOUNHA%+
MP5[TCR*PVGYE]:HRP>4Q<<K[47)>AJFV#H03\E59;=T_VDJ.VU$H-K<KZ5:$
MVT;D/#=J0U8JR6HVAXC^%1A"22>".HJ](K)AP!BJ\Q65PP.UQ^M%P(_(#+E1
MAJB>WD"Y -6XY6^ZXY]:F>=E3##CUIM@D9(=E!R#3UF !S_=JZ\,4J_NW&>I
MJG-;E=W0\4D#T/J/X'/N^'D1_P"FK5Z5TKS+X%#'P[B!_P">K5Z=6B("BBBF
M 4444 %%%% !1110 4444 %%%% !1110 444G>@#YI\=,/\ A,]2!_OUSIFV
MQ[<<UL^.Y/\ BM]2SV>N=:4N0 ,9I#(V/SY#<U)%GDFJTD>)1ZFKK($M\]Z!
ME-@WG!NRU=TPB37K5<9RV:IM*$!##K5KP_&TVOP.O1.:+@=/XXU)!:>0#^\&
M!BL6[N%.G6,0'4<FLWQ1=&ZU>3;DD'!J2\EVZ;9Y]: -ZRG"0B,G"H*U?!4S
M3+?@G(W_ "UQJ7>8I3G[HKJ/AZY>VD<="_-(KH;WB:]6RT@EFPS#%>6.S3,#
MU+-74_$74-UY'9J>%Y(KG=.A%Q<VL2CG<,T"O8['Q+??8O"^G6,?#L 36/9/
M^Z4YYQTI/%]R)M5MXH_NPJ!BJ<5QY4Z?W/2@99G+"4L.?:I%EP%['O2&6-;L
M;_ND<53N92I<^G2G<#H]%P^LQ8Z&NVFE6.<ECT%>?>%;I7U2$-U'2NDUZ\,,
M4K;OFHW);%>Y$\-ZP/3O5"V=?LIE8X(7BJ=I,Z^'I9F_Y:-CZU%/*8;6%6XW
M#I2*11D<G48R3RS5+XKN-YAB4XV@54F;_B86^/6J^NS>9J.TGD=J!MFMH,A2
M-1WI_B6X:.Q6)6^\W(JEI5SY=];Q^M,\1.?[6$&?E'.*0D5IW$**QY^6J[%C
M&')Y)Z4RX?S9PG84LA)4*>H-%AMG3^#9F34)>>2AKG;F61[ZZ4G_ ):$UI>'
M+GR=4"@\LI!K.OT$>H7!SC+'%%A$%G=?8[P-U#<&K$JHUY@O^[D[UE2N8SGK
MBI6N5D@C0]10A6);F,1R$*=RCH:I7!W1UJQQ"2P,@.1FLN5?,7Y.U,DRY5QG
M%26\N!@T2(02/6J^#&W- &LLF]<$5!,A3FI;1UD09&<5+,%8<"@$9K)Y@SCG
MM4#J\9YYK1\OTJ&2,]Z 91= $+*>U?6/P@.[X<:=G^[7RC/'M1L<<5]7?"#C
MX<Z=_NT(1WE%%%4 4444 %%%% !1110 "D/2E%(>E 'D?[00)\&VV/\ GO7S
MJXVCD\U]$_M!9'@ZVQ_SWKYVD&,$\T@&J!C'0T\$DXQFF#+L"*G)$>3CG%(!
MJ,=V%J0?(2>YJ"/.-W3-2("6R33L%R97\J,A3UJ2TF7<5(RV:K-)SM J6+,?
MS$<U-AW+%SRPJ:U4/T.,5G22EVY-:5BH6/WIV"Y++]WZ=*CD;A1FIIKE2NP)
MR.M5+?$EV%<\4P'H&DN H[5:LKC[/</D<=*;"JK=,1],TS 6X9">M %N:?GS
M,CK5.>X$TG6AV6-2K'-5%P6W#I0%PN04=7 Z'-=!8W<(M&D< EQ@UBL@G0KG
MFHK61MQ@+8 I!<O&-) R= 361*6MI3'G"GI6F0PZ=JSM0_>8/<46'<UM.;?&
M!FK4T&Y#M;#5C:3,9490<,*VU!>$OGE>#0!C-%);3&:%L..H]:O1W27\!886
M0=J0HLJD@\UEW44UO)YD7!'4>M)JP)DUX5FMS$X^;L:BTC4&M)?(=OE!X!IH
MN4NT+$[9.XJBTB6\VYU+'UI#N=9<!+@>8@P>M9MQ%YZE3C([U+IUXUU:G;@8
M[5:55DB.W&X4#,BRNWBN#:S'Y3P":OW%FV"&4$>M4[ZV\V+>HVRK2:?K4NT6
M]QC XR: 96GMRC$*#5)I2A*.*Z-XPYW( P/>L^>(F-E,//KBBQ+U,5T!.5Z4
ML<CIQNR*62(HW&<=ZCP&[XQ181?68L@0M3)HB/F4$^]4MQ4YS5F*Y.-I/!H:
M"X]"SKCJ:F23Y#&XS]:78H3<C#-1[9&&X"D4F/BC!RAX/48HEA#97G.*;!-M
MEY%6I5!!DB.6QTH0,^D?@C&8OA[$C#!$K5Z37GGP8<R^ (2PPWF'->A]ZT1
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MBF!O0V^P.=PR.U5[A=Z8_B[FK2S$E9MF4[TZ:%%0R?WJ-P.4N83'(77C'ZU
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M0]3[TT!ZCH&EIHGA^RTZ,<6\2H:TQVH&<#G-+5 %%%% !1110 4444 %%%%
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M/HH 9Y29^XO_ 'S2>5'_ ,\U_P"^:DHH C\J,_\ +-/^^:7RX^GEK_WS3Z*
M&>7'_P \U_[YH\M/[B?E3Z* (_+0?\LT_*CRHS_RS3\JDHH C\J/_GDGY4>5
M&./+3\JDHH 9Y4?_ #S7_OFD\M,X"*/^ U)10 P(JYVH!GT&*4 #IU]Z=10
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M857U759?%%O'I>DVTZB5QYTTBE1&O?K26ZR^#]4N!+;RRZ;,H*2(-Q1@,<T
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ME.=$D4JZAE/4&G8%&!0!7DLK6XVM);1N5'RY4<4065M;,6@MTB9NI48JP%
M [4M %7[%:^?]H-O'Y_]_:,U*\22KB1 Z@[@&]:DP*,<4 ,=5D4JRJ5/WE(Z
MTQK6!XA$T,;1#HA7@5-M'/O1@4 4QI=@K K9Q9!R#M'!JV,>F/2G8H(S0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %(>E+1UH 9MX /4=Z,#H<8ZFG
M8YHP,8H ;U.>WI0!Z "G;11@4 , !S@#:>V*=V]?:E(S01F@!.O']*3J1@#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !BLW4='BO[JSN6=DEM7WJP'7V-:5% %3^S[3R&A^SH
M(W;<RXZGUI[V=O(X=X4+!=H..WI5C-&: *JV-LAB*P(#",1X'W1[4-86K[]U
MNAWG+<=35K-&: *PL[=9&D6% [+M9L=1Z4W[!:^4L7D)Y:-N5=O"GUJWFC-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS;W7/!-;N.:,4 95UH5G<RI-\T11<?(<9%.NM$M;M8BQ998UPL@ZXK3Q2XH
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M2HQFM/%&* ,^WTBUMM0NKM ?-N1M?/3%1:?H%CIT-S##&"EPQ:0'OFM7%&*
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M$]2:Z+%)M'X4 5-0L8=2LWM)\^6_)Q5*]\/65Y#;))N7[.-L;*>:V-O/6C%
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MA!^AIU<+H>NS6%JPFMI)K=KDH)RW0D^E:=[XLAM;F>.&W,T<&#,_F 8^@[T
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MOG!"B8],5F?\(W=?V)8V993+;S>8<_6NMQ[48[@=: .)OO"^IW=Y.TLYD1Y
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,XH 4=*6@<"B@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )H TT# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJT@%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% "  4M%% !1110 4444 %%%(3B@!:,4SS4SC
M<*7S$_O"@!U%-\Q/[PH\Q/[PH =13?,3^\*/,3^\* '44WS$_O"CS$_O"@!U
M%-\Q/[PH\Q/[PH =13?,3^\*/,3^\* '44WS$_O"CS$_O"@!U%-\Q/[PH\Q/
M[PH =13?,3^\*/,3^\* '44WS$_O"CS$_O"@!U-*@T>8G]X4AE3^\* %VTZF
M>:G]X4^@ HHHH **** "BBB@ HHHH **** #%%%% !1110 8HHHH ,4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2'G@TM% $?DH#G%
M)Y,?]VI:3 H C\B/^[1Y$?\ =J7 HP* (O(C_NT>1'_=J7 HP* (O(C_ +M'
MD1_W:EP*,"@"+R(_[M'D1_W:EP*,"@"+R(_[M'D1_P!VI<"C H B\B/^[1Y$
M?]VI<"C H B\B/\ NT>1'_=J7 HP* (O(C_NT>1'_=J7 HP* (O(C_NT>1'_
M ':EP*,"@"+R(_[M'D1_W:EP*3 H 9Y$8_AIX'%&!2T %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !12=L=*3=@=#0 ZBF;A
MV[]:7/ITH =12 @TM !12$\]*3(]Z '44@YI: "BBB@ HI"<$#'6C..* %HH
MHH **** "BBB@ HI"0*,GO0 M%%% !1110 44A..](&R<8H =110: "BDSQD
M4*<\T +1110 4444 %%%(: %HIO3C)S1NP,F@!U%)S1[4 +10.!10 4444 %
M%%% !1110 444TM[9H =13=W0'K3J "BBB@ HHHH **** "BBB@ HII.#TI>
MHH 6BF@^W%*#GD4 +1132<'&.M #J*;D9QSFE% "T444 %%%% !1132<'&,T
M .HHHH **** "BDS2$^U #J*:#D\4Z@ HHI"<=!0 M%(#FEH **** "BB@]*
M "BF@Y[<4H.3Q0 M%%% !1110 4444 %%%% !1110 4444 5KRZ%I:R3E2P0
M9X[UDVFIWMVB74(26$GYHP>5K6N)$A@9Y%)C ^9<9XKFKVVMK9$O](N?+FR#
MY.>'YZ8H VH]0+:I-;LN$1 Q:I6O8Y'3RY, G'/>N=NX+Z^U25(6\D>2'E'=
MCZ5;\Z.6/3MJ$;"4=1V- &N=7LU8+YO.[;P.]6VF5%W$@*.22>E<U;P1#1;X
MM'EO-;![CFM">8Q>'A((C*PC  />@"W'J-M.Y6.0!O?O6>NMS.%?R1L:7R\=
M_K67*Q%SIKB>-V9A\D:YV_4U(K' RN#]JQGM0!T$FJVD$WDLYWCK@<"G7&I6
MUK&KR/PW("\FL*W>WBL;]+O G+$X/7VQ5,>?"]L& +F'#!NP]: .DCUJU> 3
M%BL;-M4GO4CZK:QJI9^3_#W%8!AMQ_9]NCB8"4LY]#4]U-NU.YB)2U5$&'9,
ME_I0!=U778+&TCE4EC*=J[1FFMKD=F;>*X#&2?[N!6/;C=HD)=0S"YQDCJ,U
MIZR(X[S3Y'4! V"Q'2@#1U'4X=-LC=3!B@';K2)K%JUO%,S%/-&54CDU%K>)
M-'E*(K@CC/2LR?R+B[TO@2;  =O\)H VGU6UCQN<Y[C'(^M.DU*UBCCD:5=L
MGW2.<UAW<WF:A>1F1+<*G!*Y+U3LU$EGIAE3+>:0HQQB@#J$U*WDC:0/A4.&
MSP11%J-O*S*'VE><-QD5AW\,+WUW%*S1QE5.Y!]TU#'<30S&!C'=CRB!*HY7
MCO0!OC5+1Y @DSDXW=LU!;:INN;F.8;%A[^M8R>2WAZ*./!F:48XYSFFB62V
M6[#QF20LHS_=]S0!TL&HVUPQ"/VSSQ3!J]FS*JR9R<9'0&N># :Q:A9EE!B.
MXHO"_6I(XD'AZ3Y#N$Q.X#KS0!KIKML^JMIX#^:.<XXQ5AM4M%DV&49SC/:L
M>(QV^LB64 &2#Y1CDUFW4YDTMY2Z(QDX@"_,.: .ADUNV74OL)#;RNX,!Q4R
MW\<5NTLTJ[0<#'6LI2D>L0RR[5W6X&6&,FJ*C;Y$T@/DB<ER>GM0!TL.J6T\
M;NC8"#G=P:(M4M9Y!&DGS,,C/0U@7Y2:]NWMANA,.&*],U++&D6GZ9MCPP(^
M8=1]: -VZE,2I\P3+8YIC:E;QOM+DX."V./SJGK@S';$YQO&0*R93]C$DEK,
MDD98;[>3J/I0!UGFC&[C;C.[M5)-9LWF$0<Y)P#C@U'.7FT.1HHV5GCX3TK&
M:2!]%M(8@INE8  =<YH Z"75;6*1T:3YT.&'I3YM0MX$1V?(?[H'.:Q+*%&F
MU)I%W2E,-D9P<5242&;3V,PCB7(WL.,T =3;7L-VA:(YP<$'@BH[K4[>U8)(
MWS=PO)'UK/TB");VYECN#,SGE@/ES5>%X8=3U#[80)'7@L."/:@"UJFNQ6<4
M!A.YICA2!TJU<WZZ?IGVJYR0!G %8")_HMINB&3-\N[N/:M_5D+:5.J(&ROW
M3VH K2:XGDVLZ*0DWKVK0AOH)T9T<83[V>,5SLOE21:4D>'"D @=C2:@DC7=
M_# "N5!(6@#?@U>TGE$:,P)X!88!J>>[AME#2N%!Z>]<W!##*MB'O-S)R$1>
M1]:O:\BLUB#SB3.,4 7QJ]H8FD#DA3R,<U))J%O% DS/\C],=361Y*+K5[^[
M'^IR!VZ50ML*]E+/GR0QQGH#0!TD.J6LT+2K)A5."#P13#J]J(9)<G"#.,<G
M\*P;J*WNM1NR&9;4@;I(^@84^VGE%P;=EBN5>,A)5ZX]Z -O3M5BU* R0J1@
MX(-/?5+6.41LQSW..!]:H^'FC^PM$-H=&.X=Q63<[;6:YEMI@^YOGADZM]*
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MOIBA+F.2#ST8&/&<BJ<>M6DAC*EMCG ?'&: +<=K#"A58U /48ZT[R$( VC
MZ#'2JIU6V-V;926<=<#@5'_;=MYXCVOMSM\S'R@T 7VA5\;@#CUJ-K*W:42-
M"A8?[-,@U"WG:14DYC^][5 ^LVRQJRAW9LX4#G% %X8(SC\*B6RMDF,JQ*&]
MA6==ZP'L$N+0YR^U@>HJ\E_#YJQ,WS[-S8Z"@"=8D4$A0"W+<=::]K!*@1HU
M*CH,=*J#6K;>.'\LG:),?+FK5Q>0VJ!I&^]T [T /CAC@CVQ(%'L*9-:03X:
M6-68=R*@CU:U=9&+;/+&6#=138M8MIG15W /]UB.#0!;,,;E/D7"=..E2,@8
M$,,@]:J7%P(KE%9PH/ZU#_;EGP=QVD[=V.,T 7$M8$/RQJ/H*?Y,>2=HR>IQ
MUJK'JEO(\BY*E!DY[BHQKEH<?>"L< XX- %I+.WBD,B1*&/H*D:-9""Z@XZ9
M%55U6V:.5P3^Z.&!'-/;4;=5A<MQ,<)[T 3^3'DG:,G@G%->VA>/RVC78.@Q
M51M:M59@-S;6VM@?=^M27.IV]N8UR79QE53DF@"9+6&*(QI&H0]1CK1%:P6Y
MS'$JGV%-M+V*]C+Q'H<$=P:BDU6VCN_LVXM+W '2@"PEO'%(9$15+?>P.M-:
MRMWD\UHD+#OBJCZS;)(1ARH^\X'"_6I9=5MXSA29!C)*\X% %A[>*4@LBDCI
MD=*<(8U4J$7!]JJ2ZM:Q^7\Q;S!D8%*FJVSV\DY?:L?WMW6@"R((U8,% (Z'
M'2J5_I:7BHZ$1R(V0<<4MOK%O/+Y9#QL1E=XQN^E(NM6C<KN*;MF_'&?2@"*
MWTD+>?:9Y?,?&T +@5?CM+>*0ND2JWJ!4$VJ6\,C+RQ49;:,@4Z;4X(ECP6=
MY!E$7J10!.L48#*L:X/48XIKVT,FT-&I9.F1TJD^I"6QEGM?O1G]XIZBKD5W
M&]HMR3A"N2: )7BC?!=0=O0$4ACCR6,8RW!..M4H=:MIIO+"N 1\K$<-]*HV
M6K2:AJTL6UTBCXY'>@#9>UA=/+,:[/3%)';Q0Q^7%&NPGD8J.XU*&VD\L@NX
M&2%YP*IW>I-YMI]F.Z.9L$=Z -!;6%3E(D!!X.*0V=N\OG-"N\=\5!-?Q 2K
M&YW1'D]J1M6MXL(27DQDA10!<\B,YRBG/7BF1V<$+[HHU0GT%+;W4=S")8R2
MIX^E2D]AUH CF@BF3;-&'4>HI([:!(A&D:B/TQP:H37\L6NQVO'E,F34BZU:
M'[N[;G;NQP#0!>^6/"@<>@J,VL!<N(EW>N.M0ZEJ"6%@]T5+@#(V]ZSI=;8Q
MV4P1D28\AAR: -EH8Y4"L@(]"*$MH$4JL2 'J M0Q:E;R1RMDKY?W@W6H8=9
MMI)DC(="_P!TL,!J +OD1X VC Z<=*8;.W\P2^4FX=]M-O+^"Q5#,V-[;0*C
MCU2V<2Y)4Q#)#=QZT -ATR%+R:Y8!C+V(S5PPQ\91?E^[QTJDNLVC6QG)8(/
MNY'WOI3[;5+>X+K\R,@R0XQ0!+]DME);R4YY/RT\+&#N6/GIG%4H];MI9E3:
MX#' 8C@U2M]6FO-:DM(U94CZDB@#:\F)T*-$N#U!'6F-9VYP&A5MO3BBYNXK
M*+=(22>@'4U3;6X?LDDBH_F(,^61R* +_D1&,KY2[3U7'%$=O%$,)& ,8Z=J
MS=!O9M0MC=2!@&. #5FYU2WM)?+;<S=]HSM^M $R6-M%(72)0Q[@=*E$,8!P
M@ /7CK5.?5[:!(R-TC2=%49-']LV@MA.6PI.W'<&@"ZJ!1@ !?2H_LEN'W^4
MF>N<5%;ZE#<22(-RE!N.[C(]:BCUBVEN!$N[:?NR8^4T 6VMHG.613GKD4CV
ML$D8B>)60<@8X%59-9MHY2@#,J\,X' HDUJT7=M8N5P6VCI0!<CAC@3$8"CV
M%-:WCE82.BEQT)'-9MYKT5O<6Z)&\J3<!E'%:%Q=Q6L'GRDJ#T7O0 AL8&F\
MW8N_UQ4^S((89!]:HQZO;R"3Y7#H-Q4CDBGC5+9P-C%QC<=O8>M $Z6D$9R(
MUS]*D\M-Q8(,D8)QUJC'K%I)(BJ3AS@-CBG7&JP02M&5=BG+%!G% $T=G;0O
MO2%0WJ!4XZ@U1FU>TB2,LY_>CY !UIJZE!&TCR285<9SU% &CWI:S1K5J6*$
M.'"[@I'+#VJ3^UK7[(;G?\@./?/I0!>HK/AU>VE+@[D9%W$,,$BDBUFUE:,*
M6Q)P&(XH O[A^=**Q[77$FU"X@:)D2'[SD<"K<6J022A<,H;[CD<-]* +U%(
M&! (Y!I: "BBB@"GJ(S83@<DKQ6)8QXU*T)C(*P\DCO72%5(P?RI-J\$* >@
MXH YKRPNBWQ2(C=/D+CGK4UJF=0GW1YS;#DCVZ5OD*>-H/KQ2! #T7VH YHI
MM\/P!8RN+@<8YZU81A;W&H&0$-*HVX'7BMT!3G('';%!C0G+*ISTR* .7LH_
MWNFLT1&">".G-/U&&0O?[%.!(&( ZBNE*KUVJ".G%+M ).U22.<=Z .=NYH;
MZYM4MAO,2;FP,;>*I62QM&GVIV6!)<J0/XJZK[+#Y;HD:J'^]@<UG_V%&8S"
M+J3R#UBQQ0!D0QQQ3WQN+N2,RL?EVY#K[59M;>.+5+'RXV:,)A2W\-;R6\*J
MB>6I$8PI(S4NU1CY1^72@#FI4^:Z4Q-Y?GJ?QJ6VFCL+N[:]7+/C;QG<*Z J
MA."H.?:FE$?!= S+TXH P&037LS1PE<P'"D<5$2#H"2H<SV3;R,8/TKI@@W$
MX )[U4N[%;KY1)Y:G[ZJ/O?6@"MH:-);&[D3$MQ\YSVID1\K7+U3R[1[ESW]
MJUE58HQ&F %'%136J23QS ?,M ')74AFTIVD8K,9!B!5Z\]:T[=O)UB.>92P
M: #..E;QBC#EMB[CU.*4JN,;5(Z8Q0!R\,3HPE8'8TQ*KCM3HT<11 H2?M!(
M&/>NG")P,#CH,=*78N.5&,T <]:Q1/=:C8RG#R<J"*;H)>\NFDG4J+7]U&/7
MWK>G@$J_(=CG@2 <BF65K'9PF),D@Y9CW- &;J)$.MVLT@_=[-N0.AJI;S0V
M:ZC'<J4=V.&(R7S71LB2@%D!&<\BD:&&1@SQJ2O3(H S-.BDA\/E9/E8QL1]
M*RXGCE\.Q0QI^\:0! !T.>M=/+&)(6C8X##!(["H;2SALX@B $+T.* ,6P@?
MSK]"NZ;RRN['>H!-%_8(LPI%UOP5QR374@+DM@#WJ/R(A)O\I0W8XH YK4%G
MTZY@\M"3=H(Y-HZ&K11=/UJ.6X&V(1;58#@UOLH[J#WY'>FO''(H$B@KGN*
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M_P!'&2/6H/[:9C:)'#EK@'CTJ(PSVSW02$OYZ?+]<4RRL;J.?3W:/&Q3O]J
M+7]LB.UFDFCQ)&VS9ZFF1ZO+!*JWT)C$BEE.<U5N=.N97N61<DN&4>N*61;C
M5)H&$/E^0IW%AP3Z4 6[?5Y+E1(D.Z+=C(//Y5(FJB6"[D"<0'CWK)-G.;V-
M[:![6XW?.5/R,/I5DVT]LM[ D6YIQ\K#H30!8.L%Y($C@)DF3(%-;7?*M#))
M%B9'V.GI5*,3VFI6*.NZ18?F45'?02QQ37TBE7FE 6.@#7752EQY5S%Y>Y-Z
M9_BJ%-<)LVNI(=D.=J9[FF36L^H7,;E-JQQ=?4XJ&73)KCP^L31_O4?.WU%
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M@!:*** (QRW';UHSU!)Q]*CN':.%G7&\#J>!6#_;$L%S")+@/YK89=O 'UH
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ME$@PZ8%/.G/ML06SY)Y%:N/>C''6@#'.D,S7N6SYQR!33IEU/<6\SN%\E"H
MK:V],GI1B@#'32I4TU[8$99RPIATVZM;KSK,J=Z;6![&MO%&T8Q0!A)I5U;6
MX$,B/*QW2H_(-,CT%O*E9W"O(<K&O"@UO[:7:,8H Q'T^Y:X2ZG<;HXBH5?I
M573;*[N=,6)\+&9"6!]*Z7:.:;LP,** .>MK>X35;I+<;5V;03TJQ'H;Q-;L
MCC<K;GSZUL;.O&">IIVW..: ,:XTNXBU)[NS6-O,&'5_YTY["]\G"R*SGK&1
M\M;&T9S2;1C':@#!@T:XM_,FCD6*5SGR1]PT1Z+.SR2N8XY6&-J<+6_BC'%
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MF]6&30!@P6MY-(NH1HGF2IB1&'0U>;3Y9]'DM9W7S7R05Z ]JTPO;H.XI=@
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M93)OE",>WX5#<A6:[8 G=,H-73H-R\45NUPJPQ,&7 Y-6)-%+^:!)Q(ZM^5
M%6-KG4IYA%+Y*0*%45"^KS26D"/,8D)*O,!WK0?2IXKAWM)MB2+AQ6??:?\
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MZ+2Q;WGGA\(J;%6J\FA$HI2;]\K[P3TH S_MTDL=Y9R.[*$W(S"K#$PV>FS
MX.0I/K4ZZ%(TL\LLX,DR[3BEDLGD>SM0#LA.6/TH V0>_<XI]5XEF6:0N04)
M^458H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH 3'2@CTZTM% "8ZT8(&!2T4 )BDV\FG44 (0:,>]+10 F*,4M% "8Z4F#[4
MZB@!H4@=<\TN.,4M% "8I"F<YYSV-.HH :$QC' ]!TI<'M2T4 (10 >IQFEH
MH 3%(5R,=!3J* &[?7H*7'%+10 F*0KGK@^QIU% #0N*4#'2EHH 3!I-I)!I
MU% " =>]&,D4M% "8YHQZTM% "8HQZTM% "$9_I2!3[4ZB@!,4M%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 449HH **2EH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#7CW
MQRXM;#_?KV"O(/C@I:#3Q_MU%3X3ORQ7Q,4>01IOJP.!CM0JA%Q2]JX3],HP
ML@HHHI&X4K ,N*2E% K7*LB%37L?P._Y!=]_UUKR1T#*?7%>N?!!"NF7P_Z:
MUO1>I\MQ##EH7/6@.:=2=Z6NL^'"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0UY%\:O]38_P"]7KQZ5Y%\
M:O\ 4V/^]45/A/1RG_>XGDW4 ^U!Z4=A]**X&?J$=A****!A2BDHH!!TZ5Z_
M\%O^/&]';S*\@->O_!?_ (\;W_KI6]'<^=XC_P!V/5QTI:0=*6NL_/PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "O(?C5_JK'_ 'J]>KR'XU?ZJQ_WJBI\+/1RG_>XGDW8?2E[4G8?2E[5
MP'Z?'82BBB@H**** "O7_@M_QX7W_72O(*]?^"W_ !X7W_72MJ.Y\YQ'_NQZ
MNO2EI%Z4M=A\ %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5Y#\:O\ 56/^]7KU>0_&K_56/^]45/A9Z.4_
M[W$\F[#Z4O:D[#Z4O:N _3X["4444%!1110 5Z_\%O\ CPOO^NE>05Z_\%O^
M/"^_ZZ5M1W/G.(_]V/5UZ4M(O2EKL/@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M**2@!:**2@!:**2@!:*2EH **** "BC-)F@!:*3-% "T4E% "T4E% "T4E%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.L1K;I,R$*>OM0!I\4M8L'B")RV]<9&Y,=Q2G69C9K<"VV@GC<>U &S16/\
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MKK/@ HHHH **** "BBB@ HHHH * ,"BB@ I,4M% "8I<444 %%%% !BBBB@
MHHHH ,4444 %&*** #%&*** "BBB@ HHHH *,444 %%%% !1BBB@!,4M%% !
M1BBB@ Q1BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHI %)2TE
M'#_$7_CQ@_WJ\_/&#7H'Q&_X\8/]ZN!B0OUZ5\QF>E1L][+OX8Z--QS5D=
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M% !12;@.O% .: %HHHH **** "BBB@ HI,TM !1110 4444 %%%% !111F@
MHHS1F@ HHS10 4449H **,T4 %%&:,T %%&:,T %%&:,T %%&:,T %%&:* "
MBBB@ HHHS0 4444 %%&:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "CO11WH *2EI*70#B/B&I>TMU[;JXI4"+M
MKNO'W_'I!_O5PW>OE<T?[QGT&6_PPI5!9MHZFDI5^^O3&>:\V"U/0GLS9MRM
MC"&NKS>#_P L@,BH9KC3[YV5(?);'!QP:LLS1P.(+9690""PS5/57\_R)&C$
M)*_= Q7?/2F<%-^^9P&UBK'.#P:  0<T=NE!KSF>@CH_ :;-7N/3:*](KSOP
M/_R$Y_H*]$KZW+OX2/F<9_%8HHI!2UZ1R!7D7QJ_U-C_ +]>NUY#\:O]38_[
M]14^%GI93_O<3R<TE*>E)7 ?IRV);>)YKA(T8(Q/5N /QKJ[2YLM)B9-0O#?
M\<1JNX _6N:TZ&.XU&"&8X5FXYKJGO;B!(VM],AD$<NPA5R2/6MJ9X>97<T8
MEV^EZFDLUO ]I*O\)XS6+SWQGVK5\09;5S*4$8(^X.U9=1-ZGHX*+4%<2O7_
M (+?\>%]_P!=*\@KU_X+_P#'C>_]=*NCN>3Q'_NQZN.E+2#I2UV'P 4444 %
M%%% !1110 4&BFL3@XH "<4QY4C7=(ZJ/4FJ&H:D+4K%"GFW+\+'Z?6JD>C2
M79,VIS,['_ED#@"@$C0?5;%3M:Z0$]ZGBN()Q^ZE5\=P:H#2M,C 4PH/J:BF
MT&U^]:2-!*>0RGB@IJQM TN:Q;>_N;&5;;4L;3PDP[_6M?/;MUS02Q^:,TVN
M=/BJ(^*?[$$9!VY\WMGTH'&+9T>:3)KG+GQ%>?VS)IUE:"5HUW,QJS9>($OK
M>8H@CGA.UT?CF@.1FW1FN7G\2WT&I_9#9 _)OW+TQ2#QE%]@68Q$3-)L,7<>
M](?(SJ<TN:K_ &A#'$SL$+XP#WH^TQ&1T652R_>&>E,GE98S1FLJ;5X[5Y&E
M=#!&FYGSS52;Q59"SMKNW;S(IWV9]*"N5G09HS56&]AN WD2!RIY%$UY! V)
M9E0XX!- K,M9HS5(ZE:#;NN$ ;[ISUH%[BZ>-F0(B[BQ- N5EW-&:IQZA;32
M&.*9'<#(&>M,@U"-HRT\D<>#CK0%F7\T9JE_:=GY;2?:8RBG!.>]/DO((XA(
M\J",]&S0%F6 W-*365J.L0V-@UTF) I QGKFKT$_G6JS@?>4, >U .+L3YI<
MU0BU",Q&29T09QUIW]IV8C\TW";,[<YH&XNQ=S1FJKWMO"JM+,BJW*G/6FG4
MK/:I-PF&/!S0*S+F:,U7^U1^<L/F)YA&X#/44CWMNJ%FG15!P6SWH#E99S0#
M56&]@N=WDRJVW[W/2HUU2SEE\F.Z0RYZ ]:!\K+V:,U5?4+6*3RY)T63TSTI
M_P!H0N(U=2^,D$\X]:!69/FC-5FO[4*3YZ  XSGO2)?VTJ.T<R-L^]STH"S+
M.:,U534+6680I.I<C(P>M'V^W\[R_.3S.A7/2@.5EO-&:H#5;)I_(6Y4R>GO
M4CZA;1RK%).BR'G:3TH'9EO-&:JS7]M;LBS3QH6Z FHY+MQ/$B;"C^IY^M D
MF7LT9J@NJV37 MUND,N<%<\U+)J%K$Y22=%9>HS0#3+0-&>:CCD$B[T8,AY!
M%/'6@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4=Z*.] !24M)2Z <;X^_P"/.#_>KAN]=SX]_P"/.#_>KAN]?*9I_%/H
M,L_AA4MO ]S)L0X[EO05#SNJ]IBJS2*9 A*XR:\^G\5COJ/W2_&;:-U']I-Y
MP& 3TK-OQ<"XS<N) ?NL.AJ8Z,S'FYC'OFDU%%AB@B\X.5&":ZJDKQL<E-6E
M<H]%P>:2@\'UHKAM8[KW.G\#_P#(3F^@KT2O._ __(3F^@KT.OKLM_A(^8QN
ME5BBEI!2UZ1R!7D/QJ_U-C_OUZ\:\A^-7^IL?]^HJ?"STLI_WN)Y.>E)BEHK
M@/TY?"7M,TZ2_<N)1!"ARTGI71P/9Q2%=/UHFY;Y=LGW2:R-(MEO=+GMTN1;
MN3U8]:5/"Y4AEOX=R_Q9[UO!Z'AXF/M)-OH9E^EQ'?S"\)>;/6JY]ZT==*_V
M@JJZN8TPS*>IK-/6LI[GJX5^XD!Z5Z_\%_\ CQO?^NE>05Z_\%O^/"^_ZZ5K
M1W/%XC_W8]7'2EI%Z4M=9\ %%%% !1110 4444 (35:^N%M;.29NBCCZU8(K
M%\2R$6,<8Z22 &@$&BVKM&]_/\UQ/W]![5JRJ6@95.&Q@$T6Z!+>-%X"J!3S
MR<@]!R*!WU//_L6KR:R\$_FF)SU!Z"NYL[8VUJD.XMM'5NM<[JOC"WTKQ39Z
M*T!:6Y'#^E=6.<4D7-LK7EG'>V[0R*",94^A]:H:)=2,DMG.2TEN<$^HK9'
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M4_?4'-3'KZ9K$LI3I%X]E<M_H\G,3'H/:MP=L=".#1T$UK<\H\8E1\4M%5F
M:O61P!Z8K!U/PI8:IK%KJLP/VFW^Z:WNV/:DC24KI"YYQ6!9XO/$=Q<+]V(;
M<^]7=5U 6T?DP_-<R#"@<XI=*LOL%J(W.9F^=VIF:+S.J#+' '5CVIL<B2 E
M'5QUR#4=W$D\'ERM\IYQG&[VK$LY%M-3D9XV@B"X$8Y+?A0!T#R1Q\R%5)X&
M3UI>.N<9Z&N<N7FGUM)G<?9XT+JA&#4XU.Y 2:0J8)\JH':@1NK@_=(/J0:
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ML&S:D0<@B@-#>R#V -!]?UJE;W9FT_[2VU#C.<=*S+?6)Y;MK>0[D=3L(7%
MM#=\Q"1\XYX%..,].E<S%+Y"VDA<DAFX_&KBZC>(89Y0DD$Q(4 8(H#0V]V%
M+8Q2DX]ZYQ-0NKN:$JQ().Y%&  /6I5U.ZDLFN&>.,,^U1MR30,W3(%&6P .
MI)Z4@DW*&3#*>]<Q<WEWJ6G.@E$;)( 3MQD4^$ZA;ZA*BR!T2'*Q@=30!TP;
M.:4'(K$TK49[F413R*KXYC*X-;8&!TQ0 M%%% !1110 4444 %%%% !1110
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M]?\ @O\ \>-[_P!=*\@KV#X+_P#'C>G_ *:5I1W/$XC_ -V/5ATI:04M=A\
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C %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %5 \\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W>BBBI+"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1ZU>I#"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M()'K6Y10%BC!I%I;:G/?QJ1+,NUQGC%4O^$4TWRA%^\\I9_/5-W"M[>U;=%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "F,3YJ@=#3N],/^O6F)DE%%%(84444 %%%% !1110 R0E8R13A
MT%-E_P!4:<.@IB%HHHI#"BBB@ HHHH *.]% ZT"(T8EW'85)44?^LDJ6@$%%
M%% PHHHH **** "F.2'0#C-.IC_ZQ*8F24444AA1110 4444 %%%% !1110
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MGWHL&@M% Z44 !IK_<:G&FO]QJ8 G^K6G4U/]6OTIU D%%%%(84444 %%%%
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M ,0_\]HORKFJ*+A<Z7_A/_$/_/>+\J/^$_\ $/\ SWB_*N:HHN%SI?\ A/\
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MYX%;%W_QXW'_ %S:J>DZ2FDQS*L[3/,V]W;UJW=_\>-Q_P!<S_*D'0^?I/\
MCYF_ZZ-_.DI9/^/B;_KH:2LF2%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !39/\ 5GZ4M))]P_2F,]V\-?\ (L6'_7,5J5E^&O\
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MKU:BBR#E1Y3_ ,*RUG_GX@_[ZH_X5EK/_/Q!_P!]5ZM11RH+'E/_  K+6?\
MGX@_[ZH_X5EK/_/Q!_WU7JU%%D%CB/"'@W4/#^L27EU+$T;)M 0\UV;_ .L2
MGTQ_]8E.P$E%%%!04444 %%%% !1110 4444 %%%% @HP*** # ]*,#THHH&
M%&***!!1110 4444#"BBB@ HQWHHH *,>E%% !BC HHH .G:C%%% !VJ&[_X
M\KC_ *YFIJ9)_JF^E F?/DB2_:)OW4G^L;^'WINR3_GC)_WS7T$MK:E1FUAZ
M?W!2_9+3_GUA_P"^!4N)-CY]V2?\\9/^^:-DG_/&3_OFOH+[):?\^L/_ 'P*
M/LEI_P ^L/\ WP*7*.Q\^[)/^>,G_?-&R3_GC)_WS7T%]DM/^?6'_O@4?9+3
M_GUA_P"^!1RA8^?=DG_/&3_OFC9)_P \9/\ OFOH+[):?\^L/_? H^R6G_/K
M#_WP*.45CY]V2?\ /&3_ +YH\N7M%)_WS7T%]DM/^?6'_O@4R.UM3N_T6'K_
M '!3Y0L> >7)_P \9/\ OFC9)_SQD_[YKZ!^RVO_ #ZP_P#? I?LEI_SZP_]
M\"CE'8^?=DG_ #QD_P"^:-DG_/&3_OFOH+[):?\ /K#_ -\"C[):?\^L/_?
MI<H6/GW9)_SQD_[YHV2?\\9/^^:^@OLEI_SZP_\ ? H^R6G_ #ZP_P#? HY0
ML?/NR3_GC)_WS1LD_P">,G_?-?07V2T_Y]8?^^!1]EM?^?6'_O@4<HK'S[Y<
MHX\J3_OFC9)_SQD_[YKW\VUMYRC[-#C']P4_[+:_\^L/_? I\H6/GW9)_P \
M9/\ OFC9)_SQD_[YKZ"^R6G_ #ZP_P#? H^R6G_/I#_WP*7*%CY]V2?\\I/^
M^::Z2"-OW,G3^[7T)]DM/^?6'_O@4&TM#_RZP_\ ? I\H[&?X9S_ ,(Q89!!
M\L=:U:1555"JH51T Z"EJA@::_W&IQIK_<:F,$_U:_2G4U/]6OTIU D%%%%(
M84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 )3#_KUI_>F-_KU^E,3)****0PHHHH **** "BBB@!DO^J-.'04
MV7_5&G#H*8NHM%%%(84444 %%%% !0.M% ZT 11_?DJ6HH_OR5+3$@HHHI#"
MBBB@ HHHH *C?_6)4E1O_K$IB9)1112&%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,D_U1^E
M/IDG^J/TH!CE^Z/I2TB_='TI:!(****!A1110 4444 %1Q?Q?6I*CB_B^M F
M/[4M)VI:8PHHHI %%%% !1110!&?]>OTJ2HS_KU^E24Q(****0PHHHH ****
M  TU_N-3C37^XU, 3_5K]*=34_U:_2G4"04444AA1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 G>F'_7K3^],
M;_7K3$R2BBBD,**** "BBB@ HHHH 9+_ *HTX=!39?\ 5&G#H*8NHM% HI#"
MBBB@ HHHH *!UHH'6@"*/[\E2U''_K)*DIB04444AA1110 4444 %1O_ *Q*
MDJ-_]8E,3)****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!*;)_JC3Z9)_JS0#'+]T?2EI%
M^Z/I2T"04444#"BBB@ HHHH *CB_B^M25'%_%]:!,?VI:3M2TQA1112 ****
M "BBB@",_P"O7Z5)49_UZ_2I*8D%%%%(84444 %%%%  ::_W&IQIK_<:F )_
MJU^E.IJ?ZM?I3J!(****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHH- "=Z8?]>M// S3"?WZ?2GN2V24444B
M@HHHH ***3- "T4F<4 Y[4 -E_U1IPZ"FRG,34X=!3%U%HH'6BD,**** "BB
MB@ H'6B@=: (X_\ 625)4<?^LDJ2F)!1112&%%%% !1110 5&_\ K$J2HW_U
MB4Q,DHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** $ILG^K-/IDG^K-"$QR_='TI:1?NK]*
M7- !111F@+A1110%PHHHH"X5'%T;ZU)FHXOXOK0(?VI:3(HS3*%HHS29I"%H
MI,TM !1110,C/^O7Z5)49_UZ_2I*8D%%%%(84444 %%%%  ::_W&IQIK_<:F
M )_JU^E.IJ?ZM?I3J!(****0PHHHH ***!S0 44$X.*,XH **,TF10 M%)F@
MG'% "T4F11D'I0 M%';/:DR* %HI-P]:-P]: %HHS29'K0 M%'>@\=: "B@9
M/2@\=>* "BDR,9I<@T %%)D>M&10 'H:S-9U2/1X([F5"RDXP*T\]JYCQS_R
M"8O]^N?%3=.E*4>A=&FIU%%]1G_"=VF/^/=Z/^$[M/\ GW>N&HKYO^UL0>Y_
M9M([G_A.[3_GW>C_ (3NT_Y]WKAJ*/[7Q ?V;1.Y_P"$[M/^?=Z/^$[M/^?=
MZX:BC^UL1Y!_9M$[G_A.K/\ Y]WH'CJT+*/L[\G%<-2I_K8_]\?SJH9K7<E=
MBEEM%)V/7=_F6V_LP!%2CH*A3_CQC[?(*F'W17U,&W%-G@/230M% HIC"BBB
M@ HHHH *!UHH'6@"./\ UDE25''_ *R2I*8D%%%%(84444 %%%% !4;_ .L2
MI*C?_6)3$R2BBBD,**** "BBB@ HHHH ***"<=: "BC(I,B@!:*3(]:7(]:
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MMK^Z/^RG_,>O>=!_SVC_ .^J/.@_Y[1_]]5Y#YDN?]=)_P!]4>9+_P ]I/\
MOJC^VE_*+^RG_,>O>=!_SVC_ .^J59(F.$D1CZ UY!YDO_/:3_OJM_P:\AU_
M#2.PV'@FMJ.;>UJ*%MS*MESI0<^;8]#SSBBD[YI:]A'G$9_UZ_2I*C/^O7Z5
M)3!!1112&%%%% !1110 &FO]QJ<::_W&I@"?ZM?I3J:G^K7Z4Z@2"BBBD,**
M** "N<\6WLUK'8I'/)!'+*5D>,9;'M71U1O]-2_GM)7<@VS[P,?>H$<O:Z]J
M.GJ89HFN(F<^3<SC;D>AK2D\1W;AWM;))$A0/.2>@]JO:QI3:H\8AN3;E 05
M X(J@/"A@39:7\L2.-LZ]?,IBU([KQ)/.+E+2WQ#!"LKR]^>PI9_%4MK):@P
M1F.15!R?FY%75\/PH+Q4E94NHEC(_N@52/@Z)I%Q>/Y2E25(YR* U'Q^(YKB
M^>V-LL<9!P2?G'O56#Q3,(K=%MP0V=TDIQNYQQ5Y_#'G7BRRWKM$ARJ 8/YU
M%)X3S!';QW\@A7.X8'.3F@-2WK=]-;'3'@.P32'S%]0!G%5+3Q5(Z)<7=H(;
M6;(B8'DD5J76CQ7<%G$9&5;4G:>[9&*J_P#",VYL;2UDF=H[9F8>^: U,QO$
M6H_VE%--;^5:^29%0?QCWJ]<>*%MS:&2#BY@\T8['THA\,XG#W%])-&L9C2,
MC[H-0Q>$D\X-=7LDP2/RXE(^X.U :C)O%%Q91HMW9+'<2X,0)^4@^M1CQ5<7
MOF6]I9JUW&C-)S\H ]*M_P#"+K-;[;J]DFN%QY4K#[@%-_X19D'F07[QW3*4
MDE4#YU- %O1-1\SPY!>W\P4L6W,WUJSJ>H16>B3WT;@H$^1AZT:?I<%AID=@
MW[^./)R_<FEO]+COHX(F)2")PYB'1O8T <I!K%]+X=FB-]NO$F ,RCD*:MZC
M>WN@.(9KM[J.5596(PRG-:>I^&8+Y]]O*;0X (0=2.]1OX7-S'(U]?23SL J
MN1]P T /\1_:?[$%[;7<ELZ*#A1G.:IC5[G2A! 0UX6A\Z263C;[5NWNGK?Z
M7]A=RJX W#KQ5=]$A>=))'9E$'DE.Q'K0!F6'BQKN?RI8(\21F2(H?3L:JS>
M*;R>SO((88TNXTWHRGC%:$'A:***6)[EFB*%(\#!3/O3;;PG';B0RW3RN\7E
M @8P/6@"F?%=Q:VT4+01M<)$))LGK]*DU'Q)=364S:7;?)&@:21NJ$U._A9I
M%C87A695V.Y4?.M27GAC[0SK;7LEO'*@69%'#XH#4V;-S)8V\C'+.@9CZFN?
M\=?\@B'_ 'ZZ*WC$%O%"I)$:A0?6N>\=?\@B+_?KDQW^[R.C"_QHG!4445\6
M?4A1110 4444 (:5/]9'_OC^=(:5/];'_OC^=53^)$R^%GKP_P"/./\ W!4H
MZ"HA_P ><?\ N"I1T%?=0^%'R4OB8M%%%4 4444 %%%% !0.M% ZT 1Q_P"L
MDJ2HX_\ 625)3$@HHHI#"BBB@ HHHH *C?\ UB5)4;_ZQ*8F24444AA1110
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M_6R?[YI*^%G\3/K8?"@HHHJ2@HHHH **** "C%%% !1110 4444 )70>#/\
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M%% B./\ UCBI*3%+0 4444#"BBB@ HHHH *C?_6)FI*3 STH$+1110,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *9)_JVI](PW*1GK0(%^XOTI:0#  ]*6@ HHHH&%%%% !1
M110 5'%T;ZU)357;G'<T"8H%+110,**** "BBB@ HHHH C/^O7Z5)32OS!NX
MIU @HHHH&%%%% !1110 4U_N-3J0C((]:!")_JUIU(HVJ!Z4M !1110,****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N=G\0WOFW4UI:1O8VC[)7+?,Q]JZ+.*Y2?3=3M_MNGVUNLEM>2;UFS
M]P=\T"9U$,JSP1S)]V1=PI]16L'V6SAMPV?+0+GUJ6@ HHHH&%%%% !534KY
M=.L)+EEW%>%7U-6ZH:Q8MJ.F201D"489,],B@3*EAK%ZVHQV.I6Z1/-'YD3(
M<CZ&EU;7GTRZMX$M&E\UPK.?NK52WM]3NM3AO[NU$7V2/:B \R-_A3-=.K7T
M=LMOIN=CB1LG]*8CISP1145O+)- C31>5(1RGI4M(84444#"BBB@ [^U<Y/X
MBO4:>Z@M$?3H)/+=L_,3Z@5T?KGH1@UR<^G:G%%<Z3!;J]M<R;A<9^Z#U!H$
MS<O]0FBM8)+"W-Q).1LST&>YJ+2-4N;VXNK6\A2.>W(RT9RI_&J]^^KV>FBR
MTJU#-&@196].^*ET"*6WMFBFLV@?.6=NLA[FF(V.M%%%(84444#"@T4'I0!D
MZIJEW;W<-CI\*2W<@+$.<*HJ32]5;4+&65X=MS"Q22(?WAZ56U2VO(=3AU6Q
MA$[JFQXL\D4W3K:_L+>640JUW=2&1ESQ'Z"F2-@UR_348;>^MH52<D(L;99/
MJ*Z C!Q7)1:9?W6N177V,6<B-F:;<2)!Z"NM)R212&A****!A1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %07=Y;V$/G74R0QYQN8\5/6!KOE#6]+:\VFS&<[AE=W;- F;5O<P7<0FM
MI5EB;HRGBI:P/#83[5JA@'^BF7]WCI[XK?H!!1110,**** "BBE7.3CKCB@1
M2DU;3XKP6CWD2W!X$9/-2W-W;V4/FW4RQ1Y^\W2N+E%H=#U!9@O]H?:25R/G
MSGC%;&K1B\TRPC>\CMYD"ES(,X./2@1LVNH6M\ADM)EF0=2O:K0]ZP/#MU+)
M/=VK/'-' 1MN(T"[_P !6\#F@:%HHHH&%%%% !1110!$]S!')'')*BR2?<0G
MEOI4M<EK:V$'B73+DS 7'F -EONCZ5UF]7^93N!Y!% A:***!A1110 4444
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MH3Z)_;G]E!-/63RVR?F)SC(H'<[L'/2ESCK7)W/B^675(M-T:T$\[P^>[2'
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ME:10?0FNBU"PM]5MC;WBEX2>0#C-3PQ)!#'%$H6-!M51V% 6)****0PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HZ444""BBB@ HHHH&%%%% !1110 4444 %%%% !1110(****!
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
-44 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %  :D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@!C,!GD #J330PQG*D'H1TQ7._$"XEM?
M &N2V[,DR6K,K X(]ZQO"][._P &[>[DF>6X-F6WYY)Q0!WB,,9#*5Z#;S2
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M.V%R;@01B8\>9M&?SJ>@ HHHH ***0]* %HI,T4M0%HIM.HN 444E,!:***
M"BBB@ I"P! />EIKXQ\WYT (9% !.>:7>-H;G%8/BW7%\-^')]1,8E*%4CC8
MX#,3@9/UKGK;Q9K5EI.J7^KVUO(+>W$L0MWW OC[AH [\R*.IQ]:"X%><V7C
MO4;*2-=>M(P+K3VU"%8N2BJ,E33M$\:ZO-KFD1ZG9QK9:Q"TMNZ'F+'0'ZT
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M7:327DLJ3:7*8XV Q!\P&%]?6N]#8D5>I(R2: ):*** "BBB@ HHHH ****
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MIKS+&NYV"@=2:JZ$W;<;(1'EN<=.*Y#6?$L^G:@T$4>Y4&3GO6W-?SW#%+!
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MU/Q%<G-AIJFWM=W9Q]\CZULZ/:RWT[ZS>KF:4;8(STC3L?J:Z,/55&HJC5[
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MN+..PU*67[9H,MU+YS[OWJKPXJQH*SZ9K?A*\BU">0W]HTEW&\F1*QYW#Z4
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M]A6[D^[$6Y-7]P )XIRBU9VL \4M1JY/;IWIV[\">E"MT =2&@'G%-9\*3T
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M@#SNUTF?2OC%:BXU:[U'S]-F<"Y(/E#?]U<=JR_BCX:UG4]2@N;6WDN;?9M
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M(Z5"@(C0%]S!0"?ZU-0 A&:88R01GKUJ2B@#SV2:YE^-EI%/:F&*+2I%AEW
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MZ4]*08*T.Y.O438I7! (I BKT%.7%&,T>8[NV@H'%&*7I12>H(3%.'2DI13
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M@>E&!Z4M% "8'I2%03R*=10 FT>E+C%%% !1@444 )@>E+110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 44C9VG;U[4PDA1D\GTH XF\CB3XSZ:\:1JS:5,7V@!F.[OZ_C7
M;+R_/&:X.6P@M/C59S0Q[9;O2Y'G;<3N(8 8]/PKO%X;W- $E%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M $=Q/';0/-,X2) 69CT ]:YK2O&6B:WJ*Z=;SLL[JSQ!@0)5'5E-7_%]O-=>
M#]7M[="\TEK(J*.Y(X%>9:%<0ZAK_@RSLK:7S;*R<71V$>21U4GW- &U:Z1<
M:5\7[);C5[S4#/ID[HUP1F(;NBX[5Z0I.X8Y&.2:\SO="^(4OCRWU.&ZT@HE
MK)%'.8VV(I;(5AU+>];/V/XD#KJ_A\_]N\E '<45Q'V+XD_]!;P__P" \E'V
M+XD_]!;P_P#^ \E ';T5Q'V+XD_]!;P__P" \E'V+XD_]!;P_P#^ \E ';%@
M!DFC(]:X@VGQ)!YU70"N.OD/52!/BC)>W-O)/H4<,.TQ7!B8B;(Y ';% 'H>
M:0$&N)^Q_$GJ=6\/CV^SR4?8_B3VU?P__P" \E ';T5Q'V+XD_\ 06\/_P#@
M/)1]B^)/_06\/_\ @/)0!VQ( R31N'K7$FS^)('_ "%O#_\ X#R4BV?Q(P"=
M6\/CV^SR<4 =Q17FFAW_ ,1]=MKB=;O1;80W,EOMEMY,MM.-P]C6I]C^).?^
M0MX?_P# >2@#MZ*XC[%\2?\ H+>'_P#P'DH^Q?$G_H+>'_\ P'DH [>C(-<1
M]B^)/_06\/\ _@/)1]C^)'?5_#__ (#R4 =MD#O1N&<9YK@KR+XD6EE/<MJ6
M@2>3&TFP6\F6P,X%5M&G^(^LZ-::D-0T.W^TQB00RVS[DSV- 'H]%<1]B^)/
M_07\/_\ @/)1]B^)/_06\/\ _@/)0!V]%<1]B^)/_06\/_\ @/)1]B^)/_06
M\/\ _@/)0!V^12;AG&>:XG[%\2?^@MX?_P# >2LS7KKXC:%HT^I/?:)<B''[
MN*V<L<D#C\Z /200<^U+7#1VOQ)DB1_[6T ;E!P;>3BG?8_B3_T%_#__ (#R
M4 =O17$?8OB3_P!!;P__ . \E'V+XD_]!;P__P" \E ';T9KB/L7Q)_Z"WA_
M_P !Y*/L?Q([:MX?_P# >2@#MZ;O7=MSS7FVKW_Q'T>XTV)[O1;@7URMONBM
MI/W61]X^U:9L_B0.FJ^'Q_V[OS0!W&0:*XC[%\2?^@MX?_\  >2C[%\2?^@M
MX?\ _ >2@#MZ*XC[%\2?^@MX?_\  >2C[%\2?^@MX?\ _ >2@#M\T@8$9!XK
MB39?$G'_ "%O#Y_[=Y*33-2\6V?C*UTC6Y+&XM;FUDF\RTA9=C+V)- ';@@Y
MQVI:;&VY<Y!]Z=0 4444 %%%% !1110 4444 (>G7%>>?$?Q+?>$-&GN=!TM
M&N'PTMQM^5!GG->A2#*$8SFN8\=:'>>(?!UYI5F1Y\H !/ - &1K'B+7+B\T
M#1=&EM[>]O[(7DUQ*FY0H&2 /7-;'@?7[W7]"\[4$1+R&5HI=GW20<9%9FJ^
M&-5BN-#UG2_+?4=.LQ9O"YPK(1ACFMCP7X=D\-Z&MK<S>=<R.TLK#IDG./PH
M Z/%&*** #%1Y8''!R>W:I*;TZ#DT ><^.?&VLZ+X@TG3[&R"VDUW'%/<R<@
MACC IGCWQ=J>E>);'3+"<VMKY#S74YMS+MQT  K9\<^&[WQ$^CFT"?Z)>)/)
MN/\ "#SBE\067B2349I=*CMI;:X@,++( &0GC=G^E &YH5Y]LT.VNA>1W0D7
M=YJ# ;\.QK25B6P1P1D5A^$/#J^&/#=KI0D,ACR[L3U8G)K=4<D\\T .Q1BB
MB@!#P"<5YEXA\0^+/#]S%?WEU8BWFOE@@TX)F1XR<;L^HKTR0X0G&3Z5Y5!X
M8\4GQ[-KFJV,.HQ*^VS#3 +;IZA>[4 2ZGXN\4O=:I?Z8UHFF:?*B>1(F7D'
M\?/:O2+"[6_L;>[52JS1API[9%>=ZEX'UM[S4;.QF3^S=5F6:61CAH<'+ #W
MKT.R@6SLX+4$[8D$:D]\<4 6\48HI,@]#0 57GEE%K*\"!Y0IV*3_%VS5FJ=
MTLZVT[VZJTY0A >C-VH \]@\1^)]*\6Z/I^LWEC</J!?SK2&/#VZ@9!SWJCH
MOC?4]1\23QWVI1V-LU^\-K#):GYE'^WTR:L^#/"GB/2]<N-1UVS@NK^Z9M]\
M90WDKV"KV%6KWPEXBUI[?3M6DMA86UY]I%Q  I< Y48]: /2!R.12XI%.5%+
MF@ Q2>M+FFDCG/2@"EK#:@NDW']E",WVW]SYGW<^]>=Z7XTURQN->M=7EM;T
M:=;^:D\";0LAXV'UKT/6(K^?2KB+2[A(+PK^ZD==P4^XKAK7P/JFJWFH7NJ&
M&Q^TVGV8P6_*NX.?-/O0!)X?\1>)8=>TRTUR2VGM]4M_-C\F/:8GZX/MBO0%
M+$X)^A]:X+0?"^LKKME>ZPP6'3(?)@V-DS'^\1VXKO@"&&1P>WI0!)BC%%%
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M&!U]KF38T)06V/E#,,%OKBJ=M\/K"'PM>Z%<74D\-Q,9%E88,1SE0/H:[>C
M]* .-TWP==Q2EM9UJXU2+R#;)$RA %(P2<=3BH-*\"W.F36L,FOW,VDV;EX;
M0H!CT!(YP*[FC% '#)X$AC5VBO7BN_M?VJ*95^8#.2OTIFM^ [K6YIX[C69&
ML+AE=[=H@2F.H1NHS7>8'I10!RTFFSWGB;3T\LKIVFQ HQZF0< ?E74T8HH
J**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %2 ;$# 2(  A$! Q$!_\0
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MJD6K07LMGJ:0^0]Q&/OIW&*>O@'0QX1/AIH";-_F9@<.S9SN)^M '&>)1O\
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MGF6TMP%1/)'3TS790HT<"+))O91@N>,T 34444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %!HI#V- !^-&:K7M_:Z=9RWEW,L,$8R[M
MT K'TWQGHFJPW<D%VJI:1^=*S9&$Z[OI0!T&2?:ER:P-)\8:-K32):7:AHT\
MSYN,I_>'M1I?C#1=7U$V-I=@W# M&IX\P#J5]: .@HI 0!BC(]: %HHHH **
M** "BBB@ HHHH *0@&EHH 3:/2C:/2EHH 3:,8H*@]12T4 (5!&#1@4M% !@
M4A -+10 @4#M05!&#TI:* $P*7%%% %=[&TDE\U[6%I!_&8P3^=3X%+10 FT
M>E&!G-+10 F *,"EHH **** "BBB@ HHHH **** "BBB@ HHHH **** $HHH
MS4@'>E%)Q2BFNX!1113 *:W;C\?2G4A&: .'^*\5S+X O!9J6E$D1.!D8##.
M?;%<5/J,]]I^NZ:MO:WJQ:<DIN+1"I*XY3W KVMHT=2K*"IX((R*KVNF65DC
MI;6T4:O]\*H^;ZT >+W#PZS<::=#MV<0^'98YO+4KM8K\JGWJUH,UE?:UX&M
MK.%Q=VUF_GE5P8\?>#'ZUZ]!I]G8[S;6T41D/S;%QFFV^GV5G-)+;6D<<DIR
M[*N"30!S_A;7M6U36M>T[58+2-]-F5$:V).]6&1G/?%=4#ST_P#K5P/@&YFO
M/&/C.>>TDM)#=0CR9""P 0X/'KUKT "@!:*** "BBB@ HHHH **** "BBB@
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MLH('F>8QJ%,KGYF]S4^<<'(]": '-TJ/!)&.@Z>E/' XZ4 CIG\Z .)\(_\
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MF%<"0GH>.37;#<"!D8S7C&K^&M4N_&E]>IX8+^3>++'< _).A(ZCU'6@#V<
M#    'RXK/@UO2[J\N[."^ADN+, W*!N8P?6J/B_7U\->');Y@V<K&"JD["W
M&[ ].M>(Z!=Z?&_CJ"SU![N2YMD<R*I#2]2Y'IUH ]XTKQ)HVM--'IFHPW)@
M.)0A^[^=)8>)-$U:]GL['48+BX@.)8T/(Q_/\*\HOA$MUI9T? !\-S>=]GQ]
M[;\N['\7UJUHPLUU3P&UGM6\-HXE5,9/][?CW]: .M\(Y_X3WQKG_GX@_P#1
M==Q7GW@+[:?&/C3^T?)%U]JASY&=NW8=O7OCK7H- !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 WN5-?,'BVS\6R?$]O"[ZG/)%=
M3B5 AX6(G/(]A7T_@9KA/#UI;:Q\1M;U\Q+(+=4M+>0C[A P^* .RL;<V5C:
MVQ;<8HU3=C@X&,U*[!<Y./KWJ7 JCJL#SZ=<0QN4=T(##M32NTAQ5W8R=9UC
M>!IMC(K7<YV$ _ZM>[5K:98QZ=9Q6T0^5%Y/J>]>:^ =(OY-<N-1GDD:($QJ
M[?Q &O5<<XK;$15.T8FU>*A[L1XI:04M8& 4444 %%%% !1110 4444 %%%%
M !1110 4UQE2/6G4=J 9PNL^%;JXOC/:O\K_ '@W-;MEHL,&CFPE#,CCGZUY
ME?\ B3Q%JGB77DL=8DLK2QF\J.( 9^[G/-=G\/\ 7+KQ!X/,]],YN8&:.2?'
M+8[BN:EAXPJ.:ZG'1P=&E5=2.[.BTW3#IWFA[@SO(<[F4+@>F!6F@(4 ]:Q]
M!%R;)[BXO'N(Y7+1%Q@JO85LCIS70CK0M%%%,9&N0QST/->=:GK_ (RM_$,T
M-MIX8+.$M81]V6'/+GW KT;H0,9(]*\QU33=<?6KRU@\3VL2SW@FCE:=0]NN
M1F+'6@#TQD61<2H&'4A@"*SX/#VDVEY=7=MIT$<]V-L[J@&\>]:&<#DYR.M2
M#H,T 8VE>%]%T.2>33-,@MGG/[PC)W?G2:9X7T/1KZ6\T_388+B8DO(N223]
M>GX5M&F;ANVD'<U '!> ;F6\\8>-)Y[22TD-U"IAD.6 "$ _CUKT&O/O 5_!
MJ?C'QI=6S,T1NH4!92IRJ$'@UZ#0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 5-3NQI^EW=Z>D$+2'\!FN?^'EG]G\+)<GK?3/=
MY]0_(I/B'>26OA9HH3F2ZF2#;W*L<']*Z+3K--/TZVLX^$@C" ?04 6JS=;N
MQ8Z1=W1Z11EJTJYOQ=+BQ@M!S]KG6!A[&JCN5'<L^&;(6>A6RX.7'F?]]<UL
M@5';H(8(XAT10@_ 5-WI2=WJ*6KU$6EI!2TA!1110 4444 %%%% !110>E "
M9HW#-'%<SXT\4+X7T8W:A7G9ML<9[^M!,I)(Z;(SBEK)T'5X=<T>WOHF!$BC
M</1NXK6H'&2:T"BBD/0T#.%U3X9:9JFKW>I"_O+6:[;,RPL K'&*Z/P_H-IX
M;T:/3+0NT4>?FDZM]:\G^(OQ"U:QURWL;1)+8VTF]\-S)[?2O2-$UJZ\0>$O
M[06W9'E3Y1GJ.YJ>;H;U,/*$%)]3HH?*$6(BA0'^$Y J85S'A"W:UL[A%.Z(
MRDJ2".?QKIATJC#K86BBB@"%Y1'$9'! 12S <G KP?6IM#U_Q*Y-S;0+-=K(
MN-)D%QD$8!?^M>ZWBR?8[G[/_KO*;9[-CC]:\7 N;C1K)H9]1;Q4)E22)P=H
M(?YC]-M 'MOW0.1G&/K3B2.,C/O69K4^HVVD22Z7:+=7P $<;MM&3WS[5Q6G
M>/K^VAUV+5X89Y]+A$GG6_W'<_\ +/ZB@#T<_,/7TH7J*\ZL?'FHZ?,J:[ C
M?:=/;4(/*&-JJ,E#[^]2Z'XTU6;5]*BU2",6>LPM+;&,8,/H&]<T 3^"YXKC
MQQXUD@D22/[3  T9!&0G/(KO*X+P1:06/C7QI;VT*0Q"YA8(@P,E"2?QKO:
M"BBB@ HI,CUI<T %%&110 4444 %%%% !1110 4444 %%%% !1110 4449%
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MUN0JE[@%N 4S_A7T7&'2$*S;R /F]:-R8RC/X63 ?G3J13GFEH*"BC-(3Z4
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M=:==SVT_GJNZ+'.>QSVKJ-0\5:/I]C)=7-THCC&>.K>P]:\^U1-4\;N-0U.
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M4;*H]*Q/%/PYTSQ'I'V2+%I(K;UD4?H:[?:*-HK*->I"2G%ZCY4U:QYAX/\
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MTA8Y  Z_I7%?\)SK/_0B:W_XY_C5.\^)EW83VD-WX,UF)[N3RH VW+O_ ':
M/00V:6N('CC61T\":Y_XY_C2_P#"<ZS_ -")K?\ XY_C0!VV:*XG_A.=9_Z$
M36__ !S_ !H_X3G6?^A$UO\ \<_QH [:D+$8^4GZ5Q7_  G.L_\ 0B:W_P".
M?XTG_"<:P3_R(FN?^._XT =MG)Q^5+7GS_$N[BU.+3&\&:R+V6,S)!\N2@."
M>OK5O_A.=9_Z$36__'/\: .VHKB?^$YUG_H1-;_\<_QH_P"$YUG_ *$36_\
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M /7K666>VBEEA,,CJ&*$Y*GTJ5>>]97AF"^M_#6G1:D^Z\2!!*??'-:P]NE
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MFW>SFL+ZV($MM,064'H>*Z&O/O!<K:QXLU77K>"5+"2-88GE0HSD=3@_E7H
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M/7!%244 1\$$@?7BD!!&X#.:EQ10 B_='7\:6BB@ IK?YQ3J,#.: (P 1P,
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M$>0) /E850L_"6OMXHLKN+38M+\BY+W$L%QF.://3R^F37J_Y>U(<YZ\8Y%
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$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %W \\# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ26VNDB#UHN*S.PSS29K'L?%.C:AA(;U _<,<5KA@RA@P*]B.13N ZBCM10
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MVW.?O$5EZVI*P*/O%N:0T=M!=0G38H\ @#I7.ZAJ:++*BX!/%$MTEOIZ-NP
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M+J+RY@PZ&L:YDQ.5'2M]\L"Q&0*YZ_3YRR]14C(UD\P,O3;4$2&;>2>E,92
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M<08C ]1FHGC2>(H3@BJ1)R%W')I[E>6MR<BECD5U66$XD4UL7$8VM;7"Y5N
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MMN>X^;FDF6;5N/+3)/6HI@7<8:HF=PVS.!5?[01-L;/6F4C5:-EV,6YJ9[D
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M'O0,KXD?+N0H%5VE" A2<FK,T1(P[Y] *J?9GW@D<>E)C1&B*1ND)R:';:,
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MAWQ1C#ZM9,7V_)7N-U_JFKP'XQ2^7J]@#D+LH&CEUF*'[H91WJW!=O<,$6/
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M.3Q5B [%R>M "R2$C!XJ/J*';>U/ *Q\4 ,ZD 5:A^7&:JQ@DY-3@EN0>E"
ML32@C&>E5]XS4;9)HVL2!B@99C.X_P!:T+51@51C 7 )J^K*$&VDQHLRQHK
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M)10!'Y*T>2M244 1^4/2CR@.U244 -" =*=110 4444 %%%% !1110 4444
M%%%% !C--*#-.'%% #/+![9H\L?W:?10 SRQZ4>6/2GT4 ,\L>E'ECTI]% #
M/+'I1Y8]*?10 SRE_NT>6/2GT4 ,\M?[M'EC^[3Z* &>6O\ =H\L?W:?10 S
MRU_NT>6/2GT4 ,\I?[M'ECTI]% #/+'I1Y8]*?10 SRQZ4>6O]VGT4 ,\L?W
M:/+7^[3Z* &^6O\ =HV#MQ3OQHH 3 I:3%+0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% @HHHS0 4444 %%%% PHHHH **** "B@44 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% @HHHH ****!A1110 4444""BBB@ HHHH&%%%% !1110 4444 %%%% @HHH
MH **** "BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% @HHHH&%%%% !1110 4444 %%%% !1110(**** "BBB@ HHHH&
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AX.2>.]* <;L#!I -
MS;>W>O,GU[4]/^(<_F7+/IHE\ORST6@1Z<.?PZ4 ?WJPO&.I/IV@2/:OBXF^
M6(CKGVK)^'NIW,_ANYGU6Y+R0R$.[]L4"N=EC@<XYHQDG(P:YP>-+'#3"TNC
M:AMIN,?)]:J>*O%LFD+9?8(9)1<.I\T?=93V'O0%SK<$\J>!3A7%^)=;F2UT
MJZB,EG&\P$@?KBM>#Q792WT5J\,T(EXBF<85S[4#N;IH(R!CK6?IVL6NJS7,
M-N6$ELVV0'UKG/&/B+;H]Q'ILKI<03(KL/K0%SLZ0YSU^@]:S+S7+/2[2U^T
MN6N)8QLA3EG.*BT_Q)9:E=/:^7+!<J,^5*,%OI0%S7P6.>W\J=7%V_C*YD\7
MS::;"9H%  0#Y@?4^U;5]XGM+.[%I'!-=W&,LD(SL^M 7-JFMUXZUG:7KMGJ
M]O++"QC,)(FCDX9/K6/?>,K26RNS:6]PZQ@K]H4?*#0%SJR,'D45S?@B\GOO
M#27%S-YK,QPY^M:=SK=G9ZK!ILVX3SC*'L: N:-%4;S5K:QO[>RF),UQ]T+V
M]S6;-XPL4FF2"VN+E(25DEB&5![T!<Z"@ XP.GJ:HVVL6-UI9U%)U6V4?,S?
MPUEQ>,].DEB#PSQ6\C;4G<81C0%SH<D]Z0#H0>!VKCYO&,R^*SIPLIWMR.BC
MD^_TK9U'Q)::==PVGDRW%W(N[R8N64>] 7-FBLO3=>M-42?RPT4L',D,GWA5
M2V\7Z??3K#9Q33,6VL5'"?6@+F_1110 4444#"BBB@ HHHH **** "BBB@ I
M.Y_2EK$\7W$UGX5O)[:0QRJN58=J!&T/6CH?I6;HDDLWA>VFD<M,T&XL>YQ6
M%X<UXVGAJ]U#596=(IR-WH,T".PHKG_^$QTX^7(L,YM7Q_I&/E%7-4\06&CI
M;27<A"7)VQ,O<T#N:E%8,?B[3S/Y5Q'-:DC,9E'$GTJ2Q\3V=[>_9'BEMI3]
MP2C&\>U 7-JD/Z=ZR=4\1V>E7D5F8Y+F[D&?)A&2H]33+7Q+9WD%Q)%#-YT'
MW[<CYZ87-CD?+U-'(//6N/\ #/BNYUJVO$FM90Z%@DH'RJ.P-0>&_%!BTN<W
M8FO)TF(81C)04A7.YH]JQG\4:9'%92%V*7;;$8=%/H:O:CJ-MI<227)X<[4
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M/P\UXH26^U,,CL,UW&A^&K/0VO3;\M=$ESZ9I-'\-VFDV%W8AO.BN79W#>]
MK&!9:=XAO/"$-O\ :]*6QD@P69#D#USZU5UZT>P\,Z%;R7*7/EW2 3)TQFMM
M?!\D=J]FNJR"P9LF+OCTK2U#P]9WVB1Z6!Y441#1,.JD=#0%C%\>1K,NCQ.
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MM'I2T4 %)BEHH 3:/2C&*6B@ HHHH **** "BBB@ HHHH **** "BBB@ I
M 12T4 (1DY/-&!Z4M% "8['M1M&,=J6B@!,=?>C:/K2T4 )@>E&!2T4 (0/3
MI1CO2T4 (55QAT5L=,CI2]:**! !CVI-H!R*6B@ ZTA&:6B@8F!1CH/2EHH
M0# I>V*** #'%)CMVI:* #\*,<444 )M&:7K110(****!A1110 4444 %%%%
M !1110 4444 %%%% !1BBB@!-HH*CO2T4 (0#1@8QVI:* $VBC'.:6B@ Q2!
M%7.U57/<#FEHH$)B@ 4M% "%03DT8S_*EHH&&.,=J0C)YI:* $VBC%+10 F/
MUHI:*!"8'I1M%+10,3:#2X!Z@444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
24444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140256991774648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 24, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Aditx Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,124,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,079,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001726711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140256989141144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 10,500,826<span></span>
</td>
<td class="nump">$ 4,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">147,642<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_ROUAssetShortTerm', window );">ROU asset - short term</a></td>
<td class="nump">384,685<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">11,033,153<span></span>
</td>
<td class="nump">4,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_FixedAssets', window );">Fixed Assets</a></td>
<td class="nump">798,919<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Intangible Assets</a></td>
<td class="nump">321,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">119,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_RightOfUseAssetLongTerm', window );">ROU asset - long term</a></td>
<td class="nump">871,136<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="nump">72,296<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">13,096,504<span></span>
</td>
<td class="nump">123,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">241,613<span></span>
</td>
<td class="nump">1,847,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued compensation to related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">962,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent', window );">Notes payable - related party</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable, net of discount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">155,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_FinancingOnFixedAssets', window );">Financing on fixed assets</a></td>
<td class="nump">587,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability - short term</a></td>
<td class="nump">391,221<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current assets</a></td>
<td class="nump">6,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">1,226,958<span></span>
</td>
<td class="nump">2,975,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability - long term</a></td>
<td class="nump">858,064<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">2,085,022<span></span>
</td>
<td class="nump">2,975,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 3,000,000 shares authorized, no shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 27,000,000 shares authorized, 13,074,495 and 3,915,900 shares issued and 12,973,692 and 3,821,088 shares outstanding, respectively</a></td>
<td class="nump">13,078<span></span>
</td>
<td class="nump">3,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, 100,803 and 94,813 shares, respectively</a></td>
<td class="num">(201,605)<span></span>
</td>
<td class="num">(189,625)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">32,079,187<span></span>
</td>
<td class="nump">9,063,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(20,879,178)<span></span>
</td>
<td class="num">(11,729,951)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS&#8217; EQUITY (DEFICIT)</a></td>
<td class="nump">11,011,482<span></span>
</td>
<td class="num">(2,852,177)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</a></td>
<td class="nump">$ 13,096,504<span></span>
</td>
<td class="nump">$ 123,532<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_FinancingOnFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing on fixed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_FinancingOnFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_FixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_FixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ROUAssetShortTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ROUAssetShortTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_RightOfUseAssetLongTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right of use asset &#8211; long term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_RightOfUseAssetLongTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140256991668328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">27,000,000<span></span>
</td>
<td class="nump">27,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">13,074,495<span></span>
</td>
<td class="nump">3,915,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">12,973,692<span></span>
</td>
<td class="nump">3,821,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock</a></td>
<td class="nump">100,803<span></span>
</td>
<td class="nump">94,813<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140256991746168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses, $3,188,840 and $4,221,733 in stock-based compensation</a></td>
<td class="nump">$ 7,852,256<span></span>
</td>
<td class="nump">$ 5,694,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, includes $0 and $10,000 in stock-based compensation</a></td>
<td class="nump">937,966<span></span>
</td>
<td class="nump">175,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Sales and marketing $0 and $0 in stock-based compensation</a></td>
<td class="nump">81,987<span></span>
</td>
<td class="nump">551<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Expenses</a></td>
<td class="nump">8,872,209<span></span>
</td>
<td class="nump">5,870,798<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS</a></td>
<td class="num">(8,872,209)<span></span>
</td>
<td class="num">(5,870,798)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Interest expense</a></td>
<td class="num">(10,081)<span></span>
</td>
<td class="num">(1,930)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">563<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on forgiveness of debt</a></td>
<td class="nump">32,500<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="num">(300,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Income (Expense)</a></td>
<td class="num">(277,018)<span></span>
</td>
<td class="nump">43,070<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (9,149,227)<span></span>
</td>
<td class="num">$ (5,827,728)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share - basic and diluted (in Dollars per share)</a></td>
<td class="num">$ (1.33)<span></span>
</td>
<td class="num">$ (1.52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of shares outstanding during the period - basic and diluted (in Shares)</a></td>
<td class="nump">6,902,696<span></span>
</td>
<td class="nump">3,830,971<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140256996224376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 3,188,840<span></span>
</td>
<td class="nump">$ 4,221,733<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales and marketing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140256991059544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders&#8217; Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th"><div>Preferred Shares</div></th>
<th class="th"><div>Treasury Shares Value</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 3,764<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,361,725<span></span>
</td>
<td class="num">$ (5,902,223)<span></span>
</td>
<td class="num">$ (1,536,734)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2018</a></td>
<td class="nump">3,763,925<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares for cash, net of issuance costs</a></td>
<td class="nump">$ 131<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">470,046<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">470,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares for cash, net of issuance costs (in Shares)</a></td>
<td class="nump">131,475<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of shares for services and licenses</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">81,979<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">82,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of shares for services and licenses (in Shares)</a></td>
<td class="nump">20,500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Stock option and warrant compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,616,422<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,616,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Warrants issued with notes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">533,311<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">533,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(189,625)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(189,625)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury stock (in Shares)</a></td>
<td class="num">(94,813)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,827,728)<span></span>
</td>
<td class="num">(5,827,728)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 3,916<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(189,625)<span></span>
</td>
<td class="nump">9,063,483<span></span>
</td>
<td class="num">(11,729,951)<span></span>
</td>
<td class="num">(2,852,177)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2019</a></td>
<td class="nump">3,821,087<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of shares for services and licenses</a></td>
<td class="nump">$ 876<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,476,558<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,477,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of shares for services and licenses (in Shares)</a></td>
<td class="nump">874,916<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_StockIssuedDuringPeriodValueIntangibleAssets', window );">Issuance of shares for intangible assets</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">320,850<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">321,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_StockIssuedDuringPeriodSharesForIntangibleAssets', window );">Issuance of shares for intangible assets (in Shares)</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable', window );">Issuance of shares and warrants for the settlement of accrued compensation and accounts payable</a></td>
<td class="nump">$ 147<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,221,878<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,222,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_IssuanceOfSharesForTheSettlementOfSharesAccruedCompensationAndAccountsPayable', window );">Issuance of shares and warrants for the settlement of accrued compensation and accounts payable (in Shares)</a></td>
<td class="nump">146,818<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts', window );">Issuance of shares and warrants for IPO, net of issuance costs</a></td>
<td class="nump">$ 1,227<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9,429,455<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9,430,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_IssuanceOfSharesAndWarrantsForIPONetOfSharesOfferingCosts', window );">Issuance of shares and warrants for IPO, net of issuance costs (in Shares)</a></td>
<td class="nump">1,226,668<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts', window );">Issuance of shares and warrants for follow-on offering, net of issuance costs (in Shares)</a></td>
<td class="nump">1,150<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,524,376<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,526,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_StockIssuedDuringPeriodSharesForCashNetOfOfferingCosts', window );">Issuance of shares and warrants for follow-on offering, net of issuance costs (in Shares)</a></td>
<td class="nump">1,150,000<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_IssuanceOfSharesForTheSettlementOfDebt', window );">Issuance of shares and warrant for the settlement of debt</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 124,937<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_IssuanceOfSharesForTheSettlementOfSharesDebtinShares', window );">Issuance of shares and warrant for the settlement of debt (in Shares)</a></td>
<td class="nump">62,500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_ExerciseConversionOfPreferredShares', window );">Exercise conversion of preferred shares</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="num">$ (1,250)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_ExerciseConversionOfSharesPreferredShares', window );">Exercise conversion of preferred shares (in Shares)</a></td>
<td class="nump">1,250,000<span></span>
</td>
<td class="num">(1,250,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Stock option and warrant compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">711,406<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">711,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,980)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,980)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury stock (in Shares)</a></td>
<td class="num">(5,990)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit', window );">Rounding adjustment from stock split</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Rounding adjustment from stock split (in Shares)</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_ExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">206,244<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">210,544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of warrants (in Shares)</a></td>
<td class="nump">4,297,703<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(9,149,227)<span></span>
</td>
<td class="num">(9,333,049)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 13,078<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (201,605)<span></span>
</td>
<td class="nump">$ 32,079,187<span></span>
</td>
<td class="num">$ (20,879,178)<span></span>
</td>
<td class="nump">$ 11,011,482<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="nump">12,973,692<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ExerciseConversionOfPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise conversion of preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ExerciseConversionOfPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ExerciseConversionOfSharesPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise conversion of preferred shares,shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ExerciseConversionOfSharesPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares and warrants for IPO, net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_IssuanceOfSharesAndWarrantsForIPONetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_IssuanceOfSharesAndWarrantsForIPONetOfSharesOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares and warrants for IPO, net of offering costs,shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_IssuanceOfSharesAndWarrantsForIPONetOfSharesOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares for the settlement of accrued compensation and accounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_IssuanceOfSharesForTheSettlementOfAccruedCompensationAndAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_IssuanceOfSharesForTheSettlementOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares for the settlement of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_IssuanceOfSharesForTheSettlementOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_IssuanceOfSharesForTheSettlementOfSharesAccruedCompensationAndAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares for the settlement of accrued compensation and accounts payable,share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_IssuanceOfSharesForTheSettlementOfSharesAccruedCompensationAndAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_IssuanceOfSharesForTheSettlementOfSharesDebtinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares for the settlement of debt Shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_IssuanceOfSharesForTheSettlementOfSharesDebtinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares and warrants for follow-on offering, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_StockIssuedDuringPeriodSharesAndWarrantsForFollowonOfferingNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_StockIssuedDuringPeriodSharesForCashNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares for cash, net of offering costs (in Shares).

..</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_StockIssuedDuringPeriodSharesForCashNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_StockIssuedDuringPeriodSharesForIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares for intangible assets (in Shares).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_StockIssuedDuringPeriodSharesForIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_StockIssuedDuringPeriodValueIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares for intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_StockIssuedDuringPeriodValueIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140256992839416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,149,227)<span></span>
</td>
<td class="num">$ (5,827,728)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,188,840<span></span>
</td>
<td class="nump">3,698,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationNonproduction', window );">Depreciation expense</a></td>
<td class="nump">17,773<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_ModificationOfOptions', window );">Modification of options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">533,311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositOtherAssets', window );">Deposits</a></td>
<td class="num">(72,296)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(147,642)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(1,483,180)<span></span>
</td>
<td class="nump">601,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_IncreaseDecreaseInAccruedCompensationToRelatedParties', window );">Accrued compensation to related parties</a></td>
<td class="nump">124,728<span></span>
</td>
<td class="nump">530,036<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used In Operating Activities</a></td>
<td class="num">(7,221,004)<span></span>
</td>
<td class="num">(464,352)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromProductiveAssets', window );">Fixed Assets</a></td>
<td class="num">(170,629)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used In Investing Activities</a></td>
<td class="num">(170,629)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from note payable - related party</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from note payable</a></td>
<td class="nump">375,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayments of note payable - related party</a></td>
<td class="num">(45,000)<span></span>
</td>
<td class="num">(42,502)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes payable</a></td>
<td class="num">(670,600)<span></span>
</td>
<td class="num">(15,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Common stock and warrants issued for cash, net of issuance costs</a></td>
<td class="nump">18,500,039<span></span>
</td>
<td class="nump">470,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs</a></td>
<td class="num">(423,139)<span></span>
</td>
<td class="num">(119,442)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants</a></td>
<td class="nump">210,544<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Financed Asset</a></td>
<td class="num">(58,475)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided By Financing Activities</a></td>
<td class="nump">17,888,369<span></span>
</td>
<td class="nump">352,733<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET INCREASE (DECREASE) IN CASH</a></td>
<td class="nump">10,496,736<span></span>
</td>
<td class="num">(111,619)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AT BEGINNING OF PERIOD</a></td>
<td class="nump">4,090<span></span>
</td>
<td class="nump">115,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AT END OF PERIOD</a></td>
<td class="nump">10,500,826<span></span>
</td>
<td class="nump">4,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest expense</a></td>
<td class="nump">5,842<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract', window );"><strong>NONCASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_LiabilitiesAssumedForCommonStock', window );">Liabilities assumed for common stock</a></td>
<td class="nump">11,980<span></span>
</td>
<td class="nump">189,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of Units for the settlement of notes payable</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_IssuanceOfUnitsForTheSettlementOfAccruedCompensationAndAccountsPayable', window );">Issuance of units for the settlement of accrued compensation and accounts payable</a></td>
<td class="nump">1,222,025<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_OriginalIssuanceDiscountOnNotesPayable', window );">Original issuance discount on notes payable</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Lease liability recognized from right of use asset</a></td>
<td class="nump">1,191,985<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_LiabilityRecognizedForFinancedAssets', window );">Liability recognized for financed assets</a></td>
<td class="nump">646,063<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_SharesIssuedForIntangibleAssets', window );">Shares issued for intangible assets</a></td>
<td class="nump">321,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_ConversionOfPreferredShares', window );">Conversion of preferred shares</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ConversionOfPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ConversionOfPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_IncreaseDecreaseInAccruedCompensationToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued compensation to related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_IncreaseDecreaseInAccruedCompensationToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_IssuanceOfUnitsForTheSettlementOfAccruedCompensationAndAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of units for the settlement of accrued compensation and accounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_IssuanceOfUnitsForTheSettlementOfAccruedCompensationAndAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_LiabilitiesAssumedForCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liabilities assumed for common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_LiabilitiesAssumedForCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_LiabilityRecognizedForFinancedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_LiabilityRecognizedForFinancedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ModificationOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ModificationOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_OriginalIssuanceDiscountOnNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Original issuance discount on notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_OriginalIssuanceDiscountOnNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_SharesIssuedForIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_SharesIssuedForIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationNonproduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationNonproduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash outflow or inflow from purchases, sales and disposals of property, plant and equipment and other productive assets, including intangibles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140256997168456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND NATURE OF BUSINESS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 &#x2013; ORGANIZATION AND NATURE OF BUSINESS</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Company
Background</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aditx
Therapeutics, Inc. (&#x201c;Aditxt&#x201d; or the &#x201c;Company&#x201d;) was incorporated in the State of Delaware on September
28, 2017 and our headquarters are located in Mountain View, CA. The Company is a Biotech Innovation company with a mission of
prolonging life and enhancing its quality by improving the health of the immune system.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing biotechnologies specifically focused on improving the health of the immune system through immune reprogramming
and monitoring. Our immune reprogramming technologies are currently at the pre-clinical stage and are designed to retrain the
immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies.
Our immune monitoring technologies are designed to provide a personalized comprehensive profile of the immune system and we plan
to utilize them in our upcoming reprogramming clinical trials to monitor subjects&#x2019; immune response before, during and after
drug administration.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Offerings</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 2, 2020, the Company completed its initial public offering (&#x201c;IPO&#x201d;). In connection therewith, the Company issued
1,226,668 Units (the &#x201c;Units&#x201d;), excluding the underwriters&#x2019; option to cover overallotments, at an offering price
of $9.00 per Unit, resulting in gross proceeds of approximately $11.0 million. The Units issued in the IPO consisted of one share
of common stock, one Series A warrant, and one Series B warrant. The Series A warrants originally had an exercise price of $9.00
and a term of 5 years. In addition, the Company issued a Unit Purchase Option at an exercise price of $11.25 per unit to the underwriters
to purchase up to 67,466 units, with each unit consisting of (i) one share of common stock and (ii) one Series A Warrant. On August
19, 2020 the Company modified the exercise price of the Series A Warrants from $9.00 per share to $4.50 per share. The term of
the Series A Warrants was not modified. The Series B warrants have an exercise price of $11.25 per share, a term of 5 years and
contain a cashless exercise option upon certain criteria being met. As of December 31, 2020, substantially all of the Series B
warrants issued in the IPO have been exercised pursuant to a cashless provision therein.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 10, 2020, the Company completed a follow-on public offering (&#x201c;September 2020 Offering&#x201d;). In connection therewith,
the Company issued 2,400,000 Units (the &#x201c;Follow-On Units&#x201d;), excluding the underwriters&#x2019; option to cover overallotments,
at an offering price of $4.00 per Follow-On Unit, resulting in gross proceeds to the Company of approximately $9.6 million. The
Follow-On Units issued in the September 2020 Offering consisted of one share of common stock (or Series A Preferred Stock for
investors who would own more than 4.99% of the Company if they invested in common stock), one Series A-1 warrant, and one Series
B-1 warrant. The Series A-1 warrants have an exercise price of $3.19 per share and a term of 5 years. The Series B-1 warrants
have exercise price of $5.00 per share, a term of 5 years and contain a cashless exercise option upon certain criteria being met.
In addition, the Company issued a warrant to the underwriters to purchase up to 60,000 shares of common stock at an exercise price
of $5.00 per share. Subsequent to quarter end, substantially all of the Series B-1 warrants issued in the September 2020 Offering
have been exercised pursuant to a cashless provision therein.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
and Uncertainties</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a limited operating history and has not generated revenue from intended operations. The Company&#x2019;s business and
operations are sensitive to general business and economic conditions in the U.S. and worldwide along with local, state, and federal
governmental policy decisions. A host of factors beyond the Company&#x2019;s control could cause fluctuations in these conditions.
Adverse conditions may include: changes in biotechnology regulatory environment, technological advances that render our technologies
obsolete, availability of resources for clinical trials, acceptance of technologies into the medical community, and competition
from larger, more well-funded companies. These adverse conditions could affect the Company&#x2019;s financial condition and the
results of its operations.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 30, 2020, the World Health Organization declared the COVID-19 novel coronavirus outbreak a &#x201c;Public Health Emergency
of International Concern&#x201d; and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate
the spread of the coronavirus include restrictions on travel, and quarantines in certain areas, and forced closures for certain
types of public places and businesses. The COVID-19 coronavirus and actions taken to mitigate it have had and are expected to
continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in
which the Company operates. While it is unknown how long these conditions will last and what the financial impact will be to the
Company, it is reasonably possible that future capital raise efforts and additional development of our technologies may be negatively
affected.</font></p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140257001891640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern Analysis<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_GoingConcernDisclosureAbstract', window );"><strong>Going Concern Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_GoingConcernDisclosureTextBlock', window );">GOING CONCERN ANALYSIS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 &#x2013; GOING CONCERN ANALYSIS</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Management
Plans</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company was incorporated on September 28, 2017 and has not generated revenues to date. During the year ended December 31, 2020,
the Company had a net loss of $9,149,227 and cash of $10,500,826. The Company will be conducting medical research and development,
and the time at which the Company will begin generating revenue is unknown. The Company believes, however, that the funds raised
by the IPO and the September 2020 Offering will be sufficient to fund the Company&#x2019;s operation for at least the next 12 months.
Because of these factors, the Company believes that this alleviates issues in connection with the Company&#x2019;s ability to continue
as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going
concern.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements included in this report do not include any adjustments to reflect the possible future effects on the recoverability
and classification of assets or the amounts and classification of liabilities that may result from the matters discussed herein.
While we believe in the viability of our strategy to generate sufficient revenue, control costs and raise additional funds when
necessary, there can be no assurances to that effect. The Company&#x2019;s ability to continue as a going concern is dependent
upon the ability to complete clinical studies and implement the business plan, generate sufficient revenues and to control operating
expenses.</font></p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_GoingConcernDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_GoingConcernDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_GoingConcernDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_GoingConcernDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140256995237256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 &#x2013; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis
of Presentation</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#x2019;s financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America (&#x201c;U.S. GAAP&#x201d;) and the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;).</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use
of Estimates</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those
estimates. Significant estimates underlying the financial statements include the fair value of stock options and warrants.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value Measurements and Fair Value of Financial Instruments</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;)
Topic 820, Fair Value Measurements. ASC Topic 820 clarifies the definition of fair value, prescribes methods for measuring fair
value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 - Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar
assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived
from or corroborated by observable market data.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 - Inputs are unobservable inputs which reflect the reporting entity&#x2019;s own assumptions on what assumptions the market participants
would use in pricing the asset or liability based on the best available information.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not identify any assets or liabilities that are required to be presented on the balance sheets at fair value in accordance
with ASC Topic 820.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the short-term nature of all financial assets and liabilities, their carrying value approximates their fair value as of the
balance sheet dates.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentrations
of Credit Risk</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation.
At times, the Company may have deposits in excess of federally insured limits.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
and Cash Equivalents</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents include short-term, liquid investments.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fixed
Assets</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Fixed assets are
stated at cost less accumulated depreciation. Cost includes expenditures for furniture, office equipment, laboratory equipment, and
other assets. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of,
the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The
costs of fixed assets are depreciated using the straight-line method over the estimated useful lives or lease life of the related
assets. Depreciation expense was $17,773 for the year ended December 31, 2020 and zero for the year ended for December 31, 2019.
Accumulated depreciation was $17,773 as of December 31, 2020 and zero as of December 31, 2019. None of the Company&#x2019;s fixed
assets serve as collateral against any loans as of December 31, 2020 and 2019, other than those subject to the financed asset liability.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intangible
Assets</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets are stated at cost less accumulated amortization. For intangible assets that have definite lives, the assets are amortized
using the straight-line method over the estimated useful lives of the related assets. For intangible assets with indefinite lives,
the assets are tested periodically for impairment. Amortization expense was zero for the year ended December 31, 2020 and 2019.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Offering
Costs</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for offering costs in accordance with ASC 340, Other Assets and Deferred Costs. Prior to the completion of an
offering, offering costs were capitalized as deferred offering costs on the balance sheet. The deferred offering costs are netted
against the proceeds of the offering in stockholders&#x2019; equity (deficit) or the related debt, as applicable. Costs related
to unsuccessful offerings are expensed.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Topic 842, adopted in 2020 with no impact related to adoption, operating lease expense is generally recognized evenly over the term
of the lease. The Company has operating leases consisting of office and laboratory space with remaining lease terms of 46 months.
Rent and Lease costs were $154,263 and $30,362 for the year ended December 31, 2020 and 2019. There was no sublease rental income
for the year ended December 31, 2020 and 2019.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
with an initial term of twelve months or less are not recorded on the balance sheet. For lease agreements entered into or reassessed
after the adoption of Topic 842, we combine the lease and non-lease components in determining the lease liabilities and right
of use (&#x201c;ROU&#x201d;) assets.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
lease agreements generally do not provide an implicit borrowing rate, therefore an internal incremental borrowing rate is determined
based on information available at lease commencement date for purposes of determining the present value of lease payments. We
used the incremental borrowing rate on December 31, 2020 and 2019 for all leases that commenced prior to that date. In determining
this rate, which is used to determine the present value of future lease payments, we estimate the rate of interest we would pay
on a collateralized basis, with similar payment terms as the lease and in a similar economic environment.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lease
Costs</i></font></p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#xa0;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#xa0;31,<br/> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Components of total lease costs:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left; padding-bottom: 1.5pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">154,263</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="width: 1%; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total lease costs</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">154,263</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lease
Positions as of December 31, 2020</i></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU
lease assets and lease liabilities for our operating leases were recorded in the balance sheet as follows:</font></p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#xa0;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#xa0;31,<br/> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Assets</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; width: 76%; text-align: left">Right of use asset &#x2013; short term</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">384,685</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Right of use asset &#x2013; long term</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">871,136</font></td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total assets</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,255,821</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Liabilities</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Operating lease liabilities &#x2013; short term</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">391,221</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Operating lease liabilities &#x2013; long term</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">858,064</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total lease liability</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,249,285</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lease
Terms and Discount Rate</i></font></p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: left">Weighted average remaining lease term (in years) &#x2013; operating lease</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">2.67</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Weighted average discount rate &#x2013; operating lease</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.00</td><td style="text-align: left">%</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
future annual minimum lease payments as of December 31, 2020 are as follows:</font></p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: left">2021</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">406,640</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">2022</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">411,753</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">2023</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">363,416</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left">2024</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">215,551</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total future minimum lease payments</font></td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,397,360</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: Lease imputed interest</font></td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">148,075</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 2pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</font></td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,249,285</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based
Compensation</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based compensation costs under the provisions of ASC 718, Compensation&#x2014;Stock Compensation, which
requires the measurement and recognition of compensation expense related to the fair value of stock-based compensation awards
that are ultimately expected to vest. Stock based compensation expense recognized includes the compensation cost for all stock-based
payments granted to employees, officers, and directors based on the grant date fair value estimated in accordance with the provisions
of ASC 718. ASC. 718 is also applied to awards modified, repurchased, or cancelled during the periods reported. Stock-based compensation
is recognized as expense over the employee&#x2019;s requisite vesting period and over the nonemployee&#x2019;s period of providing
goods or services.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patents</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company incurs fees from patent licenses, which are expensed as incurred. During the year ended December 31, 2020 and 2019, the Company had a licensing fee for
the patents of $258,635 and $18,396, respectively.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incur research and development costs during the process of researching and developing our technologies and future offerings. Our
research and development costs mainly consist of licensing costs. We expense these costs as incurred unless such costs qualify
for capitalization under applicable guidance.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basic
and Diluted Net Loss per Common Share</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Basic loss per common share is computed by dividing the net loss by the
weighted average number of shares of common stock outstanding for each period. Diluted loss per share is computed by dividing the net
loss by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common
stock equivalents. The weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion
would be anti-dilutive. As of December 31, 2020, 2,143,000 stock options and 5,799,146 warrants were excluded from dilutive earnings per
share as their effects were anti-dilutive. As of December 31, 2019, 1,102,500 stock options and 1,382,478 warrants were excluded from
dilutive earnings per share as their effects were anti-dilutive.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recent
Accounting Pronouncements</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FASB issues ASUs to amend the authoritative literature in ASC. There have been several ASUs to date, including those above, that
amend the original text of ASC. Management believes that those issued to date either (i) provide supplemental guidance, (ii) are
technical corrections, (iii) are not applicable to us or (iv) are not expected to have a significant impact our financial statements.</font></p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140257001874520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 &#x2013; RELATED PARTY TRANSACTIONS</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#x2019;s Chief Executive Officer (&#x201c;CEO&#x201d;) has provided certain periods of service without payment. As of December
31, 2020 and 2019, the CEO is owed $0 and $309,500, respectively, related to compensation. During the year ended December 31,
2020, the Company issued 38,055 Units consisting of one share of common stock and one Series A warrant and one Series B warrant
to settle $342,500 in accrued compensation.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#x2019;s Chief Innovation Officer (&#x201c;CIO&#x201d;) has provided certain periods of service without payment. As of December
31, 2020 and 2019, the CIO is owed $0 and $377,000, respectively, related to compensation. During the year ended December 31,
2020, the Company issued 47,222 Units consisting of one share of common stock, one Series A warrant, and one Series B warrant
to settle $425,000 in accrued compensation.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
July 10, 2020, the Board of Directors appointed the Company&#x2019;s Chief Operating Officer (&#x201c;COO&#x201d;). Prior to the
appointment, the COO was an independent operations consultant and had provided certain periods of service without payment. As
of December 31, 2020 and 2019, the COO was owed $0 and $275,000, respectively, related to compensation. During the year ended
December 31, 2020, the Company issued 35,555 Units consisting of one share of common stock, one Series A warrant, and one Series
B warrant to settle $320,000 in accrued compensation.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 21, 2019, the Company issued a promissory note to a related party. The note had a principal of $10,000, a maturity date
of September 21, 2019, and an interest rate of 4% per year. During the year ended December 31, 2020, this note was paid in full.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2020, the Company assumed $11,980 of liabilities from a related party in exchange for the return of
5,990 shares of the Company&#x2019;s common stock.&#xa0;</font></p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140256997154616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 &#x2013; STOCKHOLDERS&#x2019; EQUITY (DEFICIT)</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue 27,000,000 shares of common stock, par value $0.001 per share.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">During the year ended December 31, 2020, the Company issued 874,916
shares of common stock and recognized expense of $2,477,434 in stock compensation for consulting services. The Company issued 150,000
shares of common stock for intangible assets valued at $320,850. The Company also issued 4,297,703 shares of common stock for the
exercise of warrants and received $210,544 for the exercise of the warrants. The Company issued 1,250,000 shares of common stock
for the exercise of 1,250,000 shares of Series A Preferred Stock. The Company issued 146,818 shares of common stock for the settlement
of accounts payable and issued 62,500 shares of common stock for the settlement of debt. The Company issued 1,226,668 shares of
common stock related to the IPO and issued 1,150,000 shares of common stock related to the September 2020 Offering. The stock compensation
for the period was valued based on prior private placements or based on management&#x2019;s estimates of value immediately prior
to the IPO and the value of the shares based on public information post IPO.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2019, the Company issued 41,000 shares of common stock for services and recognized expense of $82,000
in stock compensation and license fees. These shares were valued based on the price which common shares were being
sold in the private placement.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reverse
Stock Split</i></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 29, 2020, the Company effectuated a 1-for-2 reverse stock split of its issued and outstanding shares of common stock by filing
a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of
Delaware. Accordingly, all share and per share amounts for all periods presented in the accompanying financial statements and
notes thereto have been adjusted retroactively, where applicable, to reflect this reverse stock split.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred
Stock</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue 3,000,000 shares of preferred stock, par value $0.001 per share.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based
Compensation</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2017, our Board of Directors adopted the Aditx Therapeutics, Inc. 2017 Equity Incentive Plan (the &#x201c;2017 Plan&#x201d;).&#xa0;The
2017 Plan provides for the grant of equity awards to employees, and consultants.&#xa0;Up to 2,500,000 shares of our common stock
may be issued pursuant to awards granted under the 2017 Plan. The 2017 Plan is administered by our Board of Directors, and expires
ten years after adoption, unless terminated earlier by the Board.&#xa0;</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2020, the Company granted 880,500 stock options with an exercise price of $1.94, $1.92 or $11.00 per
share, some of which vested immediately, and some of which vest between one and three years. The total grant date fair value was
determined to be $1,668,997.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2019, the Company granted 700,000 stock options with exercise prices of $4.00 per share vesting on
issuance. The total grant date fair value was determined to be $2,495,556. For all periods presented, the fair value of each stock
option granted was estimated using the Black-Scholes assumption ranges and or factors as follows:</font></p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Exercise price</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.92-11.00</font></td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 85%; text-align: left">Expected dividend yield</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 12%; text-align: right">0</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Risk free interest rate</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.28%-2.65</font></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Expected life in years</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.70-10.00</font></td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Expected volatility</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">141-151</font></td><td style="text-align: left">%</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
risk-free interest rate assumption for options granted is based upon observed interest rates on the United States government securities
appropriate for the expected term of stock options.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expected term of stock options is calculated using either the simplified method for employee options which takes into consideration
the contractual life and vesting terms of the options, unless the options are expected to vest in which case the contractual term
of the options.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company determined the expected volatility assumption for options granted using the historical volatility of comparable public
companies&#x2019; common stock. The Company will continue to monitor peer companies and other relevant factors used to measure
expected volatility for future stock option grants, until such time that the Company&#x2019;s common stock has enough market history
to use historical volatility.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
dividend yield assumption for options granted is based on the Company&#x2019;s history and expectation of dividend payouts. The
Company has never declared or paid any cash dividends on its common stock, and the Company does not anticipate paying any cash
dividends in the foreseeable future.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
estimated the fair value of common stock by looking at a market approach which takes into consideration past sales of stock to
third parties and Company developments to date.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes stock option forfeitures as they occur as there is insufficient historical data to accurately determine future
forfeitures rates.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is an analysis of the stock option grant activity under the Plan:</font></p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Stock Options</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/>
Average <br/>
Exercise<br/>
    Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/>
Average
    <br/>
Remaining<br/> Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left">Outstanding December 31, 2019</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">1,102,500</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4.00</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">7.77</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Granted</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,045,500</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2.32</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.91</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Expired or forfeited</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.92</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Outstanding December 31, 2020</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">2,143,000</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3.18</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">7.81</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Nonvested Options</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Nonvested at December 31, 2019</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Granted</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">1,045,500</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">2.32</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Vested</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(67,500</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2.93</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Expired or forfeited</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.92</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Nonvested at December 31, 2020 </td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">973,000</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2.28</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized compensation expense related to options issued and vesting of $406,880 during the year ended December 31, 2020,
which is included in general and administrative expenses in the accompanying statements of operations. The remaining value to
be expensed is $1,781,485 with a weighted average vesting term of 2.40 years as of December 31, 2020. The Company recognized compensation
expense related to options issued and vesting of $2,513,826 during the year ended December 31, 2019, which is included in general
and administrative expenses in the accompanying statements of operations.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 6, 2020, the Board of Directors approved the issuance of an aggregate of 40,000 stock options as compensation for the
non-employee members of the Board of Directors under the Company&#x2019;s 2017 Equity Incentive Plan. The options are subject to
certain vesting provisions.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of warrant issuances are as follows:</font></p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; border-bottom: Black 1.5pt solid"><b><i>Warrants</i></b></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Remaining<br/> Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left">Outstanding December 31, 2019</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">1,382,478</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">4.44</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">2.84</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Granted</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8,906,381</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.24</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.00</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Expired or forfeited</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(190,810</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.12</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,298,903</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7.20</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Outstanding December 31, 2020</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">5,799,146</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5.05</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">4.00</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Nonvested Warrants</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Nonvested at December 31, 2019</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">200,000</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">4.00</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Granted</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8,906,381</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.24</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Vested</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(4,296,668</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.14</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Expired or forfeited</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,489,713</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7.24</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Nonvested at December 31, 2020</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">320,000</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3.69</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants granted for compensation are valued using similar inputs as noted in the stock options section above, with the exception
of the expected life which is the contractual life.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized compensation expense related to warrants issued and vesting of $304,526 and $1,102,596 during the year ended
December 31, 2020 and 2019, which is included in general and administrative in the accompanying Statements of Operations. The
remaining value to be expensed is $294,948 with a weighted average vesting term of 0.90 years as of December 31, 2020.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2020, 4,297,703 warrants were exercised for 4,298,903 shares of common stock. The Company
recognized proceeds of $210,544 related to the exercises.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2020, the Company issued 60,000 warrants to the underwriters related to the September 2020 Offering.
These warrants have an exercise price of $5.00, a term of five years, and become exercisable beginning on March 1, 2021. The value
of these warrants were both an increase and decrease to additional paid in capital as a cost of the offering for net a zero impact
on the financial statements.</font></p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140257001891640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_AgreementsDisclosureAbstract', window );"><strong>Agreements Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_AgreementsDisclosureTextBlock', window );">AGREEMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6 &#x2013; AGREEMENTS</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 1, 2020, the Company entered into an amendment to patent and technology licensing agreement with Loma Linda University (&#x201c;LLU&#x201d;),
dated March 15, 2018. Pursuant to the amendment, the Company paid LLU $455,000 within four days of the signing of such amendment.
The amendment also updated the milestone payment dates to be $175,000 on March 31, 2022; $100,000 on March 31, 2024; $500,000
on March 31, 2026; and $500,000 on March 31, 2027.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2020, the Company entered into a 24-month financing agreement for lab equipment. The aggregate cost of this financing
agreement will be $467,691. The financing agreement has an interest rate of 8% per year.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2020, the Company entered into an additional 24-month financing agreement for lab equipment. The aggregate cost of this
financing agreement will be $215,192. The financing agreement has an interest rate of 8% per year.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Salveo
Consulting Agreement</i></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 18, 2020, we entered into a Consulting Agreement (the &#x201c;Salveo Consulting Agreement&#x201d;) with Salveo Diagnostics,
Inc., a Delaware corporation (&#x201c;Salveo&#x201d;). Pursuant to the Salveo Consulting Agreement, Salveo agreed to establish,
setup and commence commercial operations of a licensed, College of American Pathologists accredited, and Clinical Laboratory Improvement
Amendments (CLIA) certified, independent clinical and diagnostic laboratory for us and our AditxtScore&#x2122; immune monitoring
technology (the &#x201c;Salveo Services&#x201d;).</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for the Services, and upon the successful completion of certain milestones (the &#x201c;Milestones&#x201d;) described
below, we issued Salveo 650,000 shares of our common stock (the &#x201c;Salveo Shares&#x201d;) in the aggregate. The Salveo Shares
were issued to Salveo upon the completion of the following Milestones: (i) 150,000 shares upon the sale and transfer to the Company
of certain code and interpretive commenting algorithms (the &#x201c;Algorithms&#x201d;) along with related testing protocols and
all technology, codes and spreadsheets, know-how, any necessary information or tools to implement, use, and/or continue to improve
or further refine the Algorithms, and other associated intellectual property; (ii) 250,000 shares upon securing temporary laboratory
space and other related tasks in connection with the launch of the AditxtScore&#x2122; platform; and (iii) 250,000 shares upon
satisfaction of tasks related to the establishment of a long-term AditxtScore&#x2122; center in Richmond, VA. We also pay Salveo
at cost for Salveo&#x2019;s reasonable and documented purchases, general operating costs and expenses incurred in connection with
the Salveo Services.</font></p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_AgreementsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_AgreementsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_AgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreements disclosure text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_AgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140257001836616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">NOTES PAYABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7 &#x2013; NOTES PAYABLE</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 12, 2018, the Company issued an unsecured promissory note for $35,000 that accrued interest of 4% annually. The note was
due on the earlier of November 12, 2018 or in the event of default, as defined in the agreement. During the year ended December
31, 2020, this note was paid in full.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 10, 2018, the Company entered into a bridge loan with an investor for a principal amount of $15,600. The note was due on
the earlier of October 8, 2018 or in the event of default, as defined in the agreement. During the year ended December 31, 2020,
this note was paid in full.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 18, 2018, the Company entered into a bridge loan with an investor for a principal amount of $130,000. The note was due on
the earlier of October 16, 2018 or in the event of default, as defined in the agreement. During the year ended December 31, 2020,
this note was paid in full.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 1, 2019, the Company entered into a bridge loan with an investor for a principal amount of $50,000. This loan did not
accrue any interest. The note was due on the earlier of April 28, 2020 or in the event of default, as defined in the agreement.
The note was convertible into the same class of securities as those sold in the public offering with a conversion price of $2.00
per share. During the year ended December 31, 2020, the note was converted into securities of the Company in full.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 10, 2020, the Company entered into a bridge loan with an investor for a principal amount of $75,000. This Note carried
an original issue discount of $40,000. This loan did not accrue any interest. The note was due on the earlier of July 8, 2020
or in the event of default, as defined in the agreement, as amended. The note was convertible into the same class of securities
as those sold in the public offering with a conversion price of $2.00 per share. During the year ended December 31, 2020, the
note was converted into securities of the Company in full.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the first quarter of 2020, the Company entered into six bridge loans with investors for a total principal amount of $600,000.
These notes carried an aggregate original issue discount of $300,000. The notes were due on the earlier of April 19, 2020 or ten
days after the close of the Company&#x2019;s IPO. During the year ended December 31, 2020, these notes were paid in full.</font></p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140256996485464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8 &#x2013; INCOME TAXES</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December&#xa0;31, 2020 and 2019, the Company did not record a current or deferred income tax expense or benefit
due to current and historical losses incurred by the Company. The Company&#x2019;s losses before income taxes consist solely of
losses from domestic operations.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 27, 2020, the United States enacted the Coronavirus Aid, Relief, and Economic Security Act (&#x201c;CARES Act&#x201d;). The
Cares Act includes provisions relating to refundable payroll tax credits, deferment of the employer portion of certain payroll
taxes, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction
limitations and technical corrections to tax depreciation methods for qualified improvement property. The CARES Act also established
a Paycheck Protection Program whereby certain small businesses are eligible for a loan to fund payroll expenses, rent, and related
costs.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considered the provisions under the CARES Act and elected not to take advantage of the provisions of CARES Act as the
effect of such provisions was not expected to have a material impact on the Company&#x2019;s results of operations, cash flows
and financial statements.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to income taxes as reflected
in the financial statements is as follows:</font></p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Income taxes at U.S. statutory rate</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">State income taxes</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.2</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7.0</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Tax Credits</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1.3</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Permanent Differences/Others</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">30.3</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(20.4</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(60.8</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7.6</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total provision for income taxes</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">0</td><td style="padding-bottom: 2pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">0</td><td style="padding-bottom: 2pt; text-align: left">%</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income
tax purposes. The significant components of the Company&#x2019;s deferred tax assets and liabilities as of December&#xa0;31, 2020
and 2019 are comprised of the following:</font></p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td colspan="6" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31,</font></td><td style="padding-bottom: 1.5pt; font-size: 8pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 8pt; font-weight: bold; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td colspan="2" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</font></td><td style="padding-bottom: 1.5pt; font-size: 8pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td colspan="2" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</font></td><td style="padding-bottom: 1.5pt; font-size: 8pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td colspan="2" style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td colspan="2" style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 13.7pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    operating loss carryforwards</font></td><td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td><td style="width: 9%; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,651,932</font></td><td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td><td style="width: 9%; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,044,662</font></td><td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 13.7pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    credits carryforwards</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">116,949</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 13.7pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    compensation</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,350,795</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">974,644</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 13.7pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
    liability</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">367,029</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 13.7pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,920</font></td><td style="padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</font></td><td style="padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 27.35pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    deferred tax assets</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,488,625</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,019,306</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation
    allowance</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,109,685</font></td><td style="padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,019,306</font></td><td style="padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 27.35pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    deferred tax assets</font></td><td style="padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="border-bottom: Black 4pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">378,940</font></td><td style="padding-bottom: 4pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="border-bottom: Black 4pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x2014;</font></td><td style="padding-bottom: 4pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax liabilities</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 13.7pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right
    of use assets</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(368,950</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 13.7pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed
    Assets</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9,990</font></td><td style="padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 27.35pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    deferred tax liabilities</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(378,940</font></td><td style="padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x2014;</font></td><td style="padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 27.35pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    deferred taxes</font></td><td style="padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td><td style="border-bottom: Black 4pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x2014;</font></td><td style="padding-bottom: 4pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td><td style="border-bottom: Black 4pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x2014;</font></td><td style="padding-bottom: 4pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has evaluated the positive and negative
evidence bearing upon its ability to realize its deferred tax assets, which are comprised primarily of net operating loss carryforwards
and tax credits. Management has considered the Company&#x2019;s history of cumulative net losses in the United States, estimated future
taxable income and prudent and feasible tax planning strategies and has concluded that it is more likely than not that the Company will
not realize the benefits of its U.S. federal and state deferred tax assets. Accordingly, a full valuation allowance has been established
against these net deferred tax assets as of December&#xa0;31, 2020 and 2019, respectively. The Company reevaluates the positive and negative
evidence at each reporting period. The Company&#x2019;s valuation allowance increased during 2020 by approximately $4.1&#xa0;million primarily
due to the generation of net operating loss and tax credit carryforwards and stock based compensation.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December&#xa0;31, 2020 and 2019, the Company had U.S. federal net operating loss carryforwards of $12.6 million and $3.8&#xa0;million,
respectively, which may be available to offset future income tax liabilities. The 2017 Tax Cuts and Jobs Act (&#x201c; TCJA&#x201d;)
will generally allow losses incurred after 2017 to be carried over indefinitely, but will generally limit the net operating loss
deduction to the lesser of the net operating loss carryover or 80% of a corporation&#x2019;s taxable income (subject to Section&#xa0;382
of the Internal Revenue Code of 1986, as amended). Also, there will be no carryback for losses incurred after 2017. Losses incurred
prior to 2018 will generally be deductible to the extent of the lesser of a corporation&#x2019;s net operating loss carryover or
100% of a corporation&#x2019;s taxable income and be available for twenty years from the period the loss was generated. The Company
has federal net operating losses generated following 2017 of $12.5 million, which do not expire. The federal net operating losses
generated prior to 2018 of $0.1 million will expire at various dates through 2037. The CARES Act temporarily allows the Company
to carryback net operating losses arising in 2018, 2019 and 2020 to the five prior tax years. In addition, net operating losses
generated in these years could fully offset prior year taxable income without the 80% of the taxable income limitation under the
TCJA which was enacted on December 22, 2017. The Company has been generating losses since its inception, as such the net operating
loss carryback provision under the CARES Act is not applicable to the Company.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December&#xa0;31, 2020 and 2019, the Company also had U.S. state net operating loss carryforwards of $15.2&#xa0;million and
$3.8 million, respectively, which may be available to offset future income tax liabilities and expire at various dates through
2040.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December&#xa0;31, 2020, the Company had federal tax credit carryforwards of approximately $0.1 million, available to reduce
future tax liabilities which expire at various dates through 2040. As of December&#xa0;31, 2020, the Company had state research
and development tax credit carryforwards of approximately $0.1 million available to reduce future tax liabilities which expire
at various dates through 2035. The Company did not have any federal and state tax credit carryforward as of December 31, 2019.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utilization
of the U.S. federal and state net operating loss and research and development credit carryforwards may be subject to a substantial
annual limitation under Section&#xa0;382 and Section&#xa0;383 of the Internal Revenue Code of 1986, as amended, and corresponding
provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership
changes may limit the amount of net operating loss and research and development credit carryforwards that can be utilized annually
to offset future taxable income and tax liabilities, respectively. The Company has not completed a study to assess whether a change
of ownership has occurred, or whether there have been multiple ownership changes since its formation. Any limitation may result
in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before
utilization.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not, as of yet, conducted a study of research and development tax credit carryforwards. Such a study, once undertaken
by the Company, may result in an adjustment to the research and development tax credit carryforwards; however, a full valuation
allowance has been provided against the Company&#x2019;s research and development tax credits and, if an adjustment is required,
this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the balance sheet
or statement of operations if an adjustment is required.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company files tax returns in the United States, California, Virginia, and New York. The Company is subject to U.S. federal and
state tax examinations by tax authorities for years 2017 through present. As of December&#xa0;31, 2020 and 2019, the Company has
recorded no liability for unrecognized tax benefits, interest, or penalties related to federal and state income tax matters and
there currently no pending tax examinations. The Company will recognize interest and penalties related to uncertain tax positions
in income tax expense</font></p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140256997201464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 &#x2013; SUBSEQUENT EVENTS</b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated subsequent events through the filing of this Annual Report on Form 10-K and has determined that there have
been no events that have occurred that would require adjustments to the Company&#x2019;s disclosures in the financial statements,
except for the following:</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 25, 2021, the Company entered into a Securities Purchase Agreement for the sale of $6,000,000 in Convertible Notes. The
Convertible Notes have a term of 24 months, convert at $4.00 per share, and have an original issuance discount of $1,000,000.
The Company also issued 800,000 warrants to purchase shares of the Company&#x2019;s common stock. These warrants have a term of
three years, are immediately exercisable, and have an exercise price of $4.00.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During February 2021, the Company entered into
a 24 month financing agreement for lab equipment. The aggregate cost of this financing agreement will be $892,094.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Through the date of this filing, there were 1,142,306
warrants exercised for shares of the Company&#x2019;s common stock, resulting in proceeds of $3,643,956.&#xa0;</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140256989227048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis
of Presentation</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#x2019;s financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America (&#x201c;U.S. GAAP&#x201d;) and the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;).</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use
of Estimates</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those
estimates. Significant estimates underlying the financial statements include the fair value of stock options and warrants.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements and Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fair
Value Measurements and Fair Value of Financial Instruments</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;)
Topic 820, Fair Value Measurements. ASC Topic 820 clarifies the definition of fair value, prescribes methods for measuring fair
value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 - Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar
assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived
from or corroborated by observable market data.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 - Inputs are unobservable inputs which reflect the reporting entity&#x2019;s own assumptions on what assumptions the market participants
would use in pricing the asset or liability based on the best available information.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not identify any assets or liabilities that are required to be presented on the balance sheets at fair value in accordance
with ASC Topic 820.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the short-term nature of all financial assets and liabilities, their carrying value approximates their fair value as of the
balance sheet dates.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentrations
of Credit Risk</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation.
At times, the Company may have deposits in excess of federally insured limits.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
and Cash Equivalents</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents include short-term, liquid investments.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_FixedAssetPolicyTextBlock', window );">Fixed Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fixed
Assets</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Fixed assets are
stated at cost less accumulated depreciation. Cost includes expenditures for furniture, office equipment, laboratory equipment, and
other assets. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of,
the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The
costs of fixed assets are depreciated using the straight-line method over the estimated useful lives or lease life of the related
assets. Depreciation expense was $17,773 for the year ended December 31, 2020 and zero for the year ended for December 31, 2019.
Accumulated depreciation was $17,773 as of December 31, 2020 and zero as of December 31, 2019. None of the Company&#x2019;s fixed
assets serve as collateral against any loans as of December 31, 2020 and 2019, other than those subject to the financed asset liability.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intangible
Assets</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets are stated at cost less accumulated amortization. For intangible assets that have definite lives, the assets are amortized
using the straight-line method over the estimated useful lives of the related assets. For intangible assets with indefinite lives,
the assets are tested periodically for impairment. Amortization expense was zero for the year ended December 31, 2020 and 2019.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_OfferingCostsPolicyTextBlock', window );">Offering Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Offering
Costs</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for offering costs in accordance with ASC 340, Other Assets and Deferred Costs. Prior to the completion of an
offering, offering costs were capitalized as deferred offering costs on the balance sheet. The deferred offering costs are netted
against the proceeds of the offering in stockholders&#x2019; equity (deficit) or the related debt, as applicable. Costs related
to unsuccessful offerings are expensed.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Topic 842, adopted in 2020 with no impact related to adoption, operating lease expense is generally recognized evenly over the term
of the lease. The Company has operating leases consisting of office and laboratory space with remaining lease terms of 46 months.
Rent and Lease costs were $154,263 and $30,362 for the year ended December 31, 2020 and 2019. There was no sublease rental income
for the year ended December 31, 2020 and 2019.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
with an initial term of twelve months or less are not recorded on the balance sheet. For lease agreements entered into or reassessed
after the adoption of Topic 842, we combine the lease and non-lease components in determining the lease liabilities and right
of use (&#x201c;ROU&#x201d;) assets.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
lease agreements generally do not provide an implicit borrowing rate, therefore an internal incremental borrowing rate is determined
based on information available at lease commencement date for purposes of determining the present value of lease payments. We
used the incremental borrowing rate on December 31, 2020 and 2019 for all leases that commenced prior to that date. In determining
this rate, which is used to determine the present value of future lease payments, we estimate the rate of interest we would pay
on a collateralized basis, with similar payment terms as the lease and in a similar economic environment.</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lease
Costs</i></font></p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#xa0;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#xa0;31,<br/> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Components of total lease costs:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left; padding-bottom: 1.5pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">154,263</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="width: 1%; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total lease costs</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">154,263</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lease
Positions as of December 31, 2020</i></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU
lease assets and lease liabilities for our operating leases were recorded in the balance sheet as follows:</font></p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#xa0;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#xa0;31,<br/> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Assets</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; width: 76%; text-align: left">Right of use asset &#x2013; short term</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">384,685</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Right of use asset &#x2013; long term</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">871,136</font></td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total assets</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,255,821</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Liabilities</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Operating lease liabilities &#x2013; short term</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">391,221</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Operating lease liabilities &#x2013; long term</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">858,064</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total lease liability</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,249,285</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lease
Terms and Discount Rate</i></font></p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: left">Weighted average remaining lease term (in years) &#x2013; operating lease</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">2.67</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Weighted average discount rate &#x2013; operating lease</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.00</td><td style="text-align: left">%</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
future annual minimum lease payments as of December 31, 2020 are as follows:</font></p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: left">2021</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">406,640</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">2022</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">411,753</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">2023</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">363,416</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left">2024</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">215,551</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total future minimum lease payments</font></td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,397,360</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: Lease imputed interest</font></td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">148,075</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 2pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</font></td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,249,285</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based
Compensation</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for stock-based compensation costs under the provisions of ASC 718, Compensation&#x2014;Stock Compensation, which
requires the measurement and recognition of compensation expense related to the fair value of stock-based compensation awards
that are ultimately expected to vest. Stock based compensation expense recognized includes the compensation cost for all stock-based
payments granted to employees, officers, and directors based on the grant date fair value estimated in accordance with the provisions
of ASC 718. ASC. 718 is also applied to awards modified, repurchased, or cancelled during the periods reported. Stock-based compensation
is recognized as expense over the employee&#x2019;s requisite vesting period and over the nonemployee&#x2019;s period of providing
goods or services.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_PatentsPolicyTextBlock', window );">Patents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patents</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company incurs fees from patent licenses, which are expensed as incurred. During the year ended December 31, 2020 and 2019, the Company had a licensing fee for
the patents of $258,635 and $18,396, respectively.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Research
and Development</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incur research and development costs during the process of researching and developing our technologies and future offerings. Our
research and development costs mainly consist of licensing costs. We expense these costs as incurred unless such costs qualify
for capitalization under applicable guidance.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Loss per Common Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basic
and Diluted Net Loss per Common Share</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Basic loss per common share is computed by dividing the net loss by the
weighted average number of shares of common stock outstanding for each period. Diluted loss per share is computed by dividing the net
loss by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common
stock equivalents. The weighted-average number of common shares outstanding excludes common stock equivalents because their inclusion
would be anti-dilutive. As of December 31, 2020, 2,143,000 stock options and 5,799,146 warrants were excluded from dilutive earnings per
share as their effects were anti-dilutive. As of December 31, 2019, 1,102,500 stock options and 1,382,478 warrants were excluded from
dilutive earnings per share as their effects were anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recent
Accounting Pronouncements</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FASB issues ASUs to amend the authoritative literature in ASC. There have been several ASUs to date, including those above, that
amend the original text of ASC. Management believes that those issued to date either (i) provide supplemental guidance, (ii) are
technical corrections, (iii) are not applicable to us or (iv) are not expected to have a significant impact our financial statements.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_FixedAssetPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_FixedAssetPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_OfferingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering Costs Policy Text Block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_OfferingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_PatentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patents Policy Text Block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_PatentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140256995380696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of lease costs</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#xa0;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#xa0;31,<br/> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Components of total lease costs:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left; padding-bottom: 1.5pt">Operating lease expense</td><td style="width: 1%; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">154,263</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="width: 1%; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total lease costs</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">154,263</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock', window );">Schedule of right of use asset lease assets and lease liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#xa0;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#xa0;31,<br/> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Assets</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; width: 76%; text-align: left">Right of use asset &#x2013; short term</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">384,685</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Right of use asset &#x2013; long term</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">871,136</font></td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total assets</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,255,821</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Liabilities</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Operating lease liabilities &#x2013; short term</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">391,221</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Operating lease liabilities &#x2013; long term</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">858,064</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total lease liability</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,249,285</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">Schedule of lease terms and discount</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: left">Weighted average remaining lease term (in years) &#x2013; operating lease</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">2.67</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Weighted average discount rate &#x2013; operating lease</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.00</td><td style="text-align: left">%</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule future minimum lease payments under the leases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: left">2021</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">406,640</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">2022</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">411,753</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">2023</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">363,416</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left">2024</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">215,551</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total future minimum lease payments</font></td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,397,360</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: Lease imputed interest</font></td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">148,075</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 2pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</font></td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,249,285</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 1,3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41499-112717<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121555522&amp;loc=d3e12069-110248<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121549808&amp;loc=d3e36991-112694<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived, depreciable assets that are subject to a lease meeting the criteria for capitalization and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121616839&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCapitalLeasedAsssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140256997353432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of stock option granted was estimated using the Black-Scholes assumption</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Exercise price</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.92-11.00</font></td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 85%; text-align: left">Expected dividend yield</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 12%; text-align: right">0</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Risk free interest rate</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.28%-2.65</font></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Expected life in years</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.70-10.00</font></td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Expected volatility</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">141-151</font></td><td style="text-align: left">%</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock', window );">Schedule of analysis of the stock option grant activity under the plan</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Stock Options</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/>
Average <br/>
Exercise<br/>
    Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/>
Average
    <br/>
Remaining<br/> Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left">Outstanding December 31, 2019</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">1,102,500</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4.00</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">7.77</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Granted</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,045,500</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2.32</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.91</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Expired or forfeited</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.92</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Outstanding December 31, 2020</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">2,143,000</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3.18</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">7.81</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; border-bottom: Black 1.5pt solid"><b><i>Warrants</i></b></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Remaining<br/> Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left">Outstanding December 31, 2019</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">1,382,478</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">4.44</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">2.84</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Granted</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8,906,381</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.24</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.00</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Expired or forfeited</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(190,810</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.12</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,298,903</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7.20</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Outstanding December 31, 2020</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">5,799,146</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5.05</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">4.00</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of nonvested option</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Nonvested Options</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Nonvested at December 31, 2019</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Granted</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">1,045,500</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">2.32</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Vested</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(67,500</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2.93</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Expired or forfeited</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.92</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Nonvested at December 31, 2020 </td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">973,000</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2.28</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Nonvested Warrants</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> Average<br/> Exercise<br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Nonvested at December 31, 2019</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">200,000</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">4.00</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Granted</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8,906,381</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.24</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Vested</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(4,296,668</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.14</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Expired or forfeited</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,489,713</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7.24</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Nonvested at December 31, 2020</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">320,000</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3.69</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ScheduleOfAnalysisOfTheStockOptionGrantActivityUnderThePlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140257001722168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of statutory federal income tax rate</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Income taxes at U.S. statutory rate</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">State income taxes</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8.2</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7.0</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Tax Credits</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1.3</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Permanent Differences/Others</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">30.3</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(20.4</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(60.8</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7.6</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total provision for income taxes</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">0</td><td style="padding-bottom: 2pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">0</td><td style="padding-bottom: 2pt; text-align: left">%</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td colspan="6" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31,</font></td><td style="padding-bottom: 1.5pt; font-size: 8pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 8pt; font-weight: bold; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td colspan="2" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</font></td><td style="padding-bottom: 1.5pt; font-size: 8pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td colspan="2" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</font></td><td style="padding-bottom: 1.5pt; font-size: 8pt; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td colspan="2" style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td colspan="2" style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 13.7pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    operating loss carryforwards</font></td><td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td><td style="width: 9%; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,651,932</font></td><td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td><td style="width: 9%; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,044,662</font></td><td style="width: 1%; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 13.7pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    credits carryforwards</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">116,949</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 13.7pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    compensation</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,350,795</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">974,644</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 13.7pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
    liability</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">367,029</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 13.7pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,920</font></td><td style="padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</font></td><td style="padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 27.35pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    deferred tax assets</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,488,625</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,019,306</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation
    allowance</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,109,685</font></td><td style="padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,019,306</font></td><td style="padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 27.35pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    deferred tax assets</font></td><td style="padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="border-bottom: Black 4pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">378,940</font></td><td style="padding-bottom: 4pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="border-bottom: Black 4pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x2014;</font></td><td style="padding-bottom: 4pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax liabilities</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 13.7pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right
    of use assets</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(368,950</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td><td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 13.7pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed
    Assets</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9,990</font></td><td style="padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 27.35pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    deferred tax liabilities</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(378,940</font></td><td style="padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</font></td><td style="padding-bottom: 1.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x2014;</font></td><td style="padding-bottom: 1.5pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 27.35pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    deferred taxes</font></td><td style="padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td><td style="border-bottom: Black 4pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x2014;</font></td><td style="padding-bottom: 4pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td><td style="padding-bottom: 4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</font></td><td style="border-bottom: Black 4pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x2014;</font></td><td style="padding-bottom: 4pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140256991477976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Business (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 10, 2020</div></th>
<th class="th"><div>Jul. 02, 2020</div></th>
<th class="th"><div>Aug. 19, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_OrganizationandNatureofBusinessDetailsLineItems', window );"><strong>Organization and Nature of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_CommonUnitIssuedPerUnit', window );">Company issued per unit</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_OfferingPriceOfShares', window );">Total offering price</a></td>
<td class="nump">9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Exercise price term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_PurchaseOfEquityShares', window );">Purchase of equity shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonUnitIssued', window );">Company issued</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">874,916<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_PurchaseOfCommonStock', window );">Purchase of common stock</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_CommonStockExercisePricePerShare', window );">Common stock exercise price, per share</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_OrganizationandNatureofBusinessDetailsLineItems', window );"><strong>Organization and Nature of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_StockUnitIssued', window );">Common stock unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,226,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_CommonUnitIssuedPerUnit', window );">Company issued per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_OfferingPriceOfShares', window );">Total offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_OrganizationandNatureofBusinessDetailsLineItems', window );"><strong>Organization and Nature of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=us-gaap_SeriesAMember', window );">Series A warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_OrganizationandNatureofBusinessDetailsLineItems', window );"><strong>Organization and Nature of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Exercise price term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_CommonStockVotingRightsPercentage', window );">Common stock voting rights percentage</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=us-gaap_SeriesAMember', window );">Series A warrant [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_OrganizationandNatureofBusinessDetailsLineItems', window );"><strong>Organization and Nature of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=us-gaap_SeriesAMember', window );">Series A warrant [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_OrganizationandNatureofBusinessDetailsLineItems', window );"><strong>Organization and Nature of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPPredecessorEntityIesToBusinessCombination', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">$4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=us-gaap_SeriesBMember', window );">Series B warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_OrganizationandNatureofBusinessDetailsLineItems', window );"><strong>Organization and Nature of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=adtx_SeriesA1WarrantMember', window );">Series A-1 warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_OrganizationandNatureofBusinessDetailsLineItems', window );"><strong>Organization and Nature of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure', window );">Exercise price</a></td>
<td class="nump">$ 3.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=adtx_SeriesA1WarrantMember', window );">Series A-1 warrant [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_OrganizationandNatureofBusinessDetailsLineItems', window );"><strong>Organization and Nature of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Exercise price term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=adtx_SeriesB1WarrantMember', window );">Series B-1 warrant [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_OrganizationandNatureofBusinessDetailsLineItems', window );"><strong>Organization and Nature of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Exercise price term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceIncrease', window );">Exercise price</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_CommonStockExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock exercise price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_CommonStockExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_CommonStockVotingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock voting rights percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_CommonStockVotingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_CommonUnitIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_CommonUnitIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_OfferingPriceOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_OfferingPriceOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_OrganizationandNatureofBusinessDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_OrganizationandNatureofBusinessDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_PurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_PurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_PurchaseOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of equity shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_PurchaseOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_StockUnitIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Unit Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_StockUnitIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonUnitIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common units issued of limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonUnitIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPPredecessorEntityIesToBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name and brief description of each predecessor entity included in the LLC or LP as a result of a net asset transfer or exchange of equity interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120313088&amp;loc=d3e9583-128503<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPPredecessorEntityIesToBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the carrying amount of assets and liabilities in the reporting entity's statement of financial position that relate to the reporting entity's variable interest in the variable interest entity (VIE) and the reporting entity's maximum exposure to loss as a result of its involvement with the VIE, where the reporting entity is not the VIE's primary beneficiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5728-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=us-gaap_SeriesAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=us-gaap_SeriesAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=us-gaap_SeriesBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=us-gaap_SeriesBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=adtx_SeriesA1WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=adtx_SeriesA1WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=adtx_SeriesB1WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=adtx_SeriesB1WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140256996099688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Going Concern Analysis (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_GoingConcernDisclosureAbstract', window );"><strong>Going Concern Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,149,227)<span></span>
</td>
<td class="num">$ (5,827,728)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 10,500,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_GoingConcernDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_GoingConcernDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140256991787192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expenses</a></td>
<td class="nump">$ 17,773<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_AccumulatedDepreciation', window );">Accumulated depreciation</a></td>
<td class="nump">17,773<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment', window );">Rent and Lease costs</a></td>
<td class="nump">154,263<span></span>
</td>
<td class="nump">30,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_LicensingFeeForPatents', window );">Licensing fees</a></td>
<td class="nump">$ 258,635<span></span>
</td>
<td class="nump">$ 18,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_WarrantsOfStockOption', window );">Warrants of stock option (in Shares)</a></td>
<td class="nump">2,143,000<span></span>
</td>
<td class="nump">1,102,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_DilutiveEarningsShares', window );">Dilutive earnings share (in Shares)</a></td>
<td class="nump">5,799,146<span></span>
</td>
<td class="nump">1,382,478<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_AccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_AccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_DilutiveEarningsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_DilutiveEarningsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_LicensingFeeForPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_LicensingFeeForPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_WarrantsOfStockOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_WarrantsOfStockOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense incurred and directly related to generating revenue by lessor from operating lease of rented property and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DirectCostsOfLeasedAndRentedPropertyOrEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140256994019656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of lease costs - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Components of total lease costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 154,263<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 154,263<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140256995287816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of right of use asset lease assets and lease liabilities - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_AssetsAbstract0', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_RightOfUseAssetShortTerm', window );">Right of use asset &#8211; short term</a></td>
<td class="nump">$ 384,685<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_RightOfUseAssetLongTerm', window );">Right of use asset &#8211; long term</a></td>
<td class="nump">871,136<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Total assets</a></td>
<td class="nump">1,255,821<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities &#8211; short term</a></td>
<td class="nump">391,221<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities &#8211; long term</a></td>
<td class="nump">858,064<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 1,249,285<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_AssetsAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_AssetsAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_RightOfUseAssetLongTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right of use asset &#8211; long term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_RightOfUseAssetLongTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_RightOfUseAssetShortTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right of use asset &#8211; short term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_RightOfUseAssetShortTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140257001748936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of lease terms and discount<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_ScheduleOfLeaseTermsAndDiscountAbstract', window );"><strong>Schedule of lease terms and discount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years) &#8211; operating lease</a></td>
<td class="text">2 years 244 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate &#8211; operating lease</a></td>
<td class="nump">8.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ScheduleOfLeaseTermsAndDiscountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ScheduleOfLeaseTermsAndDiscountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140257029104904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule future minimum lease payments under the leases<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_ScheduleFutureMinimumLeasePaymentsUnderTheLeasesAbstract', window );"><strong>Schedule future minimum lease payments under the leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 406,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">411,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">363,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2024</a></td>
<td class="nump">215,551<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">1,397,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivableWithImputedInterestNetAmount', window );">Less: Lease imputed interest</a></td>
<td class="nump">148,075<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_LesseeOperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 1,249,285<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_LesseeOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Lease Liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_LesseeOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ScheduleFutureMinimumLeasePaymentsUnderTheLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ScheduleFutureMinimumLeasePaymentsUnderTheLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivableWithImputedInterestNetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The receivable or note face amount less the unamortized discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivableWithImputedInterestNetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140256992901736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 21, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_AccruedCompensationForRelatedParty', window );">Accrued compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 342,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_StockIssuedDuringPeriodValueNewIssued', window );">Amount of liabilities from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_StocksIssuedDuringPeriodSharesIssues', window );">Shares of liabilities from related party (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromOfficersOrStockholders', window );">Owed amount of related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 309,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Description of related party transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">During the year ended December 31, 2020, the Company issued 38,055 Units consisting of one share of common stock and one Series A warrant and one Series B warrant to settle $342,500 in accrued compensation.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=adtx_ChiefInnovationOfficerMember', window );">Chief Innovation Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromOfficersOrStockholders', window );">Owed amount of related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">377,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Description of related party transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">During the year ended December 31, 2020, the Company issued 47,222 Units consisting of one share of common stock, one Series A warrant, and one Series B warrant to settle $425,000 in accrued compensation.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_AccruedCompensationForRelatedParty', window );">Accrued compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember', window );">Chief Operating Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromOfficersOrStockholders', window );">Owed amount of related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 275,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Description of related party transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">During the year ended December 31, 2020, the Company issued 35,555 Units consisting of one share of common stock, one Series A warrant, and one Series B warrant to settle $320,000 in accrued compensation.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_AccruedCompensationForRelatedParty', window );">Accrued compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_AccruedCompensationForRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents accrued compensation for related paty.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_AccruedCompensationForRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_RelatedPartyTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_RelatedPartyTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_StockIssuedDuringPeriodValueNewIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_StockIssuedDuringPeriodValueNewIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_StocksIssuedDuringPeriodSharesIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_StocksIssuedDuringPeriodSharesIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromOfficersOrStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39599-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromOfficersOrStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919370-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121603689&amp;loc=d3e36975-112693<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918703-209980<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121606570&amp;loc=SL77919784-209982<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=adtx_ChiefInnovationOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=adtx_ChiefInnovationOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140256989408296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 06, 2020</div></th>
<th class="th"><div>Jun. 29, 2020</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 10, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_StockholdersEquityDeficitDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Deficit) (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000,000<span></span>
</td>
<td class="nump">27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonUnitIssued', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">874,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation for consulting services (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,477,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_StockIssuedDuringPeriodSharesIntangibleAssets', window );">Shares issued for intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsCurrent', window );">Intangible assets valued (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Issue of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,297,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants and received (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,544<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_CommonStockIssuedForPreferredShares', window );">Common stock issued for preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_SettlementOfAccountsPayableShares', window );">Settlement of accounts payable Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_StockIssuedSettlementOfDebt', window );">Settlement of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_StockIssuedDuringPeriodSharesIssuedForService', window );">Common stock issued for service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock for services and recognized expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,477,434<span></span>
</td>
<td class="nump">$ 82,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On June 29, 2020, the Company effectuated a 1-for-2 reverse stock split of its issued and outstanding shares of common stock by filing a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Granted stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">880,500<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Exercise prices (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_TotalGrantFairValue', window );">Total grant fair value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,495,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_StockOptionexercisePrice', window );">Stock option exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Compensation expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 406,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_ShareBasedPaymentRemnainingExpenses', window );">Share based payment remaining expenses (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,781,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Weighted average vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 146 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense', window );">Compensation expense related to options issued and vesting (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,513,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Issue of aggregate stock option</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock option [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_StockholdersEquityDeficitDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Deficit) (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_TotalGrantFairValue', window );">Total grant fair value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,668,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_StockholdersEquityDeficitDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Deficit) (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Exercise prices (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_StockholdersEquityDeficitDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Deficit) (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Exercise prices (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_StockholdersEquityDeficitDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Deficit) (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_ShareBasedPaymentRemnainingExpenses', window );">Share based payment remaining expenses (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 294,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_WarrantsIssuedAndVesting', window );">Warrants issued and vesting (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 304,526<span></span>
</td>
<td class="nump">$ 1,102,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Weighted average vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">328 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_WarrantsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,297,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,298,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercised (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adtx_TwoZeroOneSevenEquityIncentivePlanMember', window );">2017 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_StockholdersEquityDeficitDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Deficit) (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share issued for stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_StockholdersEquityDeficitDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Deficit) (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,226,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=adtx_September2020OfferingMember', window );">September 2020 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_StockholdersEquityDeficitDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Deficit) (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Stock option [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_StockholdersEquityDeficitDetailsLineItems', window );"><strong>Stockholders&#8217; Equity (Deficit) (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_PreferredStockExercise', window );">Preferred stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_CommonStockIssuedForPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_CommonStockIssuedForPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_PreferredStockExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_PreferredStockExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_SettlementOfAccountsPayableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement of accounts payable shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_SettlementOfAccountsPayableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ShareBasedPaymentRemnainingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based payment remnaining expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ShareBasedPaymentRemnainingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_StockIssuedDuringPeriodSharesIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_StockIssuedDuringPeriodSharesIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_StockIssuedDuringPeriodSharesIssuedForService">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares issued for service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_StockIssuedDuringPeriodSharesIssuedForService</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_StockIssuedSettlementOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued settlement of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_StockIssuedSettlementOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_StockOptionexercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock option exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_StockOptionexercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_StockholdersEquityDeficitDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_StockholdersEquityDeficitDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_TotalGrantFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_TotalGrantFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_WarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_WarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_WarrantsIssuedAndVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_WarrantsIssuedAndVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonUnitIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common units issued of limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonUnitIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109244457&amp;loc=d3e16649-113920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options, after deduction of related income tax (expense) benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adtx_TwoZeroOneSevenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adtx_TwoZeroOneSevenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=adtx_September2020OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=adtx_September2020OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140256993050952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit) (Details) - Schedule of stock option granted was estimated using the Black-Scholes assumption<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionLineItems', window );"><strong>Stockholders&#8217; Equity (Deficit) (Details) - Schedule of stock option granted was estimated using the Black-Scholes assumption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionLineItems', window );"><strong>Stockholders&#8217; Equity (Deficit) (Details) - Schedule of stock option granted was estimated using the Black-Scholes assumption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 1.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">0.28%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">2 years 255 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">141.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionLineItems', window );"><strong>Stockholders&#8217; Equity (Deficit) (Details) - Schedule of stock option granted was estimated using the Black-Scholes assumption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.65%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">151.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_StockholdersEquityDeficitDetailsScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140256995274280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit) (Details) - Schedule of analysis of the stock option grant activity under the plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=adtx_StockOptionsMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems', window );"><strong>Stockholders&#8217; Equity (Deficit) (Details) - Schedule of analysis of the stock option grant activity under the plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number, Outstanding beginning balance | shares</a></td>
<td class="nump">1,102,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_WeightedAverageExercisePriceOutstanding', window );">Weighted Average Exercise Price, Outstanding beginning balance | $ / shares</a></td>
<td class="nump">$ 4.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3', window );">Weighted Average Remaining Life, Outstanding beginning balance</a></td>
<td class="text">7 years 281 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number, Granted | shares</a></td>
<td class="nump">1,045,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">$ 2.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_WeightedAverageRemainingLifeGranted', window );">Weighted Average Remaining Life, Granted</a></td>
<td class="text">8 years 332 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number, Expired or forfeited | shares</a></td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired or forfeited | $ / shares</a></td>
<td class="nump">$ 1.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingLifeExpiredOrForfeited', window );">Weighted Average Remaining Life, Expired or forfeited</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number, Outstanding ending balance | shares</a></td>
<td class="nump">2,143,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_WeightedAverageExercisePriceOutstanding', window );">Weighted Average Exercise Price, Outstanding ending balance | $ / shares</a></td>
<td class="nump">$ 3.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Life, Outstanding ending balance</a></td>
<td class="text">7 years 295 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems', window );"><strong>Stockholders&#8217; Equity (Deficit) (Details) - Schedule of analysis of the stock option grant activity under the plan [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number, Outstanding beginning balance | shares</a></td>
<td class="nump">1,382,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_WeightedAverageExercisePriceOutstanding', window );">Weighted Average Exercise Price, Outstanding beginning balance | $ / shares</a></td>
<td class="nump">$ 4.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3', window );">Weighted Average Remaining Life, Outstanding beginning balance</a></td>
<td class="text">2 years 306 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number, Granted | shares</a></td>
<td class="nump">8,906,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">$ 6.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_WeightedAverageRemainingLifeGranted', window );">Weighted Average Remaining Life, Granted</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number, Expired or forfeited | shares</a></td>
<td class="num">(190,810)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired or forfeited | $ / shares</a></td>
<td class="nump">$ 8.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingLifeExpiredOrForfeited', window );">Weighted Average Remaining Life, Expired or forfeited</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number, Exercised | shares</a></td>
<td class="num">(4,298,903)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="nump">$ 7.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_ShareBasedPaymentsWeightedAverageRemainingLifeExercised', window );">Weighted Average Remaining Life, Exercised</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number, Outstanding ending balance | shares</a></td>
<td class="nump">5,799,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_WeightedAverageExercisePriceOutstanding', window );">Weighted Average Exercise Price, Outstanding ending balance | $ / shares</a></td>
<td class="nump">$ 5.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Life, Outstanding ending balance</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ShareBasedPaymentsWeightedAverageRemainingLifeExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Life, Exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ShareBasedPaymentsWeightedAverageRemainingLifeExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Life, Outstanding beginning balance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingLifeExpiredOrForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageRemainingLifeExpiredOrForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_StockholdersEquityDeficitDetailsScheduleofanalysisofthestockoptiongrantactivityundertheplanLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_WeightedAverageExercisePriceOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_WeightedAverageExercisePriceOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_WeightedAverageRemainingLifeGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_WeightedAverageRemainingLifeGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=adtx_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=adtx_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140256919476872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit) (Details) - Schedule of nonvested option<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=adtx_NonvestedWarrantsMember', window );">Nonvested Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems', window );"><strong>Stockholders&#8217; Equity (Deficit) (Details) - Schedule of nonvested option [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Nonvested at beginning balance</a></td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Outstanding beginning balance (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares, Granted</a></td>
<td class="nump">8,906,381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_WeightedAverageExercisePriceGranted', window );">Weighted- Average Exercise Price, Granted (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Shares, Vested</a></td>
<td class="num">(4,296,668)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_WeightedAverageExercisePriceVested', window );">Weighted- Average Exercise Price, Vested</a></td>
<td class="nump">5.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Expired or forfeited</a></td>
<td class="num">(4,489,713)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_WeightedAverageExercisePriceForfeited', window );">Weighted- Average Exercise Price, Expired or forfeited (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Nonvested at ending balance</a></td>
<td class="nump">320,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Outstanding ending balance (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=adtx_NonvestedOptionsMember', window );">Nonvested Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems', window );"><strong>Stockholders&#8217; Equity (Deficit) (Details) - Schedule of nonvested option [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Nonvested at beginning balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Outstanding beginning balance (in Dollars per share) | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares, Granted</a></td>
<td class="nump">1,045,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_WeightedAverageExercisePriceGranted', window );">Weighted- Average Exercise Price, Granted (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Shares, Vested</a></td>
<td class="num">(67,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_WeightedAverageExercisePriceVested', window );">Weighted- Average Exercise Price, Vested</a></td>
<td class="nump">2.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Expired or forfeited</a></td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_WeightedAverageExercisePriceForfeited', window );">Weighted- Average Exercise Price, Expired or forfeited (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Nonvested at ending balance</a></td>
<td class="nump">973,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Outstanding ending balance (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_StockholdersEquityDeficitDetailsScheduleofnonvestedoptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_WeightedAverageExercisePriceForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted- Average Exercise Price, Forfeited</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_WeightedAverageExercisePriceForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_WeightedAverageExercisePriceGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_WeightedAverageExercisePriceGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_WeightedAverageExercisePriceVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_WeightedAverageExercisePriceVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=adtx_NonvestedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=adtx_NonvestedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=adtx_NonvestedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=adtx_NonvestedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140256996270600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_AgreementsDetailsLineItems', window );"><strong>Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BroadcastersLicenseAgreementCommitmentsDescription', window );">License agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On July 1, 2020, the Company entered into an amendment to patent and technology licensing agreement with Loma Linda University (&#x201c;LLU&#x201d;), dated March 15, 2018. Pursuant to the amendment, the Company paid LLU $455,000 within four days of the signing of such amendment. The amendment also updated the milestone payment dates to be $175,000 on March 31, 2022; $100,000 on March 31, 2024; $500,000 on March 31, 2026; and $500,000 on March 31, 2027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_FinanceArrangementCost', window );">Finance arrangement cost</a></td>
<td class="nump">$ 215,192<span></span>
</td>
<td class="nump">$ 467,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=adtx_SalveoDiagnosticsIncMember', window );">Salveo Diagnostics, Inc. [Member] | Salveo Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_AgreementsDetailsLineItems', window );"><strong>Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issue of salveo shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Share issued description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Salveo Shares were issued to Salveo upon the completion of the following Milestones: (i) 150,000 shares upon the sale and transfer to the Company of certain code and interpretive commenting algorithms (the &#x201c;Algorithms&#x201d;) along with related testing protocols and all technology, codes and spreadsheets, know-how, any necessary information or tools to implement, use, and/or continue to improve or further refine the Algorithms, and other associated intellectual property; (ii) 250,000 shares upon securing temporary laboratory space and other related tasks in connection with the launch of the AditxtScore&#x2122; platform; and (iii) 250,000 shares upon satisfaction of tasks related to the establishment of a long-term AditxtScore&#x2122; center in Richmond, VA. We also pay Salveo at cost for Salveo&#x2019;s reasonable and documented purchases, general operating costs and expenses incurred in connection with the Salveo Services.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_AgreementsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_AgreementsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_FinanceArrangementCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Arrangement Cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_FinanceArrangementCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BroadcastersLicenseAgreementCommitmentsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the commitments for license agreements that have been executed but were not reported because they do not meet the conditions for recording a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472701&amp;loc=d3e49107-107924<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BroadcastersLicenseAgreementCommitmentsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=adtx_SalveoDiagnosticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=adtx_SalveoDiagnosticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_TypeOfAgreementAxis=adtx_SalveoConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_TypeOfAgreementAxis=adtx_SalveoConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140256991326312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 10, 2018</div></th>
<th class="th"><div>Apr. 12, 2018</div></th>
<th class="th"><div>Jul. 18, 2018</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jan. 10, 2020</div></th>
<th class="th"><div>Nov. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_NotesPayableDetailsLineItems', window );"><strong>Notes Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnsecuredDebt', window );">Unsecured promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Accrued interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Maturity date, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The note was due on the earlier of November 12, 2018 or in the event of default, as defined in the agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The notes were due on the earlier of April 19, 2020 or ten days after the close of the Company&#x2019;s IPO.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=adtx_SixBridgeLoansMember', window );">Six bridge loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_NotesPayableDetailsLineItems', window );"><strong>Notes Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_OriginalIssueDiscount', window );">Original issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_NotesPayableDetailsLineItems', window );"><strong>Notes Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BridgeLoan', window );">Bridge loan</a></td>
<td class="nump">$ 15,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtDescription', window );">Bridge loan, description</a></td>
<td class="text">The note was due on the earlier of October 8, 2018 or in the event of default, as defined in the agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The note was due on the earlier of October 16, 2018 or in the event of default, as defined in the agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_OriginalIssueDiscount', window );">Original issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_NotesPayableDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_NotesPayableDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_OriginalIssueDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_OriginalIssueDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BridgeLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-Term financing which is expected to be paid back relatively quickly, such as by a subsequent longer-term loan. Also called swing loan or bridge financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BridgeLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information about borrowings which initially required repayment in less than twelve months (or normal operating cycle, if longer) after its issuance and that does not otherwise qualify as long-term debt. It typically is comprised of borrowings under letters of credit, lines of credit, commercial paper, and notes payable of short duration. Disclosures include amounts of borrowings under each arrangement, description of underlying arrangements, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements such as the effects of refinancings and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=adtx_SixBridgeLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=adtx_SixBridgeLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140256992905432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance increased amount</a></td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_NetOperatingLossPercentage', window );">Net operating loss percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_CorporationsTaxableIncomePercentage', window );">Net operating loss carryover or corporation&#8217;s taxable income percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Operating loss carryforwards, description</a></td>
<td class="text">The Company has federal net operating losses generated following 2017 of $12.5 million, which do not expire. The federal net operating losses generated prior to 2018 of $0.1 million will expire at various dates through 2037. The CARES Act temporarily allows the Company to carryback net operating losses arising in 2018, 2019 and 2020 to the five prior tax years. In addition, net operating losses generated in these years could fully offset prior year taxable income without the 80% of the taxable income limitation under the TCJA which was enacted on December 22, 2017.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Federal tax credit carryforwards</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=adtx_USFederalMember', window );">U.S. federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">12.6<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=adtx_USStateMember', window );">U.S.state [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 15.2<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_CorporationsTaxableIncomePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Corporation&#8217;s taxable income Percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_CorporationsTaxableIncomePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_IncomeTaxesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_IncomeTaxesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_NetOperatingLossPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Operating Loss Percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_NetOperatingLossPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=adtx_USFederalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=adtx_USFederalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=adtx_USStateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=adtx_USStateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140257009707352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of statutory federal income tax rate<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_ScheduleOfStatutoryFederalIncomeTaxRateAbstract', window );"><strong>Schedule of statutory federal income tax rate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income taxes at U.S. statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes</a></td>
<td class="nump">8.20%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax Credits</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Permanent Differences/Others</a></td>
<td class="nump">30.30%<span></span>
</td>
<td class="num">(20.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(60.80%)<span></span>
</td>
<td class="num">(7.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total provision for income taxes</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ScheduleOfStatutoryFederalIncomeTaxRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ScheduleOfStatutoryFederalIncomeTaxRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140256995273240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of deferred tax assets and liabilities - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_DeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 3,651,932<span></span>
</td>
<td class="nump">$ 1,044,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits carryforwards</a></td>
<td class="nump">116,949<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">2,350,795<span></span>
</td>
<td class="nump">974,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">367,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">1,920<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">6,488,625<span></span>
</td>
<td class="nump">2,019,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(6,109,685)<span></span>
</td>
<td class="num">(2,019,306)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">378,940<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right of use assets</a></td>
<td class="num">(368,950)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed Assets</a></td>
<td class="num">(9,990)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(378,940)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_DeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_DeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities Right of use assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140256991034232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 25, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Convertible term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_WarrantsExercisedForShares', window );">Warrants exercised for shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,142,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_ProceedsFormWarrantsIssued', window );">Proceeds form warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,643,956<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_SaleOfConvertableNote', window );">Sale of convertible note</a></td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Convertible term</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Convertible price per share (in Dollars per share)</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Original issuance discount</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Warrants to purchase shares</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_InvestmentWarrantsExpirationPeriod', window );">Warrant term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_InvestmentWarrantsExercisePrice', window );">Warrants exercise price (in Dollars per share)</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_FinancingAgreementTerm', window );">Term of financing agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adtx_CostOfFinancingAgreement', window );">Cost of financing agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 892,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_CostOfFinancingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of financing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_CostOfFinancingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_FinancingAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of financing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_FinancingAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_InvestmentWarrantsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_InvestmentWarrantsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_InvestmentWarrantsExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_InvestmentWarrantsExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_ProceedsFormWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds form warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_ProceedsFormWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_SaleOfConvertableNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_SaleOfConvertableNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adtx_WarrantsExercisedForShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants exercised for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adtx_WarrantsExercisedForShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>59
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MA$7*N*#ZSR,;LR0QGG0<WTNGO<V<9F#]^M7[>2%>B[FGDHU%\@^/U>*X%_1
MS.9TE:A;\?25E8)<XR\2B2S^!T^E+>R!:"652,O!.H*49^N_]+E,1&T <CH&
MX'( WG< *0>00N@ZLD+6*55T>)2+)Y ;:^W-7!2Y*49K-3PSRSA5N?Z6ZW%J
M>$(3FD4,3(T'"0[ W?04?/SPZ6B@M'=C,XA*3R=K3[C#TRF+#@%!?8 AABW#
MQWL/1^'V\('6M!&&-\)PX8]T^!O?W=Z>7<W :#H]FTTM#LG&(2D<.ET.J5P
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M9&+'!A/4YV5Z9$#[LS1T1@C:#VB@5I":"R9-X4S8J^ID0UML;.IBW.33%G-
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MJ3^N"5Z2LFK ?U\5!7N^J-ZU.KX?>/T_4$L#!!0    ( 'V(>5+1C> 5EP<
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M,!*CDU$Z'IS0PU@,!\?I\?$@B#4PLH>#03IZ<8I(WT\^(L2]#%D!HD+M\Z,
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M ::Z8E8+ITM_K9MK1Y=$_YC1K1P-&]!^JHGPS8(#U/?\T;]02P,$%     @
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MEOI = ]J^WN,4F2OD?)@ ,>&=@L69[>9$>WHD/3HH*#V,Z=OU%Y(?,/9^TQ
M14>(H]:7_>V^FT+Q=;.+;XHCWV[ M>WLWJ\VA\/)3B)W22=9-80$#.NDI39?
M",TZ0C[/G.\P9XAK@HHVYQKC#;85W#2Z%Q8],4FU56/Q^"!(O)K.'UC(3$.N
MEENR-+=]".QFB8/6<4.@4:EFO<'8H;\(&XQT0],$Q!JVF7?1K<1_:,Z%M+HM
M5N#;EE3H[QL<&@A;1A@PJ1T^C!!2H:(^#;&2EYPJ-AF?2VIR;RCL-AT%E]34
M!A\>FK3C4A=T"OY"-XD'Z(YD[08 [IK/EF2T)QEZ5"@-W!8NBKRC1NRG;I2+
M]M!\%]1O=_.E4E\<,TC0^L5!#('__>D,.9%TAI>^@GF25B'+I28#:MO&XC[#
MT VKVK?1($?UZ]#"W8!F#D,/&J\ 1XUV=87T0C;E ,5PI:DA@XRF6=&A)6%F
M+YS A[L&C7;X.;9+]F# J,_!@;(7S!<HLA#U:C0-\O+&R ZD[B:(/VFF/-HW
M@-3L/0D]_$6(UO>-:R)^<0?'\%7[([KHC6%W>@TZ6AC[DXY3YGJ&^6@^C_X6
M0A_C<#9U3]/1)&6+T3*AVB9#J 8E<?%HZIJ3QZ[.LK/[F*8@%B>9&RS =#)*
M%F"Z2*+WJ@JM6JO3I6^;6U7.>DL08'>5.0.]LR/"1S_[C8]F<W?O,>XN)P_0
MYEZF4&8Y;U5)T20,AU]Q> ;0'A;TCFWVA;.;G[N>C=JY\2Q&G\R*!QZ$1C[7
M7!#G95/X@70M*B1;Z:BW@P(EW[5H13*#<VMO6J41I@X9&WIB+>AU#:WSL("<
MO>H(.OA$$SQ?)'&VF(:VGNW:,,6HJP$T!R6;F*2C;-P.)8[K'1T/:]D14T=_
MW-3(AF02+]+9PXQ-_?I]QH[^?\:^V$_,L_Y -30T$^9>!\AN.WYWK +,6:^U
M6(=#D&QHJN#F[D$W'1U7JCKKFK2MLT*'7 -"[ 'K=LD\/JY[K_;[,M-<_>J.
M-51$IST(M<Y=;EHWWCB_M$?9+Z/P2K!WP-V9P)/L3PK=OC\-H),%O2A8 #ZS
M#'&[R#H$PMR'O)TL$C8;I1F;AM%@ '"2Y3A>) 0YBU%" -H.,'A&)_M$:8*G
M\Q$0YUOP.HWGRR4@=@9, L^I _8>C'4J_U%\3<,,ZN@-*]G!+$GMC[P?0X@D
M.Z)X!E18QO,D*)=]"VWI/4A;.&9+A[;=2XRV8?/O9?IGKOLS5=]38_Z0:+B0
M?W5C7;S3"5QW:'>8#:9]Y7N%C(KWIXKB:R[<DG8,$ =S80<*0V/*D3;EVW6B
M4_8(>DW&63P%=M']TU#<ET>@++IK7MKV;4P;*B!#4'9Y &47AW4CNELWV.VZ
MD2ZS>)DM'EPUQJ/E-ZO&@\^J]F_4.J.[HW;1I28%VCX[A\^X#\I4U/,TP"L7
MHO#'->T;MULO<EI6YD\>L;7OLGS.=&H$Z@Z?=QJ)J,U#7R%%_FU%1\J=50\?
MTQ'<84+IG+.B,''.\7/+%6RQ[71TT\>56,NJ\@=5&$$T(M#KE7@SND )Z=:7
MPK\"4?[$$ &K!8WLQ*00X8+Z]:*0%'\(8#=D(61S7DLZ $.T<+C-V.ZT("CL
M?%S1%,-^%UHQ"</F-@JCX-"!_FCH1?]Y[YN*K=!K]^4(55D,O_[SBNYN]W'*
M2_]-QGZY_[(%9H&1#"O%"EO'H_GTA&G_M8B_L*IV7VC 'E9MW<^-X' U+<#S
ME0+6A0MBT'VR\^)_4$L#!!0    ( 'V(>5)YN"N2/@8  -4.   9    >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;*U7V6X;-Q1]GZ\@U+1P $6;Y27Q LA+
M6Q=.8MA)^E#T@>)0&L(<<D)RK.CO>RXY&DF)XA1H7Z0A>==S%UZ>+JQ[](64
M@7TIM?%GG2*$ZDV_[T4A2^Y[MI(&)S/K2AZP=/.^KYSD>60J=7\T&!SV2ZY,
MY_PT[MVY\U-;!ZV,O'/,UV7)W?)":KLXZPP[JXU[-2\";?3/3RL^EP\R?*SN
M'%;]5DJN2FF\LH8Y.3OK3(9O+L9$'PD^*;GP&]^,/)E:^TB+F_RL,R"#I)8B
MD 2.OR=Y*;4F03#C<R.STZHDQLWOE?1?H^_P9<J]O+3Z3Y6'XJQSW&&YG/%:
MAWN[^%TV_AR0/&&UC[]LD6CW]SM,U#[8LF&&!:4RZ9]_:7#88#@>?(=AU#",
MHMU)4;3RB@=^?NKL@CFBAC3ZB*Y&;ABG# 7E(3B<*O"%\\G<20F0@S_M!\BC
MW;YH>"\2[^@[O,,1>VM-*#R[-KG,MP7T84AKS6AES<7H68E74O38_K#+1H/1
MX!EY^ZUW^U'>_@^]8U?*"VU][23[:S+UP2$?_GY&Q;A5,8XJQM]3\=O]]?7;
MZW<?'G8!^#SON_<?KK-#]LM/QZ/A\(2M1;'W)ONCUDO60-%EH9#LTI85-TL&
M?Z23.5,F6,:1V? P)R\9UA4/],5-SH(4A;':SI=,*T&%9.:,KR!!HH6"W=J2
MLUME<LX^&M2'\RHLV1Z9-!J<W-Y^C%_#DY?=+(?DG+WE3A1L>$"&#8][[*YV
MON9)-QG9&K-M<\55SB".O1@?''0'@T%4KPR;V=JQG"\]L[/(X=7<D*%8^AJJ
M6H&][,.F?,:UMZRNDEG$62HM43!&0MLRDM"9)\NFDKT8'B7%Z 7)B2;11B<X
M&PQVGHUQ=I#.LJ_/#D\BRJOS;WB/>NS&9.]%L%/I?AA&-AJ_*JF:V$P9;L1V
MK-!]F>93)C_7JHI@L C&'!1S.,F$]2$AJ/Q:0K89;:TC#./#H^[AZV$2L$M7
MP3UEE8KF0:HC^1!]_#.KX,A2<A<]>V>?9/EO7$.&YKFB)LSU_^AFMDM"Z^8(
M*3I\/?J/;CYP_21M=FF-1YLG 6U+H1IM(1@>KPIU(;\.[$[F/8*KJ;*D9"?=
MJOI2L3:$5XK/#8!0PG>S&R-Z76BYDIHON".(7&7A#-UY>UL:5L*^+=IG+.BN
M#B-R.7$ +3[5RA?=S,M05[$,A"U!+F3Z<$(AUA@=DB&QN'G3A63>A2:MY3SB
M/0&U$HC$'0\%=2OET:ZY$(!0!2(F\9?HG:#2[)9/R3OKENRFK!P% %9FDU5;
M\&SO\O9F\I()Z8*:*1* ]B8QQ>0$O%@)(JEYBR2EW4HN96'M(P$UIPG,^!(>
M@*L$@N-C] M5EC7:#!)9@8,*;:/7[@CM@W1/\-VO(X#Z$<!%Y0U"46D,14.:
MW*XK',6N6 ML^EFM">!*R\@$^,A-S%[KYN>W#'C;;K>IE$LOG)K*/)O23!93
M5GE?([B-N8<'J:/Y @D58T<X4&"A$]+$XTXG(W6K1B7#V]I-E;A%FRU0)RO=
M2*SFL'5ZVU/:F2%O[((2=.W8&[:G7N)&VK)Y#1S7,MV&CAL_0ZTV.=_TJFP#
M0V'S1!N; H9<FAB;S(Y5P?4<X0Y%N0WRI-UNO>?:@CY6K4-EQBL*]I(0)"T@
MQ-Q&JC*.?K5.GFZT(>7>QI2-;'@T=O&JH'!1@S62L@%3-$Q-DWD$B9PCP7!1
M$72I@&LO8S;U+061/*EE0T+UDV%[5COXXVC,QHP2\5D[E5+11@+NO45MA]3>
M,$QCNJY139"$8@_+$P0#T1CMB(:7HJ9:@;LE=2@8ORZZS%=<R U%+6K</WH6
M@V-,,\I'6,E&S6N#"[=)CAV%6D$(X9.N:IBVV[;, T _XZ+-M:BUM2%E3-OW
M8@=/'0U1?H5<*7<I%_$B(-OOE2A0.VA%GR8]]J=,LPNFE-4%PT.ZVJ@+K)OU
M\.B$C. >-^>T2>/<BIKTPZRJQK2!%PD"-)<&C:3MN "9Q*4\DE\JZKH$(@*0
M+J:OT<PV;H%5!^KMFH[[&T\--.YY?%!YB*M-2*^.=K=]LTW24V5-GAY\&);F
M"E>#EC.P#GI'!QWFTB,J+8*MXL-E:@.>0?&S0$5(1P0XGUD;5@M2T+YDS_\!
M4$L#!!0    ( 'V(>5(FK*(J0P0  &8-   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;,U7;6_;-A#^KE]QT+I],JP7VXG7.@:<I$,[K(W1=!N&81]H
MZ6P1I4B5I.+XW^](O=0VDK3)&F!?;(JZ>WCW\+DC-=LJ_<D4B!9N2R'-65A8
M6[V,(I,56#(S5!5*>K-6NF26'O4F,I5&EGNG4D1I')]$)>,RG,_\W%+/9ZJV
M@DM<:C!U63*].T>AMF=A$G83'_BFL&XBFL\JML%KM+]72TU/48^2\Q*EX4J"
MQO59N$A>GH^=O3?X@^/6[(W!9;)2ZI-[>)N?A;$+" 5FUB$P^KO!"Q3" 5$8
MGUO,L%_2.>Z/._1??.Z4RXH9O%#B3Y[;XBR<AI#CFM7"?E#;-]CF,W%XF1+&
M_\*VL4U/0\AJ8U79.E,$)9?-/[MM>=ASF,;W.*2M0^KC;A;R45XRR^8SK;:@
MG36AN8%/U7M3<%RZ3;FVFMYR\K/S]\JB@27;L97 660)TKV(LM;]O'%/[W%/
M4GBGI"T,O)8YYH< $<72!Y1V 9VG#R)>8C:$43* -$[C!_!&?8(CCS>Z%V]E
MX9*;3"A3:X2_%RMC-8GAGP? QSWXV(./[V/OZN/K:U@N_EJ<__;Z+O:^[AZ<
MPD\_3-,D>04':' E@T6EN8 D=60DTP'8 N%"E163.^#&U)@#DU!+@QFEED.E
M54GS2N] TKX"U2R\&$T&<1R3+[-4 YEV7EQ:U&@LJ#6,?R0063,A=D/X2"MX
MURTS05XC4.&X59%IP5$[^_?J!LL5C;NX@%;AK=D-2@_:UL4 F'%CRCOO;-A&
M(U)9VR%<UIK+C9_=T0J 3D- "O +!)T*7.+<]'%!Q;A'6]="#!U/O]9B!TE\
M%TWH,_49*V"PTCS?( A%O&VY+1Q_7-X0%92$HXL1B5QFO&("6*GJ)IT7R61P
M$L>'_$##3W#$SU5FE:-G^KSL]#4R"+Z)G>ESLC.*G<8>14]R\G_AYXN@?40_
M/PM%DYXABL5[YQ0&!14T-0F^IMNRO)/(XSILFD,Z;;)\,HW!P5*9HERTY708
M-!D[8\-*A$PP8QRJ;S;<<CHVR,$6RI"%$CUT5:\$S\ARC7Y_&I9:9'^64^ 9
M>E;281P'%>5C"J;QV[?46QP'W6W27H"TQD'/W*\*1CU/=VVCP_S.NWXZV=MU
M=]1"QK3FF <$H#3?<$D.OI63'DS6.X[ODPL\52Z^"[1B"9XH%O^2Q.!VY6C1
M1PDG^"["@2<*)_@/PFG6\3UMS34=H)])1+9A^"LJ,OQV7T>FR:]3D6EE9)4E
M1=PI)CJ O"A<Q9J&>M/IR0F2;6B?-HQR>TA9H_BH5U,@%.2#3<;UQ*[)6)1!
MSG:D@[7+V]F[JQ4>4>;O-*>O#+Q=7CUN>\Q!6 ?=^JX;6[1W]RU1;_P-WVTM
M)=Q<@_O9_B-BT=R=OY@W7R#OF";:J-YP3:[Q\'02@FYN]<V#596_2:^4I7NY
M'Q;T(83:&=#[M:+ VP>W0/]I-?\74$L#!!0    ( 'V(>5)&"HY+N@P   0C
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;*U:68_;.!)^YZ\@>C.+
M!-"X??29"^AT,M@,)@?2R>P.%OM 2[3-C21Z**K=GE^_7Q4I67++G<EB'I+6
M01:KOKI+?KZQ[FNUTMK+NR(OJQ='*^_73X^/JW2E"U6-[%J7>+.PKE >MVYY
M7*V=5AEO*O+CZ7A\=EPH4QZ]?,[//KJ7SVWM<U/JCTY6=5$HMWVE<[MY<30Y
M:AY\,LN5IP?'+Y^OU5+?:/]E_='A[KBEDIE"EY6QI71Z\>+H:O+TU0FMYP6_
M&KVI.M>2))E;^Y5NWF8OCL;$D,YUZHF"PI];?:WSG B!C=\CS:/V2-K8O6ZH
M_\2R0Y:YJO2US?]I,K]Z<71Q)#.]4'7N/]G-/W24YY3HI3:O^'^Y"6MGLR.9
MUI6W1=P,#@I3AK_J+N+0V7 Q/K!A&C=,F>]P$'/Y6GGU\KFS&^EH-:C1!8O*
MN\&<*4DI-][AK<$^__)MF=I"R\_J3E?/CSTHTO/C-.Y^%79/#^R>3.4[6_I5
M)=^4F<[Z!([!2LO/M.'GU?1!BJ]U.I*S22*GX^GX 7JS5KX9TYM]4S[YVE1I
M;JO::?GOJWGE'2SB/P\<<=(><<)'G!PZXOWUAW=OY.>K?[VY&8+PX=WO/WQ^
M(R[DW_]V,9U,GLDN,0F[$WZEY58K5TE-$$L I(NY=BU(4I49+B:7B:2UU[98
MJW(K,Y/)TGHX3FI=)A6,R3E=>FD=6:W&329-0,<#'7T'/Z\TO9[K4B^,%UF-
M5[;=2.>L#"S2F53E$E!6NB(2-=.:;[OGC^3GW0T+=_ZL:O;,-:*)[IR.9ZF%
MHU=>5C;7^5;:A8B+%\X6,L/"RIM4(AHY1?Y<C>2'4KQ3+EW)Z7F (B#PI30>
M_-QXY36A!C7C-O#F;*ENC:LK>66R1'[2N=&+A$5[ PYL@2-N-"0R?BNO4B\?
M$^_3\;/KJT]0")[P_>39$Q907"N',V@AA,GK##=K9V\-Q:P*V.?@M5P2B@@V
M=9FI>:[E6FV=S7.&/05TQE=)T$G!"EHPL[I8YW8+1:^MXP"&YZEV'H&VH2 8
MND26"-X1&!Q&N,E4.;>=J_2KQ'-C,ZQ2N=>N5!0%*9*8HBXZ+$0&L:ZPF5E
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MI7^O8PH043CX "EH69H_@#EM SJ(/"C4D$I:#A&Z_4;K ":J(</6H.!'/@0
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MS(8,&YH7&BD:(NQ:SDHCLMIL]4#.C.41VQ8/O+HN-S4$63L?;7=IA]F2UBT
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M'R:*]B<G\&#RY+&&M%&TX>=5\O5 ;'TF8DQZ)EXB@.]-W/T>&+FAWH'O\Q]
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M2)M:0V&RML8GMR^=^^6G61@$OQ&U%U(3#;)"5J)9[*:SQ/(WHE,*Y-ZJS++
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M,'B:RG7%02Y VY @6R?+I6*-X25LF :NC4"AX6RM1;,$L^)P6;'B<8CN$CL
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M,E8)\XOVC6WD6RC;"<GJ@[,BJ EM_O'K(0\G#FYTP<$[.'CG#L$%!__@X)M
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M#$OU%0!<&ZCG!6/R.-$;M-\5DW]02P,$%     @ ?8AY4AL0?*EI @  &08
M !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&ULE57;CM,P$/T5*^)A5X+F
MUA:HTDB]@.!A1;5EX=E-)HFUCAULMUW^GK&3AE*UT?*2^';.G#/.3)*C5,^Z
M C#DI>9"S[W*F&;F^SJKH*9Z)!L0N%-(55.#4U7ZNE% <P>JN1\%P=2O*1->
MFKBUC4H3N3><"=@HHO=U3=7O)7!YG'NA=UIX9&5E[(*?)@TM80OFJ=DHG/D]
M2\YJ$)I)0104<V\1SE83>]X=^,'@J,_&Q#K92?EL)U_SN1=80< A,Y:!XNL
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MNT'9 [A?2&E.$QN@_QND?P!02P,$%     @ ?8AY4KA%+BG* @  .0D  !D
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M56Z,57?%=AV4C;O65A+-)>F:&_-5 F4GF/%*2GSOV)NR_\[-_@!02P,$%
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MWA#Y7977&N7 R,(=]&^E,3)SCVO@"U!V GY?2FF>!E9!?;DT_1=02P,$%
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M0/V^*4MYN-"OQ+2O<5W^#U!+ P04    " !]B'E2[RY$04,#   =#   &0
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M$CU:VOZ>M'XO""VIU/Z!NPVDEO1C;E '62>N[0 '_S_SQ'65QX>5^7]NG]W
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;+57VV[C-A#]E8&[+1+
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M*BC],Y1_9+Q+//>"^*XW:H!?V^&7J42X?Q8^;Z-]=!;^P0Z_I:B]YQFX[S;
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M_ (/=Y?P\>@3' &7<,V%0-'-*+08TWF&R1K_HL:/#^"3&*Z5M+F!+S)EZ5.
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M;[_<P7EB 8^?VW+-Q:H^.,Y\JP#&\^).:?*XGR&Z&K?$'NB8U5T#J$Q]]W$
M#B_#2;1)@2YAQ:@V 5SA84U3;KU K^2/^ AD6.V+I5H)5+T2R%MEF4'G&MY]
M?EZT"VYS'-">R3#ZX-1SC\^L!"^XK5M(A9U8>YO[R>_GZ[U;8#4PB5,5V: -
MMDE63-$LCGW2@Z"EL(=-80];J^_KNAB<2-B[4)NGQ;VOGH<O.UATJ(.=-CQ.
M6WG<HM)48])N(U,VQ\M,B5<3^RYB=0A"WD*,1-MQ'+52>PCN@N;0?+_V>] V
M0,C.H"<_<%"1>!LG_E]MN$W+->03,;'!G#1JUI-]8[9;#-U@>$#S[00GW5<U
M-W@VV)L$WXYLTON1@F_',7GW/'Y=\/Y+)4D_B)\+OL?LI>#ASO6S8'KF;^6^
MB4E;WT2;M\W-_]S?=\.M>?VSX9KJ&9<&!,O0-0H&2$#7-_%Z857I+[-39?%J
M[!]S_/7"M#/ [YE2=K-P 9K?0^/_ %!+ P04    " !]B'E26$$<G^H"  !N
M"0  &0   'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6R5EEUOVC 4AO^*%:E2
M*VWYI'Q4@%1@TWI1#95UNYAV89(38C6QF7T"]-_/=B"C';CK#=B.W_><QTY\
M/-P*^:0* "2[JN1JY!6(ZYL@4&D!%56^6 /73W(A*XJZ*U>!6DN@F15591"'
M83>H*./>>&C'YG(\%#66C,-<$E57%97/$RC%=N1%WF'@@:T*- /!>+BF*U@
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M!,46V&Z#NDV?&6EL$Z%$+TG'SM\O*2FR8TFLB^Z+34HS9\X9<CC4;"_DD]H
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MG*8D/%_8OIT]6:* #"<XZ[AF3JX/E.]HT[NXZ9ZTRF&(9=:+/B$XR$AZ3G/
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M7'3#$C\!0-D%^'PCT1';B3TS=A\5\W\!4$L#!!0    ( 'V(>5(L?T,Z* ,
M  P3   -    >&PO<W1Y;&5S+GAM;-U846_:,!#^*Y$[3:TT-4!&2E9 VI J
M35JG2NW#WBI#'+#DV)EC.NBOGR\."5 ?8GW8Z!)![/M\WWWV7;#%L#1KP>X7
MC)E@E0M9CLC"F.)3&):S!<MI>:D*)BV2*9U38[MZ'I:%9C0MP2D78:_3B<.<
M<DG&0[G,;W)3!C.UE&9$^HTI<(^OZ8ATXX\D<'03E;(1>3Q__W.IS/6[P#W/
M/IR==1XOKO?MYQ5P04(O:?\(TLM.!R<&$"./CR,_Q(U17QU%?8 9(Q[L$K=$
M.XYAG;+Q,%.RS5Q$G,$RTYP%3U2,R(0*/M4<O#*:<[%VYAX89DHH'1A;,C94
M%RSELX.[K@?55//D7"I=Q781W/>T'KX';'H@D O1".P19Q@/"VH,T_+&=JK!
ME?$%%-3MAW5A%<XU77=[?=(Z5 \;9*ITRG03IDLVIO%0L SD:#Y?P-.H(@30
M&)7;1LKI7$E::=AXU U+.V-"W,.K]B/;X5YE6SGK0,9DT[2"ZJ:C<1W@WV9S
MW-NTO5?Q!@5_4N;+TDY'5GTH,G:G6<9757^5-0(P]B[.3HM"K#\+/I<Y<Y,_
M.N!X2#=^P4)I_FRC0:G,K(%I$CPQ;?ALV_)+T^*!K<RFG%89KKGW!C7_W76>
M,\DT%=NB;>V?\BJ_6G%T]:\D5[\J^X*]&NO]\]1%]M^"R/CT14;)Z6NL3S&G
M+G)PDB+#>O_>.B3L'!$::P!'L1'Y#H<ZT08-IDLN#)=U;\'3E,D7)P5+;^C4
M'O5W^.WXE&5T*<Q# XY(V[YE*5_F23/J#A:B'M6VO\'TNG%S#K2QN$S9BJ63
MNJOGTZH9V(:-6E_@L(_<5)<?P7P<YD< P^)@"C ?YX7%^9_F,T#GXS!,V\"+
M#%"? >KCO'S(I+JQ.'Z?Q%[^F29)%,4QMJ*3B5?!!%NW.(:/GPW3!AY8'(CT
M9VN-9QNOD,-U@.7T4(5@,\4K$9LIOM: ^-<-/)+$GVTL#GA@6<!J!^+[XT!-
M^7VB"+**:</>8!Q)$@R!6O37:!PCJQ/#[<\/]I9$49+X$<#\"J((0^!MQ!%,
M 6C D"BJ]L&]_2C<[%-A^__7^#=02P,$%     @ ?8AY4I>*NQS     $P(
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M>R2!]7$C<U4Q,J6_6&>@,%DDH6U1SPQ[KMV&ZO+E_0QB@D@"&V(3*R#&C96
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MC/[ )2+S6HASJ+N3/Q4M-M\;-M]*3GX#4$L#!!0    ( 'V(>5*WO<)+@0$
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MZ?AQ^=A$"><CSA9NQG>_4$L#!!0    ( 'V(>5)CUHH4FP$  )07   3
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ ?8AY4IE<G",0!@  G"<  !,
M             ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" !]B'E2@2.N56P$   $$0  &               @($."   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ ?8AY4I<RSC8Z!@  !1H  !@
M             ("!L P  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4
M Q0    ( 'V(>5*JP;UU!@,  )T*   8              " @2 3  !X;"]W
M;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !]B'E2(9-;08@$  "(
M#@  &               @(%<%@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
M4$L! A0#%     @ ?8AY4FRII>Z< @  ) <  !@              ("!&AL
M 'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( 'V(>5)+W*J$
M2 @  "LX   8              " @>P=  !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6Q02P$"% ,4    " !]B'E2T8W@%9<'  !2(0  &
M@(%J)@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ ?8AY
M4G>Y%NTV"@  5QD  !@              ("!-RX  'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;%!+ 0(4 Q0    ( 'V(>5*@?^3AN@0  #X*   8
M      " @:,X  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( 'V(>5(FK*(J0P0  &8-   9              "
M@6UE  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ ?8AY
M4D8*CDNZ#   !",  !D              ("!YVD  'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6Q02P$"% ,4    " !]B'E2N@]#8OH#  "E"   &0
M        @('8=@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0
M   ( 'V(>5+,7I? 6!   *(P   9              " @0E[  !X;"]W;W)K
M<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ ?8AY4IKQM):? P  CPD
M !D              ("!F(L  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q0
M2P$"% ,4    " !]B'E2?)8(# $$   *"@  &0              @(%NCP
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( 'V(>5*C A1F
MJP,  ! (   9              " @::3  !X;"]W;W)K<VAE971S+W-H965T
M,C N>&UL4$L! A0#%     @ ?8AY4D6$E_R)!   M!<  !D
M ("!B)<  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " !]
MB'E24SQ&[D<"  !O!0  &0              @(%(G   >&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( 'V(>5*$^]NK_ (  &,(   9
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M970R-RYX;6Q02P$"% ,4    " !]B'E22(#U_UL$  !H$@  &0
M    @('$K   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (
M 'V(>5*-[HR"R0<  -(E   9              " @5:Q  !X;"]W;W)K<VAE
M971S+W-H965T,CDN>&UL4$L! A0#%     @ ?8AY4N\N1$%# P  '0P  !D
M             ("!5KD  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"
M% ,4    " !]B'E28-4OY<P$  #:%P  &0              @('0O   >&PO
M=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( 'V(>5( DA&J)@0
M ' 2   9              " @=/!  !X;"]W;W)K<VAE971S+W-H965T,S(N
M>&UL4$L! A0#%     @ ?8AY4C(R]"2$!0  E@X  !D              ("!
M,,8  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " !]B'E2
M9ZI9X?P#  "\#@  &0              @('KRP  >&PO=V]R:W-H965T<R]S
M:&5E=#,T+GAM;%!+ 0(4 Q0    ( 'V(>5)S.@N31@0  !L-   9
M      " @1[0  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%
M  @ ?8AY4EA!')_J @  ;@D  !D              ("!F]0  'AL+W=O<FMS
M:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " !]B'E2:$$<3W,#  !A#
M&0              @(&\UP  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+
M 0(4 Q0    ( 'V(>5+F!V*!7P,  & ,   9              " @6;;  !X
M;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ ?8AY4BQ_0SHH
M P  #!,   T              ( !_-X  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M    " !]B'E2EXJ[',     3 @  "P              @ %/X@  7W)E;',O
M+G)E;'-02P$"% ,4    " !]B'E2<L/Y7X #  "O&0  #P
M@ $XXP  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ ?8AY4K>]PDN! 0
M*1<  !H              ( !Y>8  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ ?8AY4F/6BA2; 0  E!<  !,              ( !
MGN@  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     "X +@!Y#   :NH

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>110</ContextCount>
  <ElementCount>375</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>34</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ConsolidatedBalanceSheet</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ConsolidatedIncomeStatement</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Statements of Operations (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ConsolidatedIncomeStatement_Parentheticals</Role>
      <ShortName>Statements of Operations (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Statements of Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ShareholdersEquityType2or3</Role>
      <ShortName>Statements of Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ConsolidatedCashFlow</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Organization and Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/OrganizationandNatureofBusiness</Role>
      <ShortName>Organization and Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Going Concern Analysis</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/GoingConcernAnalysis</Role>
      <ShortName>Going Concern Analysis</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/StockholdersEquityDeficit</Role>
      <ShortName>Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/Agreements</Role>
      <ShortName>Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.aditxt.com./role/NotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Stockholders??? Equity (Deficit) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/StockholdersEquityDeficitTables</Role>
      <ShortName>Stockholders??? Equity (Deficit) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/StockholdersEquityDeficit</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/IncomeTaxes</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Organization and Nature of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/OrganizationandNatureofBusinessDetails</Role>
      <ShortName>Organization and Nature of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/OrganizationandNatureofBusiness</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Going Concern Analysis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/GoingConcernAnalysisDetails</Role>
      <ShortName>Going Concern Analysis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/GoingConcernAnalysis</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of lease costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ScheduleofleasecostsTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of lease costs</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of right of use asset lease assets and lease liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ScheduleofrightofuseassetleaseassetsandleaseliabilitiesTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of right of use asset lease assets and lease liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of lease terms and discount</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ScheduleofleasetermsanddiscountTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of lease terms and discount</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule future minimum lease payments under the leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/SchedulefutureminimumleasepaymentsundertheleasesTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule future minimum lease payments under the leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/RelatedPartyTransactions</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Stockholders??? Equity (Deficit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/StockholdersEquityDeficitDetails</Role>
      <ShortName>Stockholders??? Equity (Deficit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/StockholdersEquityDeficitTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Stockholders??? Equity (Deficit) (Details) - Schedule of stock option granted was estimated using the Black-Scholes assumption</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ScheduleofstockoptiongrantedwasestimatedusingtheBlackScholesassumptionTable</Role>
      <ShortName>Stockholders??? Equity (Deficit) (Details) - Schedule of stock option granted was estimated using the Black-Scholes assumption</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/StockholdersEquityDeficitTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Stockholders??? Equity (Deficit) (Details) - Schedule of analysis of the stock option grant activity under the plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ScheduleofanalysisofthestockoptiongrantactivityundertheplanTable</Role>
      <ShortName>Stockholders??? Equity (Deficit) (Details) - Schedule of analysis of the stock option grant activity under the plan</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/StockholdersEquityDeficitTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Stockholders??? Equity (Deficit) (Details) - Schedule of nonvested option</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ScheduleofnonvestedoptionTable</Role>
      <ShortName>Stockholders??? Equity (Deficit) (Details) - Schedule of nonvested option</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/StockholdersEquityDeficitTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/AgreementsDetails</Role>
      <ShortName>Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/Agreements</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.aditxt.com./role/NotesPayableDetails</Role>
      <ShortName>Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/NotesPayable</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/IncomeTaxesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Income Taxes (Details) - Schedule of statutory federal income tax rate</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ScheduleofstatutoryfederalincometaxrateTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of statutory federal income tax rate</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/IncomeTaxesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/ScheduleofdeferredtaxassetsandliabilitiesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of deferred tax assets and liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/IncomeTaxesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="adtx-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aditxt.com./role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aditxt.com./role/SubsequentEvents</ParentRole>
      <Position>38</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>adtx-20201231.xml</File>
    <File>adtx-20201231.xsd</File>
    <File>adtx-20201231_cal.xml</File>
    <File>adtx-20201231_def.xml</File>
    <File>adtx-20201231_lab.xml</File>
    <File>adtx-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>64
<FILENAME>0001213900-21-017776-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-21-017776-xbrl.zip
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MS]0$U\QENC.< %9.V ,S[1FN;(X%E%?#!046G,T#NZL&!IEJH.: %^& C>L
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M&)?EF1D+L*Q! :I%C]?GX5KF@"1\NSK5&*=.R0!S",^::52QGJT0UU5KW.I
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M@8-P^;3AH9X!CG6F^'U'>6:ZXQ*A=7'W)96X.JU8N?*=X01/K7C6O,!YRGR
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M,X0Z$!^_B>5SW";X(X^M\V":6\ G[K.%"9QBF_GTZ?C2$;_AC5H+P3=FGZY
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MWB[CT0+25N3QQ.R -TR?$Y^)F@ITJV("<K5/%U0MW1/N&-[(C/R3=!U+T71
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M?95*KN+?X:N&*$LV 5LO6<>/T85EY4=4"D/#^RG(>0TTRHC=H17J8LC*!&4
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M722L8)5E&=8]?@F)\,F// R1@H1W% -DI2])7#Z*KXSD+/#CN)$E\C0-41(
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M83C<17#)QE6"+MIWF##@&?O!>L#X3L\0@/\WU':KT6PV [R(3MTH#)U&;S"
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M([58*?5HH;0R K1(\4'YO>IKJPYIPY*(4+#D(U&1WY]'0,W1PEYGA7I( N:
M,I:81,L@2V+B^?6$-,DL21G!]0=:4:=H14EL%.JS"&I0;/(#J./R4911LW)N
M 2^(_%U%O3K8&.J7J1>Z7I&-%XP\CLQ!-&BE_F/DGGR80U2N++ZZ!J=O;;T[
MU9!8[(Z];DJOB=*],T5H(1^C4G.+:LLL2P.O4G&Y>)N/U6HN\VC%:KBJL"O5
M\O1X)019T+YO+:38UE8M)5IL#D/WH.):U#M6BKJ(.&]3=\W=0F_=6W/CSO_>
M%6:Z\POYZ:E?98,"KQ%IUY=?HD"E=,%G+@9,)\"^,W]20H<789S;2(ESOU1_
MNO6&7[;&F:OC+V\CTK(3>'Z!L,JVR&%\CY;2$PN'$EY;)*&.G+QHY&3IP(ED
M'M"IKSCTY6GOL>[%=&F*3JH*>I\K.$Z;:W+:ZK<;W45=>=;16GM'\%,\U+!!
M(5HNKK!B6"&Q<R\2%]/&<_.%TK*4?;"SW=O6Y]ST>VI#;77G?8X--(E[TR0M
M&>ZHH!7?%FRW:PA1ZNE&Y-N+3B)5&OU%C=2W*3ZY:RA^H0CE%AT:K.S0O#9W
MIG;?=F@_B:;X%$5MZ_!#S;];X3E%4R1S+N0SAJ*AA6J5\()--2]., ##9)%1
ML@7;S/(K7& 5[+C%7JWS7YBSUQD%*&UX;I/;V._T&\UN>Y=<]!W&]G8[Z9NP
M^$ND"87%7M;@*NZ6H[CAIO6U+UYG"VTB6^B6W[:B_J N53U0KG4OV0MT0YDK
MQ?)1^.J*D$)6IEM@=Q5*Z>[W<\^/OB;;@:9=P59^-"RZX^S^%#?!$EE,^?)6
MYG!NM=.YDL>%"X[IM(-NK^#*7M>^GL,EHT"XZ;IF*9[(H?N+1!+Z!\T%24W9
MT_]M4>B@\KT@1<UO3?,@4?9&V1-7?77+PK92>'=XZD\3-W^S"PDZ2_1HV?[]
M8A>"H<6V#*#2@EA-<4W_\DD8[6:WT6TOT #5*/CMU>] 4FWK%75;51N]SH*[
M%3L>2EN!@/.(V38"MKJM1EOM;@<!UR%@I6,]0+9EPG2O.GJIJ9U&IU,R1:&"
MJ-HNB_\:;3H*W@F#+MV2F[?0BBFA%]%!:J,UZ#5:W:5-_EU(R2@O'6OC'RR!
M^$%4:3.F,Y^7K>.E??(9IP(UN+,Z4&WW&\U>R=#PF]"!98.VZU6,*W#PJXRX
M;_A0(V[X1;&6J")T3@760R51Q-]PV-"C,E>78WIC=&2-KJE3WI6#42WO^=(Y
M#5I[5-)DH-/6NG*7@7(@'*X+_J)]"EK-5E=; 7PE00*LH,,LEW?!XD5,ZY+<
MA6KGWF#EY/V/5*"0UYT.\$B24=?3E4*4Z66YJ?;T/B_Q.)3P)VK+4F/[H(#U
M@^'RQJACJM7=4_L-)8;S,![>YI2)_1J43B3N%[TYW;G>R+PQ$)7C#:J3QL *
MZO=*Q7ZIN4K4'1+>R%R4_DCMP??"'J'8S@=K,)K/-/)0#(F-NPX4OH:482(@
MPKK!8?>DH"1Y#)%A"4H9,D!#&!6^=W1+S,VF,]-^9DA67CC8<7D_I1'I&=MQ
MX^UCZ551;S/"0M0/(:72>H*>"B]P+&A*O<X/\!-6N02=9_/RXJ*R,L?@E!JL
M,^K!-/.=X00AHCY,0YS&-+$Z.>]!3I-1KP17-.#%ADXW6212]JB=4HA8W0W1
M'35[$"B*& X[^Q!/N=BX <F'4_-I"7GANY9MI;\N'@9$\+*JHM+_WKV-D*.H
M,.<!^SH7Z6M82*$?2KT8KN AJU;YBU6^0%2MWS/U.W5- ^W.L.X&]C*;$<H4
MX"P4([<A]0D-RO_'NZV=1));J,1WO%WH1(?AQ&PX# !"^H^DB;0!)R&*V@]:
MI]_HMCJ\;#EL**U!%W6*B[K8> "]O* Q0;K<Q/N<? I .6/LS';$*U58L@ ]
M "] 29\FT9RQ/"Q%K5*U#[A;#(IL>%XS%\@[Q,:2)]A8W28#]93S1-TY-4,#
M!5CCA.7]24+DU7I)1MY7:D9)B@6%FJ.-;)D(8\+2E*T%[)7">PL'+^%/TGO4
M6 '&]-AP8MFF?1_4F1<1V[#'R8'"BZFCQ9D[/6;_F,]!XP:J11XJL"'O.O,U
MZAX!4(;M%R3-"6),]?M='^;AO_[I ];'SZ)I0MAZ)N@;A]9UU+Q%N?<-,M,6
MFQ@%1'?>T3S5'4QQ<J^8<S,!]?\2UL8V9W+,RSJXEL8P%'/#I$#N!?.43]CX
M$TQ&W/6F0$K"Y^:%?W5L\A6:P7*&?#GNA+J(NV2;TZ+OGL$!$68QV='8PQ+?
M$BW&$4F/R7PIRR># 5TR'- 5[AS-0,Z5[7NN![@E.P$$A.D@.=P2/PCQ'0)7
M#"J$1(9L-:AFIL^=NA%" R:)PD"Y##WI=<-U?1)?;^+8_OTD\ &GY,[P(:6>
MT;Q_3 #5_CQ4,@W<&##L27B9,7#E?M1W;*C[7$,9#O=*77*KD#S43^ .,Y0\
M8S]8#_A[Z2E)\/^&VFXUFLUF@)>9J(@'PM!I] 8#^+VK@$>(+JBHY29 %&UT
M(Z0)U4-T!*1,1+X3AY.C5(Q0!#JT.=6&VM0:G53HU$:KKS7:O7XN=(B4= B+
MPY>FG!?H6=GO^RK NQR31WPYBS<4Y3RPC'5Z?G$&]BG0#\@GK,+4N>*F\HE8
M5K""&\Z#5<'3 9X!EA'PI$]VN!IR"IG+!(P*[--9.W)*P ,L"QQ; #D!G\&V
M<,2#>?#$E6-;\)'W7Q$.4;W!+S;FL9 =M:46>%3BB*P-^K06CV='-Q]IWX-1
MCFZ^N!0:!'SQ3CVZ[TUL!RQ=4JRF@1UKR"XW+!Y<Y)W&J!WL'6.PC[$'ZKL=
M##6B5CL\ILJW=FRHK=_9#]312.>;?#0A3 88HKY:3YZ(3V/#>0LV5C+R[YAI
ML(>@^0\?CL ?!=,IS*"VDS\:/X5]E5P?3/.@Y5!@FS?@$7@&]P<*:* +@N?$
M(%P.!FAQ#Z)GQ$/8J$DR\;$=(X43?S0>H@?DX#.A!9OTW%O&&-X"\$6'.W1Y
M>!MQ["%&;7EYHZ2%[D)931'7,W2HA1',6US"<NJD+LI:%V6MF^+437'JICAU
M4YPWM]Z=J@U4-\6IF^+437%PZ+HISE+5+NJF.,7%>9L*7>P6>E^\S(6<;IOJ
M'\^=MX>;8_C".M)IYV=)YOR6@R,G@OGD?K ,\]=WGN.S=^_G#QS7NL[8\I:8
MM\2ZY+%OAA,V\DUV.3[FI[DBY=>E:KNO.4*R+:Y6'1UY&W&0G<!SW;)&S%"W
MK*GC&MM<D;-N69-3HJ!N65.WK*E;UA1GW[IE3=VR9G>JX6Y%V8ZZ94W=LF:;
M4%RWK%G9H7EM[DSMONW0?A)-4;>LJ?EWVSRG:(JZ9<WFMYFZ9<TFG/^Z9<VJ
M;F/=LJ9VTK<TB:=N62/YXG7+FE?IBZ?E\I1)[TC4]J!@^.7XB\OH+/0&[3EL
M#).7A-+Z=N1>CK-27EK]=K<?U!?)&OYP92#:,A#I>3W9Z4.)"9=?+.BL3E]3
MLQ*9$O,<5@/2PJ5GSQ*XG<^K++D]T)# "V98D$E6")("1,Z;@VH;8E5);'!D
MVEBP[273G-;;LV(+3/6ZRU$U)\QUEZ.ZR]%R'GV)+D=9"CQ/:>;OJ@%1CCA-
MK@/!I1]Q/U?S]YG#*^T/K=T^R8)L\?B')< +FMYAS[LKY@QCA79GL.KBNV+[
MW6'SH-G'N@S+3CVW6T8VW1G5A_K,"_I?T\7N*U&#\\QV$L1[\5S>-6YRKV2'
MJYLRO9+K13&2UDV9ME\^<PE8-V5Z<0&KFS)5$#&NFS+539G6IX/JIDR;Y9^Z
M*5/=E*E*'5@W9=KF,Z6M:\I4210B[:XS!I@R#@2"84]\=@%#W#XR\X%]!B:9
MY-:<SS^U #<5O-1DMZGR$,S%:8H.A!6J;A_M%5:@JN"]E5^!F#A9':_$RQ.'
ML17. [LM<%J6A!NG7GC*$V--:81SZ\SV'1QG!<8!<QJLZ<Q@:8&Y#Y=CF!5.
MZ,!$ PNM/,J3X5TL-&H\H"Q_-;S).3<_SH7U<<&\HRF%W)<'M-V'75HN$%]D
MO@!*WC4B;VD5''(NGF2>/47[G"O=\9YO'=UR=5YA<]53R%==W?;B\O:48[(=
M/[ZY/OUT='MZHEP=7=_^H=Q>'UW<'!W?GE]>W-"F51>WY5@3G6SB_:&.)P8;
M*Z=/;,CKA5_RYES*C]%CPY^/3R^C/T<__Z1,=#<H)SM2X'%/-ZRP'1:6D.=-
MI:@OE^U[@2,[5_9<V<OJNG-ZB17Q[4<8_P?^XP^MY@#KHL<;Z33DGFERRZU"
M_7[V>$5XN<^/J)\+]G6STU&^@'IP@_X9.!I ;UM,5%)/5MBGEESP*Y($2P@'
M9=J3/WP,?\!2NS:@R_-,!BML\\KOO+F9XR>ZB&45Q'TK3)S'P>>693_P_B/I
M+'R^+A;.YN'S%![N];#SP&9XN-UK:)I6CH<;J0S<R.9@F7_;6H?Z*M3\F^3?
M4VJU@ H6^.4?OOD,OP?]*)!R'VW=H2Y])V$[1'TVLPW>/C$B;1KK1PGKZ9Q_
M&>?\ ^4*F-P)>DSNB7F0N04775X"=;'CA(+1@1FC$$&0)(&]*)"7?-,+-!NV
M1EM6E/;2>G0D!4D %),DK=>I0)+V4OJ#I.T&&# ON1L4E"1DB$B:Y,T 8*F%
M*4V8+BUE[S-UO=+"MBDI1-.1*:?PA^T\8SEZJE*OAQPR0^.;=ZVA'WF#OQEP
MR="8Z2;U\5.;G,=T6#YX<>@P4%5]Y-H;-O,XZT10(&U);+A#PE.-X-GVWZC_
M"C)>X3Z$N";8/@@VY/Z9;E#;T[%OFF^8^ )[)#=%4!BQA0YL,44-HJJ-0;_)
MNZ%%=WNH=TZ"/1#?[&DXT:U[WNT1QW,8L +U\ 40.HW!H"EU7,K4U;)J.$C$
MVW()*3N_A;W&N7[H/D/'46P0[J5#[6 FMCEB^:&/CAKW@K_1GA/Z"V+ SX3W
MA(<LA1=RIY\+F"T/K!;/!BX!+#@7G>;2$&=0YH2Y0\>@GCN78^G[!-2M+*<^
M%_[#$GKDI=R;$K[-0C;/0F8LV'/$AY9;%9_9CCQB%34[82U1BZ7%4U;(X.TT
M:8Q\G\K$L2)P.VGR6 Q<\)2:Y02R0HGLYDMDU@I6$LF->&LEG+55!+(B>5R6
M#HEC$136%Y'67IJTAN[:ENV=_319+00LN&(E1;4Z21WD<T@&_*OMG>MS!I=R
M!%<0U*KD=#DJ)!2^UBPKIC'&9W?>N>5ZCH^QA3-]R!:?/76;Q/.:"MYD6N_Q
M9IRM,V9(V3!C3P;'4YC+S_GNBF(CN7<)NBI'J8#LUDX%4J-K!>TL&+-FCIE,
M))SGQ-KR,[_K)IYM/_)?\K"H];.I3R) ,Z327%7!$1,D+P3'/.3N_"N\J>0Y
M[^.7W\=R6=AYWT]P_63@%X RSR>R7CS]TS>\YPOP]E_J$'";O?[D(>!>)WX$
M>'-[>?S/_[[\=')Z?2/[W<KIO[Z<W_ZA_'AR>G9^?'[[TZ9.!'?B1!4_4!-0
MT>Y[CQB2<%'W!HT?G^Y%1D#0"/0O'F8FJT#1^+D.=95.;;_=P(B2\H#:3/D!
ME'93C5HR;WTX;Q5SJ=]K-P9J5W3'GF]+CB:0PX;VO448%:VU*/R*O:Y[C7:K
MC;8/?UJV?"@B)\XB$#QQSB!:D2? 4#N<.DC+#$AP.,/R=.O>P'MNO&HG)]E(
MT3UNB?4[S?CXL!_8H0_7T :]1J_9RNK!'L00"0SVQ)RAP=<:-O06Z&#& X8J
M-;79Z+3;X7OR*]0%7KR6ON2&ULEC20(B;>2T%T/;]<IA8^8X,#YIB_29V]U&
M7^TOP@*W<*F5+<$"S^F\GRN&NY_IMB'B0XS:%7W1"P\*CXS (,I"CM9M=+LR
MD !";$CI, E'/K^ZE,%1&VH^>A.O2P<&>,8%MC!#J>+0I7"W3!U^FD;G ((?
M[[!^!_@.>&(!#\'_'_"P86;JH@,N=N,-'YJ&38/C46DP#L&B\3CP7#D9TRD;
M&?"=^2S&YDD*,@;P,W]:\*' 0 24?V<:0Y F6,"4+V>&C6M@@(,MU&_;<%R1
M<8K55O-8#/DC4'MYFK2O!<I/V4O7I?@RD(S>&#.A1-V0LH_8VCK)>L29#AWM
M3HSA) 1->N6.A<MWP=!%12[>BK/KUF^!ZS7'1-?V!W $,-&%-*MR,S,-+V&-
MO4D,77)E^ _? D-KD&9K,,JO\$G=ZHJZ#W*QKX$P<(1R=G<1G2@-&+<)SH@Q
M_N)[+FSZU)(]0\SNGI6Q81(G[^F4XD ]S/GA+C5LI_T&K4'<PJ=<P+D\4D/S
M4?(EPQK:SLSF&164&2'VB*'#/-UYIBW7$P_3+\$?"B8MF/HCVHT*MC]W$'+,
M?=!-4T2?<.;0N@1X^):*R@*?"5(S9@ <L_A](=[A?CCD^,25IK5DIX'W\$@:
M>\Z#? >-W:G?O3Y"GF"X:,^Q]3 GXQ&?E+K%-Q!18$680#)^R)U"J#4KA-WR
MSR*;BP2A=M.6==-:*5[:+$3N2SMJN\64Q(7['\D8"'$?V!,U=\K(.[<XABZ'
MGLT= +77@(W'24W\&]FS(.WO:&1X3VB).?J,^9XQA,G.K>$!C:#PF"%^ <H9
MDPNO3-U2?L07Y0Q >A9_BN<!1DDH88IX^&20S^>&;M4]'4L H(Q/BAL0["$@
M66PZ,^UGAGC [2%*#G2E*;[,\%%RX!+BAUA(>*5[4_T9MI1@DY[YCNN+0Q$Q
M+4%#8>D1X_"%H'-_*EH):H(1WJMV,1@^PKT\'?$<?+":#81LSV.B@)BBC^%-
M3A;@[ 9,:C+7I3)CL$<B&/"8:< S,':8S5DJR>>U,G[@_I1,U0K(V^\WN<M/
MC,'Q[W)K2;>BD 7W02AA[V#0;M _&OJ_/Z@J*'#2WV'<IZ&X]I3'7,AI>6!D
MLTAN+V>$^:> );U'-'3PQ(Z[P7COC9B$<YU'=_FYJ%"BX%@W@KT$?7<$8L0X
MX_!M";C\!Q7#$(W!H/>&G:#E_>2 5WJ!9IGGE3BCD-;YH1TP!K>1D;YTB&NA
MA^RBOAFR8D2=)ZC6: _PD+A[H)QEV=Q\$=)0J%IUX#0._QY?0+@ZG"@(UH#:
M<X-P+%T>WK\93FP3(P"8XLA?=#!GD1OL ,)8%WL+*G33M!_=#\5XK2[YM>I]
M^NQ;UZ<QMIR[T)US;7V3O0/6)_.HI?=)0\_SXBNM&Q+4?^ODUCD[?<(;#2#G
M(P.-,!#A9X.9HWS$%"X)M\DZI:J67QNNBJIP614M=U@S7!ON=V6,QD7L*D$)
M%?$R37'6IBJ:!UK_;_O:0;=3B:K(*8+ZTAJB@%8PC3$R!C<\RVP;.4#N*%]H
M![WFOMK<X!:RPUHE9* 'V]2]]#88E1H=6\TZ:EO=5T45O'7IDT35G#?@QX6A
M) >VL/WY+4QV43"T%/AI@9]C!(?(_@R>L._P<%,J:$9CN,'9(Z;@4AX"?7EO
M@QQ:=!#CLB'>UL.$!;S?ZMA@89/G%B8["$F@4O%X155V&M^P&QZ2+Q]#2";0
M=T/?E-Q19N"1$$\',*8SV*4,^&W*O(D](LP'@<+(.:?0BJ=_!UB!PC;/IAZ)
M>\8B$H"ICXZ.AWLFW_G0I0W<=80NO'<GAHT"=-%W"OKXT9IL'L^!/50<7%/;
M@,1DM/(@+T4:JV:/\)1%#GW(8A5M,(OD/8ID3 Q@,0>W4?EU?A([TQV*0XBT
M$DK3 0"P-::<[!F[8QE+^GDT3).(:U@^W0.&YPP/\V88<Y1P-!XN(39VF,D>
M,.03A$Y\EW/.E.F8FRN)B 0N+E&4\I0%AB^7.!,>5%P?V1Y0#@O7O6)W1JE@
M!;-L_WZ"'/&=>0)CSSP]!UO5IZ+PS;/K7MR++KP#B4TFE3(!ZL6) ? !5UF8
M<1;,-M.?,;6 ,V(D,TA'"\^[,9W<U/%( OD0;W?CSZ"*)N$8M-/Q:R9R)FF0
M@A6*H<WHHCC\ ':H,:/,&IU.\<,A(S2XP7$_K)ZYC)%D<:9]P[SR.<R0P]TO
MC+3.!VF3B2&F;7\G3'M4)H DDVP.#.8NV.%F.NQ"KF[RF#0?$A["C<]P^!WT
M0"M%*O>!F?:,IV/ LQB1?L-D0]D*12M,?G/CVA<8?0S6B>]0B!QI"AO+$$Q$
M\9>#1XU ']?'^TD&\H"D2@'#.AT]XAL\+S+<]P)E'R1KAM.0G?K&Z8(8P;,&
ME Z#ZLF C)G/KA%:;/-[I$)I0[PR7W"TB\>XK^6XHE0$07YO^4K+6=$)HMTC
M]9W!+\W<HLP\(_&2[Y7Y;G+*N$L5EY97# 0 LEEB!BV%9@M6@QD2S/E9682N
M"*@+'P\=\Y>:42!Z#I;R(9&JD)@(*[T 'L-&7)*H E"BT5'\6X0V.!6;^P'_
M=Y5Z4K9C--EN@D@,$_RX%S;2DK_]!,[XQDBQ0P%8L45TV[FG5I=2UO%<AD-%
M)WW;U))0;:A-2O^JX,2O["'D^MLW5M,H:V%;OY?!SA9Q4>^@]]8;6_[&XQ2[
M<.ZG-IKMSF*97PJ&PB;/QE:K';3F6[R]QH7V#P8+FD=M+DEG*XY8%]J!IY14
MS#/Q>) @18 7FT[+*NJM[\;S(Y6B6LJ8S(;\IS5@>)<['AT,%JBGZMH=O?D6
M>_N;PO36&BSS.C'6CRG'_=%**H("?9[6T.-I)38JV.Q):ZCM5GG-N&RSITKZ
M:>U6.ZW6@=K?(>3N*B/W#OHEVXVNVK L/_-J%XX)=O.<X,*VQ(6JC9X5;$&<
MFY=ZVUA ]-6?%^Q+,JN(X+3\5=HYP6:/!W;994V36-TK$(E>QC=::S1B@:E=
M<<QEDS>OJE_9UG@+8G_L=7/#M%FASA<*\E=](%(H.+JC!R+5XFIQ:/4%POY;
MIL=_)R5>2E^_C,+^L=M;Y4Q@/JRW=5N2=C!HK4]WO[SVKN/?%8<+Z_CWZXI_
M2[*Z>UO*@LAMGK^@-94UA+UV-.@UZ.U6[':W(K?:@;:AR&W<.'R;MSGG,NSC
M/4C"6K-2R>/HJF!8:3,LLH/U=YK=1K_?5$9%2XOO\;L4E*@_-/T1+UMYSRSF
MZ";OO"C*?.'EB@<6P.2F5K>4:EIB#;*PMRF_K>,$^8[BV@<L9^\N')'N"/V@
M-GI]M='N=T0]*N4QR*O412:E?$D19]$.VLV@I%B\B7"PROBEM2QDB^N9Y?"M
M-3IJJ]'7NL4PCE66<A%.;%$9UDFRWN1%"6QF&I0%["YN">S8#^)64E"DBDK0
M6HI^?^^P^Z#?:%HI+-V=KYY/'8 MV]H/[^9.B0O"&QHI4$07,U*OQF57)N3<
M+=_(=?V[_U 16!NY*6@='+ MU2!T-\ ?*:3?XKJ;7T7-?T)#76)3C'S$-9+K
M3Z>B?'+02BL0%,YR+U0!K3B2BYTJQOV PBZ&_-JZO(?B1SU+\/;Z#\#J:T>O
MZAA1DN;M/$5\I7Q<$/_US:+Z9M'*!VFM/G:*6A .J _2[O&*4;M=HZG >6-_
MK6C:FG/X5W'-J-\8-+N@!*J_E+*-QZ?= VT!;[Z2A7867H=\8]>,HBD*G:?F
M4?1E#O[50;/15S=T\O]2=^/4MW$)<'W):=NV)Q;(;N ^Y#I2&O*6M?5'[C]B
M/U3<G1=DPVQ':L/.HKEW4/;*5'VS[Y7>[-L*.Z6^^K?$%$GCM]$;#!IJNUL.
M(?75O^(8/FAV=@BYN\K(BXO:U%?_7MO5O]@IWMI/.NI[?Z_JP*Z^]U>E;5;L
MHE7).X#+QOBW*<+/NP467-J&ST*V"$_KKDE7GX14&GVL3T+J P*<8G<N V*(
ML(L-<)>E9)E3@1<ZQU*WADTWH3GKVX"KA\W;_4&CI]9A\S6'S1?(97TA</4+
M@=7'PG8T$-;2"G@<6Q1RW*UH;NN@N\!/K:\#5G<=4%RMB)IFX5VBV.4BO&I!
M=^>"%F^N 7/KCF)8,]^CRTB6[?$K9<E.,"[V;^2CW-D/K,$OV/$&<T,V$W?@
MHKY\+-88-[RUEM8\\ U?-%OE+F=([XS+A2W8D#I:E[[_053Z'V3=- 00YJ^-
MXYL%;AVF7#A,NV=X$[MG>)FXW;F7<KTS>;M3&[0;@W:_\-W.YL%@T=W.M\MZ
M)YP/B/L67_1%C[#7Z#5;$=L],FK?*=)L2-N$J26*2P'X9&NV^%5:;$@;L?O,
ML8>,C5Q^,59M-CKMMLSN7*GPV=[RW=2(;@7()C<D%&JBRZ^AAF04J*4+I(\.
MN'T@+0FTWX!^YR.36K@<CQG"<$!  $5!+X7#34 8\>IK0"J@J\'OP_Z N:,-
MD-M /,>H*4@\>??$.V"&:4AD.A*\8X!V4@K 0I]U!Y007YO*68FK"K'GR& 0
M<P*Y)@@+*"V'83=9G&7$Q!_8/0ZL#]1!H,2HUR.HK:$^,SQ4:J S@'==+VQD
M*U9-C&YA/T'E+^;8B@'8'7H @^C?:%BZ-31@A.A>=0%N_>6][^[?Z_KL S7U
MFM@FD,/E-W8O8$\^,=RA:6./TUM@NX\F/',8A#1_"5X])E'#!LSGG-8^?+QF
MXU_?<7%\1ULOO$_?#5O?CMS+<4L%OD&ZOD/4&%/==']]=WYQ]NZPWVL/U&X$
M67+XP^3\1R; A8Q#QV\?L6'GL;2)G8H]+(3*=T<)D)K?SAQ[JOY#MQ"B6SL5
MN.:[0ZW=Z[5;[0BV8E.'$.LC[XECFB^%"]45$-CF([CGEJ=;]P8PX9'K,L]=
M@,M"@!-6U0Z(7_.7]^5!.(PA._GKL>\XV"0Q![LY! ><@B_4[S0CE&9,<)@@
M^BF8?ZY+"Q%@5\%[;=AN8+>)H,F8)DY1SJ$24L]LY\IA(+B.X(P*Z:C)A"PP
M\Z$$:/03OA&<GBZ K:ME ?>-AN'%?3^3IOZ&VPASC^(3\=\6+"4=ML.8Y##/
M,TFW78Z/P,;S0<E=Z<^HLJO&<KO;5_N!M"R:]C!=NN7W3MB=5QET743<O"@G
MYYM3E+EB#R8!_;0(B=U6)CN<7UUFDEKK=KO]Q':S$)3YO:::);2S.3JP.?"O
MP.+(6E2@4\LOJN!F$(@T2-4#FC/YR^I(JU('X:K4P;R:4XON!0D(,@@2LQNN
ML:&UR[C.G)F&ET!^ *8OD*\-Q,=WAY>6 I^9H@W2+$D&Y$#WG7PO1=T'BVA?
M Z.1IA-1 Y<F!-O)B'NHMI1HFNXD8/_FL6'B V"!80QV; Q%#14=A&I$_:#!
M>L.1Z0LQ-(SE$4R)E\#\LYV9+=H[AW&+&S0$/5&7@IS3P-0+_S@!.QA,2G:0
M9Y[-H?FPA*2DFRN+Q*9+E-,NAQX6=D$&$Q^_W3[:_P:K]-)B-P"6Q2$,*[Y@
MP9<,&>);0%$92@<[N?#4AX[00N=-O3\^1X^ 'L>OC@#=HPO;XGM9 +[K.3Y9
MTN+8OS(%WN\W.[%%KPWD--S<+9[H+CF1J.#/SY*#]"R1D453G0#OGNF&\SNY
M1K(U" 1<'ET:J-F#03N!JO6O($71;1'JNKW,#>RS81E3?SHO;AR36HW).";[
MV9C4G[(QJ1[,R>\F4!G:#;>VIYOT1/IZD\L<%+?A$_Z9"G;;8- 3UD+*O/-F
MYDLIX.(&4"^YZZQ; 4>F%G\\B%-1MFHA3BVT.&#-]D'<M$N9;WD^*@0$!4H&
MG4ZGNX!IYNT5#BS:"Q5&;=K-+FRX"1-C;B8)*7.DOF93BY\2G 8E#2N 2^WU
MU7:_$Q!K\:15&3KTO]_YJ04WK]2B*SB\TOX Y_BD M%)@2(9Y,DP!HF#)"JZ
MX:W;"P:^[ZW^])%9;&QX!9BH,$=WU%9?ZRXT5,O"5M+%/16U&?D,CQ8J"V.&
M;+Q -_8$3<EB1YIVQ:=YY["$09X-CB1.P140/LB1%1 ]CRP]-7/#$L.E;E:M
M9KNC!6HG:]YX\&XIZ+0LKLF%3E6;6F=0"+S*E-&2B-0&[4&[7T8U5:>9KAGL
MI:[A,1%T2%51A==U>-72^I7IJPS8TEDJ%/U%LKD$C>+AZO1I#XOKE4MOPIPU
M@MD?R%'UQ:#$0;\2A[0X?:IN78<$J,U.6W(\%\*0W+R.3=UU+\=BCDOG&JU[
M7M+Q<GS#AK!PSV#NL6Z:;/3Q^50?3N+/KGB6T8WK\97!.5R\NE/9R@Q_=,6O
MKEK(T,U9%YBWG8.%BUH$1<J6.YRPD6_"P^FB+],;-WBN,H!_I_R[6SP+"$](
M"]M2E)GVNNZ@;DF:JIQ@+B<$E+D%L<GV;NO+V\"8SSZ%*^:S 5[I)03!\?U.
M[C6TTR!3<&0\&##$2'DVF%E5@[E-7MM3M?Q[>U5<VOM;!KEW6#-<&^YW9>RP
M_]_>M_:VC22+?O>O: 29@PS :$B]E>P:\#C.PGN3V#=VYMQ\&M!2R^(.16KX
ML*W]];>JN_D4Q9<HD9*YP$YLD^RNKJYW5U=AVJ!#\12'6*I31$34<H5H?Z)"
M[G3'O[SO=H:#2D3%-I)I@(3((158_K!F\$2Q8I?G3HTNNIV1_%Z1#ZA"CEBJ
M^ 3T9.I@)NJ:L]ZOT=%HTE'ZRGMEH.Q5GL3N7H2\S$JM^NJ..?P@>&BNJ\+G
M :.(GZ1,BI[\[07RQB&I'T=2P4.]_6%IGVCB(NB3,&R_8UJ)CZV5:]&21TOR
M/O&S"?.>T83VWV<P_ZZ%]9>)IM%6/&WGO3['6G>\)[PE+:*J8Z)JD#;<CK1M
MO,B1UAT.:D9:F1/]-.*^I]8R'L;.2U-X\ ;&3#R0O1<0$X+YAT!%7DHYOU7D
MGX?!PP&D]!^^G;@7 <24?U_9L]B.+F+?5D!QQ)400@QQ@YH0QX_=?/OUPE#U
MM:V!)7._"!\NLYR*BZD#2M-9_\"K5/ <3U]/.B!]E!41V:X1X6VDNT G4@RQ
M[5Y6;3%$$KJW!T")+,'H7Q':I**(_C).HI]9LS<D1##>P[.VM5G;VFS'ZHNB
ME$)3ZU3NB*N,H]-F%*@\AL/ #!2-.J/1/E'4UO"L,C"O2')_D,WS)U+#L]OI
MO8Y^2>/.I/JJK,=<K+0M$[EKF<A!\7IR]92(/%X<XQE:Q1AN6RL=9VNE0Q@L
M;>>D$E/$+0I)Z?>.JM+F\=7:5#*J=3<*N<=*R*-.5AW_ W1.JN9D('\YO'QG
M"#%9G%N*A[_;EP3/'U-D<4'O!XU%&<.-DS1_>QZ"C=I[Z+L]0#BI P1&8TUN
MIG2B=)P3_^T907M&L/,906_<E?JC#)/L2,\(JNYFU<]H^="BB05EQWM%4V/]
M[V".(SHP:)M^G>1"!YD'FZ_LP""8(M?)0-J.UM/J3)G(TE@IO:E%&IW5=\JE
MO([CO(Q8]:Y!F ;IQ!SG=*(81@F?I?+P79/.,][Y/2I*>7,'/J0[6C2/.D4/
M/]HSNA,]HVN$G=(>XI68(F[\2J/)1%+ZPV((:0_Q\F.X(P^."+G'2LC9Z:E[
M/L3SROE5=:^HHJ)_&Z5S606X^X4J2NO:?E=1?B*45:9N%+OS';[GO[65@]RM
MIB)[T<5$ND'$*D!'"YF%=$6NJ^_%T!"M')P3D'C-W!U*8(=&C4WNGXM<!@T<
M\7IF+[;>[96\$U9^?COZV1TKG\(5+@\+?86WVS-I[E^\T*C!RRQF\4\A1&YP
MDMP?'(B3HJLJ*(SL;=,F#I[&#_FXL2Q2@2\Q+[H /JM;69IL\ND:3RB]\NP[
M,>3X9Z_7_90L@))F.R0#??9"BP?AH4$UM>F+KZJZB]O1&5S T(4Q8[%:WGVU
M$8Q5456<*M8:N_F]HSI*XQX1,+^Q_-W?":$O]@=#T__Y!FB,OOGMD#Q9T"J<
M1,O*YN'#KM+O'8@5#V85%D,#, EF>!Z151@O*E+<*IP,ZK,*DVH3-X2!QG+,
MGTBO^8W=$OJC*LH>-89W\F. .5-8//QHV";N3.6OKM_]V9.'K1]58;G\\40>
M]L955)XY+1>J!#Z!$3%)Y!B]I_P<./A9Q&EJJ,-4EEF4B3Q6ZO*6CLQ5*L=
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M033ZY@]#BM;J[Q!+*&-/B3_3N(Q+0B%YA^P3UL "YXGX#FMFKM+%VY\T]=$
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M6YFF+,LPA> QS%E)CF$/67"7SF*S%F,=Q$ EW%.6<\Y:UBG..@+#_E'.7+/
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MI5],K$.-&VQR/ G>I1 W[E^'N@)3WQ"4'7J;JJ(@RQX5=.0%'</:PP7[";:
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M7.;+5"Q52\5E6%<MJ5XU.JK7)2IH,J8UX#Y4*>%*R  ;NR5D9 SD^D$TPZ:
MQ(/N\X9G"%-K51EM45'RM.)MD5M,R=[-T2U*T["HA5,TY*Q>S>;]6*O=.Y4D
M:(O6OII'NX 6LGYKR\=1Y*ZHX-:CT'4H[N\I! +>\K1O)YC/Y9"0_>1A[!&R
MU.)<CZ\0X7(\G2)JD$[B1-$ZFXP[J'6L!%0I,'L9F1J\%*$*(-'Q1A_8:M2
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M97L%#GUC=TW(169F3O#I_B\;Z<3;"V$86C;B%"(R%>H.GJ('%,9+>IXK6IG
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MAHZY,X:YZ=X2@FL^M$/#W;5)BTM9#_,VD8&1P(<HH4F-:+);8=,._'4"#K,
M5<^' F2 ^@>+ I%Y,217P=T=ZLZB\[I2TT&TI[#]>R^E6<-K6LP#^-Y+C?!
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M\^W/\5U>;V]_R)&&7:X$(&UEM*G0<"DWMU> Z>XI2?,Y3==6O 0G>SLUM&!
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MA#$Q?&3_T;6\![GG#*3N.<U4G=[:,KMX!T:)0!0E+[QTJ[]<5'<0$>ZQGE$
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MX^=,0Z"!#TWE<)*R\;@EE;JP%A8V+?X'O""4&1'U%7DS%7I-7[J^*S2NY-E
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MN7UXT68=WW><!4PV.:^U^VU3E:7??X2*F/5JXILJ\55+#Q>_^VZ=>EZME>@
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M.T9+0EO@#+7NPT_A9H38;7<M*BGBZ--N[O(QR+D;YXT_7AK8R+3;&%L0 ;@
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MP+H/!12@9W_B>O*JG+1["(V6X:'GP-X+5B6>KDD]_ GL;-5>V#+& $SV>Y=
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MT+<*Y>-&D0@ \4;=2K:EKG0_(,+7W7)9EZ-!-=&W%J(" CH1PE?RL.L+FXU
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ME\$$F8,/$U[.X#KX>A>'D:\1$"\,&!,% _1((]S>-VS%IX"G_UA81.5@[I@
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M8(9=L00IUI#1=KD*43T<P[TG.F"L8F1G@OE[O%HX2O7A]M*/C/T\M0%LG=
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M/JF<I(YD[S5#R8GE/B.GLID!LX(^!NE/E'LG"@-(_]JGF"?,P6IF:0F.HH.
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M=(@Y1_?)OQCR)\@ '@5OY4@(F'X,R.A4,&UPN@IY1)I7@HR <_' SW7ZZY.
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M>'/R -CX15OB;]IW>*-RIHVE=AK$]ANW7PR)@-7@L9'[ZE/@T658,&44^ER
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MV ]1R:/M+PZ1CY;T#<IW>4^#,.I+-#KC.4XYZLX>6XF%M=V<(8I@?D=N]0R
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M/U!+ 0(4 Q0    ( 'V(>5+SSJ:?'IH  &18!@ 1              "  0
M  !A9'1X+3(P,C Q,C,Q+GAM;%!+ 0(4 Q0    ( 'V(>5)EZFZ3;A(  +#(
M   1              "  4V:  !A9'1X+3(P,C Q,C,Q+GAS9%!+ 0(4 Q0
M   ( 'V(>5+B;U<*+0L  +9_   5              "  >JL  !A9'1X+3(P
M,C Q,C,Q7V-A;"YX;6Q02P$"% ,4    " !]B'E2P1UL&#LY  "H?0, %0
M            @ %*N   861T>"TR,#(P,3(S,5]D968N>&UL4$L! A0#%
M  @ ?8AY4@(CH($CB@  G08' !4              ( !N/$  &%D='@M,C R
M,#$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( 'V(>5)HGP:Q13D  #:H P 5
M          "  0Y\ 0!A9'1X+3(P,C Q,C,Q7W!R92YX;6Q02P4&      8
,!@"* 0  AK4!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
